No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, d2wipA1, 1.0000, 0.00, 1.000, 293, 293, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
2, d1vywA1, 0.9987, 0.23, 1.000, 298, 293, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
3, d2wxvA1, 0.9985, 0.24, 1.000, 298, 293, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
4, d2wihA1, 0.9984, 0.25, 1.000, 298, 293, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
5, d2bpmA2, 0.9975, 0.31, 1.000, 298, 293, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
6, d2wpaA1, 0.9971, 0.34, 1.000, 298, 293, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
7, d5if1A_, 0.9955, 0.44, 1.000, 298, 293, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
8, d2bkzA2, 0.9951, 0.50, 1.000, 298, 293, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
9, d2c4gA2, 0.9933, 0.36, 1.000, 297, 292, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
10, d4fx3C_, 0.9919, 0.57, 1.000, 298, 293, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
11, d4fx3A_, 0.9917, 0.58, 1.000, 298, 293, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
12, d1fvvA_, 0.9911, 0.64, 1.000, 298, 293, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
13, d3f5xC_, 0.9908, 0.78, 1.000, 298, 293, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
14, d1finA_, 0.9907, 0.81, 1.000, 298, 293, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
15, d2wxvC1, 0.9896, 0.87, 1.000, 298, 293, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
16, d2c4gC2, 0.9892, 0.85, 1.000, 298, 293, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
17, d1vywC1, 0.9886, 0.90, 1.000, 298, 293, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
18, d2wihC1, 0.9885, 0.88, 1.000, 298, 293, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
19, d3f5xA_, 0.9883, 0.75, 1.000, 297, 292, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
20, d2wpaC1, 0.9873, 0.87, 1.000, 298, 293, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
21, d2bkzC2, 0.9869, 0.82, 1.000, 297, 292, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
22, d1finC_, 0.9866, 0.92, 1.000, 298, 293, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
23, d1fvvC_, 0.9865, 0.91, 1.000, 298, 293, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
24, d2bpmC2, 0.9861, 0.97, 1.000, 298, 293, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
25, d2wipC1, 0.9846, 0.83, 1.000, 291, 291, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
26, d5if1C_, 0.9819, 0.86, 1.000, 296, 291, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
27, d1urcC_, 0.9819, 0.73, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
28, d2c5vA_, 0.9813, 0.77, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
29, d1okuA_, 0.9810, 0.79, 1.000, 296, 291,  
30, d2c5oA_, 0.9809, 0.86, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
31, d2c5vC_, 0.9804, 0.80, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
32, d2c5pA_, 0.9803, 0.87, 1.000, 296, 291,  
33, d1okuC_, 0.9802, 0.81, 1.000, 296, 291,  
34, d2wevA_, 0.9801, 0.87, 1.000, 296, 291, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
35, d2v22A_, 0.9801, 0.89, 1.000, 296, 291, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
36, d2c5xA_, 0.9800, 0.88, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
37, d2whaC_, 0.9799, 0.86, 1.000, 296, 291,  
38, d2c5oC_, 0.9799, 0.88, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
39, d2c5nA_, 0.9799, 0.87, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
40, d2x1nC_, 0.9798, 0.86, 1.000, 296, 291, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
41, d1urcA_, 0.9798, 0.87, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
42, d2uueA_, 0.9797, 0.90, 1.000, 296, 291, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
43, d2whbA_, 0.9796, 0.92, 1.000, 296, 291, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
44, d2whaA_, 0.9796, 0.89, 1.000, 296, 291,  
45, d2c5tA_, 0.9795, 0.91, 1.000, 296, 291,  
46, d5cyiA1, 0.9794, 0.81, 0.979, 297, 291, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
47, d2x1nA_, 0.9793, 0.91, 1.000, 296, 291, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
48, d2c5tC_, 0.9793, 0.90, 1.000, 296, 291,  
49, d1ol2A_, 0.9793, 0.91, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
50, d2uueC_, 0.9792, 0.91, 1.000, 296, 291, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
51, d1ol1C_, 0.9792, 0.89, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
52, d2i40C_, 0.9791, 0.97, 1.000, 296, 291, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
53, d2v22C_, 0.9788, 0.92, 1.000, 296, 291, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
54, d1ol1A_, 0.9788, 0.93, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
55, d2c5xC_, 0.9780, 0.93, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
56, d1okwA_, 0.9779, 0.95, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
57, d2whbC_, 0.9778, 0.92, 1.000, 296, 291, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
58, d1okwC_, 0.9776, 0.94, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
59, d2c5nC_, 0.9770, 1.00, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
60, d4cfwA1, 0.9768, 0.88, 0.979, 297, 291, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
61, d2wfyC_, 0.9768, 0.96, 1.000, 296, 291, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
62, d2wevC_, 0.9762, 0.99, 1.000, 296, 291, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
63, d2c5pC_, 0.9757, 1.03, 1.000, 296, 291,  
64, d2wfyA_, 0.9748, 0.93, 1.000, 295, 290, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
65, d1ol2C_, 0.9747, 1.03, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
66, d3eidA_, 0.9744, 0.47, 1.000, 292, 287, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
67, d4bcpA1, 0.9741, 0.96, 0.979, 297, 291, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
68, d4cfvA1, 0.9738, 0.98, 0.979, 297, 291, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
69, d4bcoA1, 0.9736, 0.98, 0.979, 297, 291, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
70, d4bcnA1, 0.9733, 0.79, 0.979, 295, 289, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
71, d1jstC_, 0.9728, 1.07, 0.979, 297, 291, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
72, d1okvA_, 0.9727, 0.99, 0.997, 295, 290, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
73, d1okvC_, 0.9721, 1.10, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
74, d3ddpA1, 0.9717, 0.98, 0.979, 296, 290, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
75, d2i40A_, 0.9716, 0.43, 1.000, 291, 286, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
76, d4eonA1, 0.9710, 1.15, 0.969, 297, 291, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
77, d2g9xA2, 0.9706, 1.10, 0.979, 297, 291, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
78, d2uzeC_, 0.9698, 0.93, 0.979, 295, 289, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
79, d3qhrC1, 0.9697, 0.89, 0.979, 295, 289, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
80, d3qhrA1, 0.9697, 0.89, 0.979, 295, 289, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
81, d2cchC2, 0.9697, 0.89, 0.983, 295, 289, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
82, d3ddpC1, 0.9696, 1.06, 0.979, 297, 291, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
83, d2cchA2, 0.9696, 0.89, 0.979, 295, 289, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
84, d5lmkA1, 0.9693, 0.91, 0.979, 295, 289, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
85, d5nevC1, 0.9692, 1.02, 0.979, 295, 289, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
86, d4ii5C_, 0.9691, 0.91, 0.979, 295, 289, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
87, d4ii5A_, 0.9691, 0.91, 0.979, 295, 289, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
88, d2uzlC_, 0.9691, 0.97, 0.979, 295, 289, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
89, d2uzlA_, 0.9691, 0.98, 0.979, 295, 289, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
90, d4i3zA_, 0.9690, 0.91, 0.979, 295, 289, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
91, d3dogA1, 0.9690, 1.03, 0.976, 296, 290, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
92, d4i3zC_, 0.9689, 0.91, 0.979, 295, 289, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
93, d4cfuA1, 0.9689, 0.92, 0.979, 295, 289, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
94, d3tnwA1, 0.9687, 0.82, 0.979, 294, 288, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
95, d3qhwC1, 0.9687, 0.91, 0.979, 295, 289, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
96, d3qhwA1, 0.9687, 0.91, 0.979, 295, 289, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
97, d4cfmA1, 0.9686, 1.06, 0.979, 295, 289, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
98, d3bhuA1, 0.9685, 0.93, 0.979, 295, 289, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
99, d1e9hA_, 0.9685, 1.04, 0.979, 295, 289, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
100, d3bhvA1, 0.9684, 0.93, 0.979, 295, 289, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
101, d1h1rA1, 0.9684, 1.04, 0.979, 295, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
102, d1h1qA1, 0.9684, 1.04, 0.979, 295, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
103, d3bhtA2, 0.9681, 0.94, 0.979, 295, 289, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
104, d1jstA_, 0.9681, 1.17, 0.979, 297, 291, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
105, d2wmbA1, 0.9680, 1.04, 0.979, 295, 289, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
106, d2wmaA1, 0.9679, 0.98, 0.979, 295, 289, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
107, d4cfwC1, 0.9678, 1.04, 0.979, 295, 289, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
108, d1h26A1, 0.9678, 1.04, 0.979, 295, 289, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
109, d3ddqA1, 0.9676, 0.95, 0.979, 295, 289, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
110, d1pkdA1, 0.9676, 1.05, 0.979, 295, 289, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
111, d2uzeA_, 0.9675, 1.06, 0.979, 295, 289, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
112, d2iw8A1, 0.9673, 1.15, 0.969, 296, 290, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
113, d1h1qC1, 0.9673, 1.06, 0.979, 295, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
114, d1gy3C_, 0.9672, 1.07, 0.979, 295, 289, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
115, d2cciA2, 0.9671, 1.02, 0.979, 295, 289, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
116, d1h27A1, 0.9671, 1.05, 0.979, 295, 289, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
117, d1e9hC1, 0.9669, 1.09, 0.979, 295, 289, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
118, d5cyiC1, 0.9668, 1.07, 0.979, 295, 289, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
119, d4eomA1, 0.9668, 0.89, 0.969, 294, 288, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
120, d2cjmC_, 0.9667, 1.08, 0.979, 294, 289, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
121, d1h1sA1, 0.9666, 1.10, 0.979, 295, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
122, d1pkdC1, 0.9664, 1.12, 0.979, 295, 289, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
123, d1gy3A_, 0.9664, 1.06, 0.979, 295, 289, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
124, d3my5A1, 0.9663, 0.90, 0.979, 294, 288, CDK2/CYCLINA IN COMPLEX WITH DRB
125, d2uzdC_, 0.9661, 1.08, 0.979, 295, 289, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
126, d1oi9A1, 0.9661, 0.96, 0.976, 294, 288, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
127, d1h1rC1, 0.9660, 1.09, 0.983, 295, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
128, d1h1sC1, 0.9658, 1.09, 0.979, 295, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
129, d1h28A1, 0.9657, 1.12, 0.979, 295, 289, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
130, d2uzbA_, 0.9656, 1.09, 0.979, 295, 289, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
131, d1oiyC1, 0.9655, 1.08, 0.979, 295, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
132, d4eolC1, 0.9654, 1.13, 0.969, 296, 290, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
133, d2c6tC_, 0.9654, 1.08, 0.979, 295, 289, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
134, d4cfnA1, 0.9652, 0.83, 0.979, 293, 287, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
135, d1h28C1, 0.9652, 1.13, 0.979, 295, 289, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
136, d5nevA1, 0.9649, 1.03, 0.979, 294, 288, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
137, d1qmzC1, 0.9648, 1.10, 0.979, 295, 289, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
138, d1qmzA1, 0.9648, 1.10, 0.979, 295, 289, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
139, d2cciC2, 0.9647, 1.05, 0.979, 295, 289, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
140, d1p5eA1, 0.9647, 1.11, 0.979, 295, 289, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
141, d4eokC1, 0.9640, 1.18, 0.969, 296, 290, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
142, d4eopA1, 0.9636, 0.98, 0.972, 294, 288, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
143, d1oguA1, 0.9635, 0.88, 0.979, 293, 287, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
144, d4eonC1, 0.9633, 1.18, 0.966, 296, 290, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
145, d3eidC_, 0.9633, 0.64, 1.000, 290, 285, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
146, d4eooC1, 0.9630, 1.15, 0.976, 295, 289, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
147, d1oiuA1, 0.9630, 0.90, 0.979, 293, 287, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
148, d4eoqA1, 0.9628, 0.90, 0.979, 293, 287, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
149, d4eopC1, 0.9626, 1.15, 0.976, 295, 289, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
150, d4cfnC1, 0.9624, 0.99, 0.979, 293, 287, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
151, d1oiyA1, 0.9624, 0.81, 0.979, 292, 286, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
152, d4bcmA1, 0.9622, 0.82, 0.979, 292, 286, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
153, d3tnwC_, 0.9622, 1.01, 0.979, 291, 287, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
154, d4eosA1, 0.9621, 0.93, 0.979, 293, 287, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
155, d4eooA1, 0.9620, 0.83, 0.976, 292, 286, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
156, d4bcnC1, 0.9620, 1.02, 0.979, 293, 287, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
157, d4eoiA1, 0.9614, 0.94, 0.972, 293, 287, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
158, d2uzdA_, 0.9613, 1.15, 0.979, 295, 289, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
159, d4bcmC1, 0.9609, 1.04, 0.979, 293, 287, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
160, d2c6tA_, 0.9608, 1.17, 0.979, 295, 289, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
161, d4eosC1, 0.9605, 1.20, 0.979, 295, 289, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
162, d1p5eC1, 0.9604, 1.22, 0.979, 295, 289, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
163, d4eojA1, 0.9603, 0.97, 0.969, 293, 287, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
164, d2iw9A2, 0.9602, 0.89, 0.976, 292, 286, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
165, d4eoiC1, 0.9601, 1.21, 0.972, 295, 289, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
166, d2uzbC_, 0.9601, 0.88, 0.979, 292, 286, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
167, d2iw6C2, 0.9593, 1.16, 0.976, 294, 288, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
168, d2iw6A1, 0.9587, 0.82, 0.975, 291, 285, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
169, d4eolA1, 0.9580, 1.01, 0.969, 293, 287, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
170, d4eorA1, 0.9579, 0.94, 0.979, 292, 286, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
171, d1h25A1, 0.9577, 1.05, 0.979, 292, 286, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
172, d1h24A1, 0.9572, 1.08, 0.979, 292, 286, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
173, d5uq2A_, 0.9571, 1.31, 0.983, 296, 290, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
174, d1oi9C1, 0.9565, 1.26, 0.979, 295, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
175, d4bckA1, 0.9555, 1.26, 0.979, 296, 290, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
176, d1h1pA1, 0.9551, 1.29, 0.983, 295, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
177, d1h24C1, 0.9547, 1.13, 0.979, 292, 286, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
178, d4eokA1, 0.9532, 1.04, 0.969, 292, 286, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
179, d1h1pC1, 0.9502, 1.40, 0.983, 295, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
180, d1fq1B_, 0.9480, 1.44, 0.983, 295, 289, CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2
181, d1h27C1, 0.9477, 1.15, 0.979, 290, 284, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
182, d1f5qA_, 0.9477, 1.87, 0.997, 296, 293, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
183, d4bcqA1, 0.9463, 1.30, 0.979, 289, 288, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
184, d5l2wA1, 0.9457, 1.07, 0.979, 296, 283, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK2/CYCLINE AND DINACICLIB.
185, d4bckC1, 0.9433, 1.40, 0.979, 291, 287, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
186, d4bcqC1, 0.9430, 1.40, 0.979, 291, 287, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
187, d1w98A2, 0.9426, 1.14, 0.979, 296, 283, THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
188, d2cjmA_, 0.9391, 0.91, 0.979, 285, 280, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
189, d2jgzA_, 0.9385, 0.99, 0.979, 288, 281, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
190, d4nstA_, 0.9276, 1.88, 0.410, 322, 290, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
191, d4cxaA_, 0.9271, 1.84, 0.408, 329, 289, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
192, d5acbC_, 0.9266, 1.86, 0.414, 324, 290, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
193, d4nstC_, 0.9252, 1.96, 0.410, 317, 290, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
194, d4un0C_, 0.9246, 1.83, 0.415, 308, 289, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
195, d5efqA_, 0.9242, 1.96, 0.417, 321, 290, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
196, d5efqC_, 0.9238, 1.94, 0.417, 325, 290, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
197, d1unlA_, 0.9236, 1.59, 0.580, 292, 283, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
198, d3miaA_, 0.9231, 1.96, 0.400, 324, 290, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
199, d5acbD_, 0.9220, 1.89, 0.415, 319, 289, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
200, d3mi9A_, 0.9211, 2.00, 0.400, 328, 290, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
201, d4imyE_, 0.9210, 1.97, 0.408, 313, 289, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
202, d4imyC_, 0.9205, 2.03, 0.407, 310, 290, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
203, d4imyA_, 0.9203, 2.03, 0.407, 314, 290, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
204, d4cjyC_, 0.9196, 1.86, 0.403, 303, 288,  
205, d1f5qC_, 0.9193, 1.97, 0.989, 288, 285, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
206, d1ungA_, 0.9192, 1.71, 0.580, 288, 283, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
207, d1jsuA_, 0.9189, 2.05, 0.936, 285, 283, P27(KIP1)/CYCLIN A/CDK2 COMPLEX
208, d3o0gA_, 0.9185, 1.56, 0.584, 289, 281, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
209, d4or5F_, 0.9181, 2.04, 0.403, 324, 290, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
210, d4krcA_, 0.9169, 1.67, 0.558, 297, 283, CRYSTAL STRUCTURE OF PHO85-PCL10-ATP-GAMMA-S COMPLEX
211, d4bchA_, 0.9161, 1.93, 0.406, 308, 288, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
212, d3lq5A_, 0.9160, 1.89, 0.404, 307, 287, STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
213, d4or5A_, 0.9148, 2.10, 0.400, 319, 290, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
214, d4krdA_, 0.9136, 1.60, 0.562, 294, 281, CRYSTAL STRUCTURE OF PHO85-PCL10 COMPLEX
215, d1unlB_, 0.9136, 1.73, 0.572, 292, 283, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
216, d3my1A_, 0.9135, 1.90, 0.401, 314, 287, STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
217, d4bcgA_, 0.9134, 1.94, 0.404, 312, 287, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
218, d4bciA_, 0.9097, 1.86, 0.407, 308, 285, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
219, d4bcjA_, 0.9094, 1.98, 0.404, 309, 287, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
220, d4bcfA_, 0.9093, 1.96, 0.409, 307, 286, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
221, d4cxaC_, 0.9092, 1.99, 0.418, 330, 285, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
222, d4ogrE_, 0.9079, 2.13, 0.405, 310, 289, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
223, d3tn8A_, 0.9075, 1.91, 0.411, 304, 285, CDK9/CYCLIN T IN COMPLEX WITH CAN508
224, d4yc3A1, 0.9063, 1.98, 0.644, 294, 281, CDK1/CYCLINB1/CKS2 APO
225, d4ogrA_, 0.9058, 2.24, 0.407, 314, 290, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
226, d4ez7A1, 0.9055, 2.17, 0.958, 298, 283, CDK2 IN COMPLEX WITH STAUROSPORINE AND 2 MOLECULES OF 8-ANILINO-1- NAPHTHALENE SULFONIC ACID
227, d1h25C1, 0.9040, 1.17, 0.978, 277, 271, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
228, d3pxzA1, 0.9035, 2.50, 0.954, 298, 285, CDK2 TERNARY COMPLEX WITH JWS648 AND ANS
229, d4ogrI_, 0.9017, 2.30, 0.403, 318, 290, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
230, d3pxfA1, 0.9017, 2.50, 0.961, 298, 285, CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
231, d2pk9A_, 0.9006, 1.62, 0.567, 287, 277, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
232, d5hq0A1, 0.8992, 2.19, 0.668, 289, 283, TERNARY COMPLEX OF HUMAN PROTEINS CDK1 CYCLIN B AND CKS2 BOUND TO AN INHIBITOR
233, d4y72A1, 0.8992, 2.19, 0.668, 289, 283, HUMAN CDK1/CYCLINB1/CKS2 WITH INHIBITOR
234, d1h4lB_, 0.8977, 1.53, 0.584, 278, 274, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
235, d3blrA_, 0.8976, 1.93, 0.404, 300, 282, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
236, d3blqA_, 0.8972, 1.67, 0.406, 295, 278, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
237, d2pmiC_, 0.8968, 1.64, 0.569, 285, 276, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
238, d1h4lA_, 0.8965, 1.55, 0.580, 278, 274, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
239, d4ic7A_, 0.8941, 1.98, 0.389, 355, 280, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
240, d2gphA_, 0.8938, 2.03, 0.367, 345, 281, DOCKING MOTIF INTERACTIONS IN THE MAP KINASE ERK2
241, d4eojC1, 0.8937, 1.51, 0.949, 278, 272, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
242, d1j1bA_, 0.8937, 2.03, 0.320, 354, 281, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
243, d1j1cA_, 0.8931, 2.04, 0.320, 354, 281, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
244, d5lqfA1, 0.8929, 1.94, 0.651, 284, 278, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
245, d3i4bB_, 0.8928, 2.05, 0.320, 347, 281, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
246, d5a14A_, 0.8925, 1.95, 0.975, 284, 276, HUMAN CDK2 WITH TYPE II INHIBITOR
247, d1j1cB_, 0.8925, 2.06, 0.324, 364, 281, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
248, d1j1bB_, 0.8919, 2.07, 0.324, 364, 281, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
249, d3i4bA_, 0.8915, 2.08, 0.320, 359, 281, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
250, p3zu7A_, 0.8912, 2.10, 0.359, 344, 281, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE MAP KINASE ERK2
251, d4kd1A_, 0.8911, 2.50, 0.983, 298, 287, CDK2 IN COMPLEX WITH DINACICLIB
252, d3qyiA_, 0.8906, 2.08, 0.374, 346, 281,  
253, d1ykrA_, 0.8903, 2.53, 0.983, 298, 287, CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINE INHIBITOR
254, d1unhB_, 0.8903, 1.51, 0.588, 276, 272, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
255, d1q41B_, 0.8903, 2.09, 0.320, 343, 281, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
256, d4iz5B_, 0.8901, 2.10, 0.363, 347, 281, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
257, d4iz5D_, 0.8900, 2.10, 0.363, 347, 281, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
258, d4iz5A_, 0.8900, 2.10, 0.363, 347, 281, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
259, d4iz5C_, 0.8899, 2.11, 0.363, 347, 281, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
260, d2b53A_, 0.8899, 2.36, 0.922, 294, 283, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN- 234325
261, d4acgB_, 0.8898, 2.09, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
262, d3pxqA1, 0.8898, 2.14, 0.996, 294, 278, CDK2 IN COMPLEX WITH 3 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
263, d2b54A_, 0.8895, 2.65, 0.965, 298, 287, HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN- 232305
264, d4achB_, 0.8892, 2.10, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
265, d4acgA_, 0.8891, 2.11, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
266, d1unhA_, 0.8889, 1.54, 0.588, 276, 272, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
267, d4nm0A1, 0.8887, 2.11, 0.320, 355, 281, CRYSTAL STRUCTURE OF PEPTIDE INHIBITOR-FREE GSK-3/AXIN COMPLEX
268, d4ic7D_, 0.8886, 2.07, 0.389, 353, 280, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
269, p3zuvC_, 0.8882, 2.03, 0.369, 357, 279, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
270, d4acdB_, 0.8881, 2.12, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
271, d2g9xC2, 0.8881, 1.20, 0.978, 273, 267, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
272, d4achA_, 0.8880, 2.13, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
273, d4accA_, 0.8880, 2.12, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
274, d4acdA_, 0.8879, 2.12, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
275, d5v60A_, 0.8878, 2.09, 0.366, 347, 279, PHOSPHO-ERK2 BOUND TO AMP-PCP
276, d5lqfD1, 0.8878, 1.78, 0.647, 282, 275, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
277, d1h8fB_, 0.8878, 2.14, 0.324, 350, 281, GLYCOGEN SYNTHASE KINASE 3 BETA.
278, d4accB_, 0.8877, 2.12, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
279, d5f94B_, 0.8875, 2.13, 0.320, 349, 281, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
280, d5f94A_, 0.8875, 2.13, 0.320, 346, 281, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
281, d1h8fA_, 0.8875, 2.15, 0.324, 352, 281, GLYCOGEN SYNTHASE KINASE 3 BETA.
282, d4nm5A1, 0.8874, 2.15, 0.320, 360, 281, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 C-MOTIF
283, d3pj8A1, 0.8873, 2.20, 0.989, 287, 281, STRUCTURE OF CDK2 IN COMPLEX WITH A PYRAZOLO[43-D]PYRIMIDINE BIOISOSTERE OF ROSCOVITINE.
284, p3zuvA_, 0.8872, 2.07, 0.369, 357, 279, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
285, d3qqlA_, 0.8871, 2.34, 0.940, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR L3
286, d3r83A_, 0.8869, 2.36, 0.943, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-92
287, d2jldA_, 0.8867, 2.09, 0.321, 349, 280, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
288, d3pupB_, 0.8866, 2.10, 0.321, 347, 280, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
289, d3pupA_, 0.8866, 2.10, 0.321, 346, 280, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
290, p5v61A_, 0.8865, 2.09, 0.366, 348, 279, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP2
291, d2pmiA_, 0.8865, 1.75, 0.569, 284, 274, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
292, d5hlnA_, 0.8864, 2.09, 0.321, 346, 280, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
293, p4h3qA_, 0.8864, 2.18, 0.367, 352, 281, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
294, d2erkA_, 0.8864, 2.07, 0.369, 351, 279, PHOSPHORYLATED MAP KINASE ERK2
295, d1r0eB_, 0.8863, 2.13, 0.320, 344, 281, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
296, d5anjA_, 0.8862, 2.52, 0.979, 291, 285, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH N-(9H-PURIN-6-YL) THIOPHENE-2-CARBOXAMIDE  PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
297, d5aneA_, 0.8862, 2.38, 0.979, 294, 283, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-METHOXY-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
298, d4ptcA_, 0.8862, 2.15, 0.320, 342, 281, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
299, d3r8pA_, 0.8862, 2.33, 0.940, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-6
300, d2o5kA1, 0.8862, 2.14, 0.320, 350, 281, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A BENZOIMIDAZOL INHIBITOR
301, d4lynA_, 0.8861, 2.20, 0.996, 287, 282, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH (2S)-N-(5-(((5-TERT-BUTYL-13-OXAZOL-2-YL)METHYL)SULFANYL)-13- THIAZOL-2-YL)-2-PHENYLPROPANAMIDE
302, d3m1sB_, 0.8860, 2.10, 0.321, 349, 280, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
303, d2jldB_, 0.8860, 2.10, 0.321, 349, 280, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
304, d4nm7A1, 0.8858, 2.18, 0.320, 354, 281, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 E-MOTIF
305, d2exmA_, 0.8858, 2.51, 0.983, 298, 286, HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE
306, d4pteB_, 0.8857, 2.17, 0.320, 347, 281, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
307, d1o9uA_, 0.8856, 2.10, 0.321, 349, 280, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE
308, d1r0eA_, 0.8855, 2.14, 0.320, 344, 281, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
309, p5v62A_, 0.8853, 2.11, 0.366, 349, 279, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP3
310, d1uv5A_, 0.8853, 2.16, 0.320, 348, 281, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3 -OXIME
311, d4ptcB_, 0.8852, 2.17, 0.320, 347, 281, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
312, d1pw2A_, 0.8852, 2.41, 0.979, 294, 283, APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
313, d4qteA_, 0.8851, 2.24, 0.367, 348, 281, STRUCTURE OF ERK2 IN COMPLEX WITH VTX-11E 4-{2-[(2-CHLORO-4- FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3- CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE
314, d3m1sA_, 0.8851, 2.08, 0.323, 348, 279, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
315, d4nifB_, 0.8850, 2.18, 0.371, 349, 280, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
316, d4izaA_, 0.8850, 2.21, 0.363, 346, 281, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
317, d5nhlA_, 0.8849, 2.24, 0.370, 345, 281, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
318, d3sd0B_, 0.8849, 2.18, 0.320, 349, 281, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
319, d4nifE_, 0.8848, 2.19, 0.371, 348, 280, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
320, d5hlnB_, 0.8845, 2.12, 0.321, 346, 280, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
321, d3rm6A_, 0.8845, 2.40, 0.975, 293, 283, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-80
322, p4fmqA_, 0.8844, 2.17, 0.368, 350, 280, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
323, d3zrkB_, 0.8844, 2.21, 0.320, 348, 281, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
324, d4pteA_, 0.8843, 2.07, 0.326, 341, 279, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
325, d5nhpA_, 0.8842, 2.26, 0.370, 338, 281, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
326, d3sayB_, 0.8842, 2.14, 0.321, 347, 280, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
327, d3blhA1, 0.8842, 1.74, 0.418, 291, 275, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
328, d5nhvA_, 0.8841, 2.25, 0.370, 345, 281, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
329, d3qtwA_, 0.8841, 2.39, 0.968, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-13
330, d3r1qA_, 0.8839, 2.40, 0.937, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-102
331, d5ke0A_, 0.8837, 2.26, 0.370, 340, 281, DISCOVERY OF 1-1H-PYRAZOLO 43-C PYRIDINE-6-YL UREA INHIBITORS OF EXTRACELLULAR SIGNAL REGULATED KINASE ERK FOR THE TREATMENT OF CANCERS
332, d1hckA_, 0.8835, 2.43, 0.975, 294, 283, HUMAN CYCLIN-DEPENDENT KINASE 2
333, d3sd0A_, 0.8834, 2.19, 0.320, 350, 281, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
334, d3erkA_, 0.8834, 2.23, 0.370, 350, 281, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025
335, d5nhoA_, 0.8833, 2.26, 0.370, 343, 281, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
336, d5nhhA_, 0.8833, 2.27, 0.370, 348, 281, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
337, d5u6iA_, 0.8832, 2.25, 0.370, 339, 281, DISCOVERY OF MLI-2 AN ORALLY AVAILABLE AND SELECTIVE LRRK2 INHIBITOR THAT REDUCES BRAIN KINASE ACTIVITY
338, d5hd7A_, 0.8832, 2.26, 0.367, 347, 281, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT MUTANT SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
339, d3sayA_, 0.8832, 2.05, 0.324, 347, 278, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
340, d3qxoA_, 0.8831, 2.49, 0.972, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-84
341, d2clxA_, 0.8831, 2.37, 0.982, 293, 282, 4-ARYLAZO-35-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY CRYSTAL STRUCTURE IN COMPLEX WITH CDK2 SELECTIVITY AND CELLULAR EFFECTS
342, d3rpoA_, 0.8829, 2.29, 0.975, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-156
343, d3r28A_, 0.8829, 2.41, 0.937, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-140
344, d1q5kA_, 0.8829, 2.05, 0.327, 345, 278, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
345, d4gcjA1, 0.8827, 2.29, 0.986, 298, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
346, d1pyxA_, 0.8827, 1.99, 0.329, 343, 277, GSK-3 BETA COMPLEXED WITH AMP-PNP
347, d3zrlB_, 0.8826, 2.25, 0.320, 347, 281, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
348, d3r7yA_, 0.8826, 2.44, 0.979, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-88
349, d3r71A_, 0.8825, 2.42, 0.943, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-162
350, d2ojjA_, 0.8825, 2.29, 0.367, 344, 281, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-N-(1-(3- CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
351, d3qzhA_, 0.8824, 2.46, 0.937, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-124
352, d3qx2A_, 0.8824, 2.41, 0.943, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-190
353, d1hclA_, 0.8824, 2.46, 0.979, 294, 283, HUMAN CYCLIN-DEPENDENT KINASE 2
354, d4qtbA_, 0.8823, 2.27, 0.374, 351, 281, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
355, d4qnyB_, 0.8821, 2.20, 0.313, 339, 281, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
356, d4iz7A_, 0.8821, 2.06, 0.363, 344, 278, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
357, d1buhA_, 0.8821, 2.13, 0.942, 287, 276, CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1
358, d3zrmB_, 0.8820, 2.26, 0.320, 347, 281, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
359, d3r6xA_, 0.8820, 2.38, 0.940, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-158
360, d2ojgA_, 0.8820, 2.29, 0.363, 337, 281, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH NN-DIMETHYL-4-(4- PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
361, d1pxjA_, 0.8819, 2.46, 0.979, 294, 283, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE
362, d4j71A_, 0.8818, 2.17, 0.321, 347, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
363, d2z7lA_, 0.8818, 2.29, 0.367, 329, 281, UNPHOSPHORYLATED MITOGEN ACTIVATED PROTEIN KINASE ERK2 IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN 2-YL]AMINO}PHENYL)ACETIC ACID
364, d3qx4A_, 0.8817, 2.52, 0.972, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-78
365, d2a0cX_, 0.8817, 2.40, 0.972, 294, 283, HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II A NOVEL 269- TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR
366, d4qyyA_, 0.8816, 2.30, 0.370, 337, 281, DISCOVERY OF NOVEL DUAL MECHANISM ERK INHIBITORS BY AFFINITY SELECTION SCREENING OF AN INACTIVE KINASE STATE
367, d3raiA_, 0.8813, 2.41, 0.940, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-160
368, d3r73A_, 0.8813, 2.39, 0.940, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-164
369, d3qziA_, 0.8813, 2.47, 0.937, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-126
370, d2ojiA_, 0.8813, 2.29, 0.367, 344, 281, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
371, d1pxoA_, 0.8813, 2.42, 0.982, 294, 283, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YL]-(3-NITRO-PHENYL)-AMINE
372, d5f95A_, 0.8812, 2.07, 0.327, 345, 278, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
373, d3qwkA_, 0.8811, 2.40, 0.975, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-150
374, d3f88A_, 0.8811, 2.08, 0.327, 340, 278, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
375, p6g97A_, 0.8810, 2.24, 0.368, 344, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
376, d4erkA_, 0.8810, 2.28, 0.359, 350, 281, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINE
377, d4qtbB_, 0.8809, 2.29, 0.374, 348, 281, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
378, p6gdqA_, 0.8808, 2.27, 0.368, 339, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
379, p6g93A_, 0.8808, 2.25, 0.368, 343, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
380, d5byzA_, 0.8808, 2.16, 0.391, 348, 279, ERK5 IN COMPLEX WITH SMALL MOLECULE
381, d3pxrA_, 0.8808, 2.54, 0.975, 294, 284, APO CDK2 CRYSTALLIZED FROM JEFFAMINE
382, d1golA_, 0.8808, 2.28, 0.356, 357, 281, COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52
383, p6g9aA_, 0.8807, 2.25, 0.368, 341, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
384, d3royA_, 0.8807, 2.39, 0.940, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-154
385, d3f88B_, 0.8807, 2.10, 0.324, 340, 278, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
386, d1erkA_, 0.8807, 2.29, 0.367, 357, 281, STRUCTURE OF SIGNAL-REGULATED KINASE
387, d4fv3A_, 0.8806, 2.27, 0.364, 346, 280, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK6
388, d3qzfA_, 0.8806, 2.50, 0.972, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-52
389, d5hd4A_, 0.8805, 2.31, 0.370, 347, 281, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT WILD TYPE SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
390, d3r7vA_, 0.8805, 2.40, 0.975, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-9
391, d1pxiA_, 0.8805, 2.48, 0.979, 294, 283, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(25-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN-2- YLAMINE
392, d5nhjA_, 0.8804, 2.30, 0.370, 345, 281, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
393, d4eoqC1, 0.8804, 1.24, 0.974, 271, 265, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
394, d3nizA1, 0.8804, 2.12, 0.598, 284, 276, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH ADP BOUND.
395, d3qwjA_, 0.8803, 2.39, 0.975, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-142
396, d4erwA_, 0.8802, 2.28, 0.964, 292, 280, CDK2 IN COMPLEX WITH STAUROSPORINE
397, d3tiyA_, 0.8802, 2.46, 0.961, 293, 283, CDK2 IN COMPLEX WITH NSC 35676
398, d4s2zA_, 0.8801, 2.30, 0.359, 346, 281, ERK2 INTRINSICALLY ACTIVE MUTANT R65S
399, d4eomC1, 0.8800, 1.25, 0.966, 271, 265, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
400, d5byyA_, 0.8799, 2.00, 0.388, 338, 276, ERK5 IN COMPLEX WITH SMALL MOLECULE
401, d3rniA_, 0.8799, 2.40, 0.975, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR RC-3-86
402, d3q3bA_, 0.8799, 2.06, 0.325, 344, 277, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
403, d4xrlA_, 0.8798, 2.27, 0.375, 337, 280, CRYSTAL STRUCTURE AT ROOM TEMPERATURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
404, d3rk9A_, 0.8798, 2.53, 0.972, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-74
405, d3rk5A_, 0.8798, 2.50, 0.972, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-72
406, d3r7eA_, 0.8798, 2.54, 0.968, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-67
407, d2xnbA_, 0.8798, 2.48, 0.979, 296, 284, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
408, d3r1sA_, 0.8797, 2.41, 0.940, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-127
409, d3lfnA_, 0.8796, 2.16, 0.996, 285, 278, CRYSTAL STRUCTURE OF CDK2 WITH SAR57 AN AMINOINDAZOLE TYPE INHIBITOR
410, d5nguA_, 0.8795, 2.28, 0.375, 339, 280, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
411, d4fv2A_, 0.8795, 2.28, 0.364, 344, 280, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK5
412, p6g9hA_, 0.8793, 2.28, 0.361, 343, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
413, p5nzzG_, 0.8793, 2.13, 0.375, 342, 277, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
414, d3zrkA_, 0.8793, 2.14, 0.319, 345, 279, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
415, d3rm7A_, 0.8793, 2.54, 0.972, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-91
416, d2ds1A_, 0.8793, 2.30, 0.943, 290, 279, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
417, d1wccA_, 0.8793, 2.09, 0.993, 283, 278, SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY
418, d4zsjA_, 0.8792, 2.15, 0.391, 344, 279, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
419, d3r1yA_, 0.8790, 2.44, 0.940, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-134
420, d2xmyA_, 0.8790, 2.62, 0.968, 295, 285, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
421, d5umoA_, 0.8789, 2.31, 0.359, 347, 281, STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASE
422, d4qnyA_, 0.8789, 2.20, 0.314, 333, 280, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
423, d4j71B_, 0.8789, 2.19, 0.321, 347, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
424, d3qrtA_, 0.8789, 2.47, 0.926, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC2-55
425, d3q3bB_, 0.8789, 2.00, 0.330, 341, 276, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
426, d4s34A_, 0.8788, 2.32, 0.363, 343, 281, ERK2 (I84A) IN COMPLEX WITH AMP-PNP
427, d3qqfA_, 0.8788, 2.52, 0.937, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR L1
428, d5nhfA_, 0.8787, 2.28, 0.368, 339, 280, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
429, d3r9dA_, 0.8786, 2.47, 0.975, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR RC-2-135
430, d3rk7A_, 0.8785, 2.55, 0.972, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-71
431, d1pyxB_, 0.8785, 1.93, 0.331, 338, 275, GSK-3 BETA COMPLEXED WITH AMP-PNP
432, d4xj0A_, 0.8784, 2.20, 0.366, 345, 279, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
433, d3rkbA_, 0.8784, 2.54, 0.979, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR RC-2-73
434, d2zoqA_, 0.8784, 2.37, 0.374, 351, 281, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
435, d3py1A1, 0.8783, 2.39, 0.982, 298, 281, CDK2 TERNARY COMPLEX WITH SU9516 AND ANS
436, d1pmeA_, 0.8783, 2.28, 0.371, 333, 280, STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE
437, d4s33A_, 0.8782, 2.34, 0.367, 347, 281, ERK2 R65S MUTANT COMPLEXED WITH AMP-PNP
438, d4cfuC1, 0.8781, 1.12, 0.977, 269, 263, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
439, p6g9mA_, 0.8780, 2.31, 0.368, 341, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
440, d3qu0A_, 0.8780, 2.56, 0.975, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-38
441, d3bhvC1, 0.8780, 1.12, 0.977, 269, 263, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
442, p5nzzE_, 0.8778, 2.15, 0.375, 343, 277, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
443, d4s30A_, 0.8778, 2.33, 0.363, 342, 281, ERK2 INTRINSICALLY ACTIVE MUTANT (I84A)
444, d4qp1A_, 0.8778, 2.18, 0.355, 342, 279, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
445, d3zrlA_, 0.8777, 2.17, 0.319, 345, 279, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
446, d4g6oA_, 0.8775, 2.27, 0.369, 339, 279, CRYSTAL STRUCTURE OF THE ERK2
447, d3zrmA_, 0.8775, 2.17, 0.319, 344, 279, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
448, d3bhtC1, 0.8775, 1.13, 0.977, 269, 263, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
449, d2zoqB_, 0.8775, 2.29, 0.375, 351, 280, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
450, d2ow3B_, 0.8774, 2.25, 0.321, 351, 280, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
451, d1oguC1, 0.8774, 1.14, 0.977, 269, 263, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
452, d4zsgA_, 0.8772, 2.18, 0.384, 347, 279, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
453, d2f49A_, 0.8772, 1.97, 0.382, 335, 275, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
454, d2b9iA_, 0.8772, 2.02, 0.380, 338, 276, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM MSG5
455, d4j1rC_, 0.8771, 2.25, 0.321, 344, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
456, d4fv1A_, 0.8771, 2.32, 0.364, 342, 280, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK4
457, d4s31A_, 0.8770, 2.34, 0.363, 347, 281, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 1 WTERK2 AT 1.45A
458, d4j1rA_, 0.8770, 2.25, 0.321, 343, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
459, d4gt3A_, 0.8770, 2.31, 0.375, 347, 280, ATP-BOUND FORM OF THE ERK2 KINASE
460, d4j1rD_, 0.8769, 2.25, 0.321, 345, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
461, d3ql8A_, 0.8769, 2.54, 0.947, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-260
462, d3bhuC1, 0.8769, 1.15, 0.977, 269, 263, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
463, p5nzzF_, 0.8768, 2.12, 0.373, 341, 276, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
464, d4ez3A_, 0.8768, 2.41, 0.982, 294, 282, CDK2 IN COMPLEX WITH NSC 134199
465, d3qruA_, 0.8768, 2.45, 0.912, 295, 284, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-12
466, d4mygA_, 0.8767, 2.23, 0.386, 335, 277, MAPK13 ACTIVE FORM
467, d4bcpC1, 0.8767, 1.18, 0.981, 266, 263, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
468, d3r63A_, 0.8767, 2.34, 0.359, 347, 281, STRUCTURE OF ERK2 (SPE) MUTANT (S246E)
469, d1xo2B_, 0.8767, 1.98, 0.482, 289, 278, CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR FISETIN
470, d2ow3A_, 0.8766, 2.26, 0.325, 346, 280, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
471, d1b38A_, 0.8766, 2.31, 0.950, 290, 279, HUMAN CYCLIN-DEPENDENT KINASE 2
472, d3qxpA_, 0.8765, 2.35, 0.968, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
473, d1q3wB_, 0.8765, 2.04, 0.330, 341, 276, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
474, d3qtzA_, 0.8764, 2.54, 0.975, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-36
475, d1tvoA_, 0.8762, 2.35, 0.363, 350, 281, THE STRUCTURE OF ERK2 IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
476, p6g9dA_, 0.8761, 2.33, 0.368, 345, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
477, d4s32A_, 0.8761, 2.36, 0.367, 346, 281, CRYSTAL STRUCTURE OF ERK2 AMP-PNP COMPLEX
478, d4fuxA_, 0.8761, 2.31, 0.368, 342, 280, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E75
479, d3uliA_, 0.8761, 2.23, 0.961, 286, 279, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) BOUND TO AZABENZIMIDAZOLE DERIVATIVE
480, d3rpvA_, 0.8761, 2.54, 0.972, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-88
481, d1v0oA_, 0.8761, 1.90, 0.624, 276, 271, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
482, d1pxpA_, 0.8761, 2.60, 0.972, 294, 284, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- N N -DIMETHYL-BENZENE-14-DIAMINE
483, d4zzmA_, 0.8760, 2.33, 0.375, 344, 280, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
484, p6g8xA_, 0.8759, 2.35, 0.371, 338, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
485, d1h0uA_, 0.8759, 2.36, 0.954, 291, 280,  
486, d4fkuA_, 0.8758, 2.70, 0.940, 293, 284, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
487, d3du8A_, 0.8758, 2.00, 0.331, 336, 275, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
488, p6g91A_, 0.8756, 2.33, 0.368, 344, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
489, d3qtqA_, 0.8756, 2.50, 0.975, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR RC-1-137
490, d3lfsA_, 0.8756, 2.33, 0.957, 290, 279, CRYSTAL STRUCTURE OF CDK2 WITH SAR37 AN AMINOINDAZOLE TYPE INHIBITOR
491, d3lfqA_, 0.8756, 2.26, 0.957, 289, 278, CRYSTAL STRUCTURE OF CDK2 WITH SAR60 AN AMINOINDAZOLE TYPE INHIBITOR
492, d3r8zA_, 0.8755, 2.40, 0.979, 290, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-1-136
493, p6ge0A_, 0.8754, 2.30, 0.369, 343, 279, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
494, p6g9nA_, 0.8754, 2.36, 0.361, 344, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
495, d4zzoA_, 0.8754, 2.34, 0.375, 339, 280, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
496, d4qpaB_, 0.8754, 2.30, 0.361, 345, 280, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
497, d3ti1A_, 0.8754, 2.61, 0.972, 294, 284, CDK2 IN COMPLEX WITH SUNITINIB
498, d3gb2A_, 0.8754, 2.10, 0.332, 340, 277, GSK3BETA INHIBITOR COMPLEX
499, d2c5yA_, 0.8754, 2.21, 0.982, 290, 278, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
500, d1q3wA_, 0.8753, 2.13, 0.325, 344, 277, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
501, d4zslA_, 0.8752, 2.16, 0.392, 341, 278, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
502, d3rjcA_, 0.8752, 2.47, 0.975, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR L4-12
503, d3qqkA_, 0.8752, 2.45, 0.975, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR L4
504, d3ns9A_, 0.8752, 2.29, 0.975, 289, 278, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR BS-194
505, d4g6nA_, 0.8750, 2.34, 0.368, 341, 280, CRYSTAL STRUCTURE OF THE ERK2
506, d3du8B_, 0.8749, 2.02, 0.331, 339, 275, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
507, d4qp1B_, 0.8748, 2.26, 0.362, 343, 279, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
508, d3qtxA_, 0.8748, 2.56, 0.972, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-35
509, d2vtmA_, 0.8748, 2.36, 0.968, 290, 279, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
510, d2r3fA_, 0.8748, 2.33, 0.953, 290, 279, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
511, d5lcjA_, 0.8747, 2.34, 0.368, 345, 280, IN-GEL ACTIVITY-BASED PROTEIN PROFILING OF A CLICKABLE COVALENT ERK 1/2 INHIBITOR
512, d4zznA_, 0.8747, 2.33, 0.368, 338, 280, HUMAN ERK2 IN COMPLEX WITH AN INHIBITOR
513, d4fv7A_, 0.8747, 2.27, 0.369, 342, 279, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E94
514, d3wblA_, 0.8747, 2.28, 0.989, 283, 278, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR
515, d1h0vA_, 0.8746, 2.39, 0.954, 288, 280, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5 -YL]METHOXYPURINE
516, d2fysA_, 0.8745, 2.35, 0.368, 348, 280, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
517, p5o7iA_, 0.8743, 2.18, 0.385, 340, 278, ERK5 IN COMPLEX WITH A PYRROLE INHIBITOR 
518, d4xozA_, 0.8743, 2.32, 0.361, 341, 280, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
519, d2b52A_, 0.8743, 2.12, 0.986, 283, 276, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH- 042562
520, d2vtlA_, 0.8742, 2.35, 0.953, 290, 279, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
521, d2vtoA_, 0.8741, 2.14, 0.967, 283, 276, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
522, d2b9hA_, 0.8741, 2.02, 0.382, 337, 275, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM STE7
523, p6g92A_, 0.8740, 2.36, 0.371, 343, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
524, d5iexA_, 0.8740, 2.25, 0.986, 285, 279, CRYSTAL STRUCTURE OF (RS)-S-{4-[(5-BROMO-4-{[(2R3R)-2-HYDROXY-1- METHYLPROPYL]OXY}- PYRIMIDIN-2-YL)AMINO]PHENYL}-S- CYCLOPROPYLSULFOXIMIDE BOUND TO CDK2
525, d4afjB_, 0.8740, 2.18, 0.329, 346, 277, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
526, d2c6lA_, 0.8739, 2.43, 0.968, 291, 280, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
527, d5ievA_, 0.8738, 2.25, 0.989, 284, 278, CRYSTAL STRUCTURE OF BAY 1000394 (RONICICLIB) BOUND TO CDK2
528, d4xneA_, 0.8738, 2.28, 0.362, 344, 279, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
529, d2c69A_, 0.8738, 2.47, 0.964, 292, 281, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
530, d2b9jA_, 0.8738, 2.02, 0.382, 337, 275, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM FAR1
531, d1i09B_, 0.8738, 2.04, 0.330, 341, 276, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
532, d4fklA_, 0.8737, 2.35, 0.953, 290, 279, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
533, d4ek5A_, 0.8737, 2.18, 0.957, 289, 277, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
534, d1wzyA_, 0.8736, 2.29, 0.364, 350, 280, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A PYRAZOLOPYRIDAZINE DERIVATIVE
535, d5jq5A_, 0.8735, 2.21, 0.953, 287, 276, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0942
536, d3r8uA_, 0.8735, 2.54, 0.975, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR RC-1-132
537, d3o71A_, 0.8735, 2.14, 0.371, 340, 278, CRYSTAL STRUCTURE OF ERK2/DCC PEPTIDE COMPLEX
538, d2r3rA_, 0.8735, 2.36, 0.953, 290, 279, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
539, d2fa2A_, 0.8735, 2.01, 0.382, 333, 275, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
540, d1gz8A_, 0.8735, 2.37, 0.953, 290, 279, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3 -METHYL-2 -OXO)BUTOXYPURINE
541, d4j1rB_, 0.8733, 2.19, 0.327, 346, 278, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
542, d4gvaA_, 0.8733, 2.33, 0.361, 345, 280, ADP-BOUND FORM OF THE ERK2 KINASE
543, d4bcoC1, 0.8733, 1.17, 0.977, 268, 262, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
544, d3qqjA_, 0.8733, 2.54, 0.975, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR L2
545, d4qp8B_, 0.8732, 2.06, 0.376, 337, 274, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
546, d1y8yA_, 0.8732, 2.45, 0.954, 292, 281, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
547, d1q3dB_, 0.8732, 2.16, 0.330, 339, 276, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
548, d1oirA_, 0.8732, 2.18, 0.960, 286, 275, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
549, d3f7zB1, 0.8731, 2.09, 0.322, 338, 276, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
550, d3r9hA_, 0.8730, 2.66, 0.972, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-142
551, d2c6kA_, 0.8730, 2.48, 0.964, 292, 281, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
552, d1b39A_, 0.8730, 2.35, 0.950, 290, 279, HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
553, d3s00A_, 0.8729, 2.64, 0.972, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR L4-14
554, d3iggA_, 0.8729, 2.39, 0.950, 290, 279, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFQ WITH CDK-2
555, d1aq1A_, 0.8729, 1.83, 0.970, 277, 271, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE
556, d2v0dA_, 0.8728, 2.48, 0.964, 292, 281, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
557, d3tizA_, 0.8727, 2.55, 0.965, 293, 283, CDK2 IN COMPLEX WITH NSC 111848
558, d2r3hA_, 0.8727, 2.32, 0.953, 289, 278, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
559, d2r3oA_, 0.8725, 2.32, 0.953, 289, 278, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
560, d4eorC1, 0.8724, 1.26, 0.939, 269, 263, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
561, d3qqgA_, 0.8724, 2.61, 0.968, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR L2-5
562, d2f49B_, 0.8723, 2.03, 0.382, 337, 275, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
563, d4afjA_, 0.8722, 2.11, 0.326, 342, 276, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
564, d3qyzA_, 0.8722, 2.39, 0.371, 339, 280, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
565, d5ieyA_, 0.8721, 2.33, 0.989, 286, 279, CRYSTAL STRUCTURE OF A CDK INHIBITOR BOUND TO CDK2
566, p4h3pA_, 0.8721, 2.24, 0.372, 342, 277, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
567, d3s0oA_, 0.8720, 2.57, 0.940, 293, 283, CDK2 IN COMPLEX WITH INHIBITOR RC-1-138
568, d3juhA_, 0.8720, 2.35, 0.301, 334, 279, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
569, d1pxlA_, 0.8720, 2.35, 0.978, 290, 279, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- (4-TRIFLUOROMETHYL-PHENYL)-AMINE
570, d1pf8A_, 0.8720, 2.54, 0.986, 298, 283, CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR
571, d4iz7C_, 0.8719, 2.08, 0.367, 340, 275, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
572, d4xrjA_, 0.8718, 2.31, 0.366, 344, 279, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
573, d3qywA_, 0.8718, 2.38, 0.368, 340, 280, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
574, d1q4lA_, 0.8718, 2.02, 0.328, 342, 274, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
575, d3qtuA_, 0.8717, 2.58, 0.926, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-132
576, d2vtsA_, 0.8717, 2.15, 0.971, 282, 275, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
577, d2c6iA_, 0.8717, 2.38, 0.964, 292, 280, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
578, d1q41A_, 0.8717, 2.01, 0.332, 339, 274, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
579, d1ckpA_, 0.8717, 1.96, 0.967, 279, 274, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B
580, d3py3A1, 0.8716, 1.98, 0.369, 352, 274, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38ALPHA MAP KINASE
581, d5lckA_, 0.8715, 2.34, 0.366, 345, 279, A CLICKABLE COVALENT ERK 1/2 INHIBITOR
582, d5hlpA_, 0.8715, 2.12, 0.330, 337, 276, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
583, d4gsbA_, 0.8715, 2.33, 0.376, 343, 279, MONOCLINIC CRYSTAL FORM OF THE APO-ERK2
584, d4fkvA_, 0.8715, 2.14, 0.996, 282, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
585, d2w1hA_, 0.8714, 2.22, 0.993, 283, 278, FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA (AT9283) A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY
586, d2a4lA_, 0.8714, 2.21, 0.964, 286, 275, HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE
587, d1y91A_, 0.8714, 2.19, 0.986, 286, 276, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
588, d4xp2A_, 0.8713, 2.42, 0.371, 337, 280, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
589, d2w17A_, 0.8713, 2.03, 0.971, 278, 274, CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE COMPOUND (S)-8B
590, d3unkA_, 0.8712, 2.71, 0.968, 295, 285, CDK2 IN COMPLEX WITH INHIBITOR YL5-083
591, d3r8lA_, 0.8711, 2.62, 0.933, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR L3-4
592, d3bw5A_, 0.8710, 2.36, 0.305, 334, 279,  
593, d2vtrA_, 0.8709, 2.38, 0.968, 290, 279, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
594, p6g9jA_, 0.8708, 2.32, 0.371, 347, 278, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
595, d4fkiA_, 0.8708, 2.34, 0.964, 287, 277, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
596, d1ymiA_, 0.8706, 2.37, 0.305, 334, 279,  
597, d1q3dA_, 0.8706, 2.11, 0.331, 339, 275, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
598, d1gngA_, 0.8705, 2.38, 0.325, 348, 280, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
599, d2vtpA_, 0.8704, 2.16, 0.982, 281, 275, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
600, d2r3pA_, 0.8702, 2.36, 0.968, 289, 278, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
601, d1h0wA_, 0.8702, 2.16, 0.960, 283, 277, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL]METHOXYPURINE
602, d4qp7A_, 0.8701, 2.10, 0.376, 337, 274, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
603, d3h30A_, 0.8701, 2.29, 0.299, 333, 278, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
604, d4rj3A_, 0.8700, 2.27, 0.953, 287, 276, CDK2 WITH EGFR INHIBITOR COMPOUND 8
605, d4mygB_, 0.8700, 2.10, 0.389, 335, 275, MAPK13 ACTIVE FORM
606, d3qzgA_, 0.8700, 2.63, 0.937, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-76
607, d2fa2B_, 0.8700, 2.07, 0.382, 332, 275, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
608, d1pxnA_, 0.8700, 2.55, 0.975, 294, 283, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)- PYRIMIDIN-2-YLAMINO]-PHENOL
609, p6gdmA_, 0.8699, 2.27, 0.375, 341, 277, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
610, d1q99B_, 0.8698, 2.05, 0.308, 364, 276, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
611, d1e1vA_, 0.8698, 2.44, 0.978, 290, 279, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
612, d4xp3A_, 0.8697, 2.45, 0.375, 339, 280, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
613, d4qp4A_, 0.8697, 2.10, 0.376, 337, 274, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
614, d3s2pA_, 0.8697, 1.99, 0.967, 279, 274, CRYSTAL STRUCTURE OF CDK2 WITH A 2-AMINOPYRIMIDINE COMPOUND
615, d2r3gA_, 0.8697, 2.27, 0.960, 287, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
616, d2jd5B_, 0.8697, 2.04, 0.308, 360, 276, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
617, d4au8B_, 0.8696, 1.75, 0.593, 277, 270, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
618, d2iw9C2, 0.8696, 1.18, 0.973, 267, 261, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
619, d3r8vA_, 0.8693, 2.70, 0.972, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-1-135
620, d1w8cA_, 0.8693, 2.43, 0.968, 290, 279, CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H- PURIN-2-YLAMINE AND MONOMERIC CDK2
621, d1h01A_, 0.8693, 2.24, 0.956, 286, 275, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
622, d3juhB_, 0.8692, 2.40, 0.305, 334, 279, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
623, d2rkpA_, 0.8692, 2.37, 0.297, 334, 279,  
624, d5k4jA1, 0.8691, 2.12, 0.985, 281, 275, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH COMPOUND 22
625, d1q5kB_, 0.8691, 2.13, 0.335, 344, 275, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
626, d3qqhA_, 0.8690, 2.67, 0.972, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR L2-2
627, d5m4cA_, 0.8688, 2.32, 0.300, 329, 277, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER LOW-SALT CONDITIONS
628, d4un0D_, 0.8688, 1.64, 0.428, 276, 269, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
629, d4qp9A_, 0.8688, 2.13, 0.376, 335, 274, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-PROPYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
630, d1q97B_, 0.8688, 2.07, 0.308, 361, 276, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
631, d4fv0A_, 0.8687, 2.32, 0.363, 341, 278, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK3
632, d2r3iA_, 0.8687, 2.38, 0.953, 289, 278, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
633, d5nqcA_, 0.8686, 2.31, 0.299, 331, 278, CK2ALPHA IN COMPLEX WITH NMR154
634, d4ptgA_, 0.8686, 2.02, 0.337, 333, 273, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
635, d4fkgA_, 0.8686, 2.33, 0.964, 286, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
636, d4ek4A_, 0.8686, 2.29, 0.953, 287, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
637, d3fz1A_, 0.8686, 2.35, 0.993, 284, 277, CRYSTAL STRUCTURE OF A BENZTHIOPHENE INHIBITOR BOUND TO HUMAN CYCLIN-DEPENDENT KINASE-2 (CDK-2)
638, d4iq6B_, 0.8685, 2.00, 0.333, 332, 273, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
639, d1q8zB_, 0.8684, 2.07, 0.308, 364, 276, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
640, d1h07A_, 0.8684, 2.32, 0.971, 285, 276, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
641, d1e1xA_, 0.8684, 2.44, 0.953, 290, 279, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
642, d2uzoA_, 0.8681, 2.43, 0.961, 290, 279, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
643, d1jsvA_, 0.8680, 2.29, 0.960, 287, 276, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL) AMINO]BENZENESULFONAMIDE
644, d2b9fA_, 0.8678, 2.14, 0.385, 337, 275, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED FUS3
645, d3f7zA1, 0.8677, 2.03, 0.322, 338, 273, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
646, d4ek3A_, 0.8676, 2.30, 0.953, 287, 276, CRYSTAL STRUCTURE OF APO CDK2
647, d3sqqA_, 0.8675, 2.26, 0.982, 288, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-3-96
648, d1pxkA_, 0.8675, 2.46, 0.953, 290, 279, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)PYRIMIDIN-2-YL]- N -HYDROXYIMINOFORMAMIDE
649, p5oo0A_, 0.8674, 2.37, 0.975, 288, 277, CDK2(WT) COVALENT ADDUCT WITH D28 AT C177
650, d5mhqA1, 0.8674, 2.32, 0.957, 288, 277, CCT068127 IN COMPLEX WITH CDK2
651, d4au8A1, 0.8674, 1.62, 0.584, 274, 267, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
652, d1fvtA_, 0.8674, 2.19, 0.964, 282, 276, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR
653, d2r64A_, 0.8673, 2.03, 0.967, 279, 274, CRYSTAL STRUCTURE OF A 3-AMINOINDAZOLE COMPOUND WITH CDK2
654, d1q8yB_, 0.8673, 2.09, 0.308, 357, 276, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
655, d1jwhA_, 0.8673, 2.29, 0.296, 336, 277, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
656, d1h26C1, 0.8673, 1.17, 0.977, 266, 260, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
657, p3teiA_, 0.8672, 2.11, 0.369, 339, 274, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
658, d2c68A_, 0.8671, 2.47, 0.950, 290, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
659, d2vv9A_, 0.8670, 2.09, 0.974, 279, 274, CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE
660, d3r7iA_, 0.8669, 2.19, 0.964, 282, 276, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-74
661, d3c9wB2, 0.8669, 1.98, 0.376, 335, 271, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
662, d2jd5A_, 0.8669, 2.03, 0.310, 353, 274, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
663, d3c9wA2, 0.8668, 1.98, 0.376, 335, 271, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
664, d4n4sA_, 0.8666, 2.15, 0.372, 342, 277, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
665, d4fkwA_, 0.8665, 2.05, 0.996, 280, 274, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
666, d4cfmC1, 0.8665, 1.11, 0.977, 265, 259, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
667, d2uznA_, 0.8665, 2.13, 0.985, 279, 274, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
668, d3pxyA_, 0.8664, 2.70, 0.972, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR JWS648
669, d2c6oA_, 0.8664, 2.47, 0.964, 290, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
670, d2w06A_, 0.8663, 2.27, 0.967, 282, 276, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5C
671, d1gngB_, 0.8663, 2.41, 0.325, 355, 280, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
672, d5m4fA_, 0.8662, 2.32, 0.296, 330, 277, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER LOW-SALT CONDITIONS
673, d2f2cB_, 0.8662, 1.82, 0.493, 280, 270, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
674, d2bhhA_, 0.8661, 1.70, 0.974, 274, 269, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE
675, d1v0oB_, 0.8661, 1.91, 0.628, 274, 269, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
676, d1pxmA_, 0.8661, 2.43, 0.950, 290, 279, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL
677, d4fkqA_, 0.8660, 2.33, 0.971, 283, 278, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
678, d3sa0A_, 0.8660, 2.45, 0.369, 354, 279, COMPLEX OF ERK2 WITH NORATHYRIOL
679, d1q97A_, 0.8655, 2.00, 0.308, 351, 273, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
680, d1di8A_, 0.8653, 2.30, 0.996, 283, 276, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-67-DIMETHOXYQUINAZOLINE
681, d1cm8B_, 0.8653, 2.19, 0.370, 327, 273, PHOSPHORYLATED MAP KINASE P38-GAMMA
682, d3py0A_, 0.8652, 2.69, 0.972, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR SU9516
683, d3ig7A_, 0.8652, 1.99, 0.967, 278, 273, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFP WITH CDK-2
684, d2c6mA_, 0.8652, 2.51, 0.964, 290, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
685, d1cm8A_, 0.8652, 2.19, 0.370, 327, 273, PHOSPHORYLATED MAP KINASE P38-GAMMA
686, d1ungB_, 0.8651, 1.53, 0.577, 268, 265, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
687, d1q99A_, 0.8651, 2.10, 0.305, 354, 275, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
688, d3dogC1, 0.8650, 1.20, 0.977, 266, 260, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
689, d4qtaA_, 0.8649, 1.93, 0.374, 335, 270, STRUCTURE OF HUMAN ERK2 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
690, d3nszA_, 0.8649, 2.19, 0.298, 327, 275, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH AMPPN
691, d2r3qA_, 0.8649, 2.29, 0.964, 286, 275, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
692, d1q8zA_, 0.8649, 2.10, 0.305, 354, 275, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
693, d4zxtA_, 0.8648, 2.46, 0.366, 348, 279, COMPLEX OF ERK2 WITH CATECHOL
694, d4cfvC1, 0.8648, 1.12, 0.977, 263, 259, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
695, d4b99A_, 0.8648, 2.29, 0.399, 335, 273, CRYSTAL STRUCTURE OF MAPK7 (ERK5) WITH INHIBITOR
696, d1q8yA_, 0.8648, 2.06, 0.307, 351, 274, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
697, p6cpwA_, 0.8647, 2.33, 0.373, 328, 276, DISCOVERY OF 3(S)-THIOMETHYL PYRROLIDINE ERK INHIBITORS FOR ONCOLOGY 
698, d3r9oA_, 0.8647, 2.24, 0.989, 282, 276, CDK2 IN COMPLEX WITH INHIBITOR RC-2-143
699, d3r7uA_, 0.8647, 2.22, 0.964, 282, 276, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-75
700, d1h00A_, 0.8646, 2.13, 0.971, 278, 274, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
701, d4xp0A_, 0.8645, 2.42, 0.378, 336, 278, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
702, d3my5C1, 0.8645, 1.14, 0.981, 265, 259, CDK2/CYCLINA IN COMPLEX WITH DRB
703, p2no3A_, 0.8644, 2.35, 0.356, 357, 278, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
704, d1h08A_, 0.8644, 2.38, 0.993, 283, 276, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
705, d3fwqB_, 0.8643, 2.44, 0.294, 334, 279, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
706, d2zjwA_, 0.8643, 2.26, 0.301, 332, 276, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH ELLAGIC ACID
707, d1w0xC_, 0.8643, 2.18, 0.982, 280, 275, CRYSTAL STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE.
708, d3h30B_, 0.8642, 2.37, 0.299, 333, 278, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
709, d4n0sA_, 0.8641, 2.40, 0.363, 348, 278, COMPLEX OF ERK2 WITH CAFFEIC ACID
710, d1ke6A_, 0.8641, 2.18, 0.982, 280, 275, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4- [2-(7-OXO-67-DIHYDRO-8H-[13]THIAZOLO[54-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
711, d3w8lA_, 0.8640, 2.26, 0.301, 326, 276, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
712, d4qp3A_, 0.8639, 2.10, 0.359, 339, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
713, p4md9P_, 0.8639, 2.40, 0.296, 328, 277, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
714, d2r3mA_, 0.8639, 2.00, 0.971, 278, 272, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
715, d5hlpB_, 0.8638, 2.10, 0.330, 335, 273, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
716, d2wmbC1, 0.8638, 1.15, 0.977, 265, 259, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
717, d2w05A_, 0.8638, 2.00, 0.970, 276, 271, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5B
718, d4fkrA_, 0.8637, 2.25, 0.964, 282, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
719, p2gmxA_, 0.8636, 2.30, 0.354, 357, 277, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
720, d1ke8A_, 0.8636, 2.26, 0.978, 282, 276, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO- 12-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(13- THIAZOL-2-YL)BENZENESULFONAMIDE
721, d1ke7A_, 0.8636, 2.17, 0.982, 281, 275, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(22- DIOXIDO-13-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5- (13-OXAZOL-5-YL)-13-DIHYDRO-2H-INDOL-2-ONE
722, d4fkjA_, 0.8635, 2.11, 0.974, 278, 273, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
723, d2oxyA_, 0.8635, 2.38, 0.300, 327, 277, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
724, p5ooiA_, 0.8634, 2.40, 0.303, 329, 277, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
725, d2vtaA_, 0.8632, 2.06, 0.974, 278, 273, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
726, d5aniA_, 0.8630, 2.17, 0.960, 280, 274, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-CHLORO-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
727, d3kxhA_, 0.8630, 2.38, 0.300, 326, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR (2-DYMETHYLAMMINO-4567-TETRABROMOBENZOIMIDAZOL-1YL- ACETIC ACID (K66)
728, d2vtiA_, 0.8630, 2.23, 0.967, 280, 275, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
729, d5b0xA_, 0.8629, 2.40, 0.300, 329, 277, CRYSTAL STRUCTURE OF THE CK2A/BENZOIC ACID DERIVATIVE COMPLEX
730, d4ek6A_, 0.8628, 2.07, 0.978, 278, 272, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
731, d1j91B_, 0.8628, 2.36, 0.300, 327, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
732, d4ek8A_, 0.8627, 2.21, 0.985, 280, 274, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
733, d3ofmA_, 0.8626, 2.42, 0.300, 325, 277, STRUCTURE OF A HUMAN CK2ALPHA PRIME THE PARALOG ISOFORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM HOMO SAPIENS
734, d1j91A_, 0.8626, 2.41, 0.300, 327, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
735, p4md9K_, 0.8625, 2.39, 0.296, 328, 277, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
736, d3rzbA_, 0.8625, 2.33, 0.978, 282, 276, CDK2 IN COMPLEX WITH INHIBITOR RC-2-23
737, d5n1vB_, 0.8624, 2.43, 0.300, 331, 277, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
738, d4qp2A_, 0.8624, 2.13, 0.359, 336, 273, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
739, d3fwqA_, 0.8624, 2.47, 0.294, 334, 279, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
740, d2vthA_, 0.8624, 2.08, 0.974, 278, 273, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN
741, d5n1vA_, 0.8623, 2.42, 0.300, 331, 277, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
742, d5csvA_, 0.8623, 2.25, 0.305, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 6 BOUND
743, d2oxyB_, 0.8622, 2.39, 0.300, 327, 277, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
744, d1vyzA_, 0.8621, 2.18, 0.989, 279, 273, STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
745, p5nzzH_, 0.8620, 2.10, 0.379, 335, 272, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
746, d5cspA_, 0.8620, 2.25, 0.305, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
747, d4qp6A_, 0.8620, 2.13, 0.359, 339, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
748, p4md9G_, 0.8620, 2.29, 0.297, 329, 276, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
749, d3wikA_, 0.8620, 2.38, 0.296, 334, 277, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND10 COMPLEX
750, d3ezvA_, 0.8620, 2.06, 0.978, 277, 272, CDK-2 WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
751, p4md8G_, 0.8619, 2.43, 0.296, 332, 277, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
752, d1howA_, 0.8619, 2.18, 0.313, 346, 275, THE X-RAY CRYSTAL STRUCTURE OF SKY1P AN SR PROTEIN KINASE IN YEAST
753, d4o6eA_, 0.8618, 2.02, 0.378, 328, 270, DISCOVERY OF 5678-TETRAHYDROPYRIDO[34-D]PYRIMIDINE INHIBITORS OF ERK2
754, d4qp2B_, 0.8617, 2.12, 0.371, 329, 272, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
755, d2j9mA_, 0.8617, 1.82, 0.967, 275, 270, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE
756, d1pjkA_, 0.8617, 2.30, 0.301, 331, 276, CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
757, d1dm2A_, 0.8617, 1.78, 0.967, 274, 269, HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE
758, d5cu4A_, 0.8616, 2.31, 0.301, 327, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
759, p4md9E_, 0.8616, 2.29, 0.297, 329, 276, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
760, p4md8E_, 0.8616, 2.43, 0.296, 332, 277, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
761, d5k5nA_, 0.8615, 2.07, 0.331, 331, 272, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
762, p4h3pD_, 0.8615, 2.17, 0.370, 338, 273, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
763, d1q4lB_, 0.8615, 2.09, 0.324, 337, 272, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
764, d5xvuA_, 0.8614, 2.22, 0.302, 321, 275, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
765, d1ds5B_, 0.8614, 2.41, 0.300, 328, 277, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
766, d3q9wA_, 0.8613, 2.26, 0.305, 328, 275, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 8.5
767, d4xj0B_, 0.8612, 2.21, 0.372, 338, 274, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
768, d4dglC_, 0.8612, 2.40, 0.292, 334, 277, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
769, d3c13A_, 0.8612, 2.27, 0.305, 328, 275, LOW PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
770, p5oulA_, 0.8611, 2.36, 0.301, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 9
771, d5jq8A_, 0.8611, 2.15, 0.967, 278, 272, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0943
772, d5ct0A_, 0.8611, 2.22, 0.298, 326, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
773, d4rllA_, 0.8611, 2.32, 0.301, 329, 276, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
774, p4md9F_, 0.8611, 2.29, 0.297, 327, 276, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
775, d3q9yA_, 0.8611, 2.31, 0.301, 327, 276, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 8.5
776, d3ddqC1, 0.8611, 1.22, 0.977, 265, 259, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
777, d5motA_, 0.8610, 2.27, 0.305, 328, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0627 BOUND
778, d5mmrA_, 0.8610, 2.23, 0.298, 326, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
779, d4grbA_, 0.8610, 2.25, 0.298, 327, 275, CASEIN KINASE 2 (CK2) BOUND TO INHIBITOR
780, d3axwA_, 0.8610, 2.45, 0.300, 329, 277, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA COMPLEXED WITH A POTENT INHIBITOR
781, d1ke9A_, 0.8610, 2.22, 0.967, 281, 275, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4- ({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2- OXO-23-DIHYDRO-1H-INDOLE
782, d5clpB_, 0.8609, 2.31, 0.301, 327, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
783, p4ib5C_, 0.8609, 2.45, 0.300, 332, 277, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
784, d3unjA_, 0.8609, 2.69, 0.951, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR YL1-038-31
785, d1na7A_, 0.8609, 2.29, 0.301, 326, 276, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2
786, p4md9L_, 0.8608, 2.46, 0.296, 328, 277, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
787, d4fkpA_, 0.8608, 2.20, 0.971, 279, 274, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
788, d5xvuB_, 0.8607, 2.24, 0.302, 321, 275, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
789, d4izaC_, 0.8607, 2.01, 0.365, 335, 271, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
790, d4bzdA_, 0.8607, 2.01, 0.963, 277, 272, STRUCTURE OF CDK2 IN COMPLEX WITH A BENZIMIDAZOPYRIMIDINE
791, d3owjA_, 0.8607, 2.47, 0.300, 328, 277, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A PYRIDOCARBAZOLE DERIVATIVE INHIBITOR
792, d3le6A_, 0.8607, 2.22, 0.949, 283, 272, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A PYRAZOLOBENZODIAZEPINE INHIBITOR
793, d3bqcA_, 0.8607, 2.27, 0.305, 328, 275, HIGH PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
794, d2fysB_, 0.8607, 2.35, 0.373, 338, 276, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
795, d1ke5A_, 0.8607, 2.21, 0.967, 281, 275, CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-12-DIHYDRO-3H- INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
796, d1g5sA_, 0.8607, 1.82, 0.981, 275, 269, CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717
797, d3qtrA_, 0.8606, 2.34, 0.957, 282, 276, CDK2 IN COMPLEX WITH INHIBITOR RC-1-148
798, d1oiuC1, 0.8606, 1.15, 0.981, 264, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
799, p4md8H_, 0.8605, 2.45, 0.296, 331, 277, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
800, d4md7H_, 0.8605, 2.38, 0.304, 330, 276, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
801, p4looA_, 0.8605, 2.19, 0.376, 349, 274, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (MONOCLINIC CRYSTAL FORM)
802, d3owlA_, 0.8605, 2.32, 0.301, 330, 276, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
803, d4md7G_, 0.8604, 2.39, 0.304, 332, 276, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
804, d5cx9A_, 0.8603, 2.34, 0.301, 328, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
805, p2h96A_, 0.8603, 2.46, 0.356, 358, 278, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
806, d1lr4A_, 0.8603, 2.42, 0.300, 327, 277, ROOM TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
807, p3vuiA_, 0.8602, 2.18, 0.358, 355, 274, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
808, d2eufB_, 0.8602, 1.83, 0.500, 282, 268, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
809, d5mp8A_, 0.8601, 2.18, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
810, p4md8F_, 0.8601, 2.45, 0.296, 332, 277, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
811, d4md7E_, 0.8601, 2.44, 0.300, 332, 277, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
812, p3vuhA_, 0.8601, 2.31, 0.356, 355, 275, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M3 IN MAP KINASE JNK1
813, p3vugA_, 0.8601, 2.31, 0.356, 356, 275, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
814, d3amyA_, 0.8601, 2.13, 0.297, 318, 273, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH APIGENIN
815, d5xvuC_, 0.8600, 2.27, 0.302, 321, 275, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
816, d5modA_, 0.8600, 2.26, 0.298, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
817, d5cu2A_, 0.8600, 2.33, 0.301, 328, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
818, d1ds5C_, 0.8600, 2.43, 0.300, 328, 277, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
819, d5t1hA_, 0.8599, 2.46, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2
820, d5cu0A_, 0.8599, 2.26, 0.298, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
821, d5ctpB_, 0.8599, 2.35, 0.301, 327, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
822, p3vudA_, 0.8599, 2.17, 0.354, 355, 274, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
823, d5cvhA_, 0.8598, 2.30, 0.298, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA
824, p2no3B_, 0.8598, 2.45, 0.356, 357, 278, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
825, p5otzA_, 0.8597, 2.34, 0.301, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 1
826, p4nh1B_, 0.8597, 2.45, 0.300, 332, 277, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
827, d2qc6A_, 0.8597, 2.43, 0.300, 326, 277, PROTEIN KINASE CK2 IN COMPLEX WITH DBC
828, d1lp4A_, 0.8597, 2.42, 0.300, 327, 277, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 WITH MG-AMPPNP
829, p4nh1A_, 0.8596, 2.45, 0.300, 330, 277, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
830, d4anmA1, 0.8596, 2.43, 0.300, 327, 277, COMPLEX OF CK2 WITH A CDC7 INHIBITOR
831, d5mmfA_, 0.8595, 2.25, 0.298, 326, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
832, d5m56B_, 0.8595, 2.47, 0.303, 328, 277, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
833, d4qp6B_, 0.8595, 2.16, 0.382, 334, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
834, d3w55A_, 0.8595, 2.12, 0.368, 335, 272, THE STRUCTURE OF ERK2 IN COMPLEX WITH FR148083
835, d3u87A_, 0.8595, 2.47, 0.300, 329, 277, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
836, d2e14A_, 0.8595, 2.12, 0.368, 335, 272,  
837, d1dawA_, 0.8595, 2.42, 0.300, 327, 277, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP
838, d5h8bA_, 0.8594, 2.47, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
839, d4bxbA_, 0.8594, 2.34, 0.301, 328, 276,  
840, d3wowA_, 0.8594, 2.30, 0.297, 334, 276, CRYSTAL STRUCTURE OF HUMAN CK2A WITH AMPPNP
841, d3rpsA_, 0.8594, 2.24, 0.298, 334, 275, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
842, d3rp0C_, 0.8594, 2.46, 0.300, 329, 277,  
843, d2vtqA_, 0.8594, 1.92, 0.989, 274, 269, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
844, d2r3kA_, 0.8594, 2.09, 0.971, 277, 272, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
845, d5cquA_, 0.8593, 2.34, 0.301, 328, 276, MONOCLINIC COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
846, d2pvrA_, 0.8593, 2.35, 0.301, 328, 276, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (C- TERMINAL DELETION MUTANT 1-335) IN COMPLEX WITH TWO SULFATE IONS
847, p5os8A_, 0.8592, 2.34, 0.301, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 11
848, p4md9M_, 0.8592, 2.45, 0.300, 331, 277, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
849, d3pe2A_, 0.8592, 2.35, 0.301, 327, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR CX-5011
850, d5mo8A_, 0.8591, 2.28, 0.298, 325, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
851, d5lmkC1, 0.8591, 1.19, 0.977, 264, 258, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
852, d3pzhA_, 0.8591, 2.43, 0.300, 327, 277, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH EMODIN AT 1.92 A RESOLUTION
853, d1dayA_, 0.8591, 2.41, 0.300, 327, 277, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP
854, p5n9kA_, 0.8590, 2.35, 0.301, 329, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF107 (5)
855, d5moeA_, 0.8589, 2.22, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
856, d3wilA_, 0.8589, 2.34, 0.301, 331, 276, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND3 COMPLEX
857, d3pvgA_, 0.8589, 2.44, 0.300, 326, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMO-1-CARBOXYMETHYLBENZIMIDAZOLE (K68)
858, d1ds5A_, 0.8589, 2.44, 0.300, 328, 277, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
859, d5mohA_, 0.8588, 2.22, 0.303, 326, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0583 BOUND.
860, d4dgoA_, 0.8588, 2.44, 0.300, 325, 277, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH TYRPHOSTIN AG99
861, d4cjyD_, 0.8588, 1.58, 0.426, 272, 265,  
862, p3vukA_, 0.8588, 2.32, 0.356, 355, 275, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M5 IN MAP KINASE JNK1
863, d1lpuA_, 0.8588, 2.44, 0.300, 327, 277, LOW TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
864, d5mpjA_, 0.8587, 2.30, 0.298, 326, 275, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
865, d4qp3B_, 0.8587, 2.17, 0.382, 331, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
866, d4md7F_, 0.8587, 2.45, 0.300, 332, 277, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
867, d3mb6A_, 0.8587, 2.34, 0.305, 329, 275, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (CPA)
868, d3kxjA_, 0.8587, 2.44, 0.300, 326, 277,  
869, d5mo7A_, 0.8586, 2.29, 0.298, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
870, p5owlB_, 0.8585, 2.48, 0.300, 332, 277, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
871, d3owkA_, 0.8585, 2.49, 0.300, 330, 277, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
872, d5mo5A_, 0.8584, 2.24, 0.299, 326, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
873, d3pwdA_, 0.8584, 2.46, 0.300, 327, 277, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH NBC (Z1)
874, d3pe1A_, 0.8584, 2.36, 0.301, 327, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-4945
875, d2btsA_, 0.8584, 1.85, 0.970, 274, 269, STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032
876, d1zoeA_, 0.8584, 2.45, 0.300, 325, 277, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
877, d1m2pA_, 0.8584, 2.45, 0.300, 325, 277, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO- ANTHRAQUINONE/CK2 KINASE COMPLEX
878, p5n9nA_, 0.8582, 2.37, 0.301, 329, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF85 (4A)
879, d5h8eA_, 0.8582, 2.48, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
880, p4ux9B_, 0.8581, 2.21, 0.360, 327, 272, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
881, p3v3vA_, 0.8581, 2.30, 0.358, 351, 274, STRUCTURAL AND FUNCTIONAL ANALYSIS OF QUERCETAGETIN A NATURAL JNK1 INHIBITOR
882, d1om1A_, 0.8581, 2.45, 0.300, 325, 277, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH IQA
883, d1ds5D_, 0.8581, 2.46, 0.300, 328, 277, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
884, d5mo7B_, 0.8580, 2.25, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
885, d4ubaB_, 0.8580, 2.35, 0.297, 333, 276, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
886, p3o17A_, 0.8580, 2.48, 0.360, 357, 278, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
887, d3kxnA_, 0.8580, 2.44, 0.300, 327, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR TETRAIODOBENZIMIDAZOLE (K88)
888, d1giiA_, 0.8580, 2.20, 0.971, 279, 274, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
889, d5movA_, 0.8579, 2.26, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0633 BOUND
890, d4fbxA_, 0.8579, 2.26, 0.302, 333, 275, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT CRYSTALLIZED IN THE PRESENCE OF A BISUBSTRATE INHIBITOR
891, d3rp0B_, 0.8579, 2.47, 0.296, 329, 277,  
892, d3at2A_, 0.8579, 2.35, 0.297, 334, 276, CRYSTAL STRUCTURE OF CK2ALPHA
893, d5mowA1, 0.8578, 2.26, 0.299, 326, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
894, d5anoA_, 0.8578, 2.14, 0.978, 277, 272, CRYSTAL STRUCTURE OF CDK2 PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
895, d2iw8C2, 0.8578, 1.22, 0.969, 264, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
896, d4acmA_, 0.8577, 2.00, 0.970, 277, 271, CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL] SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
897, d2vtnA_, 0.8577, 1.88, 0.985, 274, 269, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
898, d5larA_, 0.8575, 2.35, 0.372, 350, 277, CRYSTAL STRUCTURE OF P38 ALPHA MAPK14 IN COMPLEX WITH VPC00628
899, d4dgnA_, 0.8575, 2.46, 0.300, 325, 277, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR LUTEOLIN
900, d3r0tA_, 0.8575, 2.37, 0.301, 327, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-5279
901, d3q9xB_, 0.8575, 2.42, 0.304, 330, 276, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
902, d2vu3A_, 0.8575, 1.91, 0.993, 285, 269, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
903, d2oxxA_, 0.8575, 2.47, 0.300, 325, 277, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
904, d1jamA_, 0.8575, 2.47, 0.300, 327, 277, CRYSTAL STRUCTURE OF APO-FORM OF Z. MAYS CK2 PROTEIN KINASE ALPHA SUBUNIT
905, d3r8mA_, 0.8574, 2.40, 0.968, 286, 278, CDK2 IN COMPLEX WITH INHIBITOR L3-3
906, d5cu3A_, 0.8573, 2.27, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
907, d3rp0A_, 0.8573, 2.50, 0.296, 329, 277,  
908, d3qtsA_, 0.8573, 2.36, 0.964, 282, 276, CDK2 IN COMPLEX WITH INHIBITOR RC-2-12
909, d3ngaA_, 0.8573, 2.49, 0.300, 331, 277, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
910, d2b55A_, 0.8573, 2.01, 0.996, 276, 270, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH INDENOPYRAXOLE DIN-101312
911, d5cu0B_, 0.8572, 2.30, 0.298, 325, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
912, d4yc6E_, 0.8572, 2.48, 0.656, 285, 273, CDK1/CKS1
913, d3u87B_, 0.8572, 2.50, 0.300, 329, 277, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
914, d3sw4A_, 0.8572, 2.27, 0.967, 279, 274, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
915, p3e3bX_, 0.8572, 2.35, 0.301, 334, 276, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2ALPHA PRIME WITH A POTENT INDAZOLE-DERIVATIVE INHIBITOR
916, d2r3jA_, 0.8572, 2.13, 0.971, 278, 272, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
917, d5cu6A_, 0.8571, 2.42, 0.301, 327, 276, CRYSTAL STRUCTURE OF CK2ALPHA
918, d4qpaA_, 0.8571, 2.22, 0.379, 331, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
919, d1m2rA_, 0.8571, 2.51, 0.300, 327, 277, CRYSTAL STRUCTURE OF 58-DI-AMINO-14-DI-HYDROXY- ANTHRAQUINONE/CK2 KINASE COMPLEX
920, p5n9lA_, 0.8570, 2.38, 0.301, 329, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE DIBENZOFURAN INHIBITOR TF (4B)
921, d3kxgA_, 0.8570, 2.47, 0.300, 326, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 34567-PENTABROMO-1H-INDAZOLE (K64)
922, d2vtjA_, 0.8570, 2.02, 0.978, 276, 271, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
923, p2pvnA_, 0.8570, 2.46, 0.296, 327, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
924, d2oxdA_, 0.8570, 2.45, 0.300, 325, 277, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE K17 K22 AND K32 INHIBITORS
925, d1zohA_, 0.8570, 2.47, 0.300, 326, 277, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
926, p5otyA_, 0.8569, 2.41, 0.301, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712
927, d5mmrB_, 0.8569, 2.24, 0.296, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
928, p4jqeA_, 0.8569, 2.53, 0.278, 369, 277, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH AMPPN
929, d4dgmA_, 0.8569, 2.47, 0.300, 326, 277, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR APIGENIN
930, d5cvfA_, 0.8568, 2.29, 0.303, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
931, d5cqwA_, 0.8568, 2.50, 0.300, 331, 277, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
932, d4qp8A_, 0.8568, 2.20, 0.375, 335, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
933, d4bxaA_, 0.8568, 2.50, 0.300, 331, 277,  
934, d3qa0B_, 0.8567, 2.45, 0.304, 330, 276, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
935, d3fl5A_, 0.8567, 2.47, 0.300, 324, 277, PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR QUINALIZARIN
936, d5h8gA_, 0.8565, 2.19, 0.300, 324, 273, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7B
937, d4ub7A_, 0.8565, 2.32, 0.293, 334, 276, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26) SHOWING AN EXTREME DISTORTION OF THE ATP-BINDING LOOP COMBINED WITH A PI-HALOGEN BOND
938, d4fuyA_, 0.8565, 2.31, 0.377, 329, 273, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK2
939, d3ngaB_, 0.8565, 2.51, 0.300, 331, 277, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
940, d3q04A_, 0.8564, 2.38, 0.301, 328, 276, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 8.5
941, p4ux9A_, 0.8563, 2.19, 0.360, 343, 272, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
942, p2h96B_, 0.8563, 2.46, 0.354, 357, 277, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
943, d5mo6A_, 0.8562, 2.27, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
944, d5m4iA_, 0.8562, 2.32, 0.293, 331, 276, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
945, p4md9H_, 0.8562, 2.37, 0.297, 328, 276, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
946, p3u9cA_, 0.8561, 2.46, 0.304, 331, 276, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
947, d2wmaC1, 0.8561, 1.25, 0.969, 264, 258, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
948, d3rahA_, 0.8560, 2.38, 0.964, 282, 276, CDK2 IN COMPLEX WITH INHIBITOR RC-2-22
949, p5omyA_, 0.8559, 2.28, 0.302, 332, 275, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
950, d5m56A_, 0.8559, 2.52, 0.303, 331, 277, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
951, d5m4uA_, 0.8559, 2.42, 0.301, 332, 276, ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
952, d3od6X_, 0.8559, 2.34, 0.373, 344, 276, CRYSTAL STRUCTURE OF P38ALPHA Y323T ACTIVE MUTANT
953, d1gihA_, 0.8559, 2.05, 0.989, 276, 271, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
954, d3qa0A_, 0.8558, 2.53, 0.300, 330, 277, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
955, d3kxmA_, 0.8558, 2.49, 0.300, 326, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR K74
956, d2f9gA_, 0.8558, 2.07, 0.385, 332, 270, CRYSTAL STRUCTURE OF FUS3 PHOSPHORYLATED ON TYR182
957, d5mo6B_, 0.8557, 2.27, 0.296, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
958, d5modB_, 0.8555, 2.28, 0.296, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
959, d5buiA_, 0.8555, 2.32, 0.370, 338, 273, ERK2 COMPLEXED WITH 2-PYRIDIYL TETRAHYDROAZAINDAZOLE
960, d3rprA_, 0.8555, 2.38, 0.964, 282, 276, CDK2 IN COMPLEX WITH INHIBITOR RC-2-49
961, p2pvmA_, 0.8555, 2.50, 0.296, 327, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
962, d1jowB_, 0.8555, 1.76, 0.494, 277, 267, CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
963, d5mmfB_, 0.8554, 2.28, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
964, d5kwhA_, 0.8554, 2.54, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2
965, d5mo8B_, 0.8553, 2.30, 0.299, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
966, d5mo5B_, 0.8553, 2.28, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
967, d5cu3B_, 0.8553, 2.30, 0.299, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
968, d3rpyA_, 0.8553, 2.05, 0.974, 277, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-2-40
969, d3oz6A_, 0.8553, 2.60, 0.368, 343, 277, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
970, p3be9A_, 0.8553, 2.50, 0.296, 327, 277, STRUCTURE-BASED DESIGN AND SYNTHESIS OF NOVEL MACROCYCLIC PYRAZOLO[15-A] [135]TRIAZINE COMPOUNDS AS POTENT INHIBITORS OF PROTEIN KINASE CK2 AND THEIR ANTICANCER ACTIVITIES
971, d1zogA_, 0.8553, 2.48, 0.300, 325, 277, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES
972, d4fktA_, 0.8552, 2.23, 0.971, 278, 272, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
973, d3u4uA_, 0.8552, 2.33, 0.298, 327, 275, CASEIN KINASE 2 IN COMPLEX WITH AZ-INHIBITOR
974, p2pvhA_, 0.8552, 2.50, 0.296, 327, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
975, p5owlA_, 0.8551, 2.53, 0.300, 331, 277, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
976, d3rp0D_, 0.8550, 2.54, 0.296, 329, 277,  
977, d3rmfA_, 0.8550, 2.09, 0.974, 278, 272, CDK2 IN COMPLEX WITH INHIBITOR RC-2-33
978, d1h06A_, 0.8550, 2.03, 0.982, 277, 271,  
979, d5cshA_, 0.8548, 2.30, 0.299, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
980, p3u9cB_, 0.8548, 2.46, 0.304, 331, 276, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
981, d2r3nA_, 0.8548, 2.03, 0.963, 275, 270, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
982, d5ct0B_, 0.8547, 2.28, 0.296, 326, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
983, d3mb7A_, 0.8547, 2.44, 0.301, 330, 276, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (AMR)
984, d5k5nB_, 0.8546, 2.02, 0.335, 334, 269, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
985, p4ux9C_, 0.8546, 2.19, 0.362, 333, 271, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
986, p4ib5B_, 0.8546, 2.55, 0.296, 329, 277, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
987, d4fksA_, 0.8546, 2.07, 0.974, 275, 270, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
988, d5cx9B_, 0.8545, 2.29, 0.296, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
989, d5cqwB_, 0.8545, 2.53, 0.300, 331, 277, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
990, d4yc6A_, 0.8545, 2.50, 0.656, 285, 273, CDK1/CKS1
991, d4nj3A_, 0.8545, 2.02, 0.993, 277, 270, MODULATING THE INTERACTION BETWEEN CDK2 AND CYCLIN A WITH A QUINOLINE- BASED INHIBITOR
992, d4bxaB_, 0.8545, 2.53, 0.300, 331, 277,  
993, d2vttA_, 0.8545, 1.82, 0.989, 272, 267, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
994, d5ctpA_, 0.8544, 2.29, 0.296, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
995, d4yc6C_, 0.8544, 2.50, 0.656, 285, 273, CDK1/CKS1
996, d4rlkA_, 0.8544, 2.51, 0.300, 327, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
997, d3i60A_, 0.8544, 1.91, 0.376, 335, 266, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-4-(2-(2-CHLOROPHENYLAMINO)-5- METHYLPYRIMIDIN-4-YL)-N-(2-HYDROXY-1-PHENYLETHYL)-1H-PYRROLE-2- CARBOXAMIDE
998, d2btrA_, 0.8544, 1.99, 0.996, 275, 269, STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873
999, d5h8bB_, 0.8543, 2.55, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
1000, d5cvgA_, 0.8543, 2.22, 0.305, 326, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH A NOVEL CLOSED CONFORMATION OF THE AD LOOP
1001, d4qp4B_, 0.8543, 2.20, 0.375, 335, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
1002, d3q9xA_, 0.8543, 2.54, 0.300, 330, 277, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
1003, p2pvjA_, 0.8543, 2.52, 0.296, 326, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1004, d5h8eB_, 0.8542, 2.55, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
1005, d4ubaA_, 0.8542, 2.39, 0.297, 333, 276, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
1006, p4gubA_, 0.8542, 2.43, 0.301, 329, 276, CASEIN KINASE II BOUND TO INHIBITOR
1007, d3o2mB_, 0.8542, 2.37, 0.360, 358, 275, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
1008, d5ku8A_, 0.8541, 2.50, 0.301, 328, 276, CRYSTAL STRUCTURE OF CK2
1009, d4qp7B_, 0.8541, 2.13, 0.376, 335, 271, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
1010, d4kwpA_, 0.8541, 2.41, 0.301, 329, 276, CRYSTAL STRUCTURE OF HUMAN CK2-ALPHA IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR (K164) AT 1.25 A RESOLUTION
1011, d3rpsB_, 0.8541, 2.42, 0.297, 334, 276, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
1012, p2pvkA_, 0.8540, 2.52, 0.296, 327, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1013, d5t1hB_, 0.8539, 2.55, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2
1014, d5mpjB_, 0.8539, 2.33, 0.299, 324, 274, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
1015, d5cu2B_, 0.8538, 2.30, 0.296, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
1016, d4yc6G_, 0.8538, 2.48, 0.621, 285, 272, CDK1/CKS1
1017, d2duvA_, 0.8538, 1.78, 0.989, 272, 267, STRUCTURE OF CDK2 WITH A 3-HYDROXYCHROMONES
1018, d1r78A_, 0.8538, 1.89, 0.989, 273, 268, CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR
1019, d5cvhB_, 0.8537, 2.34, 0.299, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA
1020, d4fkoA_, 0.8537, 2.38, 0.949, 291, 275, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1021, d3warA_, 0.8537, 2.51, 0.296, 334, 277, CRYSTAL STRUCTURE OF HUMAN CK2A
1022, d1urwA_, 0.8537, 2.04, 0.981, 274, 270, CDK2 IN COMPLEX WITH AN IMIDAZO[12-B]PYRIDAZINE
1023, d3o2mA_, 0.8536, 2.48, 0.357, 358, 277, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
1024, d3q9zB_, 0.8535, 2.48, 0.304, 332, 276, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1025, d1p2aA_, 0.8535, 1.89, 0.967, 271, 269, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A TRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR
1026, d5mowB_, 0.8534, 2.32, 0.299, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1027, d3s1hA_, 0.8534, 2.06, 0.974, 277, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-2-39
1028, d3at3A_, 0.8534, 2.45, 0.301, 332, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVATIVE
1029, d3ezrA_, 0.8533, 1.88, 0.985, 273, 268, CDK-2 WITH INDAZOLE INHIBITOR 17 BOUND AT ITS ACTIVE SITE
1030, d1m2qA_, 0.8533, 2.57, 0.300, 327, 277, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO-XANTEN-9- ONE/CK2 KINASE COMPLEX
1031, d2r3lA_, 0.8532, 2.00, 0.970, 275, 270, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1032, p2g01A_, 0.8532, 2.48, 0.354, 355, 277, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
1033, d3e3pA_, 0.8531, 2.38, 0.337, 337, 276, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
1034, p2pvlA_, 0.8531, 2.53, 0.296, 327, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1035, d3r9nA_, 0.8530, 2.30, 0.967, 282, 275, CDK2 IN COMPLEX WITH INHIBITOR RC-2-21
1036, d2bheA_, 0.8529, 1.92, 0.967, 274, 269, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE
1037, d5k4iA_, 0.8528, 2.11, 0.375, 336, 269, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH COMPOUND 22
1038, d4ewqA_, 0.8528, 2.35, 0.366, 346, 273, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A PYRIDAZINE BASED INHIBITOR
1039, d5kwhB_, 0.8527, 2.57, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2
1040, d5moeB_, 0.8525, 2.27, 0.293, 323, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1041, d5ankA_, 0.8525, 1.96, 0.974, 273, 268, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 246-TRIOXO-1- PHENYL-HEXAHYDROPYRIMIDINE-5-CARBOXAMIDE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1042, p4mwhA_, 0.8525, 2.57, 0.278, 371, 277, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1043, p4fi1A_, 0.8525, 2.57, 0.278, 371, 277, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1044, d1f0qA_, 0.8524, 2.57, 0.296, 329, 277, CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN
1045, d3sw7A_, 0.8523, 2.12, 0.960, 278, 272, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1046, d3rakA_, 0.8523, 2.09, 0.974, 277, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-2-32
1047, p3nieA_, 0.8523, 2.62, 0.394, 369, 277, CRYSTAL STRUCTURE OF PF11_0147
1048, d1v0pA_, 0.8523, 2.46, 0.614, 277, 272, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
1049, d3w8lB_, 0.8522, 2.47, 0.301, 326, 276, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
1050, p4lfiA_, 0.8520, 2.58, 0.278, 370, 277, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1051, d3e3pB_, 0.8519, 2.50, 0.329, 337, 277, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
1052, d3at4A_, 0.8519, 2.47, 0.301, 331, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVERTIVE
1053, d5ku8B_, 0.8518, 2.58, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2
1054, p4lfiB_, 0.8517, 2.58, 0.278, 371, 277, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1055, d3ralA_, 0.8517, 2.13, 0.974, 277, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-2-34
1056, d5cs6A_, 0.8514, 2.52, 0.298, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
1057, p3o17B_, 0.8511, 2.60, 0.360, 357, 278, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
1058, d1v1kA_, 0.8510, 2.09, 0.978, 277, 271, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1059, d1oitA_, 0.8510, 1.93, 0.974, 273, 267, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
1060, d2pk9C_, 0.8509, 1.54, 0.579, 266, 261, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
1061, d1v0bA_, 0.8509, 2.60, 0.609, 286, 274, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
1062, d4bghA_, 0.8507, 2.06, 0.989, 275, 270, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PAN-CDK INHIBITOR
1063, d5ci6B_, 0.8506, 2.11, 0.361, 350, 269, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
1064, d4ptgB_, 0.8506, 2.05, 0.332, 332, 268, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
1065, p2gmxB_, 0.8506, 2.55, 0.356, 357, 278, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
1066, d4n4sB_, 0.8505, 2.12, 0.368, 337, 272, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
1067, d5f95B_, 0.8503, 2.11, 0.331, 338, 269, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
1068, p4ib5A_, 0.8503, 2.53, 0.304, 331, 276, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1069, d1jwhB_, 0.8503, 2.48, 0.301, 335, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
1070, d4fv6A_, 0.8502, 2.01, 0.376, 332, 266, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E57
1071, d5mp8B_, 0.8501, 2.25, 0.298, 323, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1072, p6ehuA_, 0.8500, 2.48, 0.301, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1073, d4aa4A_, 0.8498, 2.36, 0.377, 347, 273, P38ALPHA MAP KINASE BOUND TO CMPD 22
1074, d3o0gB_, 0.8492, 1.58, 0.590, 264, 261, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
1075, d4xoyA_, 0.8491, 2.36, 0.370, 326, 270, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1076, d4fv8A_, 0.8491, 1.94, 0.381, 333, 265, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E63
1077, d3q9zA_, 0.8491, 2.60, 0.300, 332, 277, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1078, d5cshB_, 0.8490, 2.26, 0.303, 323, 271, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
1079, d2r7iA_, 0.8490, 2.50, 0.297, 322, 276, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1080, d2qkrA1, 0.8489, 1.96, 0.570, 269, 265, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH INDIRUBIN 3 -MONOXIME BOUND
1081, d1pyeA_, 0.8487, 1.82, 0.992, 266, 264, CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR
1082, d4aguC_, 0.8485, 1.98, 0.395, 278, 266, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1083, d2r7iC_, 0.8485, 2.46, 0.298, 321, 275, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1084, d2fvdA_, 0.8484, 1.86, 0.981, 284, 267, CYCLIN DEPENDENT KINASE 2 (CDK2) WITH DIAMINOPYRIMIDINE INHIBITOR
1085, d5andA_, 0.8479, 2.03, 0.963, 273, 268, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 2-IMIDAZOL-1-YL-1H- BENZIMIDAZOLE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1086, d5ci6A_, 0.8478, 2.16, 0.357, 335, 269, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
1087, d3l1sA_, 0.8476, 2.01, 0.335, 336, 266, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
1088, d1ob3A_, 0.8476, 2.49, 0.614, 277, 272, STRUCTURE OF P. FALCIPARUM PFPK5
1089, d5fp6A_, 0.8475, 2.19, 0.978, 278, 271, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 3-(47-DICHLORO-1H-INDOL-3-YL)PROP-2-YN-1-OL (AT17833) IN AN ALTERNATE BINDING SITE.
1090, d3l1sB_, 0.8475, 2.00, 0.331, 330, 266, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
1091, p3nieB_, 0.8474, 2.63, 0.395, 367, 276, CRYSTAL STRUCTURE OF PF11_0147
1092, p5ax3A_, 0.8470, 1.99, 0.376, 329, 266, CRYSTAL STRUCTURE OF ERK2 COMPLEXED WITH ALLOSTERIC AND ATP- COMPETITIVE INHIBITORS.
1093, p2g01B_, 0.8469, 2.51, 0.359, 356, 276, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
1094, d3nwwA_, 0.8468, 2.17, 0.375, 339, 269, P38 ALPHA KINASE COMPLEXED WITH A 2-AMINOTHIAZOL-5-YL-PYRIMIDINE BASED INHIBITOR
1095, d5clpA_, 0.8467, 2.32, 0.303, 322, 271, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
1096, d4d1xA_, 0.8467, 2.15, 0.970, 274, 269, CDK2 IN COMPLEX WITH LUCIFERIN
1097, d4aacA_, 0.8467, 2.30, 0.380, 350, 271, P38ALPHA MAP KINASE BOUND TO CMPD 29
1098, d3bx5A_, 0.8467, 2.18, 0.375, 338, 269, P38 ALPHA MAP KINASE COMPLEXED WITH BMS-640994
1099, p3n9xB_, 0.8465, 2.64, 0.404, 362, 277, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
1100, d4fv4A_, 0.8464, 2.02, 0.377, 329, 265, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK7
1101, d2r7iB_, 0.8463, 2.45, 0.299, 322, 274, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1102, d4i5hA_, 0.8459, 2.22, 0.378, 335, 267, CRYSTAL STRUCTURE OF A DOUBLE MUTANT RAT ERK2 COMPLEXED WITH A TYPE II QUINAZOLINE INHIBITOR
1103, p4f9bA_, 0.8459, 2.41, 0.259, 318, 274, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
1104, p5lw1B_, 0.8455, 2.46, 0.344, 355, 273, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1105, p4jr7A_, 0.8454, 2.60, 0.280, 367, 275, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1106, d2r7iD_, 0.8454, 2.46, 0.299, 322, 274, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1107, d3mvlA_, 0.8453, 2.11, 0.377, 339, 268, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
1108, d2i6lA_, 0.8453, 2.37, 0.328, 292, 271, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
1109, p6ehuB_, 0.8452, 2.56, 0.301, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1110, d3dt1A2, 0.8452, 2.65, 0.376, 352, 274, P38 COMPLEXED WITH A QUINAZOLINE INHIBITOR
1111, p5lw1H_, 0.8451, 2.46, 0.344, 355, 273, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1112, d4dglD_, 0.8450, 2.66, 0.300, 328, 277, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
1113, d3hl7A_, 0.8448, 2.08, 0.367, 336, 267, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH SD-0006
1114, d2ozaB_, 0.8445, 2.34, 0.376, 340, 271, STRUCTURE OF P38ALPHA COMPLEX
1115, d1gijA_, 0.8440, 2.04, 0.970, 273, 268, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1116, p5lw1E_, 0.8437, 2.47, 0.344, 355, 273, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1117, d3v6rA_, 0.8437, 2.39, 0.352, 349, 273, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1118, d5m44A_, 0.8431, 2.53, 0.296, 329, 274, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
1119, d5d1jA_, 0.8430, 1.70, 0.992, 265, 262, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(11-DIMETHYLETHYL)-2-OXAZOLYL] METHYL]THIO]-2-THIAZOLYL]- 4-PIPERIDINECARBOXAMIDE (BMS-387032)
1120, p6gihA_, 0.8429, 2.46, 0.304, 324, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH CAM187 BOUND 
1121, p5xyyA_, 0.8427, 2.55, 0.379, 350, 272, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
1122, d4aa5A_, 0.8425, 2.35, 0.389, 340, 270, P38ALPHA MAP KINASE BOUND TO CMPD 33
1123, d3i5zA_, 0.8425, 1.93, 0.380, 331, 263, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-N-(2-HYDROXY-1-PHENYLETHYL)-4- (5-METHYL-2-(PHENYLAMINO)PYRIMIDIN-4-YL)-1H-PYRROLE-2-CARBOXAMIDE
1124, d4aguA_, 0.8423, 2.14, 0.395, 277, 266, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1125, d3gc9B_, 0.8422, 2.37, 0.363, 339, 270, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
1126, d3ds6D_, 0.8422, 2.54, 0.369, 349, 274, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1127, d1oiqA_, 0.8421, 1.82, 0.973, 264, 263, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
1128, d3v6sA_, 0.8419, 2.42, 0.355, 349, 273, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1129, d5bveA_, 0.8416, 1.99, 0.376, 330, 263, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
1130, d4iq6A_, 0.8415, 2.05, 0.332, 324, 265, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
1131, p3n9xA_, 0.8414, 2.57, 0.411, 374, 275, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
1132, d3hllA_, 0.8414, 2.18, 0.367, 337, 267, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH PH-797804
1133, d1wbwA_, 0.8414, 2.65, 0.377, 351, 273, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1134, d1ua2C_, 0.8414, 2.05, 0.442, 286, 265, CRYSTAL STRUCTURE OF HUMAN CDK7
1135, d1oukA_, 0.8414, 2.58, 0.375, 348, 272, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR
1136, d4fv5A_, 0.8413, 1.94, 0.376, 330, 263, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK9
1137, d4fv9A_, 0.8412, 2.05, 0.379, 331, 264, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E71
1138, d4fa2A_, 0.8412, 2.13, 0.376, 339, 266, HUMAN P38 ALPHA MITOGEN-ACTIVATED KINASE IN COMPLEX WITH SB239063
1139, d1ua2B_, 0.8411, 2.07, 0.442, 286, 265, CRYSTAL STRUCTURE OF HUMAN CDK7
1140, d4f9wA_, 0.8410, 2.08, 0.376, 336, 266, HUMAN P38ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
1141, d4eh2A_, 0.8410, 2.13, 0.368, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F1 AND RL87
1142, p4lopD_, 0.8409, 2.43, 0.368, 351, 272, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1143, d4zthA_, 0.8407, 2.15, 0.376, 339, 266, STRUCTURE OF HUMAN P38AMAPK-ARYLPYRIDAZINYLPYRIDINE FRAGMENT COMPLEX USED IN INHIBITOR DISCOVERY
1144, d2lgcA1, 0.8407, 2.52, 0.378, 353, 270, JOINT NMR AND X-RAY REFINEMENT REVEALS THE STRUCTURE OF A NOVEL DIBENZO[AD]CYCLOHEPTENONE INHIBITOR/P38 MAP KINASE COMPLEX IN SOLUTION
1145, d5bvdA_, 0.8406, 2.01, 0.376, 330, 263, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
1146, d3kf7A_, 0.8406, 2.09, 0.368, 337, 266, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A TRIAZOLOPYRIMIDINE COMPOUND
1147, d1ouyA_, 0.8406, 2.58, 0.379, 350, 272, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROPYRIDO- PYRIMIDINE INHIBITOR
1148, d3e7oA_, 0.8405, 2.55, 0.341, 342, 273, CRYSTAL STRUCTURE OF JNK2
1149, d1ua2D_, 0.8405, 2.06, 0.445, 286, 265, CRYSTAL STRUCTURE OF HUMAN CDK7
1150, d3gfeA_, 0.8404, 2.60, 0.377, 352, 273, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR
1151, d3rocA_, 0.8403, 2.11, 0.368, 337, 266, CRYSTAL STRUCTURE OF HUMAN P38 ALPHA COMPLEXED WITH A PYRIMIDINONE COMPOUND
1152, d3gc8B_, 0.8403, 2.49, 0.367, 346, 270, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
1153, d2zazA_, 0.8403, 2.56, 0.379, 345, 272, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH 4-ANILINO QUINOLINE INHIBITOR
1154, d3ds6A_, 0.8401, 2.47, 0.359, 343, 273, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1155, p4lopB_, 0.8400, 2.31, 0.356, 350, 270, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1156, d4kinB_, 0.8397, 2.35, 0.379, 341, 269, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1157, d3s3iA_, 0.8397, 2.65, 0.377, 349, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1158, d3mptA_, 0.8397, 2.51, 0.365, 347, 271, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A PYRROLE-2- CARBOXAMIDE INHIBITOR
1159, d3d7zA_, 0.8397, 2.52, 0.380, 348, 271, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
1160, d4f9yA_, 0.8396, 2.23, 0.366, 339, 268, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
1161, d3flsA_, 0.8396, 2.47, 0.370, 343, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((R)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
1162, d2zb1A_, 0.8396, 2.55, 0.365, 345, 271, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
1163, d2zb0A_, 0.8396, 2.52, 0.379, 349, 272, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
1164, d5bujA_, 0.8395, 2.06, 0.375, 331, 264, ERK2 COMPLEXED WITH A N-H TETRAHYDROAZAINDAZOLE
1165, d2rg6A_, 0.8395, 2.22, 0.381, 335, 268, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11J
1166, d1m7qA_, 0.8394, 2.58, 0.375, 348, 272, CRYSTAL STRUCTURE OF P38 MAP KINASE IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
1167, d3obgA_, 0.8392, 2.09, 0.365, 332, 266, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
1168, p4lopA_, 0.8391, 2.44, 0.368, 351, 272, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1169, d4kipA_, 0.8391, 2.21, 0.367, 337, 267, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
1170, d3e92A_, 0.8391, 2.54, 0.376, 348, 271, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
1171, d3itzA1, 0.8390, 2.72, 0.372, 353, 274, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDAZINE INHIBITOR
1172, d1ywrA_, 0.8390, 2.23, 0.381, 338, 268, CRYSTAL STRUCTURE ANALYSIS OF INACTIVE P38 KINASE DOMAIN IN COMPLEX WITH A MONOCYCLIC PYRAZOLONE INHIBITOR
1173, d4aguB_, 0.8389, 2.15, 0.392, 276, 265, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1174, d2balA_, 0.8389, 2.22, 0.367, 337, 267, P38ALPHA MAP KINASE BOUND TO PYRAZOLOAMINE
1175, d1r3cA_, 0.8389, 2.54, 0.379, 349, 272, THE STRUCTURE OF P38ALPHA C162S MUTANT
1176, d1di9A_, 0.8388, 2.52, 0.379, 348, 272, THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-67- DIMETHOXYQUINAZOLINE
1177, d3mvlB_, 0.8386, 2.30, 0.379, 339, 269, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
1178, d4kinC_, 0.8385, 2.32, 0.375, 338, 269, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1179, d3ocgA_, 0.8385, 2.16, 0.368, 336, 266, P38 ALPHA KINASE COMPLEXED WITH A 5-AMINO-PYRAZOLE BASED INHIBITOR
1180, d3gc8A_, 0.8384, 2.38, 0.362, 347, 268, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
1181, d3flyA_, 0.8384, 2.56, 0.373, 347, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-ISOPROPYLAMINO-8-METHYL-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1182, p4loqB_, 0.8383, 2.31, 0.356, 351, 270, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1183, d3fmhA_, 0.8383, 2.46, 0.367, 347, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((R)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1184, d3bv2A_, 0.8382, 2.22, 0.372, 337, 266, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 30
1185, d5angA_, 0.8381, 1.94, 0.962, 268, 264, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 7-HYDROXY-4-( MORPHOLINOMETHYL)CHROMEN-2-ONE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1186, d4eh6A_, 0.8381, 2.14, 0.370, 335, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F5 AND RL87
1187, p4loqD_, 0.8380, 2.33, 0.356, 351, 270, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1188, d2ghmA_, 0.8380, 2.27, 0.378, 336, 267, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-895449
1189, d3mvmB_, 0.8379, 2.21, 0.382, 332, 267, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
1190, d3mpaA_, 0.8379, 2.00, 0.367, 331, 264, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1191, d2pkjA_, 0.8379, 2.19, 0.363, 332, 267,  
1192, d3fklA_, 0.8378, 2.35, 0.377, 344, 268, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO9552
1193, d1w84A_, 0.8378, 2.55, 0.375, 351, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1194, d4eh7A_, 0.8377, 2.20, 0.372, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F6 AND RL87
1195, d3rinA_, 0.8377, 2.65, 0.377, 349, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1196, d3oz6B_, 0.8377, 2.74, 0.375, 341, 275, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
1197, d3mh0A_, 0.8377, 2.19, 0.363, 332, 267, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1198, d3zyaA1, 0.8376, 2.25, 0.367, 341, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO- DIBENZOSUBERONE
1199, d1zzlA_, 0.8376, 2.62, 0.374, 351, 273, CRYSTAL STRUCTURE OF P38 WITH TRIAZOLOPYRIDINE
1200, d4ehvA_, 0.8375, 2.26, 0.368, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F10 AND RL87
1201, d3flqA_, 0.8375, 2.61, 0.379, 345, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((S)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN
1202, d4eh8A_, 0.8374, 2.14, 0.366, 336, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F7 AND RL87
1203, d5bueA_, 0.8373, 2.10, 0.375, 329, 264, ERK2 COMPLEXED WITH N-BENZYLPYRIDONE TETRAHYDROAZAINDAZOLE
1204, d3gc9A_, 0.8373, 2.19, 0.350, 335, 266, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
1205, d2rg5A_, 0.8373, 2.22, 0.382, 333, 267, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11B
1206, d4eh3A_, 0.8372, 2.22, 0.368, 339, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F2 AND RL87
1207, p4loqA_, 0.8371, 2.31, 0.356, 352, 270, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1208, d3u8wA_, 0.8370, 2.61, 0.374, 349, 273, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A TRIAZOLOPYRIDAZINONE INHIBITOR
1209, d2gtnA_, 0.8369, 2.14, 0.374, 337, 265, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-951717
1210, d1i09A_, 0.8369, 2.12, 0.340, 338, 265, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
1211, d5n66A_, 0.8368, 2.14, 0.366, 332, 265, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9J
1212, d4o2zA1, 0.8366, 2.46, 0.336, 357, 268, CRYSTAL STRUCTURE OF MPK3 FROM LEISHMANIA DONOVANI LDBPK_100540 IN THE PRESENCE OF NVP-BBT594
1213, d5awmA_, 0.8365, 2.56, 0.342, 345, 272, THE CRYSTAL STRUCTURE OF JNK FROM DROSOPHILA MELANOGASTER REVEALS AN EVOLUTIONARILY CONSERVED TOPOLOGY WITH THAT OF MAMMALIAN JNK PROTEINS.
1214, d3mvmA_, 0.8364, 2.47, 0.385, 335, 270, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
1215, d1w82A_, 0.8364, 2.53, 0.374, 351, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1216, d1zyjA_, 0.8363, 2.09, 0.370, 331, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1A
1217, d4kipB_, 0.8362, 2.40, 0.377, 338, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
1218, d3flzA_, 0.8362, 2.48, 0.367, 347, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 8-METHYL-6-PHENOXY-2- (TETRAHYDRO-PYRAN-4-YLAMINO)-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
1219, d2ptoA_, 0.8362, 2.01, 0.367, 330, 264,  
1220, d1bl6A_, 0.8362, 2.64, 0.377, 351, 273, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995
1221, d1yw2A_, 0.8360, 2.11, 0.374, 341, 265, MUTATED MUS MUSCULUS P38 KINASE (MP38)
1222, d1oveA_, 0.8358, 2.67, 0.374, 349, 273, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROQUINOLINONE
1223, d3hv3A_, 0.8357, 2.21, 0.368, 335, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL49
1224, d3hp5A_, 0.8357, 2.15, 0.370, 330, 265, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIMIDOPYRIDAZINONE COMPOUND
1225, d3flwA_, 0.8357, 2.45, 0.368, 345, 269, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH PAMAPIMOD
1226, d3bv3A_, 0.8357, 2.25, 0.372, 338, 266, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 2
1227, d1ua2A_, 0.8357, 2.13, 0.438, 286, 265, CRYSTAL STRUCTURE OF HUMAN CDK7
1228, d3hp2A_, 0.8355, 2.17, 0.374, 341, 265, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIDINONE COMPOUND
1229, d3queA_, 0.8352, 2.17, 0.374, 343, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH SKEPINONE-L
1230, d3fmkA_, 0.8352, 2.57, 0.373, 346, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((S)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1231, d3fknA_, 0.8351, 2.46, 0.364, 346, 269, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO7125
1232, d3nnuA_, 0.8350, 2.56, 0.378, 348, 270, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP1376
1233, d3mh2A_, 0.8350, 2.03, 0.367, 330, 264, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1234, d4w4yA_, 0.8349, 2.76, 0.349, 350, 275, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-METHYLPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1235, d3nnwA_, 0.8349, 2.56, 0.378, 349, 270, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP802
1236, d3nnvA_, 0.8348, 2.53, 0.374, 348, 270, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP437
1237, d3gcqA_, 0.8348, 2.23, 0.365, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL45
1238, d3fmmA_, 0.8348, 2.51, 0.363, 346, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6226
1239, d3ds6C_, 0.8348, 2.54, 0.377, 349, 273, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1240, d4kiqC_, 0.8347, 2.26, 0.367, 338, 267, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1241, d5cs6B_, 0.8346, 2.21, 0.308, 316, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
1242, d4w4vA_, 0.8345, 2.69, 0.354, 342, 274, JNK2/3 IN COMPLEX WITH 3-(4-{[(2-CHLOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1243, d3gc0A_, 0.8345, 2.37, 0.524, 278, 267, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA IN COMPLEX WITH AMP
1244, d2yixA_, 0.8345, 2.65, 0.377, 351, 273, TRIAZOLOPYRIDINE INHIBITORS OF P38
1245, d4kiqB_, 0.8344, 2.26, 0.371, 338, 267, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1246, d1w7hA_, 0.8343, 2.59, 0.371, 351, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1247, d1a9uA_, 0.8343, 2.55, 0.357, 351, 272, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580
1248, d5etcA_, 0.8342, 2.79, 0.369, 355, 274, STRUCTURE OF INACTIVE MAPK14 WITH ORDERED ACTIVATION LOOP
1249, p4lopC_, 0.8342, 2.16, 0.370, 341, 265, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1250, d3iphA_, 0.8341, 2.41, 0.369, 345, 268, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH A BIPHENYLAMIDE INHIBITOR
1251, d3fmjA_, 0.8341, 2.60, 0.369, 344, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 4-(5-METHYL-3-PHENYL- ISOXAZOL-4-YL)-PYRIMIDIN-2-YLAMINE
1252, d1wboA_, 0.8341, 2.80, 0.372, 351, 274, FRAGMENT BASED P38 INHIBITORS
1253, d1bl7A_, 0.8340, 2.49, 0.362, 351, 271, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025
1254, d3fmnA_, 0.8339, 2.48, 0.368, 341, 269, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO2530
1255, d3ds6B_, 0.8339, 2.54, 0.374, 343, 273, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1256, d4kinD_, 0.8338, 2.36, 0.375, 339, 269, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1257, d3gp0A1, 0.8338, 2.14, 0.360, 332, 264, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 11 (P38 BETA) IN COMPLEX WITH NILOTINIB
1258, d4w4xA_, 0.8337, 2.77, 0.349, 342, 275, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-FLUOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1259, p3lhjA_, 0.8337, 2.33, 0.378, 341, 267, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR.
1260, d2ghlA_, 0.8337, 2.19, 0.374, 334, 265, MUTANT MUS MUSCULUS P38 KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-874743
1261, d4y5hA_, 0.8335, 2.59, 0.357, 349, 272, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1262, p4ux9D_, 0.8335, 2.64, 0.350, 344, 274, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
1263, d3uvqA_, 0.8334, 2.06, 0.373, 333, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOSUBERONE DERIVATIVE
1264, d3o8uA_, 0.8334, 2.31, 0.372, 332, 266, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1265, d4kiqD_, 0.8333, 2.28, 0.367, 338, 267, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1266, d4y46A_, 0.8332, 2.59, 0.357, 340, 272, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1267, d4ic8B_, 0.8332, 2.54, 0.365, 336, 271, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
1268, d3mw1A_, 0.8331, 2.64, 0.375, 342, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1269, d1yqjA2, 0.8331, 2.67, 0.359, 351, 273, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH A SELECTIVE PYRIDAZINE INHIBITOR
1270, d4ynoA_, 0.8330, 2.54, 0.385, 342, 270, CRYSTAL STRUCTURE OF MAPK13 AT INACTIVE FORM
1271, d5bvfA_, 0.8329, 1.96, 0.373, 327, 260, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
1272, d1bmkA_, 0.8329, 2.68, 0.374, 351, 273, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655
1273, d3p7bA_, 0.8328, 2.18, 0.374, 332, 265, P38 INHIBITOR-BOUND
1274, d3fmlA_, 0.8327, 2.55, 0.363, 342, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6224
1275, d4r3cA_, 0.8326, 2.05, 0.373, 335, 263, CRYSTAL STRUCTURE OF P38 ALPHA MAP KINASE IN COMPLEX WITH A NOVEL ISOFORM SELECTIVE DRUG CANDIDATE
1276, d3newA_, 0.8324, 2.18, 0.366, 334, 265, P38-ALPHA COMPLEXED WITH COMPOUND 10
1277, d3o8pA_, 0.8322, 2.19, 0.362, 336, 265, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1278, d1wbvA_, 0.8322, 2.58, 0.374, 351, 270, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1279, d3o8tA_, 0.8321, 2.20, 0.370, 332, 265, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG-MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1280, d4eh4A_, 0.8320, 2.21, 0.375, 337, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F3 AND RL87
1281, d1zz2A_, 0.8320, 2.28, 0.371, 337, 267, TWO CLASSES OF P38ALPHA MAP KINASE INHIBITORS HAVING A COMMON DIPHENYLETHER CORE BUT EXHIBITING DIVERGENT BINDING MODES
1282, d1wbtA_, 0.8320, 2.59, 0.374, 351, 270, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1283, d3hrbA_, 0.8319, 2.76, 0.377, 344, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1284, d1p38A_, 0.8318, 2.64, 0.357, 351, 272, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTOMS RESOLUTION
1285, d2puuA_, 0.8317, 2.20, 0.370, 330, 265, CRYSTAL STRUCTURE OF P38 COMPLEX WITH 1-(5-TERT-BUTYL-2-P- TOLYL-2H-PYRAZOL-3-YL)-3-[4-(6-MORPHOLIN-4-YLMETHYL- PYRIDIN-3-YL)NAPHTHALEN-1-YL]UREA
1286, d3qudA_, 0.8316, 2.29, 0.372, 345, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO-BENZOPHENONE
1287, d3p5kA_, 0.8316, 2.20, 0.374, 332, 265, P38 INHIBITOR-BOUND
1288, d2ptjA_, 0.8314, 2.21, 0.362, 334, 265,  
1289, d3mh3A_, 0.8313, 2.21, 0.362, 334, 265, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1290, d1wbsA_, 0.8313, 2.61, 0.378, 351, 270, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1291, d4qtdA_, 0.8312, 2.58, 0.347, 355, 271, STRUCTURE OF HUMAN JNK1 IN COMPLEX WITH SCH772984 AND THE AMPPNP- HYDROLYSED TRIPHOSPHATE REVEALING THE SECOND TYPE-I BINDING MODE
1292, d3p78A_, 0.8312, 2.20, 0.374, 332, 265, P38 INHIBITOR-BOUND
1293, d3p79A_, 0.8311, 2.20, 0.374, 332, 265, P38 INHIBITOR-BOUND
1294, d4w4wA_, 0.8310, 2.63, 0.357, 349, 272, JNK2/3 IN COMPLEX WITH N-(2-METHYLPYRIDIN-4-YL)-3-{4- [(PHENYLCARBAMOYL)AMINO]-1H-PYRAZOL-1-YL}BENZAMIDE
1295, d4kiqA_, 0.8310, 2.29, 0.375, 338, 267, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1296, d4kinA_, 0.8310, 2.46, 0.377, 338, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1297, d3gc7A_, 0.8308, 2.70, 0.370, 349, 273, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH A DIHYDROQUINAZOLINONE
1298, d3mh1A_, 0.8307, 2.22, 0.366, 337, 265, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1299, d4kkeA_, 0.8306, 2.70, 0.355, 354, 273, THE CRYSTAL STRUCTURE OF AMP-BOUND JNK3
1300, d3e93A_, 0.8306, 2.57, 0.379, 346, 269, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
1301, d2pv8A_, 0.8305, 2.22, 0.366, 337, 265,  
1302, d2i0hA_, 0.8305, 2.74, 0.370, 349, 273, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH AN ARYLPYRIDAZINONE
1303, d5mz3A_, 0.8304, 2.63, 0.378, 350, 270, P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-METHYL-3-(4455- TETRAMETHYL-132-DIOXABOROLAN-2-YL)PHENYL)-3-(TRIFLUOROMETHYL) BENZAMIDE]
1304, d4yr8A_, 0.8304, 2.23, 0.351, 320, 265, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1305, d4l8mA_, 0.8304, 2.23, 0.375, 339, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOXEPINONE
1306, d1w83A_, 0.8304, 2.65, 0.378, 351, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1307, d3kq7A_, 0.8303, 2.60, 0.378, 348, 270, STRUCTURE OF HUMAN P38ALPHA WITH N-[4-METHYL-3-(6-{[2-(1- METHYLPYRROLIDIN-2-YL)ETHYL]AMINO}PYRIDINE-3-AMIDO)PHENYL]- 2-(MORPHOLIN-4-YL)PYRIDINE-4-CARBOXAMIDE
1308, d3oc1A_, 0.8302, 2.22, 0.370, 330, 265, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1309, d4kkgA_, 0.8301, 2.60, 0.358, 353, 271, CRYSTAL STRUCTURE OF APO AND AMP-BOUND JNK3
1310, d3hv4A_, 0.8301, 2.47, 0.375, 339, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
1311, d3fkoA_, 0.8300, 2.57, 0.372, 343, 269, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3668
1312, d3p7cA_, 0.8299, 2.23, 0.374, 332, 265, P38 INHIBITOR-BOUND
1313, d2gfsA_, 0.8299, 2.62, 0.363, 344, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3201195
1314, d4kkhA_, 0.8298, 2.66, 0.357, 351, 272, THE CRYSTAL STRUCTURE OF INHIBITOR-BOUND JNK3
1315, d1r39A_, 0.8298, 2.62, 0.358, 345, 271, THE STRUCTURE OF P38ALPHA
1316, d4awiA_, 0.8295, 2.54, 0.349, 352, 269, HUMAN JNK1ALPHA KINASE WITH 4-PHENYL-7-AZAINDOLE IKK2 INHIBITOR.
1317, d3gbzA_, 0.8293, 2.28, 0.541, 274, 266, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA
1318, d3hv6A_, 0.8291, 2.21, 0.375, 331, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH RL39
1319, d3fsfA_, 0.8290, 2.70, 0.365, 340, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 3-(26- DICHLORO-PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]- 1-METHYL-34-DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
1320, d3fskA_, 0.8289, 2.50, 0.366, 342, 268, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6257
1321, d4dljA_, 0.8288, 2.16, 0.365, 336, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH RL163
1322, d3uvpA_, 0.8288, 2.30, 0.368, 334, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZAMIDE SUBSTITUTED BENZOSUBERONE
1323, d3gcuA_, 0.8288, 2.51, 0.375, 339, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
1324, d2onlB1, 0.8288, 2.37, 0.375, 339, 267, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1325, d3objA_, 0.8287, 2.38, 0.371, 332, 267, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
1326, d5etiA1, 0.8286, 2.68, 0.368, 352, 272, STRUCTURE OF DEAD KINASE MAPK14
1327, d3hvcA_, 0.8286, 1.95, 0.377, 327, 260, CRYSTAL STRUCTURE OF HUMAN P38ALPHA MAP KINASE
1328, d2p5aA_, 0.8286, 1.95, 0.377, 327, 260,  
1329, d1wbnA_, 0.8285, 2.65, 0.374, 351, 270, FRAGMENT BASED P38 INHIBITORS
1330, d3pg1A_, 0.8283, 2.22, 0.331, 341, 266, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR (1.95 ANGS RESOLUTION)
1331, d4tyhB_, 0.8281, 2.26, 0.377, 335, 265, TERNARY COMPLEX OF P38 AND MK2 WITH A P38 INHIBITOR
1332, d2wajA_, 0.8278, 2.63, 0.358, 348, 271, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH A 1-ARYL-34- DIHYDROISOQUINOLINE INHIBITOR
1333, d4eh9A_, 0.8277, 2.25, 0.376, 334, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F11 AND RL87
1334, d4yr8E_, 0.8276, 2.32, 0.350, 317, 266, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1335, d3hv5A_, 0.8276, 2.52, 0.375, 339, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
1336, d1wfcA_, 0.8276, 2.51, 0.362, 340, 268, STRUCTURE OF APO UNPHOSPHORYLATED P38 MITOGEN ACTIVATED PROTEIN KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUE OF THE YEAST HOG1 PROTEIN
1337, d4ditA_, 0.8275, 2.08, 0.337, 328, 261, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A IMIDAZOPYRIDINE INHIBITOR
1338, d5o8uA_, 0.8274, 2.21, 0.364, 331, 264, COVALENT INHIBITOR 4B BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S252C
1339, d5fp5A_, 0.8274, 1.85, 0.985, 264, 260, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 4-FLUOROBENZOIC ACID (AT222) IN AN ALTERNATE BINDING SITE.
1340, d4dliA_, 0.8274, 2.27, 0.371, 334, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH RL87
1341, d1lewA_, 0.8274, 2.35, 0.375, 341, 267, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS NUCLEAR SUBSTRATE MEF2A
1342, d5ekoA_, 0.8273, 2.57, 0.375, 341, 269, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
1343, d3hegA_, 0.8272, 2.24, 0.370, 333, 265, P38 IN COMPLEX WITH SORAFENIB
1344, d2onlA1, 0.8272, 2.30, 0.376, 338, 266, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1345, d3cgoA_, 0.8271, 2.57, 0.361, 332, 269, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
1346, d2okrA_, 0.8270, 2.39, 0.375, 339, 267, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1347, d1lezA_, 0.8270, 2.39, 0.381, 343, 268, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS ACTIVATOR MKK3B
1348, d3cg2A_, 0.8269, 2.22, 0.380, 327, 263,  
1349, d3tg1A_, 0.8267, 2.20, 0.367, 334, 264, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH A MAPK DOCKING PARTNER
1350, d3cgfA_, 0.8267, 2.56, 0.361, 346, 269, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
1351, d3flnC_, 0.8263, 2.47, 0.372, 343, 266, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH R1487
1352, p6f5eB_, 0.8262, 2.19, 0.364, 346, 264, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1353, p5lenB_, 0.8262, 2.19, 0.364, 346, 264, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX WITH JNK1A1 AND JIP1 PEPTIDE
1354, d3pzeA_, 0.8260, 2.58, 0.347, 347, 268, JNK1 IN COMPLEX WITH INHIBITOR
1355, d1jvpP_, 0.8259, 2.10, 0.969, 268, 262, CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) IN COMPLEX WITH PKF049-365
1356, d1jnkA_, 0.8258, 2.59, 0.361, 346, 269, THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP
1357, d2p33A_, 0.8257, 2.57, 0.361, 332, 269, SYNTHESIS AND SAR OF AMINOPYRIMIDINES AS NOVEL C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1358, d3l8xA_, 0.8256, 2.16, 0.379, 326, 261, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-PYRIMIDINE BASED INHIBITOR
1359, d2zdtA_, 0.8255, 2.61, 0.361, 342, 269, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
1360, d3v6rB_, 0.8254, 2.52, 0.353, 346, 269, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1361, d2gtmA_, 0.8254, 2.16, 0.378, 341, 262, MUTATED MOUSE P38 MAP KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-892579
1362, d4ka3A_, 0.8253, 2.33, 0.368, 340, 266, STRUCTURE OF MAP KINASE IN COMPLEX WITH A DOCKING PEPTIDE
1363, d1kv1A_, 0.8250, 2.19, 0.378, 331, 262, P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1
1364, p5o90A_, 0.8249, 2.25, 0.382, 330, 262, CRYSTAL STRUCTURE OF A P38ALPHA T185G MUTANT IN COMPLEX WITH TAB1 PEPTIDE.
1365, d5n68A_, 0.8249, 2.09, 0.372, 328, 261, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9M
1366, d5mtxA_, 0.8249, 2.20, 0.367, 331, 264, DIBENZOOXEPINONE INHIBITOR 12B IN COMPLEX WITH P38 MAPK
1367, d4eymA_, 0.8248, 2.53, 0.384, 340, 268, MAPK13 COMPLEX WITH INHIBITOR
1368, d3c5uA_, 0.8248, 2.31, 0.368, 338, 266, P38 ALPHA MAP KINASE COMPLEXED WITH A BENZOTHIAZOLE BASED INHIBITOR
1369, d2qd9A_, 0.8248, 2.20, 0.369, 330, 263, P38 ALPHA MAP KINASE INHIBITOR BASED ON HETEROBICYCLIC SCAFFOLDS
1370, d4eyjA_, 0.8246, 2.38, 0.383, 338, 266, MAPK13 COMPLEX WITH INHIBITOR
1371, d3nnxA_, 0.8244, 2.25, 0.385, 336, 262, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38 ALPHA IN COMPLEX WITH DP802
1372, d3ctqA_, 0.8243, 2.31, 0.377, 336, 265, STRUCTURE OF MAP KINASE P38 IN COMPLEX WITH A 1-O-TOLYL-12 3-TRIAZOLE-4-CARBOXAMIDE
1373, d3mgyA_, 0.8242, 2.17, 0.376, 329, 263, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1374, d3lfbA_, 0.8240, 2.32, 0.377, 333, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH RL98
1375, d4u79A_, 0.8238, 2.42, 0.360, 337, 267, CRYSTAL STRUCTURE OF HUMAN JNK3 IN COMPLEX WITH A BENZENESULFONAMIDE INHIBITOR.
1376, d2pv5A_, 0.8236, 2.18, 0.373, 329, 263,  
1377, d3g90X_, 0.8235, 2.61, 0.361, 345, 269, JNK-3 BOUND TO (Z)-5-FLUORO-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL) METHYL)-3-(HYDROXYIMINO)INDOLIN-2-ONE
1378, p5xyxA_, 0.8234, 2.47, 0.374, 337, 265, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
1379, d5uojA_, 0.8234, 2.50, 0.363, 343, 267, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTROMS RESOLUTION
1380, p4loqC_, 0.8234, 2.16, 0.370, 337, 262, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1381, d3p7aA_, 0.8234, 2.32, 0.374, 332, 265, P38 INHIBITOR-BOUND
1382, d3g9nA_, 0.8234, 2.60, 0.361, 346, 269, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-PHENYLINDOLIN-2-ONE
1383, d3k3iA_, 0.8233, 2.22, 0.378, 332, 262, P38ALPHA BOUND TO NOVEL DGF-OUT COMPOUND PF-00215955
1384, d3hecA_, 0.8233, 2.28, 0.371, 329, 264, P38 IN COMPLEX WITH IMATINIB
1385, d1pmuA_, 0.8233, 2.61, 0.356, 342, 270, THE CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PHENANTROLINE INHIBITOR
1386, d3gi3A_, 0.8232, 2.29, 0.367, 330, 264, CRYSTAL STRUCTURE OF A N-PHENYL-N -NAPHTHYLUREA ANALOG IN COMPLEX WITH P38 MAP KINASE
1387, d3fc1X_, 0.8232, 2.29, 0.373, 330, 263, CRYSTAL STRUCTURE OF P38 KINASE BOUND TO PYRIMIDO-PYRIDAZINONE INHIBITOR
1388, d3lffA_, 0.8231, 2.30, 0.371, 335, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH RL166
1389, d1pmnA_, 0.8229, 2.62, 0.361, 344, 269, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE- PYRIMIDINE INHIBITOR
1390, d3ptgA_, 0.8227, 2.31, 0.374, 340, 265, DESIGN AND SYNTHESIS OF A NOVEL ORALLY EFFICACIOUS TRI-SUBSTITUTED THIOPHENE BASED JNK INHIBITOR
1391, d1oz1A_, 0.8227, 2.65, 0.384, 344, 268, P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4-AZAINDOLE INHIBITOR
1392, d5mtyA_, 0.8226, 2.22, 0.369, 328, 263, DIBENZOSUBERONE INHIBITOR 8E IN COMPLEX WITH P38 MAPK
1393, d2o0uA_, 0.8226, 2.59, 0.362, 331, 268, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-{3-CYANO-6-[3-(1- PIPERIDINYL)PROPANOYL]-4567-TETRAHYDROTHIENO[23-C]PYRIDIN-2-YL}- 1-NAPHTHALENECARBOXAMIDE
1394, p4h3bA_, 0.8224, 2.29, 0.374, 351, 265, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
1395, d2okrD_, 0.8224, 2.32, 0.374, 339, 265, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1396, p4h3bC_, 0.8223, 2.29, 0.374, 351, 265, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
1397, d3hv7A_, 0.8223, 2.33, 0.380, 330, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH RL38
1398, d4x21A_, 0.8222, 2.29, 0.364, 336, 264, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
1399, d3d83A_, 0.8222, 2.64, 0.377, 347, 268, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
1400, d4h36A_, 0.8219, 2.30, 0.374, 353, 265, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH ATF2 PEPTIDE
1401, d3hv4B_, 0.8218, 2.48, 0.380, 338, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
1402, p4whzA_, 0.8217, 2.64, 0.357, 342, 269, DESIGN AND SYNTHESIS OF HIGHLY POTENT AND ISOFORM SELECTIVE JNK3 INHIBITORS: SAR STUDIES ON AMINOPYRAZOLE DERIVATIVES
1403, d4d1zA_, 0.8212, 1.80, 0.984, 258, 257, CDK2 IN COMPLEX WITH A LUCIFERIN DERIVATE
1404, d3npcA_, 0.8212, 2.35, 0.360, 357, 264, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
1405, d4ic8A_, 0.8211, 2.63, 0.384, 325, 268, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
1406, p5etaB_, 0.8208, 2.18, 0.374, 335, 262, STRUCTURE OF MAPK14 WITH BOUND THE KIM DOMAIN OF THE TOXOPLASMA PROTEIN GRA24
1407, d5eknA_, 0.8207, 2.33, 0.375, 336, 264, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
1408, d3hv5B_, 0.8207, 2.51, 0.380, 339, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
1409, d3ttiA_, 0.8205, 2.66, 0.361, 341, 269, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-930 AN ORALLY ACTIVE ANTI-FIBROTIC JNK INHIBITOR
1410, d3ha8A_, 0.8204, 2.65, 0.354, 342, 268, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/COMPOUND 14B
1411, p2xs0A_, 0.8204, 2.32, 0.348, 346, 264, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
1412, d1ukiA_, 0.8204, 2.23, 0.364, 328, 264, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
1413, d5n67A_, 0.8200, 2.16, 0.377, 327, 260, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9L
1414, d5tbeA_, 0.8199, 2.29, 0.365, 332, 263, HUMAN P38ALPHA MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 2
1415, d3s4qA_, 0.8199, 2.28, 0.372, 326, 261, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-TRIAZINE BASED INHIBITOR
1416, d3p4kA_, 0.8199, 2.35, 0.374, 338, 265, THE THIRD CONFORMATION OF P38A MAP KINASE OBSERVED IN PHOSPHORYLATED P38A AND IN SOLUTION
1417, d4bgqA_, 0.8198, 2.22, 0.378, 276, 262, CRYSTAL STRUCTURE OF THE HUMAN CDKL5 KINASE DOMAIN
1418, d3da6A_, 0.8198, 2.56, 0.358, 328, 268, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-METHYL- 4-(3-(2-(METHYLAMINO)PYRIMIDIN-4-YL)PYRIDIN-2-YLOXY) NAPHTHALEN-1-YL)-1H-BENZO[D]IMIDAZOL-2-AMINE
1419, d3eljA_, 0.8196, 2.63, 0.351, 347, 268, JNK1 COMPLEXED WITH A BIS-ANILINO-PYRROLOPYRIMIDINE INHIBITOR.
1420, d3npcB_, 0.8194, 2.27, 0.363, 356, 262, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
1421, d4a9yA_, 0.8192, 2.35, 0.373, 334, 263, P38ALPHA MAP KINASE BOUND TO CMPD 8
1422, d3gcuB_, 0.8192, 2.51, 0.380, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
1423, d2bakA_, 0.8192, 2.35, 0.373, 334, 263, P38ALPHA MAP KINASE BOUND TO MPAQ
1424, d3ttjA_, 0.8186, 2.61, 0.358, 333, 268, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-359 A JNK INHIBITOR FOR THE PREVENTION OF ISCHEMIA-REPERFUSION INJURY
1425, d3g9lX_, 0.8186, 2.55, 0.360, 336, 267, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-STYRYLINDOLIN-2-ONE
1426, d3e7oB_, 0.8186, 2.33, 0.346, 326, 263, CRYSTAL STRUCTURE OF JNK2
1427, d3gcvA_, 0.8185, 2.25, 0.378, 338, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH RL62
1428, d3iw6A_, 0.8184, 2.45, 0.376, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZYLPIPERAZIN- PYRROL
1429, d2o2uA_, 0.8184, 2.41, 0.362, 319, 265, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-CYANO-4567- TETRAHYDRO-1-BENZOTHIEN-2-YL)-2-FLUOROBENZAMIDE
1430, d5tcoA_, 0.8182, 2.18, 0.368, 327, 261, HUMAN P38 MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 1
1431, d3zduA_, 0.8181, 2.60, 0.335, 297, 269, CRYSTAL STRUCTURE OF THE HUMAN CDKL3 KINASE DOMAIN
1432, d1ianA_, 0.8181, 2.11, 0.378, 328, 259, HUMAN P38 MAP KINASE INHIBITOR COMPLEX
1433, d1pmvA_, 0.8179, 2.76, 0.356, 347, 270, THE STRUCTURE OF JNK3 IN COMPLEX WITH A DIHYDROANTHRAPYRAZOLE INHIBITOR
1434, d5o8vA_, 0.8178, 2.15, 0.375, 328, 259, COVALENT INHIBITOR 4A BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S251C
1435, d3fl4A_, 0.8174, 2.52, 0.375, 339, 264, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO5634
1436, d3k3jA_, 0.8171, 2.25, 0.368, 329, 261, P38ALPHA BOUND TO NOVEL DFG-OUT COMPOUND PF-00416121
1437, d3rtpA_, 0.8169, 2.36, 0.361, 331, 263, DESIGN AND SYNTHESIS OF BRAIN PENETRANT SELECTIVE JNK INHIBITORS WITH IMPROVED PHARMACOKINETIC PROPERTIES FOR THE PREVENTION OF NEURODEGENERATION
1438, d3iw7A_, 0.8169, 2.48, 0.376, 335, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH AN IMIDAZO-PYRIDINE
1439, d3v6sB_, 0.8164, 2.27, 0.361, 340, 263, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1440, d3fi4A_, 0.8164, 2.49, 0.376, 339, 263, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO4499
1441, d1blxA_, 0.8164, 2.81, 0.466, 305, 268, P19INK4D/CDK6 COMPLEX
1442, d3oy1A_, 0.8162, 2.42, 0.364, 329, 264, HIGHLY SELECTIVE C-JUN N-TERMINAL KINASE (JNK) 2 AND 3 INHIBITORS WITH IN VITRO CNS-LIKE PHARMACOKINETIC PROPERTIES
1443, d4z9lA_, 0.8161, 2.59, 0.360, 333, 267, THE STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE-PYRIMIDINE INHIBITOR
1444, d4eh5A_, 0.8161, 2.17, 0.375, 329, 259, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F4 AND RL87
1445, d2hy81_, 0.8161, 2.05, 0.298, 293, 258, PAK1 COMPLEX WITH ST2001
1446, d3lfeA_, 0.8160, 2.48, 0.376, 334, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL116
1447, d5n63A_, 0.8158, 2.23, 0.375, 325, 259, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9C
1448, d5n65A_, 0.8157, 2.37, 0.367, 333, 264, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9H
1449, d3lfcA_, 0.8156, 2.49, 0.372, 334, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL99
1450, d5n64A_, 0.8154, 2.23, 0.369, 329, 260, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9G
1451, d4l7fA1, 0.8153, 2.50, 0.356, 343, 264, CO-CRYSTAL STRUCTURE OF JNK1 AND AX13587
1452, p3vulA_, 0.8152, 2.46, 0.356, 344, 264, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
1453, d2ewaA_, 0.8152, 2.15, 0.382, 330, 259, DUAL BINDING MODE OF PYRIDINYLIMIDAZOLE TO MAP KINASE P38
1454, d2ok1A_, 0.8151, 2.50, 0.362, 333, 265, CRYSTAL STRUCTURE OF JNK3 BOUND TO N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1455, d3pg3A_, 0.8150, 2.50, 0.368, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL182
1456, d2zduA_, 0.8150, 2.42, 0.364, 330, 264, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
1457, d1v0pB_, 0.8147, 1.84, 0.589, 258, 253, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
1458, d4x21B_, 0.8143, 2.34, 0.364, 336, 264, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
1459, d3oefX_, 0.8139, 2.54, 0.374, 334, 265, CRYSTAL STRUCTURE OF Y323F INACTIVE MUTANT OF P38ALPHA MAP KINASE
1460, d3uvrA_, 0.8133, 2.48, 0.375, 331, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH KM064
1461, d4tthB_, 0.8132, 1.63, 0.524, 256, 252, CRYSTAL STRUCTURE OF A CDK6/VCYCLIN COMPLEX WITH INHIBITOR BOUND
1462, d1v0bB_, 0.8132, 2.07, 0.584, 261, 257, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
1463, d3zsiA_, 0.8130, 2.21, 0.378, 326, 259, X-RAY STRUCTURE OF P38ALPHA BOUND TO VX-745
1464, d4p41B_, 0.8123, 1.65, 0.524, 256, 252,  
1465, d3q53A_, 0.8121, 2.05, 0.296, 291, 257, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN IN COMPLEX WITH ATP
1466, d3iw5A_, 0.8121, 2.55, 0.361, 336, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH AN INDOLE DERIVATIVE
1467, p3vumA_, 0.8116, 2.40, 0.359, 347, 262, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M7 IN MAP KINASE JNK1
1468, p4h39A_, 0.8115, 2.23, 0.368, 340, 261, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH JIP1 PEPTIDE
1469, d3fi2A_, 0.8115, 2.48, 0.367, 326, 264, CRYSTAL STRUCTURE OF JNK3 WITH AMINO-PYRAZOLE INHIBITOR SR- 3451
1470, d2excX_, 0.8115, 2.51, 0.362, 335, 265, INHIBITOR COMPLEX OF JNK3
1471, d3uibA_, 0.8114, 2.19, 0.342, 309, 257, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR IN COMPLEX WITH SB203580
1472, d3hubA_, 0.8113, 2.43, 0.370, 335, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH SCIOS-469
1473, d3fv8A_, 0.8112, 2.48, 0.365, 331, 263, JNK3 BOUND TO PIPERAZINE AMIDE INHIBITOR SR2774.
1474, d2yiwA_, 0.8112, 2.09, 0.379, 325, 256, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE
1475, d1g3nE_, 0.8111, 2.61, 0.481, 293, 264, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
1476, d4geoA_, 0.8109, 2.31, 0.373, 326, 260, P38A MAP KINASE DEF-POCKET PENTA MUTANT (M194A L195A H228A I229A Y258A)
1477, d3lfaA_, 0.8105, 2.46, 0.367, 333, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH DASATINIB
1478, d1kv2A_, 0.8104, 2.09, 0.379, 325, 256, HUMAN P38 MAP KINASE IN COMPLEX WITH BIRB 796
1479, d1g3nA_, 0.8104, 2.62, 0.481, 293, 264, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
1480, d1ob3B_, 0.8098, 2.01, 0.571, 258, 254, STRUCTURE OF P. FALCIPARUM PFPK5
1481, d1ukhA_, 0.8097, 2.07, 0.353, 321, 258, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
1482, d2b1pA_, 0.8096, 2.45, 0.361, 331, 263, INHIBITOR COMPLEX OF JNK3
1483, d3ocbA_, 0.8095, 2.16, 0.271, 315, 258, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
1484, d3l8sA_, 0.8095, 2.54, 0.362, 334, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH CP-547632
1485, d4e6cA_, 0.8093, 2.37, 0.374, 330, 262, P38A-PERIFOSINE COMPLEX
1486, d3iw4C_, 0.8092, 2.19, 0.259, 332, 259, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1487, d1yhwA_, 0.8092, 2.15, 0.279, 293, 258, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH ONE POINT MUTATIONS (K299R)
1488, d1yhvA_, 0.8091, 2.15, 0.283, 293, 258, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH TWO POINT MUTATIONS (K299R T423E)
1489, d3zshA_, 0.8089, 2.48, 0.367, 331, 264, X-RAY STRUCTURE OF P38ALPHA BOUND TO SCIO-469
1490, d3oxiA_, 0.8089, 2.39, 0.366, 322, 262, DESIGN AND SYNTHESIS OF DISUBSTITUTED THIOPHENE AND THIAZOLE BASED INHIBITORS OF JNK FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
1491, d3hucA_, 0.8088, 2.62, 0.365, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL40
1492, d3kvxA_, 0.8085, 2.44, 0.368, 327, 261, JNK3 BOUND TO AMINOPYRIMIDINE INHIBITOR SR-3562
1493, d4yr8C_, 0.8084, 2.43, 0.351, 318, 262, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1494, d4eqcA1, 0.8083, 2.11, 0.300, 292, 257, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN IN COMPLEX WITH FRAX597 INHIBITOR
1495, d2yisA_, 0.8082, 2.12, 0.379, 325, 256, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE.
1496, d2jedB1, 0.8082, 2.27, 0.278, 315, 259, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1497, d5dfpA_, 0.8079, 2.10, 0.300, 292, 257, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND FRAX1036
1498, d3coiA1, 0.8079, 2.85, 0.381, 342, 270, CRYSTAL STRUCTURE OF P38DELTA KINASE
1499, d4dawA_, 0.8076, 2.13, 0.300, 293, 257, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH THE RUTHENIUM PHTHALIMIDE COMPLEX
1500, d1u5qA_, 0.8074, 2.18, 0.270, 308, 259, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1501, d3cqwA_, 0.8073, 2.21, 0.275, 318, 258, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1502, d2baqA_, 0.8073, 2.25, 0.389, 329, 257, P38ALPHA BOUND TO RO3201195
1503, d5veeA_, 0.8072, 2.19, 0.268, 289, 257, PAK4 KINASE DOMAIN IN COMPLEX WITH FRAX486
1504, d3gcsA_, 0.8070, 2.45, 0.379, 331, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH SORAFENIB
1505, d3iw8A_, 0.8069, 2.63, 0.372, 334, 266, STRUCTURE OF INACTIVE HUMAN P38 MAP KINASE IN COMPLEX WITH A THIAZOLE-UREA
1506, d3fxzA_, 0.8067, 2.14, 0.284, 292, 257, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX LAMBDA-FL172
1507, d2gcdA_, 0.8067, 2.20, 0.270, 308, 259, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1508, d3q52A_, 0.8066, 2.12, 0.296, 292, 257, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN
1509, d3ocbB_, 0.8064, 2.14, 0.276, 319, 257, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
1510, d3iw4B_, 0.8064, 2.21, 0.259, 325, 259, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1511, d1u5rA_, 0.8064, 2.20, 0.270, 308, 259, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1512, d4aa0A_, 0.8063, 2.33, 0.378, 328, 259, P38ALPHA MAP KINASE BOUND TO CMPD 2
1513, d4bbmA1, 0.8060, 3.32, 0.396, 306, 275, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
1514, d4e5bA_, 0.8057, 2.29, 0.375, 324, 259, STRUCTURE OF P38A MAP KINASE WITHOUT BOG
1515, d3ow4A_, 0.8054, 2.24, 0.271, 317, 258, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1516, d2jedA_, 0.8054, 2.22, 0.279, 324, 258, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1517, d4e6aA_, 0.8050, 2.43, 0.372, 324, 261, P38A-PIA23 COMPLEX
1518, d2gcdB_, 0.8049, 2.23, 0.270, 308, 259, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1519, d3mvhA_, 0.8045, 2.19, 0.280, 311, 257, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
1520, d2ou7A_, 0.8044, 2.10, 0.245, 292, 257, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1521, d5deyA_, 0.8043, 2.22, 0.279, 295, 258, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
1522, p3lfdA_, 0.8043, 2.57, 0.370, 331, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH RL113
1523, d2jdoA_, 0.8042, 2.16, 0.276, 314, 257, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1524, d2x39A_, 0.8041, 2.17, 0.280, 316, 257, STRUCTURE OF 4-AMINO-N-(4-CHLOROBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE BOUND TO PKB
1525, d2owbA_, 0.8038, 2.11, 0.245, 294, 257, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1526, d4j53A_, 0.8036, 2.11, 0.245, 293, 257, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH TAK-960
1527, d2r9sB_, 0.8035, 2.45, 0.362, 325, 260, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
1528, d1u5qB_, 0.8034, 2.25, 0.270, 308, 259, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1529, d3iw4A_, 0.8032, 2.28, 0.259, 330, 259, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1530, d3fy0A_, 0.8032, 2.19, 0.284, 292, 257, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX DW1
1531, d1u5rB_, 0.8031, 2.27, 0.270, 308, 259, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1532, d3odzX_, 0.8030, 2.86, 0.353, 335, 266, CRYSTAL STRUCTURE OF P38ALPHA Y323R ACTIVE MUTANT
1533, d2xrwA1, 0.8030, 2.35, 0.353, 346, 258, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
1534, d5dewA_, 0.8029, 2.25, 0.279, 295, 258, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
1535, d4q9zB_, 0.8027, 2.36, 0.278, 308, 259, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
1536, d3mv5A_, 0.8023, 2.28, 0.275, 315, 258, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
1537, d2yacA_, 0.8023, 2.14, 0.245, 290, 257, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH NMS-P937
1538, d3thbA_, 0.8022, 2.14, 0.245, 287, 257, STRUCTURE OF PLK1 KINASE DOMAIN IN COMPLEX WITH A BENZOLACTAM-DERIVED INHIBITOR
1539, d3fi3A_, 0.8022, 2.53, 0.366, 328, 262, CRYSTAL STRUCTURE OF JNK3 WITH INDAZOLE INHIBITOR SR-3737
1540, d2fsmX_, 0.8020, 2.39, 0.373, 326, 260, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327S) ACTIVATING MUTANT FORM-B
1541, d5f9eB_, 0.8018, 2.36, 0.274, 293, 259, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
1542, d3kb7A_, 0.8018, 2.15, 0.245, 289, 257, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1543, d3a8xA1, 0.8017, 2.14, 0.272, 331, 257, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1544, d2npqA_, 0.8016, 2.41, 0.369, 326, 260, A NOVEL LIPID BINDING SITE IN THE P38 ALPHA MAP KINASE
1545, d2r9sA_, 0.8014, 2.51, 0.362, 325, 260, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
1546, d1stcE_, 0.8013, 2.22, 0.261, 334, 257, CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE
1547, d4e5aX_, 0.8012, 2.40, 0.375, 332, 259, THE W197A MUTANT OF P38A MAP KINASE
1548, d3fc2A_, 0.8012, 2.15, 0.245, 293, 257, PLK1 IN COMPLEX WITH BI6727
1549, d5ta6A_, 0.8009, 2.16, 0.245, 294, 257, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR.
1550, d2fslX_, 0.8009, 2.46, 0.373, 332, 260, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327S) ACTIVATING MUTANT FORM-A
1551, d4a4lA_, 0.8008, 2.17, 0.245, 290, 257, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO-PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR
1552, d2xh5A_, 0.8008, 2.24, 0.276, 316, 257, STRUCTURE OF 4-(4-TERT-BUTYLBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDIN-4-AMINE BOUND TO PKB
1553, d3g33C_, 0.8006, 2.96, 0.453, 291, 265, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
1554, d3pvwA2, 0.8005, 2.34, 0.262, 343, 260, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD103A)
1555, d4j52A_, 0.8004, 2.17, 0.245, 293, 257, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A PYRIMIDODIAZEPINONE INHIBITOR
1556, d4a4oA_, 0.8001, 2.18, 0.245, 290, 257, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2- (2-AMINO-PYRIMIDIN-4-YL)-1567-TETRAHYDRO-PYRROLOPYRIDIN- 4-ONE INHIBITOR
1557, d2uw9A_, 0.8001, 2.23, 0.276, 316, 257, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1558, d3ow4B_, 0.8000, 2.26, 0.276, 317, 257, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1559, d2rkuA_, 0.8000, 2.17, 0.245, 294, 257, STRUCTURE OF PLK1 IN COMPLEX WITH BI2536
1560, d1bx6A_, 0.7999, 2.22, 0.261, 337, 257, CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1561, d4q9zA1, 0.7998, 2.37, 0.279, 330, 258, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
1562, d4b6lA_, 0.7998, 2.35, 0.263, 281, 259, DISCOVERY OF ORAL POLO-LIKE KINASE (PLK) INHIBITORS WITH ENHANCED SELECTIVITY PROFILE USING RESIDUE TARGETED DRUG DESIGN
1563, d2y7jA_, 0.7998, 2.08, 0.285, 284, 253, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1564, d4nusA_, 0.7997, 2.44, 0.285, 301, 260, RSK2 N-TERMINAL KINASE IN COMPLEX WITH LJH685
1565, d3o7lD_, 0.7997, 2.20, 0.261, 333, 257, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
1566, d4eklA_, 0.7994, 2.33, 0.275, 329, 258, AKT1 WITH GDC0068
1567, d3g33A_, 0.7994, 2.91, 0.473, 291, 264, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
1568, d4ra5A1, 0.7993, 2.45, 0.278, 331, 259, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1569, d3zs5A1, 0.7993, 2.72, 0.366, 339, 265, STRUCTURAL BASIS FOR KINASE SELECTIVITY OF THREE CLINICAL P38ALPHA INHIBITORS
1570, d4gv1A1, 0.7991, 2.27, 0.276, 328, 257, PKB ALPHA IN COMPLEX WITH AZD5363
1571, d5f9eA1, 0.7990, 2.46, 0.278, 331, 259, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
1572, d3qklA_, 0.7990, 2.35, 0.271, 317, 258, SPIROCHROMANE AKT INHIBITORS
1573, d2biyA_, 0.7989, 2.20, 0.270, 287, 256, STRUCTURE OF PDK1-S241A MUTANT KINASE DOMAIN
1574, d3pvuA2, 0.7987, 2.39, 0.242, 340, 260, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD101)
1575, d3gcpA_, 0.7987, 2.67, 0.370, 337, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH SB203580
1576, d3cquA_, 0.7987, 2.34, 0.271, 318, 258, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1577, d2fstX_, 0.7987, 2.39, 0.375, 324, 259, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327L) ACTIVATING MUTANT
1578, d4ra5B_, 0.7986, 2.44, 0.278, 310, 259, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1579, d3zsgA_, 0.7986, 2.77, 0.365, 337, 266, X-RAY STRUCTURE OF P38ALPHA BOUND TO TAK-715
1580, d1cmkE_, 0.7985, 2.24, 0.265, 348, 257, CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS
1581, d2i6lB_, 0.7984, 2.64, 0.327, 269, 260, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
1582, d4w8eA_, 0.7982, 2.21, 0.270, 290, 256, STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF-06645342)
1583, d2y7jC_, 0.7980, 2.11, 0.285, 284, 253, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1584, d4qmwA_, 0.7979, 2.23, 0.246, 286, 256, MST3 IN COMPLEX WITH PP-121 1-CYCLOPENTYL-3-(1H-PYRROLO[23- B]PYRIDIN-5-YL)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
1585, d3d5uA_, 0.7978, 2.19, 0.257, 288, 257, CRYSTAL STRUCTURE OF A WILDTYPE POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
1586, d2jdrA_, 0.7978, 2.28, 0.276, 316, 257, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A- 443654
1587, d3krwA2, 0.7977, 2.41, 0.262, 349, 260, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (SOAK)
1588, d5ta8A_, 0.7976, 2.23, 0.249, 294, 257, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR
1589, d3l9mA_, 0.7974, 2.32, 0.265, 338, 257, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
1590, d5vedA_, 0.7973, 2.40, 0.268, 289, 257, PAK4 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1591, d4e8aA_, 0.7973, 2.44, 0.375, 327, 259, THE CRYSTAL STRUCTURE OF P38A MAP KINASE IN COMPLEX WITH PIA24
1592, d4ra4A_, 0.7972, 2.29, 0.261, 317, 257, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE C ALPHA IN COMPLEX WITH COMPOUND 28 ((R)-6-((3S4S)-13-DIMETHYL-PIPERIDIN-4-YL)-7-(2-FLUORO- PHENYL)-4-METHYL-210-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1593, d2f57A1, 0.7971, 2.33, 0.257, 290, 257, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
1594, d2f57B1, 0.7969, 2.38, 0.272, 293, 257, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
1595, d3rcjA_, 0.7968, 2.20, 0.275, 281, 255, RAPID PREPARATION OF TRIAZOLYL SUBSTITUTED NH-HETEROCYCLIC KINASE INHIBITORS VIA ONE-POT SONOGASHIRA COUPLING TMS-DEPROTECTION CUAAC SEQUENCE
1596, d3a8wB1, 0.7967, 2.09, 0.278, 324, 255, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1597, d3a7iA_, 0.7966, 2.23, 0.270, 286, 256, HUMAN MST3 KINASE IN COMPLEX WITH ADENINE
1598, d4qmzA_, 0.7965, 2.25, 0.266, 286, 256, MST3 IN COMPLEX WITH SUNITINIB
1599, d1smhA_, 0.7965, 2.31, 0.261, 348, 257, PROTEIN KINASE A VARIANT COMPLEX WITH COMPLETELY ORDERED N- TERMINAL HELIX
1600, d2bcjA3, 0.7962, 2.51, 0.246, 348, 260, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GALPHA-Q AND GBETAGAMMA SUBUNITS
1601, d5mrdA_, 0.7961, 2.31, 0.273, 283, 256, HUMAN PDK1-PKCIOTA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS267 BOUND TO THE PIF-POCKET
1602, d4aaaA1, 0.7960, 2.91, 0.401, 290, 267, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN
1603, d4qmxA_, 0.7959, 2.24, 0.270, 287, 256, MST3 IN COMPLEX WITH SARACATINIB
1604, d3l9lA_, 0.7958, 2.34, 0.265, 338, 257, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
1605, d2i0eA_, 0.7958, 2.33, 0.248, 326, 258, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
1606, d5lvmA_, 0.7957, 2.32, 0.273, 283, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENINE BOUND TO THE ATP- BINDING SITE
1607, d3qkkA_, 0.7956, 2.40, 0.271, 326, 258, SPIROCHROMANE AKT INHIBITORS
1608, d3krxA2, 0.7956, 2.44, 0.262, 349, 260, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (CO-CRYSTAL)
1609, d3a8xB1, 0.7956, 2.05, 0.280, 325, 254, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1610, d2x4zA1, 0.7955, 2.44, 0.257, 289, 257, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH PF-03758309
1611, d1rejA_, 0.7955, 2.35, 0.261, 333, 257, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 1
1612, d3iecA_, 0.7954, 2.07, 0.313, 311, 252, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1613, d2fsoX_, 0.7954, 2.39, 0.376, 325, 258, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A) ACTIVATING MUTANT
1614, d1ctpE_, 0.7954, 2.24, 0.262, 332, 256, STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION
1615, d3iecC_, 0.7953, 2.08, 0.313, 311, 252, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1616, d1h1wA_, 0.7953, 2.26, 0.267, 284, 255, HIGH RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PDK1 CATALYTIC DOMAIN
1617, d4qmlA_, 0.7952, 2.24, 0.270, 280, 256, MST3 IN COMPLEX WITH AMP-PNP
1618, d3pscA2, 0.7952, 2.52, 0.242, 344, 260, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
1619, d2uw7A_, 0.7952, 2.38, 0.257, 335, 257, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1620, d5lvlA_, 0.7951, 2.34, 0.273, 285, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND PS653 BOUND TO THE ATP-BINDING SITE
1621, d4figA_, 0.7950, 2.45, 0.268, 292, 257, CATALYTIC DOMAIN OF HUMAN PAK4
1622, d3rwqA_, 0.7950, 2.27, 0.267, 283, 255, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
1623, d4figB_, 0.7949, 2.45, 0.268, 292, 257, CATALYTIC DOMAIN OF HUMAN PAK4
1624, d3hrfA_, 0.7949, 2.28, 0.271, 284, 255, CRYSTAL STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN ALLOSTERIC ACTIVATOR BOUND TO THE PIF-POCKET
1625, d1xh8A_, 0.7949, 2.34, 0.261, 337, 257, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1626, d1uvrA_, 0.7949, 2.25, 0.267, 284, 255, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-8
1627, d5ml5A_, 0.7948, 2.54, 0.373, 326, 260, HUMAN P38ALPHA MAPK IN COMPLEX WITH IMIDAZOLYL PYRIDINE INHIBITOR 11B
1628, d3db6A_, 0.7947, 2.24, 0.253, 287, 257, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 902
1629, d1xhaA_, 0.7947, 2.34, 0.261, 348, 257, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1630, d3hrcA_, 0.7946, 2.35, 0.273, 279, 256, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ATP
1631, d4o0vA1, 0.7945, 2.50, 0.268, 289, 257, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1632, d4nw5A1, 0.7945, 2.25, 0.293, 296, 256, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 8
1633, d2jdvA_, 0.7945, 2.40, 0.257, 334, 257, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH A-443654
1634, d4rqvA_, 0.7944, 2.26, 0.271, 288, 255, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS2
1635, d4qnaA_, 0.7944, 2.27, 0.270, 284, 256, MST3 IN COMPLEX WITH 2-(46-DIAMINO-135-TRIAZIN-2-YL)PHENOL
1636, d4nw6A1, 0.7944, 2.26, 0.293, 296, 256, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 27
1637, d4ntsB_, 0.7944, 2.29, 0.257, 341, 257, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
1638, d1xh5A_, 0.7944, 2.37, 0.261, 335, 257, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1639, d5he2A2, 0.7943, 2.55, 0.246, 353, 260, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224406
1640, d5he0A2, 0.7943, 2.55, 0.258, 346, 260, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG215022
1641, d4jdiA_, 0.7942, 2.52, 0.268, 289, 257, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
1642, d2welA_, 0.7942, 2.29, 0.294, 304, 255, CRYSTAL STRUCTURE OF SU6656-BOUND CALCIUM/CALMODULIN- DEPENDENT PROTEIN KINASE II DELTA IN COMPLEX WITH CALMODULIN
1643, d2bajA2, 0.7942, 2.51, 0.391, 334, 256, P38ALPHA BOUND TO PYRAZOLOUREA
1644, d5lvoA_, 0.7941, 2.34, 0.273, 285, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PSE10 BOUND TO THE PIF-POCKET
1645, d5l2sA_, 0.7941, 2.22, 0.492, 263, 254, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND ABEMACICLIB.
1646, d4qmyA_, 0.7941, 2.27, 0.270, 287, 256, MST3 IN COMPLEX WITH STAUROSPORINE
1647, d4qmtA_, 0.7941, 2.28, 0.266, 284, 256, MST3 IN COMPLEX WITH HESPERADIN
1648, d4qmsA_, 0.7941, 2.27, 0.270, 283, 256, MST3 IN COMPLEX WITH DASATINIB
1649, d4o0yA1, 0.7941, 2.50, 0.268, 289, 257, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1650, d5lvnA_, 0.7940, 2.34, 0.273, 283, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENOSINE BOUND TO THE ATP- BINDING SITE
1651, d5bmsA1, 0.7940, 2.51, 0.268, 289, 257, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 4 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
1652, d4o0tA_, 0.7940, 2.40, 0.279, 292, 258, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1653, d4o0rA_, 0.7940, 2.41, 0.279, 293, 258, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1654, d4ct1A_, 0.7940, 2.34, 0.277, 283, 256, HUMAN PDK1-PKCZETA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS315 BOUND TO THE PIF-POCKET
1655, d2vo0A_, 0.7940, 2.41, 0.257, 340, 257, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
1656, d1svhA_, 0.7940, 2.30, 0.250, 335, 256, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 8
1657, d4xx9A_, 0.7939, 2.34, 0.273, 288, 256, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RF4
1658, d4rqkA_, 0.7939, 2.27, 0.267, 285, 255, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS1
1659, d3l9mB_, 0.7939, 2.38, 0.265, 336, 257, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
1660, d2uztA_, 0.7939, 2.44, 0.260, 336, 258, PKA STRUCTURES OF AKT INDAZOLE-PYRIDINE INHIBITORS
1661, d4qmnA_, 0.7938, 2.27, 0.270, 283, 256, MST3 IN COMPLEX WITH BOSUTINIB
1662, d4a06A_, 0.7938, 2.19, 0.268, 282, 254, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS114 BOUND TO THE PIF-POCKET
1663, d4qmmA_, 0.7936, 2.28, 0.266, 288, 256, MST3 IN COMPLEX WITH AT-9283 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]- 1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
1664, d3iecB_, 0.7936, 2.10, 0.313, 313, 252, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1665, d3iecD_, 0.7935, 2.12, 0.313, 311, 252, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1666, d1bkxA_, 0.7935, 2.29, 0.250, 337, 256, A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY
1667, d4o0xA1, 0.7934, 2.51, 0.268, 289, 257, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1668, d4qmuA_, 0.7933, 2.29, 0.246, 286, 256, MST3 IN COMPLEX WITH JNJ-7706621 4-({5-AMINO-1-[(26-DIFLUOROPHENYL) CARBONYL]-1H-124-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE
1669, d2uw6A_, 0.7933, 2.37, 0.258, 334, 256, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (S)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1670, d4c2vA_, 0.7932, 2.15, 0.292, 270, 253, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
1671, d3nuxA_, 0.7930, 2.23, 0.488, 261, 254, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
1672, d3ag9B_, 0.7930, 2.33, 0.262, 317, 256, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
1673, d4pnkA2, 0.7929, 2.54, 0.250, 350, 260, G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GSK180736A
1674, d1zysA_, 0.7929, 2.46, 0.261, 271, 257, CO-CRYSTAL STRUCTURE OF CHECKPOINT KINASE CHK1 WITH A PYRROLO-PYRIDINE INHIBITOR
1675, d5kbqA_, 0.7928, 2.44, 0.279, 289, 258, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
1676, d2uw0A_, 0.7928, 2.37, 0.258, 334, 256, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  6-(4-(4-(4- CHLORO-PHENYL)-PIPERIDIN-4-YL)-PHENYL)-9H-PURINE
1677, d2uvyA_, 0.7928, 2.37, 0.258, 333, 256, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH METHYL-(4-(9H- PURIN-6-YL)-BENZYL)-AMINE
1678, d1j3hA_, 0.7928, 2.27, 0.254, 329, 256, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
1679, d4jdhA_, 0.7927, 2.43, 0.270, 289, 256, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
1680, d3qkmA_, 0.7927, 2.44, 0.275, 329, 258, SPIROCYCLIC SULFONAMIDES AS AKT INHIBITORS
1681, d1ym7C3, 0.7927, 2.55, 0.242, 346, 260, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1682, d3cikA2, 0.7926, 2.57, 0.242, 347, 260, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
1683, d1rekA_, 0.7926, 2.37, 0.261, 336, 257, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 8
1684, d1o6kA_, 0.7926, 2.33, 0.280, 317, 257, STRUCTURE OF ACTIVATED FORM OF PKB KINASE DOMAIN S474D WITH GSK3 PEPTIDE AND AMP-PNP
1685, d2y7jB_, 0.7925, 2.21, 0.285, 281, 253, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1686, d2uw4A_, 0.7925, 2.41, 0.257, 334, 257, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-(5-METHYL- 1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1687, d1ym7A3, 0.7925, 2.48, 0.238, 347, 260, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1688, d1xh9A_, 0.7925, 2.33, 0.254, 336, 256, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1689, d5ackA_, 0.7924, 2.39, 0.273, 286, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND 7 BOUND TO THE PIF-POCKET
1690, d2jdtA_, 0.7924, 2.40, 0.257, 334, 257, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1691, d1ym7D3, 0.7924, 2.48, 0.238, 340, 260, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1692, d4crsA1, 0.7923, 2.30, 0.277, 329, 256, HUMAN PROTEIN KINASE N2 (PKN2 PRKCL2) IN COMPLEX WITH ATPGAMMAS
1693, d3d5wA_, 0.7923, 2.22, 0.263, 284, 255, CRYSTAL STRUCTURE OF A PHOSPHORYLATED POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH ADP.
1694, d1ym7B3, 0.7923, 2.49, 0.238, 347, 260, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1695, d2ydiA_, 0.7922, 2.58, 0.264, 279, 258, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
1696, d2vnwA_, 0.7922, 2.38, 0.258, 334, 256, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)METHANAMINE
1697, d2uvxA_, 0.7922, 2.42, 0.257, 335, 257, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 7-AZAINDOLE
1698, d3l9lB_, 0.7921, 2.34, 0.254, 337, 256, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
1699, d4w8dA_, 0.7920, 2.30, 0.266, 289, 256, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06454589).
1700, d4otdA_, 0.7920, 2.28, 0.281, 334, 256, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN
1701, d1okyA_, 0.7920, 2.26, 0.276, 281, 254, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1702, d1o6lA_, 0.7920, 2.34, 0.280, 316, 257, CRYSTAL STRUCTURE OF AN ACTIVATED AKT/PROTEIN KINASE B (PKB-PIF CHIMERA) TERNARY COMPLEX WITH AMP-PNP AND GSK3 PEPTIDE
1703, d1j3hB_, 0.7920, 2.28, 0.262, 327, 256, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
1704, d3e87B_, 0.7919, 2.36, 0.276, 321, 257, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1705, d3e87A_, 0.7919, 2.36, 0.276, 321, 257, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1706, d3a8wA1, 0.7919, 2.04, 0.277, 323, 253, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1707, d5li9A1, 0.7918, 2.22, 0.278, 328, 255, STRUCTURE OF A NUCLEOTIDE-BOUND FORM OF PKCIOTA CORE KINASE DOMAIN
1708, d5he1A2, 0.7918, 2.58, 0.265, 342, 260, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224062
1709, d4ntsA_, 0.7918, 2.35, 0.245, 341, 257, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
1710, d3otuA_, 0.7918, 2.34, 0.276, 276, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR JS30
1711, d3a7gB_, 0.7918, 2.25, 0.270, 290, 256, HUMAN MST3 KINASE
1712, d2vo3A_, 0.7918, 2.38, 0.258, 334, 256, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
1713, d2x8dA_, 0.7917, 2.48, 0.265, 279, 257, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
1714, d2ojfE_, 0.7917, 2.46, 0.260, 336, 258, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1715, d1ql6A_, 0.7916, 2.28, 0.283, 281, 254, THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES
1716, d4qmvA_, 0.7915, 2.32, 0.266, 288, 256, MST3 IN COMPLEX WITH PF-03814735 N-{2-[(1S4R)-6-{[4- (CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1234- TETRAHYDRO-14-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE
1717, d1omwA3, 0.7915, 2.54, 0.242, 344, 260, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN G PROTEIN-COUPLED RECEPTOR KINASE 2 AND HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNITS
1718, d3agmA_, 0.7914, 2.41, 0.265, 337, 257, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-670
1719, d2uw3A_, 0.7914, 2.40, 0.258, 334, 256, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 5-METHYL-4- PHENYL-1H-PYRAZOLE
1720, d1q8wA_, 0.7914, 2.32, 0.262, 334, 256, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR FASUDIL (HA-1077)
1721, d5ukmA2, 0.7913, 2.60, 0.246, 353, 260, BOVINE GRK2 IN COMPLEX WITH HUMAN GBETAGAMMA SUBUNITS AND CCG258208 (14AS)
1722, d4u8zA_, 0.7913, 2.30, 0.266, 289, 256, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06447475)
1723, d3a7hB_, 0.7913, 2.25, 0.270, 290, 256, HUMAN MST3 KINASE IN COMPLEX WITH ATP
1724, d5li1A1, 0.7912, 2.29, 0.281, 329, 256, STRUCTURE OF A PAR3-INHIBITORY PEPTIDE BOUND TO PKCIOTA CORE KINASE DOMAIN
1725, d4fijA_, 0.7912, 2.57, 0.268, 291, 257, CATALYTIC DOMAIN OF HUMAN PAK4
1726, d3e88B_, 0.7911, 2.36, 0.276, 319, 257, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1727, d3e88A_, 0.7911, 2.36, 0.276, 319, 257, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1728, d1zrzA_, 0.7911, 2.23, 0.275, 310, 255, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF ATYPICAL PROTEIN KINASE C-IOTA
1729, d1szmA_, 0.7911, 2.21, 0.264, 317, 254, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
1730, d1q61A_, 0.7911, 2.37, 0.250, 335, 256, PKA TRIPLE MUTANT MODEL OF PKB
1731, d4a07A_, 0.7910, 2.25, 0.268, 282, 254, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS171 BOUND TO THE PIF-POCKET
1732, d2vnyA_, 0.7910, 2.40, 0.258, 334, 256, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)AMINE
1733, d4i6fA_, 0.7909, 2.35, 0.236, 285, 258, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
1734, d3dneA_, 0.7909, 2.36, 0.250, 336, 256, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1735, d3ckxA_, 0.7909, 2.23, 0.276, 276, 254, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24) IN COMPLEX WITH STAUROSPORINE
1736, d4qmoA_, 0.7908, 2.31, 0.266, 288, 256, MST3 IN COMPLEX WITH IMIDAZOLO-OXINDOLE PKR INHIBITOR C16
1737, d3l9nA_, 0.7908, 2.41, 0.265, 332, 257, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 27
1738, d2f7zE_, 0.7908, 2.42, 0.253, 336, 257, PROTEIN KINASE A BOUND TO (R)-1-(1H-INDOL-3-YLMETHYL)-2-(2- PYRIDIN-4-YL-[17]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
1739, d2f7xE_, 0.7907, 2.46, 0.260, 336, 258, PROTEIN KINASE A BOUND TO (S)-2-(1H-INDOL-3-YL)-1-[5-((E)-2- PYRIDIN-4-YL-VINYL)-PYRIDIN-3-YLOXYMETHYL]-ETHYLAMINE
1740, d3orxC_, 0.7906, 2.33, 0.270, 283, 256, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1741, d2uvzA_, 0.7906, 2.41, 0.258, 334, 256, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH C-PHENYL-C-(4-( 9H-PURIN-6-YL)-PHENYL)-METHYLAMINE
1742, d3orxA_, 0.7905, 2.33, 0.270, 283, 256, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1743, d2oh0E_, 0.7905, 2.46, 0.260, 336, 258, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1744, d3orxD_, 0.7904, 2.33, 0.270, 282, 256, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1745, d3d0eB_, 0.7904, 2.40, 0.276, 322, 257, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1746, d3d0eA_, 0.7904, 2.40, 0.276, 322, 257, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1747, d2bujA1, 0.7904, 2.42, 0.242, 283, 256, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
1748, d3e8dB_, 0.7903, 2.39, 0.276, 317, 257, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1749, d3e8dA_, 0.7903, 2.39, 0.276, 315, 257, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1750, d2uzuE_, 0.7903, 2.46, 0.260, 336, 258, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1751, d2vo6A_, 0.7902, 2.42, 0.258, 335, 256, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4- CHLOROBENZYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YLAMINE
1752, d3ztxA_, 0.7901, 2.22, 0.296, 269, 253, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
1753, d2uzvA_, 0.7901, 2.50, 0.264, 336, 258, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1754, d2gnlA_, 0.7901, 2.45, 0.272, 338, 257, PKA THREEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR H- 1152P
1755, d1xh6A_, 0.7901, 2.37, 0.250, 331, 256, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1756, d1phkA_, 0.7900, 2.28, 0.283, 277, 254, TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE SUBSTRATE-ANALOGUE AND PRODUCT
1757, d4jdkA_, 0.7899, 2.53, 0.270, 288, 256, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
1758, d3ag9A_, 0.7899, 2.46, 0.257, 323, 257, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
1759, d3a7jA_, 0.7899, 2.37, 0.246, 286, 256, HUMAN MST3 KINASE IN COMPLEX WITH MNADP
1760, d2gnjA_, 0.7899, 2.38, 0.262, 335, 256, PKA THREE FOLD MUTANT MODEL OF RHO-KINASE WITH Y-27632
1761, d2f7eE_, 0.7899, 2.49, 0.260, 336, 258, PKA COMPLEXED WITH (S)-2-(1H-INDOL-3-YL)-1-(5-ISOQUINOLIN-6- YL-PYRIDIN-3-YLOXYMETHYL-ETYLAMINE
1762, d1re8A_, 0.7899, 2.41, 0.261, 337, 257, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 2
1763, d4qmqA_, 0.7897, 2.32, 0.266, 289, 256, MST3 IN COMPLEX WITH CP-673451
1764, d4i6hA_, 0.7897, 2.37, 0.236, 285, 258, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE ALPHA-SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
1765, d2uw5A_, 0.7897, 2.43, 0.258, 333, 256, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (R)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1766, d2c1bA_, 0.7897, 2.39, 0.250, 335, 256, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ( 4R2S)-5 -(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2- YLMETHANESULFONYL)ISOQUINOLINE
1767, d2c1aA_, 0.7897, 2.38, 0.250, 335, 256, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
1768, d1uu7A_, 0.7897, 2.20, 0.269, 280, 253, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-2
1769, d4ks7A_, 0.7896, 2.54, 0.276, 286, 257, PAK6 KINASE DOMAIN IN COMPLEX WITH PF-3758309
1770, d4b8mA_, 0.7896, 2.20, 0.296, 270, 253, AURORA B KINASE IN COMPLEX WITH VX-680
1771, d6aywB_, 0.7895, 2.56, 0.293, 293, 256, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1772, d5dh3B_, 0.7895, 2.41, 0.272, 283, 257, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
1773, d4o22A1, 0.7895, 2.30, 0.251, 333, 255, BINARY COMPLEX OF METAL-FREE PKAC WITH SP20.
1774, d3orxB_, 0.7895, 2.37, 0.266, 280, 256, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1775, d2q0nA_, 0.7895, 2.42, 0.270, 293, 256, STRUCTURE OF HUMAN P21 ACTIVATING KINASE 4 (PAK4) IN COMPLEX WITH A CONSENSUS PEPTIDE
1776, d2i0eB_, 0.7895, 2.37, 0.248, 300, 258, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
1777, d1xh4A_, 0.7895, 2.34, 0.251, 334, 255, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1778, d5vefA_, 0.7894, 2.49, 0.270, 289, 256, PAK4 KINASE DOMAIN IN COMPLEX WITH FASUDIL
1779, d1sveA_, 0.7894, 2.37, 0.250, 341, 256, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 1
1780, d4ae6A_, 0.7893, 2.35, 0.257, 319, 257, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
1781, d3ambA_, 0.7893, 2.45, 0.268, 340, 257, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR VX- 680
1782, d1svgA_, 0.7893, 2.37, 0.250, 338, 256, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 4
1783, d2vgoA_, 0.7892, 2.20, 0.292, 268, 253, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
1784, d5l2tA_, 0.7891, 2.16, 0.496, 261, 252, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND RIBOCICLIB.
1785, d5h9bA_, 0.7891, 2.30, 0.324, 269, 253, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/AMPPN
1786, d4otgA_, 0.7891, 2.35, 0.285, 322, 256, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH LESTAURTINIB
1787, d4jdjA_, 0.7891, 2.55, 0.270, 288, 256, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
1788, d4fihA_, 0.7891, 2.50, 0.270, 291, 256, CATALYTIC DOMAIN OF HUMAN PAK4 WITH QKFTGLPRQW PEPTIDE
1789, d3pooA_, 0.7891, 2.42, 0.254, 331, 256, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1790, d3aglB_, 0.7891, 2.37, 0.266, 335, 256, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
1791, d2bfxA_, 0.7891, 2.23, 0.296, 269, 253, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
1792, d2vrxA_, 0.7890, 2.21, 0.292, 268, 253, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
1793, d2vgpA_, 0.7890, 2.21, 0.292, 265, 253, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
1794, d1q62A_, 0.7890, 2.42, 0.246, 336, 256, PKA DOUBLE MUTANT MODEL OF PKB
1795, d4qmpA_, 0.7889, 2.35, 0.266, 289, 256, MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
1796, d4i6bA_, 0.7889, 2.41, 0.236, 285, 258, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
1797, d3dndA_, 0.7889, 2.38, 0.250, 334, 256, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1798, d2uzwE_, 0.7889, 2.44, 0.249, 336, 257, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1799, d1xh7A_, 0.7889, 2.42, 0.262, 337, 256, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1800, d3kk8A_, 0.7888, 2.56, 0.300, 283, 257, CAMKII SUBSTRATE COMPLEX A
1801, d1fotA_, 0.7888, 2.34, 0.234, 299, 256, STRUCTURE OF THE UNLIGANDED CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT FROM SACCHAROMYCES CEREVISIAE
1802, d5he3A2, 0.7887, 2.65, 0.262, 346, 260, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224411
1803, d1vebA_, 0.7887, 2.45, 0.261, 338, 257, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 5
1804, d4yxrA_, 0.7886, 2.47, 0.261, 334, 257, CRYSTAL STRUCTURE OF PKA IN COMPLEX WITH INHIBITOR.
1805, d4i5pA_, 0.7886, 2.39, 0.236, 284, 258, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
1806, d3e5aA_, 0.7886, 2.21, 0.298, 264, 252, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH VX-680 AND TPX2
1807, d2vo7A_, 0.7886, 2.40, 0.250, 335, 256, STRUCTURE OF PKA COMPLEXED WITH 4-(4-CHLOROBENZYL)-1-(7H- PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN-4-YLAMINE
1808, d4aw0A_, 0.7885, 2.39, 0.275, 283, 255, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS182 BOUND TO THE PIF-POCKET
1809, d3amaA_, 0.7885, 2.47, 0.268, 342, 257, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR JNJ- 7706621
1810, d3oogA_, 0.7884, 2.41, 0.254, 333, 256, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH A SMALL FRAGMENT
1811, d2gnfA_, 0.7884, 2.46, 0.276, 339, 257, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH Y- 27632
1812, d2xikA_, 0.7882, 2.32, 0.275, 288, 255, STRUCTURE OF HUMAN YSK1 (YEAST SPS1-STE20-RELATED KINASE 1)
1813, d4qo9B_, 0.7881, 2.38, 0.270, 285, 256, MST3 IN COMPLEX WITH DANUSERTIB
1814, d4ks8A_, 0.7881, 2.47, 0.286, 286, 255, PAK6 KINASE DOMAIN IN COMPLEX WITH SUNITINIB
1815, d2w99B_, 0.7881, 3.01, 0.472, 291, 265, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
1816, d1ydrE_, 0.7881, 2.46, 0.261, 334, 257, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5- ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE
1817, d2gu8A_, 0.7880, 2.42, 0.250, 335, 256, DISCOVERY OF 2-PYRIMIDYL-5-AMIDOTHIOPHENES AS NOVEL AND POTENT INHIBITORS FOR AKT: SYNTHESIS AND SAR STUDIES
1818, d4c2wA_, 0.7879, 2.25, 0.300, 268, 253, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
1819, d2gnhA_, 0.7878, 2.46, 0.276, 338, 257, PKA FIVE FOLD MUTANT MODEL OF RHO-KINASE WITH H1152P
1820, d2bfyA_, 0.7878, 2.27, 0.277, 270, 253, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
1821, d1ydsE_, 0.7878, 2.47, 0.261, 334, 257, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H8 PROTEIN KINASE INHIBITOR [N-(2-METHYLAMINO)ETHYL]-5- ISOQUINOLINESULFONAMIDE
1822, d2bfxB_, 0.7877, 2.28, 0.269, 275, 253, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
1823, d2qvsE_, 0.7875, 2.43, 0.253, 323, 257, CRYSTAL STRUCTURE OF TYPE IIA HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
1824, d2gngA_, 0.7875, 2.46, 0.276, 338, 257, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE
1825, d2xckA_, 0.7873, 2.19, 0.267, 275, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1826, d2uw8A_, 0.7873, 2.45, 0.258, 334, 256, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-CHLORO- PHENYL)-2-PHENYL-ETHYLAMINE
1827, d2erzE_, 0.7872, 2.48, 0.261, 334, 257, CRYSTAL STRUCTURE OF C-AMP DEPENDENT KINASE (PKA) BOUND TO HYDROXYFASUDIL
1828, d2gfcA_, 0.7871, 2.42, 0.250, 335, 256, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1829, d5vloB_, 0.7870, 2.59, 0.293, 293, 256, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1830, d4hyiA_, 0.7870, 2.44, 0.267, 269, 255, X-RAY CRYSTAL STRUCTURE OF COMPOUND 40 BOUND TO HUMAN CHK1 KINASE DOMAIN
1831, d4c2wB_, 0.7870, 2.27, 0.292, 277, 253, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
1832, d3p0mA_, 0.7870, 2.42, 0.254, 335, 256, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1833, d5l2iA_, 0.7868, 2.28, 0.484, 260, 252, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND PALBOCICLIB.
1834, d4c2vB_, 0.7868, 2.28, 0.292, 280, 253, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
1835, d4b8mB_, 0.7868, 2.21, 0.290, 279, 252, AURORA B KINASE IN COMPLEX WITH VX-680
1836, d3oxtA_, 0.7867, 2.50, 0.254, 335, 256, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1837, d3e8eI_, 0.7866, 2.41, 0.250, 345, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1838, d3o7lB_, 0.7865, 2.40, 0.242, 326, 256, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
1839, d2gniA_, 0.7865, 2.42, 0.266, 338, 256, PKA FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR FASUDIL (HA1077)
1840, d3v5wA2, 0.7864, 2.58, 0.243, 355, 259, HUMAN G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH SOLUBLE GBETAGAMMA SUBUNITS AND PAROXETINE
1841, d5uklA2, 0.7863, 2.60, 0.243, 353, 259, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG222886 (14BD)
1842, d3mfuA_, 0.7863, 2.78, 0.304, 302, 257, CASK-4M CAM KINASE DOMAIN AMPPNP-MN2+
1843, d1q8uA_, 0.7863, 2.48, 0.261, 341, 257, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR H-1152P
1844, d3nx8A_, 0.7862, 2.49, 0.265, 333, 257, HUMAN CAMP DEPENDENT PROTEIN KINASE IN COMPLEX WITH PHENOL
1845, d1xjdA_, 0.7862, 2.17, 0.287, 280, 251, CRYSTAL STRUCTURE OF PKC-THETA COMPLEXED WITH STAUROSPORINE AT 2A RESOLUTION
1846, d3nayB_, 0.7861, 2.20, 0.279, 278, 251, PDK1 IN COMPLEX WITH INHIBITOR MP6
1847, d2xchA_, 0.7861, 2.20, 0.271, 278, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1848, d1ydtE_, 0.7861, 2.43, 0.250, 334, 256, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2- (4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE
1849, d1q8tA_, 0.7860, 2.43, 0.250, 338, 256, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH RHO-KINASE INHIBITOR Y-27632
1850, d6babD_, 0.7859, 2.47, 0.294, 291, 255, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1851, d3ztxB_, 0.7859, 2.30, 0.296, 272, 253, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
1852, d3e8cF_, 0.7859, 2.49, 0.261, 341, 257, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1853, d3e8cD_, 0.7859, 2.48, 0.261, 344, 257, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1854, d2vrxB_, 0.7859, 2.30, 0.296, 274, 253, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
1855, d2vgpB_, 0.7859, 2.30, 0.269, 277, 253, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
1856, d1jbpE_, 0.7859, 2.42, 0.250, 339, 256, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE COMPLEXED WITH A SUBSTRATE PEPTIDE ADP AND DETERGENT
1857, d1ia8A_, 0.7859, 2.54, 0.267, 272, 255, THE 1.7 A CRYSTAL STRUCTURE OF HUMAN CELL CYCLE CHECKPOINT KINASE CHK1
1858, d3e8cA_, 0.7858, 2.49, 0.261, 341, 257, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1859, d1jluE_, 0.7858, 2.44, 0.250, 337, 256, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PHOSPHORYLATED SUBSTRATE PEPTIDE AND DETERGENT
1860, d3e8cE_, 0.7857, 2.49, 0.261, 336, 257, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1861, d3e8cC_, 0.7857, 2.49, 0.261, 341, 257, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1862, d3e8cB_, 0.7857, 2.49, 0.261, 344, 257, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1863, d4l67A_, 0.7856, 2.55, 0.270, 289, 256, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF PAK4
1864, d5k3yA_, 0.7855, 2.27, 0.289, 267, 253, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
1865, d5dh3A_, 0.7855, 2.48, 0.272, 287, 257, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
1866, d4appA1, 0.7855, 2.66, 0.257, 290, 257, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH (S)-N-(5-(3-BENZYL-1-METHYLPIPERAZINE-4- CARBONYL)-66-DIMETHYL-1456-TETRAHYDROPYRROLO(34-C) PYRAZOL-3-YL)-3-PHENOXYBENZAMIDE
1867, d3tnqB_, 0.7855, 2.46, 0.262, 331, 256, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1868, d2ywpA_, 0.7855, 2.52, 0.267, 269, 255, CRYSTAL STRUCTURE OF CHK1 WITH A UREA INHIBITOR
1869, d5i0bA_, 0.7854, 2.44, 0.272, 288, 254, STRUCTURE OF PAK4
1870, d4zy4A_, 0.7854, 2.27, 0.281, 288, 253, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
1871, d2fgaA_, 0.7854, 2.52, 0.267, 269, 255,  
1872, d3ow3A_, 0.7853, 2.46, 0.250, 334, 256, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1873, d3idbA_, 0.7852, 2.44, 0.250, 341, 256, CRYSTAL STRUCTURE OF (108-268)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
1874, d5fg8A_, 0.7851, 2.36, 0.320, 269, 253, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
1875, d3mvjE_, 0.7851, 2.49, 0.265, 334, 257, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
1876, d2y7jD_, 0.7851, 2.31, 0.262, 281, 252, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1877, d2e9oA_, 0.7851, 2.42, 0.268, 269, 254, STRUCTURE OF H-CHK1 COMPLEXED WITH AA582939
1878, d1q24A_, 0.7851, 2.47, 0.246, 335, 256, PKA DOUBLE MUTANT MODEL OF PKB IN COMPLEX WITH MGATP
1879, d4wbbB_, 0.7850, 2.47, 0.262, 334, 256, SINGLE TURNOVER AUTOPHOSPHORYLATION CYCLE OF THE PKA RIIB HOLOENZYME
1880, d2cdzA_, 0.7850, 2.43, 0.272, 289, 254, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A
1881, d2vgoB_, 0.7849, 2.23, 0.294, 277, 252, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
1882, d5ho7A_, 0.7847, 2.21, 0.275, 280, 251, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1883, d4aw1A_, 0.7847, 2.26, 0.270, 283, 252, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS210 BOUND TO THE PIF-POCKET
1884, d1zltA_, 0.7847, 2.44, 0.268, 272, 254, CRYSTAL STRUCTURE OF CHK1 COMPLEXED WITH A HYMENALDISINE ANALOG
1885, d3e8eP_, 0.7846, 2.45, 0.250, 341, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1886, d1sykA_, 0.7846, 2.54, 0.249, 348, 257, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
1887, d4ae9A_, 0.7844, 2.38, 0.262, 321, 256, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
1888, d3c0iA_, 0.7844, 2.80, 0.300, 298, 257, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P212121 FORM
1889, d3sc1A_, 0.7843, 2.21, 0.271, 278, 251, NOVEL ISOQUINOLONE PDK1 INHIBITORS DISCOVERED THROUGH FRAGMENT-BASED LEAD DISCOVERY
1890, d3mfsA_, 0.7843, 2.77, 0.304, 303, 257, CASK-4M CAM KINASE DOMAIN AMPPNP
1891, d5ig1A_, 0.7842, 2.55, 0.282, 300, 255, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
1892, d2aypA_, 0.7842, 2.39, 0.268, 268, 254, CRYSTAL STRUCTURE OF CHK1 WITH AN INDOL INHIBITOR
1893, d2jdsA_, 0.7841, 2.42, 0.251, 334, 255, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A- 443654
1894, d2bfyB_, 0.7841, 2.43, 0.281, 278, 253, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
1895, d2cgxA_, 0.7840, 2.41, 0.272, 265, 254, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
1896, d4ct2A_, 0.7839, 2.11, 0.280, 277, 250, HUMAN PDK1-PKCZETA KINASE CHIMERA
1897, d2qurA_, 0.7839, 2.45, 0.250, 338, 256, CRYSTAL STRUCTURE OF F327A/K285P MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
1898, d2e9uA_, 0.7839, 2.56, 0.271, 269, 255, STRUCTURE OF H-CHK1 COMPLEXED WITH A780125
1899, d5k3yB_, 0.7837, 2.40, 0.300, 277, 253, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
1900, d4ez5A_, 0.7835, 2.25, 0.494, 258, 251, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
1901, d3nayA_, 0.7835, 2.23, 0.275, 278, 251, PDK1 IN COMPLEX WITH INHIBITOR MP6
1902, d3fjqE_, 0.7835, 2.48, 0.250, 334, 256, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA IN COMPLEX WITH PEPTIDE INHIBITOR PKI ALPHA (6-25)
1903, d2vn9B_, 0.7834, 2.48, 0.290, 301, 255, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
1904, d2e9nA_, 0.7834, 2.46, 0.268, 269, 254, STRUCTURE OF H-CHK1 COMPLEXED WITH A767085
1905, d2c30A_, 0.7834, 2.62, 0.257, 289, 257, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 6
1906, d2brbA_, 0.7834, 2.59, 0.271, 272, 255, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1907, d4qo9A_, 0.7833, 2.46, 0.270, 280, 256, MST3 IN COMPLEX WITH DANUSERTIB
1908, d2ghgA1, 0.7833, 2.54, 0.267, 269, 255, H-CHK1 COMPLEXED WITH A431994
1909, d1fmoE_, 0.7832, 2.47, 0.250, 336, 256, CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE
1910, d2cgvA_, 0.7831, 2.35, 0.273, 264, 253, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
1911, d1sykB_, 0.7831, 2.56, 0.253, 323, 257, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
1912, d1apmE_, 0.7831, 2.47, 0.250, 338, 256, 2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT
1913, d5eykB_, 0.7830, 2.38, 0.285, 275, 253, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
1914, d4o21A_, 0.7830, 2.44, 0.251, 333, 255, PRODUCT COMPLEX OF METAL-FREE PKAC ATP-GAMMA-S AND SP20.
1915, d4njdA1, 0.7829, 2.58, 0.270, 289, 256, STRUCTURE OF P21-ACTIVATED KINASE 4 WITH A NOVEL INHIBITOR KY-04031
1916, d3mfrA_, 0.7829, 2.81, 0.304, 302, 257, CASK-4M CAM KINASE DOMAIN NATIVE
1917, d3c0hB_, 0.7829, 2.76, 0.296, 300, 257, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
1918, d2vn9A_, 0.7829, 2.49, 0.290, 301, 255, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
1919, d2hxqA_, 0.7829, 2.59, 0.267, 272, 255, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2
1920, d4yr8F_, 0.7828, 2.47, 0.368, 300, 253, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1921, d4j7bA_, 0.7828, 2.12, 0.268, 284, 250, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
1922, d3e8eE_, 0.7827, 2.46, 0.250, 341, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1923, d3e8eB_, 0.7827, 2.47, 0.250, 337, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1924, d1rdqE_, 0.7827, 2.51, 0.246, 340, 256, HYDROLYSIS OF ATP IN THE CRYSTAL OF Y204A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
1925, d3qamE_, 0.7826, 2.50, 0.246, 348, 256, CRYSTAL STRUCTURE OF GLU208ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1926, d1atpE_, 0.7826, 2.49, 0.250, 334, 256, 2.2 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH MNATP AND A PEPTIDE INHIBITOR
1927, d3e8eA_, 0.7825, 2.54, 0.261, 341, 257, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1928, d6aywA_, 0.7821, 2.45, 0.295, 293, 254, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1929, d2hxlA_, 0.7821, 2.50, 0.272, 272, 254, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1
1930, d2w9zB_, 0.7820, 3.14, 0.472, 287, 265, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
1931, d5vloA_, 0.7818, 2.47, 0.295, 290, 254, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1932, d3rwpA_, 0.7818, 2.23, 0.272, 277, 250, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
1933, d3c0hA_, 0.7817, 2.82, 0.296, 300, 257, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
1934, d3a7gA_, 0.7817, 2.46, 0.270, 289, 256, HUMAN MST3 KINASE
1935, d2cpkE_, 0.7817, 2.46, 0.251, 333, 255, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE
1936, d2cguA_, 0.7817, 2.37, 0.273, 263, 253, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
1937, d5hngA_, 0.7816, 2.27, 0.271, 280, 251, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1938, d3iopA_, 0.7816, 2.22, 0.272, 275, 250, PDK-1 IN COMPLEX WITH THE INHIBITOR COMPOUND-8I
1939, d2br1A_, 0.7816, 2.60, 0.271, 272, 255, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1940, d3e8eL_, 0.7815, 2.48, 0.250, 336, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1941, d3nusA_, 0.7814, 2.12, 0.273, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT8
1942, d4x6rA_, 0.7813, 2.51, 0.262, 347, 256, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
1943, d4j7bD_, 0.7813, 2.11, 0.269, 281, 249, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
1944, d4ae6B_, 0.7813, 2.60, 0.257, 321, 257, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
1945, d3orzB_, 0.7813, 2.30, 0.271, 278, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
1946, d3orzD_, 0.7812, 2.30, 0.271, 278, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
1947, d4fzaB1, 0.7811, 2.47, 0.254, 280, 256, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX
1948, d3nuuA_, 0.7811, 2.12, 0.273, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT11
1949, d1okzA_, 0.7811, 2.12, 0.273, 276, 249, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH UCN-01
1950, d3qalE_, 0.7810, 2.52, 0.246, 339, 256, CRYSTAL STRUCTURE OF ARG280ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1951, d3nuyA_, 0.7809, 2.13, 0.273, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT17
1952, d3mftA_, 0.7808, 2.80, 0.304, 302, 257, CASK-4M CAM KINASE DOMAIN MN2+
1953, d5ukkA2, 0.7807, 2.72, 0.258, 348, 260, HUMAN GRK2 IN COMPLEX WITH HUMAN G-BETA-GAMMA SUBUNITS AND CCG211998 (14AK)
1954, d3h9oA_, 0.7807, 2.23, 0.272, 275, 250, PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK-1) IN COMPLEX WITH COMPOUND 9
1955, d1u7eA_, 0.7807, 2.52, 0.250, 338, 256,  
1956, d3nunA_, 0.7806, 2.14, 0.273, 278, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH LEAD COMPOUND
1957, d1uu8A_, 0.7805, 2.12, 0.273, 277, 249, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-1
1958, d3fhiA_, 0.7804, 2.53, 0.250, 336, 256, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE CATALYTIC AND REGULATORY (RI{ALPHA}) SUBUNITS OF PKA
1959, d2brnA_, 0.7804, 2.53, 0.264, 268, 254, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1960, d5ho8A_, 0.7803, 2.12, 0.273, 278, 249, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1961, d3qd3A_, 0.7803, 2.15, 0.273, 278, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL {(3R6S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-6-METHYL-3-PIPERIDINYL}CARBAMATE
1962, d2bdwB_, 0.7803, 2.51, 0.298, 309, 255, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
1963, d2gdoA_, 0.7802, 2.45, 0.273, 269, 253, 4-(AMINOALKYLAMINO)-3-BENZIMIDAZOLE-QUINOLINONES AS POTENT CHK1 INHIBITORS
1964, d6b16A_, 0.7801, 2.24, 0.283, 285, 251, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
1965, d4ewhB_, 0.7800, 2.45, 0.248, 273, 254, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
1966, d4ewhA_, 0.7800, 2.45, 0.248, 274, 254, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
1967, d3qcqA_, 0.7800, 2.15, 0.273, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-(3- AMINO-1H-INDAZOL-6-YL)-N4-ETHYL-24-PYRIMIDINEDIAMINE
1968, d3a7hA_, 0.7800, 2.49, 0.254, 289, 256, HUMAN MST3 KINASE IN COMPLEX WITH ATP
1969, d2e9vA_, 0.7800, 2.50, 0.268, 268, 254, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
1970, d3a7fA_, 0.7799, 2.29, 0.266, 283, 252, HUMAN MST3 KINASE
1971, d4bbmB1, 0.7798, 3.04, 0.408, 288, 260, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
1972, d3comA_, 0.7798, 2.41, 0.278, 264, 255, CRYSTAL STRUCTURE OF MST1 KINASE
1973, d3mvjA_, 0.7797, 2.53, 0.254, 334, 256, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
1974, d2c3kA_, 0.7797, 2.39, 0.274, 262, 252, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
1975, d1cdkB_, 0.7797, 2.54, 0.254, 342, 256, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
1976, d6babB_, 0.7796, 2.48, 0.300, 285, 253, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1977, d3qcxA_, 0.7796, 2.16, 0.273, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-{2- AMINO-6-[(3R)-3-METHYL-4-MORPHOLINYL]-4-PYRIMIDINYL}-1H-INDAZOL-3- AMINE
1978, d2broA_, 0.7796, 2.65, 0.267, 272, 255, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1979, d3qcsA_, 0.7794, 2.16, 0.273, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-[2- AMINO-6-(4-MORPHOLINYL)-4-PYRIMIDINYL]-1H-INDAZOL-3-AMINE
1980, d4x6qC_, 0.7793, 2.47, 0.251, 334, 255, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
1981, d3tnpC_, 0.7793, 2.47, 0.251, 334, 255, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1982, d3mvjB_, 0.7793, 2.55, 0.258, 320, 256, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
1983, d3c0gA_, 0.7793, 2.81, 0.293, 309, 256, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
1984, d2qcsA_, 0.7793, 2.56, 0.262, 335, 256, A COMPLEX STRUCTURE BETWEEN THE CATALYTIC AND REGULATORY SUBUNIT OF PROTEIN KINASE A THAT REPRESENTS THE INHIBITED STATE
1985, d1l3rE_, 0.7793, 2.52, 0.251, 338, 255, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
1986, d3tnpF_, 0.7792, 2.47, 0.251, 334, 255, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1987, d3c0gB_, 0.7788, 2.85, 0.296, 320, 257, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
1988, d2cgwA_, 0.7788, 2.37, 0.270, 262, 252, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
1989, d3bhhB1, 0.7786, 2.77, 0.312, 288, 256, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
1990, d3d5xA_, 0.7785, 2.16, 0.256, 279, 250, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH WORTMANNIN.
1991, d2e9vB_, 0.7785, 2.52, 0.268, 268, 254, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
1992, d5oq5A_, 0.7783, 2.38, 0.270, 265, 252, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
1993, d3orzC_, 0.7783, 2.30, 0.272, 276, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
1994, d3orzA_, 0.7783, 2.31, 0.272, 276, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
1995, d2x7fB_, 0.7783, 2.22, 0.248, 288, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
1996, d1uu3A_, 0.7783, 2.22, 0.273, 276, 249, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH LY333531
1997, d3orxE_, 0.7782, 2.23, 0.276, 274, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1998, d3comB_, 0.7782, 2.52, 0.272, 279, 257, CRYSTAL STRUCTURE OF MST1 KINASE
1999, d4zy6A_, 0.7781, 2.23, 0.284, 284, 250, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
2000, d3bwjA_, 0.7781, 2.53, 0.251, 338, 255, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR LEAD COMPOUND ARC-1034
2001, d4auaA_, 0.7780, 2.17, 0.498, 256, 249, LIGANDED X-RAY CRYSTAL STRUCTURE OF CYCLIN DEPENDENT KINASE 6 (CDK6)
2002, d2z8cA1, 0.7780, 2.57, 0.197, 297, 254, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN-2- YL]AMINO}PHENYL)ACETIC ACID
2003, d2v7oA1, 0.7780, 2.62, 0.302, 297, 255, CRYSTAL STRUCTURE OF HUMAN CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II GAMMA
2004, d2r7bA_, 0.7779, 2.22, 0.273, 274, 249, CRYSTAL STRUCTURE OF THE PHOSPHOINOSITIDE-DEPENDENT KINASE- 1 (PDK-1)CATALYTIC DOMAIN BOUND TO A DIBENZONAPHTHYRIDINE INHIBITOR
2005, d5xdkA_, 0.7778, 2.67, 0.203, 307, 256, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH CO-1686
2006, d3ionA_, 0.7778, 2.23, 0.273, 274, 249, PDK1 IN COMPLEX WITH COMPOUND 8H
2007, d2x7fC_, 0.7778, 2.09, 0.250, 285, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2008, d3w2qA1, 0.7777, 2.70, 0.198, 306, 257, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH HKI-272
2009, d3qcyA_, 0.7777, 2.14, 0.274, 275, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 4-[2- AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-N-PHENYL-2- MORPHOLINECARBOXAMIDE
2010, d4j96B_, 0.7776, 2.55, 0.236, 305, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
2011, d3f3zA_, 0.7776, 2.52, 0.265, 271, 253, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840 IN PRESENCE OF INDIRUBIN E804
2012, d1uu9A_, 0.7776, 2.20, 0.273, 276, 249, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-3
2013, d5jznB_, 0.7775, 2.16, 0.291, 266, 247, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
2014, d3gu5A1, 0.7775, 2.34, 0.267, 276, 251, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP-MG2+
2015, d2pe2A_, 0.7775, 2.24, 0.273, 275, 249, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-OXO-5-UREIDO-12-DIHYDRO-INDOL-(3Z)-YLIDENEMETHYL]-1H- PYRROL-3-YL}-N-(2-PIPERIDIN-1-YL-ETHYL)-BENZAMIDE COMPLEX
2016, d3uodA_, 0.7772, 2.30, 0.295, 266, 251, AURORA A IN COMPLEX WITH RPM1693
2017, d2pe0A_, 0.7772, 2.23, 0.273, 275, 249, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-HYDROXY-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-13-DIHYDRO- INDOL-2-ONE COMPLEX
2018, d3lcdA_, 0.7771, 2.32, 0.218, 290, 252, INHIBITOR BOUND TO A DFG-IN STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
2019, d3orxG_, 0.7770, 2.20, 0.277, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2020, d3orxF_, 0.7770, 2.20, 0.277, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2021, d2hz4A_, 0.7770, 2.50, 0.230, 262, 252, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
2022, d2eb2A_, 0.7770, 2.67, 0.199, 305, 256, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (G719S)
2023, d4zy5A_, 0.7768, 2.25, 0.284, 283, 250, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
2024, d3orxH_, 0.7768, 2.20, 0.277, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2025, d3ha6A1, 0.7768, 2.38, 0.304, 262, 250, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH TPX2 AND COMPOUND 10
2026, d3dlsA_, 0.7767, 2.59, 0.256, 285, 254, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2027, d1z5mA_, 0.7766, 2.25, 0.273, 275, 249, CRYSTAL STRUCTURE OF N1-[3-[[5-BROMO-2-[[3-[(1-PYRROLIDINYLCARBONYL) AMINO]PHENYL]AMINO]-4-PYRIMIDINYL]AMINO]PROPYL]-22- DIMETHYLPROPANEDIAMIDE COMPLEXED WITH HUMAN PDK1
2028, d4u44A_, 0.7765, 2.32, 0.254, 286, 252, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
2029, d5hkmA_, 0.7763, 2.14, 0.274, 272, 248, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2030, d4u45A_, 0.7763, 2.42, 0.257, 289, 253, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
2031, d4xliB_, 0.7762, 2.43, 0.218, 264, 252, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
2032, d1cdkA_, 0.7762, 2.59, 0.254, 342, 256, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
2033, d3gu4A1, 0.7761, 2.35, 0.267, 276, 251, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP
2034, d1jkkA_, 0.7761, 2.35, 0.267, 277, 251, 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG.
2035, d5ui0B_, 0.7760, 2.63, 0.232, 304, 254, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
2036, d3up2A_, 0.7760, 2.32, 0.295, 266, 251, AURORA A IN COMPLEX WITH RPM1686
2037, d1jksA_, 0.7760, 2.35, 0.267, 280, 251, 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2038, d1ig1A_, 0.7760, 2.35, 0.267, 280, 251, 1.8A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MN.
2039, d2j0iA_, 0.7759, 2.49, 0.272, 289, 254, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
2040, d4qyeA_, 0.7758, 2.51, 0.271, 271, 251, CHK1 KINASE DOMAIN IN COMPLEX WITH DIARYLPYRAZINE COMPOUND 1
2041, d1jklA_, 0.7758, 2.36, 0.267, 280, 251, 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE
2042, d1eh4B_, 0.7758, 2.67, 0.178, 293, 258, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
2043, d4fsnA_, 0.7757, 2.50, 0.271, 270, 251, CRYSTAL STRUCTURE OF THE CHK1
2044, d4ae9B_, 0.7757, 2.53, 0.263, 321, 255, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
2045, d3nupA_, 0.7757, 2.19, 0.492, 252, 248, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
2046, d5uyjA1, 0.7756, 2.46, 0.274, 279, 252, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2047, d4rvkA_, 0.7756, 2.39, 0.272, 264, 250, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 8: N-[3-(6-CYANO-9H- PYRROLO[23-B:54-C ]DIPYRIDIN-3-YL)PHENYL]ACETAMIDE
2048, d4j98B_, 0.7755, 2.52, 0.237, 304, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
2049, d3bhhA1, 0.7755, 2.64, 0.319, 287, 254, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2050, d2f4jA_, 0.7755, 2.63, 0.236, 287, 254, STRUCTURE OF THE KINASE DOMAIN OF AN IMATINIB-RESISTANT ABL MUTANT IN COMPLEX WITH THE AURORA KINASE INHIBITOR VX-680
2051, d5jznA_, 0.7753, 2.25, 0.290, 268, 248, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
2052, d3gu7A1, 0.7753, 2.37, 0.267, 276, 251, CRYSTAL STRUCTURE OF DAPKQ23V-ADP-MG2+
2053, d3dfcB1, 0.7752, 2.36, 0.267, 276, 251, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH AMPPNP
2054, d4qyfA_, 0.7751, 2.41, 0.272, 269, 250, CHK1 KINASE DOMAIN IN COMPLEX WITH AMINOPYRAZINE COMPOUND 13
2055, d3dgkA1, 0.7751, 2.37, 0.267, 276, 251, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN
2056, d3w2oA1, 0.7750, 2.73, 0.198, 304, 257, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH TAK-285
2057, d2w4jA_, 0.7750, 2.38, 0.267, 276, 251, X-RAY STRUCTURE OF A DAP-KINASE 2-277
2058, d2c3jA_, 0.7750, 2.33, 0.268, 257, 250, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
2059, d1nvsA_, 0.7750, 2.40, 0.272, 264, 250, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/SB218078
2060, d4pf4A1, 0.7749, 2.37, 0.267, 277, 251, 1.1A X-RAY STRUCTURE OF THE APO CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1 AA 1-277
2061, d4deaA_, 0.7749, 2.32, 0.295, 266, 251, AURORA A IN COMPLEX WITH YL1-038-18
2062, d3eqrB_, 0.7749, 2.39, 0.251, 271, 251, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
2063, d3aglA_, 0.7749, 2.62, 0.265, 338, 257, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
2064, d4i23A_, 0.7748, 2.68, 0.200, 304, 255, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH DACOMITINIB (SOAKED)
2065, d3gu6A1, 0.7748, 2.38, 0.267, 276, 251, CRYSTAL STRUCTURE OF DAPKQ23V-ADP
2066, d2brmA_, 0.7748, 2.53, 0.274, 263, 252, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2067, d1nvrA_, 0.7747, 2.41, 0.272, 264, 250, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/STAUROSPORINE
2068, d3idcA_, 0.7746, 2.57, 0.250, 341, 256, CRYSTAL STRUCTURE OF (102-265)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
2069, d2pe1A_, 0.7746, 2.28, 0.273, 275, 249, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-OXO-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-23-DIHYDRO-1H- INDOL-5-YL}-UREA {BX-517} COMPLEX
2070, d2gqgB1, 0.7745, 2.51, 0.218, 270, 252, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
2071, d1nvqA_, 0.7745, 2.41, 0.272, 264, 250, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/UCN-01
2072, d5hibA_, 0.7744, 2.84, 0.195, 314, 257, EGFR KINASE DOMAIN MUTANT TMLR WITH A PYRAZOLOPYRIMIDINE INHIBITOR
2073, d4ft9A_, 0.7744, 2.53, 0.271, 270, 251, CRYSTAL STRUCTURE OF THE CHK1
2074, d5eykA_, 0.7742, 2.24, 0.297, 263, 249, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
2075, d5b2lA_, 0.7742, 2.39, 0.226, 288, 252, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
2076, d3zh8A_, 0.7742, 2.58, 0.281, 318, 256, A NOVEL SMALL MOLECULE APKC INHIBITOR
2077, d2qhmA_, 0.7742, 2.42, 0.272, 268, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2A
2078, d5ugbA_, 0.7741, 2.58, 0.201, 307, 254, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN IN COMPLEX WITH 4-(4-{[2- {[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9-(PROPAN-2-YL)-9H-PURIN-6- YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
2079, d3w2pA1, 0.7739, 2.84, 0.198, 307, 258, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 2
2080, d3odyX_, 0.7739, 2.89, 0.369, 321, 255, CRYSTAL STRUCTURE OF P38ALPHA Y323Q ACTIVE MUTANT
2081, d3gu8A1, 0.7739, 2.38, 0.267, 276, 251, CRYSTAL STRUCTURE OF DAPKL93G WITH N6-CYCLOPENTYLADENOSINE
2082, d2phkA_, 0.7739, 2.48, 0.285, 277, 253, THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION
2083, d5jzjA_, 0.7738, 2.20, 0.285, 271, 246, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
2084, d3tkiA_, 0.7738, 2.53, 0.271, 272, 251, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S25
2085, d4hyhA_, 0.7737, 2.37, 0.272, 263, 250, X-RAY CRYSTAL STRUCTURE OF COMPOUND 39 BOUND TO HUMAN CHK1 KINASE DOMAIN
2086, d3qd4A_, 0.7737, 2.16, 0.271, 276, 247, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL{(3R5R)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-5-METHYL-3-PIPERIDINYL}CARBAMATE
2087, d5oorA_, 0.7736, 2.34, 0.269, 273, 249, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH STAUROSPORINE
2088, d4l3lA_, 0.7736, 2.42, 0.295, 291, 251, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN (ZINC ANOMALOUS)
2089, d4j97D_, 0.7736, 2.65, 0.236, 285, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
2090, d3zh8B_, 0.7736, 2.58, 0.281, 317, 256, A NOVEL SMALL MOLECULE APKC INHIBITOR
2091, d3uo5A_, 0.7736, 2.39, 0.299, 267, 251, AURORA A IN COMPLEX WITH YL1-038-31
2092, d3ue4B_, 0.7735, 2.62, 0.209, 268, 253, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
2093, d3eqrA_, 0.7735, 2.46, 0.251, 270, 251, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
2094, d5ui0A_, 0.7734, 2.61, 0.232, 301, 254, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
2095, d3nlbA_, 0.7734, 2.46, 0.271, 261, 251, NOVEL KINASE PROFILE HIGHLIGHTS THE TEMPORAL BASIS OF CONTEXT DEPENDENT CHECKPOINT PATHWAYS TO CELL DEATH
2096, d1rqqB_, 0.7734, 2.70, 0.200, 294, 255, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
2097, d4rvmA_, 0.7731, 2.43, 0.272, 264, 250, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 19
2098, d5eg3A_, 0.7730, 2.60, 0.227, 301, 255, CRYSTAL STRUCTURE OF THE ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH THE CSH2 DOMAIN OF PHOSPHOLIPASE C GAMMA (PLCGAMMA)
2099, d4twpB_, 0.7729, 2.60, 0.221, 271, 253, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
2100, d4ftiA_, 0.7729, 2.56, 0.271, 270, 251, CRYSTAL STRUCTURE OF THE CHK1
2101, d3uo4A_, 0.7729, 2.36, 0.299, 266, 251, AURORA A IN COMPLEX WITH RPM1680
2102, d2hy0A_, 0.7729, 2.44, 0.272, 272, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 22
2103, d5uy6A1, 0.7727, 2.38, 0.288, 280, 250, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2104, d4j96A_, 0.7727, 2.82, 0.230, 302, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
2105, d2hogA_, 0.7727, 2.42, 0.276, 272, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 20
2106, d5av3A_, 0.7726, 2.36, 0.268, 275, 250, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF IODIDE IONS.
2107, d5auyA_, 0.7726, 2.35, 0.268, 275, 250, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH MORIN.
2108, d4yo4A1, 0.7726, 2.41, 0.267, 276, 251, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT PHTHALAZINE
2109, d3ehaA1, 0.7726, 2.35, 0.268, 275, 250, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH AMPPNP
2110, d2qhnA_, 0.7726, 2.44, 0.272, 268, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1A
2111, d4xeyA_, 0.7725, 2.40, 0.211, 269, 251, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
2112, d2c3lA_, 0.7725, 2.44, 0.272, 265, 250, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
2113, d4j97A_, 0.7724, 2.56, 0.237, 282, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
2114, d3qd0A_, 0.7724, 2.19, 0.271, 274, 247, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH (2R5S)- 1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-6-METHYL-N- PHENYL-3-PIPERIDINECARBOXAMIDE
2115, d1szmB_, 0.7724, 2.55, 0.253, 320, 253, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
2116, d4utdA_, 0.7723, 2.41, 0.303, 266, 251, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION
2117, d4obpA_, 0.7723, 2.48, 0.253, 285, 253, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
2118, d5oopA_, 0.7722, 2.39, 0.268, 261, 250, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMP-PNP
2119, d5em8A_, 0.7722, 2.65, 0.197, 303, 254, EGFR KINASE DOMAIN WITH PYRIDONE COMPOUND 13: 4-[(2-METHOXYPHENYL) AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2-OXIDANYLIDENE-1~{H}- PYRIDINE-3-CARBOXAMIDE
2120, d4rvlA_, 0.7722, 2.39, 0.273, 258, 249, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 7: 3-(2- HYDROXYPHENYL)-9H-PYRROLO[23-B:54-C ]DIPYRIDINE-6-CARBONITRILE
2121, d3dlsD_, 0.7722, 2.62, 0.257, 284, 253, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2122, d6brcA1, 0.7721, 2.33, 0.289, 263, 249, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
2123, d4fsrA_, 0.7720, 2.45, 0.272, 269, 250, CRYSTAL STRUCTURE OF THE CHK1
2124, d3f5uA1, 0.7720, 2.36, 0.264, 275, 250, CRYSTAL STRUCTURE OF THE DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH AMPPNP AND MG2+
2125, d5ig1B_, 0.7719, 2.67, 0.276, 304, 254, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
2126, d5dt3A_, 0.7719, 2.44, 0.295, 263, 251, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
2127, d5av2A_, 0.7719, 2.37, 0.268, 275, 250, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2128, d4j98A_, 0.7719, 2.69, 0.236, 304, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
2129, d4ypdA1, 0.7718, 2.43, 0.267, 276, 251, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT 4-METHYLPYRIDAZINE
2130, d3f5gA1, 0.7718, 2.37, 0.268, 275, 250, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH ADP AND MG2+
2131, d2v7aB_, 0.7718, 2.51, 0.234, 268, 252, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
2132, d2gs6A2, 0.7718, 2.63, 0.201, 308, 254, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AN ATP ANALOG-PEPTIDE CONJUGATE
2133, d5av1A_, 0.7717, 2.37, 0.268, 275, 250, CRYSTAL STRUCTURE OF DAPK1 IN THE PRESENCE OF BROMIDE IONS.
2134, d4ftuA_, 0.7717, 2.52, 0.272, 270, 250, CRYSTAL STRUCTURE OF THE CHK1
2135, d2v7aA_, 0.7717, 2.55, 0.218, 269, 252, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
2136, d1m52A_, 0.7717, 2.43, 0.215, 271, 251, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
2137, d5auvA_, 0.7715, 2.37, 0.268, 275, 250, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH APIGENIN.
2138, d4o0sA_, 0.7715, 2.36, 0.300, 265, 250, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
2139, d4j99B_, 0.7715, 2.57, 0.233, 291, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
2140, d4j97C_, 0.7715, 2.57, 0.237, 283, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
2141, d1m52B_, 0.7715, 2.44, 0.227, 272, 251, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
2142, d4j97B_, 0.7714, 2.69, 0.236, 283, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
2143, d4deeA_, 0.7714, 2.42, 0.295, 271, 251, AURORA A IN COMPLEX WITH ADP
2144, d4debA_, 0.7714, 2.42, 0.295, 264, 251, AURORA A IN COMPLEX WITH RK2-17-01
2145, d5av0A_, 0.7713, 2.38, 0.268, 275, 250, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH 73 4 - TRIHYDROXYISOFLAVONE.
2146, d4zogB_, 0.7713, 2.53, 0.223, 268, 251, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
2147, d3zh8C_, 0.7713, 2.58, 0.282, 312, 255, A NOVEL SMALL MOLECULE APKC INHIBITOR
2148, d3bhhD1, 0.7713, 2.57, 0.303, 285, 254, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2149, d4ft5A_, 0.7712, 2.53, 0.272, 265, 250, CRYSTAL STRUCTURE OF THE CHK1
2150, d2itqA_, 0.7712, 2.50, 0.206, 300, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AFN941
2151, d1eh4A_, 0.7712, 2.73, 0.182, 293, 258, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
2152, d2itpA_, 0.7711, 2.61, 0.206, 305, 253, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AEE788
2153, d1m17A_, 0.7711, 2.68, 0.209, 312, 254, EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE DOMAIN WITH 4-ANILINOQUINAZOLINE INHIBITOR ERLOTINIB
2154, d4qyhB_, 0.7710, 2.46, 0.272, 264, 250, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
2155, d3ikaA_, 0.7710, 2.88, 0.203, 310, 256, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
2156, d3eh9A1, 0.7710, 2.38, 0.268, 274, 250, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH ADP
2157, d2j5eA_, 0.7710, 2.82, 0.202, 309, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 13-JAB
2158, d4b4lA_, 0.7709, 2.69, 0.256, 299, 254, CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT
2159, d3eqpB_, 0.7709, 2.51, 0.251, 270, 251, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
2160, d6bkuA1, 0.7708, 2.25, 0.286, 264, 248, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO GSK650394
2161, d5e8xA_, 0.7708, 2.74, 0.213, 304, 253, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F) IN COMPLEX WITH STAUROSPORINE
2162, d5auxA_, 0.7708, 2.38, 0.268, 275, 250, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH KAEMPFEROL.
2163, d4zk5A_, 0.7708, 2.49, 0.253, 286, 253, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
2164, d4qygB_, 0.7708, 2.46, 0.272, 264, 250, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
2165, d4j95B_, 0.7708, 2.52, 0.230, 282, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
2166, d3c4eB_, 0.7708, 2.33, 0.261, 273, 249, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2167, d2xynC_, 0.7708, 2.40, 0.228, 262, 250, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
2168, d2r2pA1, 0.7708, 2.35, 0.207, 276, 251, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 5 (EPHA5)
2169, d2ivsA_, 0.7708, 2.62, 0.237, 284, 253, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
2170, d5op7A_, 0.7707, 2.35, 0.265, 261, 249, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
2171, d4j99C_, 0.7707, 2.71, 0.232, 291, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
2172, d4j8nC_, 0.7707, 2.44, 0.295, 266, 251, AURORA A KINASE APO
2173, d4j8nB_, 0.7707, 2.44, 0.295, 266, 251, AURORA A KINASE APO
2174, d2r0uA_, 0.7707, 2.47, 0.272, 269, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 54
2175, d2itwA_, 0.7707, 2.48, 0.210, 300, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AFN941
2176, d1u59A1, 0.7707, 2.55, 0.221, 276, 253, CRYSTAL STRUCTURE OF THE ZAP-70 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2177, d5xgnA_, 0.7706, 2.62, 0.202, 302, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
2178, d2e9pA_, 0.7706, 2.81, 0.267, 269, 255, STRUCTURE OF H-CHK1 COMPLEXED WITH A771129
2179, d5hu3A_, 0.7705, 2.43, 0.320, 266, 250, DROSOPHILA CAMKII-D136N IN COMPLEX WITH A PHOSPHORYLATED FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
2180, d5flfB_, 0.7705, 2.77, 0.236, 292, 254, DISEASE LINKED MUTATION IN FGFR
2181, d4j8nD_, 0.7704, 2.45, 0.295, 265, 251, AURORA A KINASE APO
2182, d4j8nA_, 0.7704, 2.45, 0.295, 266, 251, AURORA A KINASE APO
2183, d3c4eA_, 0.7704, 2.34, 0.265, 273, 249, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2184, d2bvaB_, 0.7704, 2.34, 0.260, 274, 250, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
2185, d1rqqA_, 0.7704, 2.77, 0.200, 294, 255, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
2186, d4qygA_, 0.7703, 2.49, 0.272, 264, 250, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
2187, d4lg4C_, 0.7703, 2.54, 0.268, 288, 254, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2188, d4lg4A_, 0.7703, 2.52, 0.264, 289, 254, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2189, d3dlsE_, 0.7703, 2.39, 0.260, 282, 250, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2190, d3dlsC_, 0.7703, 2.42, 0.264, 281, 250, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2191, d3bu6A_, 0.7703, 2.74, 0.196, 294, 255, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PHOSPHOPEPTIDE
2192, d3b2tA_, 0.7703, 2.70, 0.236, 288, 254, STRUCTURE OF PHOSPHOTRANSFERASE
2193, d2g2hB_, 0.7703, 2.70, 0.206, 272, 253, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2194, d5w4wB_, 0.7702, 2.87, 0.178, 291, 258, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2195, d5dr2A1, 0.7702, 2.55, 0.298, 263, 252, AURORA A KINASE IN COMPLEX WITH AA30 AND ATP IN SPACE GROUP P6122
2196, d4ft7A_, 0.7702, 2.44, 0.273, 270, 249, CRYSTAL STRUCTURE OF THE CHK1
2197, d2gs2A_, 0.7702, 2.68, 0.197, 305, 254, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN
2198, d3wf9A_, 0.7701, 2.37, 0.301, 287, 249, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 1-OXO-1-[(4-SULFAMOYLPHENYL)AMINO]PROPAN-2-YL-2-METHYL-1 234-TETRAHYDROACRIDINE-9-CARBOXYLATE
2199, d3up7A_, 0.7701, 2.39, 0.296, 264, 250, AURORA A IN COMPLEX WITH YL1-038-09
2200, d3ot3A_, 0.7701, 2.45, 0.273, 259, 249, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22K BOUND TO HUMAN CHK1 KINASE DOMAIN
2201, d2itxA_, 0.7701, 2.75, 0.200, 307, 255, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AMP- PNP
2202, d3nsvC_, 0.7700, 2.41, 0.228, 262, 250,  
2203, d4fszA_, 0.7699, 2.43, 0.273, 268, 249, CRYSTAL STRUCTURE OF THE CHK1
2204, d4dedA_, 0.7699, 2.43, 0.295, 265, 251, AURORA A IN COMPLEX WITH YL1-038-21
2205, d3gubA1, 0.7699, 2.44, 0.267, 276, 251, CRYSTAL STRUCTURE OF DAPKL93G COMPLEXED WITH N6-(2- PHENYLETHYL)ADENOSINE
2206, d2yexA_, 0.7699, 2.67, 0.259, 269, 255, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
2207, d1kobA_, 0.7699, 2.96, 0.236, 352, 258, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
2208, d3ppzB_, 0.7698, 2.23, 0.243, 264, 247, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2209, d1ol5A_, 0.7698, 2.35, 0.298, 263, 248, STRUCTURE OF AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288 AND BOUND TO TPX2 1-43
2210, d4qyhA_, 0.7697, 2.51, 0.272, 264, 250, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
2211, d2pvyD_, 0.7697, 2.67, 0.233, 283, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
2212, d2oi4X_, 0.7697, 2.32, 0.257, 275, 249, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH FLUORINATED RUTHENIUM PYRIDOCARBAZOLE
2213, d5ootA_, 0.7696, 2.33, 0.266, 260, 248, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
2214, d5flfA_, 0.7695, 2.65, 0.237, 296, 253, DISEASE LINKED MUTATION IN FGFR
2215, d5autA_, 0.7695, 2.35, 0.269, 274, 249, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH ANS.
2216, d4zy4B_, 0.7695, 2.72, 0.304, 292, 253, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
2217, d3vjnA_, 0.7695, 2.46, 0.203, 297, 251, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH AMPPNP.
2218, d2xuuA_, 0.7695, 2.61, 0.257, 301, 253, CRYSTAL STRUCTURE OF A DAP-KINASE 1 MUTANT
2219, d2bzhB_, 0.7695, 2.43, 0.256, 275, 250, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
2220, d5oryA_, 0.7694, 2.37, 0.296, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2221, d3wf8A_, 0.7694, 2.38, 0.301, 287, 249, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 2-OXO-2-[(4-SULFAMOYLPHENYL)AMINO]ETHYL 78910- TETRAHYDRO-6H-CYCLOHEPTA[B]QUINOLINE-11-CARBOXYLATE
2222, d3bu5A_, 0.7694, 2.78, 0.196, 291, 255, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE AND ATP
2223, d1kobB_, 0.7694, 2.98, 0.236, 352, 258, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
2224, d5dnrA_, 0.7693, 2.52, 0.303, 264, 251, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P41212
2225, d5d7aA_, 0.7693, 2.36, 0.255, 289, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2226, d4jq8A_, 0.7693, 2.54, 0.210, 303, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4B
2227, d5jzjB_, 0.7692, 2.03, 0.292, 261, 243, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
2228, d5cavA_, 0.7692, 2.53, 0.210, 306, 252, EGFR KINASE DOMAIN WITH COMPOUND 41A
2229, d5c1qB_, 0.7692, 2.36, 0.265, 273, 249, SERINE/THREONINE-PROTEIN KINASE PIM-1
2230, d3ue4A_, 0.7692, 2.51, 0.219, 270, 251, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
2231, d2zm3B2, 0.7692, 2.59, 0.201, 295, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2232, d2gqgA1, 0.7692, 2.59, 0.226, 271, 252, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
2233, d5dn3A_, 0.7691, 2.43, 0.300, 264, 250, AURORA A IN COMPLEX WITH ATP AND AA35.
2234, d2pvfA_, 0.7691, 2.89, 0.223, 285, 256, CRYSTAL STRUCTURE OF TYROSINE PHOSPHORYLATED ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH ATP ANALOG AND SUBSTRATE PEPTIDE
2235, d2izuA_, 0.7691, 2.70, 0.191, 297, 257, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
2236, d5w4wA_, 0.7690, 2.88, 0.178, 291, 258, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2237, d4ll5A_, 0.7690, 2.39, 0.261, 268, 249, CRYSTAL STRUCTURE OF PIM-1 IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
2238, d3c4eC_, 0.7690, 2.37, 0.261, 272, 249, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2239, d6bqqA1, 0.7689, 2.41, 0.281, 269, 249, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH BI2526
2240, d5telA_, 0.7689, 2.37, 0.257, 273, 249, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2241, d4xlvA_, 0.7689, 2.79, 0.196, 307, 255, CRYSTAL STRUCTURE OF THE ACTIVATED INSULIN RECEPTOR TYROSINE KINASE DIMER
2242, d4wnpB_, 0.7689, 2.53, 0.296, 272, 250, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2243, d2j6mA_, 0.7689, 2.53, 0.210, 306, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AEE788
2244, d4twcB_, 0.7688, 2.81, 0.194, 292, 258, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
2245, d4mbiA_, 0.7688, 2.48, 0.260, 274, 250, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
2246, d1koaA2, 0.7688, 2.92, 0.233, 350, 257, TWITCHIN KINASE FRAGMENT (C.ELEGANS) AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS
2247, d5opvA_, 0.7687, 2.40, 0.266, 261, 248, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
2248, d5d9kB_, 0.7687, 2.26, 0.290, 280, 248, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
2249, d4l3jA_, 0.7687, 2.51, 0.295, 291, 251, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN
2250, d3bu3A_, 0.7687, 2.77, 0.196, 294, 255, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE
2251, d2j2iB_, 0.7687, 2.27, 0.262, 273, 248, CRYSTAL STRUCTURE OF THE HUMAB PIM1 IN COMPLEX WITH LY333531
2252, d2hz4C_, 0.7687, 2.44, 0.229, 259, 249, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
2253, d1m14A_, 0.7687, 2.53, 0.210, 307, 252, TYROSINE KINASE DOMAIN FROM EPIDERMAL GROWTH FACTOR RECEPTOR
2254, d5flfD_, 0.7686, 2.66, 0.237, 290, 253, DISEASE LINKED MUTATION IN FGFR
2255, d5d7aC_, 0.7686, 2.32, 0.252, 286, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2256, d5av4A_, 0.7686, 2.37, 0.269, 274, 249, CRYSTAL STRUCTURE OF DAPK1-GENISTEIN COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2257, d4tw9B_, 0.7686, 2.82, 0.190, 289, 258, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
2258, d4l46A_, 0.7686, 2.47, 0.304, 317, 250, CRYSTAL STRUCTURES OF HUMAN P70S6K1-WT
2259, d4ft3A_, 0.7686, 2.35, 0.274, 269, 248, CRYSTAL STRUCTURE OF THE CHK1
2260, d3vbyA_, 0.7686, 2.30, 0.262, 267, 248, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2261, d3vbtA_, 0.7686, 2.28, 0.258, 267, 248, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2262, d2xynA_, 0.7686, 2.44, 0.224, 264, 250, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
2263, d1xwsA_, 0.7686, 2.35, 0.265, 273, 249, CRYSTAL STRUCTURE OF THE HUMAN PIM1 KINASE DOMAIN
2264, d4jq7A_, 0.7685, 2.55, 0.210, 303, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 2A
2265, d3eqpA_, 0.7685, 2.37, 0.253, 268, 249, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
2266, d2qg5B1, 0.7685, 2.52, 0.266, 275, 252, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
2267, d5auwA_, 0.7684, 2.38, 0.269, 274, 249, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH QUERCETIN.
2268, d5auuA_, 0.7684, 2.37, 0.269, 274, 249, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH LUTEOLIN.
2269, d4zy5B_, 0.7684, 2.73, 0.304, 287, 253, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
2270, d4jr3A_, 0.7684, 2.56, 0.210, 303, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 3G
2271, d5u6bB1, 0.7683, 2.56, 0.209, 289, 254, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
2272, d5auzA_, 0.7683, 2.37, 0.269, 274, 249, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH GENISTEIN.
2273, d4jajA_, 0.7683, 2.50, 0.299, 265, 251, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH BENZO[C][1 8]NAPHTHYRIDIN-6(5H)-ONE
2274, d4hokW_, 0.7683, 2.91, 0.182, 289, 258, CRYSTAL STRUCTURE OF APO CK1E
2275, d3we4A_, 0.7683, 2.48, 0.296, 286, 250, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRIMIDINE DERIVATIVE PF-4708671 2-{[4-(5-ETHYLPYRIMIDIN-4-YL)PIPERAZIN-1- YL]METHYL}-5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOLE
2276, d2c47D1, 0.7683, 2.72, 0.210, 289, 257, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
2277, d4hnfB_, 0.7682, 2.73, 0.179, 290, 257, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
2278, d3jvrA_, 0.7682, 2.36, 0.271, 258, 247, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
2279, d2iztA_, 0.7682, 2.71, 0.191, 296, 257, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
2280, d6babA_, 0.7681, 2.72, 0.298, 290, 255, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2281, d5ng0B_, 0.7681, 2.69, 0.224, 282, 255, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
2282, d5d9kA_, 0.7681, 2.21, 0.296, 280, 247, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
2283, d5ax9C_, 0.7681, 2.35, 0.252, 282, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2284, d4btkA_, 0.7681, 2.71, 0.191, 287, 257, TTBK1 IN COMPLEX WITH INHIBITOR
2285, d2pvyA_, 0.7681, 2.58, 0.234, 288, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
2286, d2o64A_, 0.7681, 2.53, 0.256, 274, 250, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETAGETIN
2287, d2bzjA_, 0.7681, 2.29, 0.262, 273, 248, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU3
2288, d1yxsA_, 0.7681, 2.39, 0.261, 274, 249, CRYSTAL STRUCTURE OF KINASE PIM1 WITH P123M MUTATION
2289, d4riyD_, 0.7680, 2.55, 0.206, 297, 252, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
2290, d3uzpA_, 0.7680, 2.77, 0.183, 292, 257, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
2291, d3kulB_, 0.7680, 2.40, 0.204, 271, 250, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
2292, d3dlsF_, 0.7680, 2.70, 0.258, 281, 252, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2293, d3dlsB_, 0.7680, 2.46, 0.265, 280, 249, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2294, d1xr1A_, 0.7680, 2.50, 0.260, 277, 250, CRYSTAL STRUCTURE OF HPIM-1 KINASE IN COMPLEX WITH AMP-PNP AT 2.1 A RESOLUTION
2295, d5orzA_, 0.7679, 2.39, 0.296, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2296, d5flfC_, 0.7679, 2.77, 0.232, 283, 254, DISEASE LINKED MUTATION IN FGFR
2297, d5dgzA_, 0.7679, 2.41, 0.261, 273, 249, DISCOVERY OF 35-SUBSTITUTED 6-AZAINDAZOLES AS POTENT PAN-PIM INHIBITORS
2298, d4yc8B_, 0.7679, 2.50, 0.216, 264, 250, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
2299, d4wt6A_, 0.7679, 2.40, 0.257, 273, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIADIAZOLAMINE-INDOLE INHIBITOR.
2300, d4id7A_, 0.7679, 2.30, 0.253, 268, 249, ACK1 KINASE IN COMPLEX WITH THE INHIBITOR CIS-3-[8-AMINO-1-(4- PHENOXYPHENYL)IMIDAZO[15-A]PYRAZIN-3-YL]CYCLOBUTANOL
2301, d3b2tB_, 0.7679, 2.71, 0.237, 287, 253, STRUCTURE OF PHOSPHOTRANSFERASE
2302, d2yerA_, 0.7679, 2.61, 0.264, 268, 254, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
2303, d1yxuB_, 0.7679, 2.39, 0.261, 273, 249, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2304, d1k3aA_, 0.7679, 2.78, 0.204, 288, 255, STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR KINASE
2305, d5u6bD1, 0.7678, 2.57, 0.209, 289, 254, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
2306, d5oseA_, 0.7678, 2.41, 0.296, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2307, d5osdA_, 0.7678, 2.41, 0.296, 266, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2308, d5orrA_, 0.7678, 2.39, 0.296, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2309, d5kgdA_, 0.7678, 2.27, 0.258, 273, 248, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-PYRIDIN-3-YL-1~{H}- BENZIMIDAZOLE
2310, d5w4wC_, 0.7677, 2.82, 0.175, 284, 257, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2311, d4wsyA_, 0.7677, 2.42, 0.261, 273, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIAZOLAMINE-INDAZOLE INHIBITOR.
2312, d4wrsA_, 0.7676, 2.40, 0.257, 273, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AZASPIRO PYRAZINYL-INDAZOLE INHIBITOR.
2313, d4nfmA_, 0.7676, 2.73, 0.191, 293, 257, HUMAN TAU TUBULIN KINASE 1 (TTBK1)
2314, d4mblA_, 0.7676, 2.49, 0.256, 274, 250, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
2315, d3gqiA_, 0.7676, 2.71, 0.232, 304, 254, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
2316, d2wtkC1, 0.7676, 2.39, 0.278, 261, 248, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
2317, d1yxuC_, 0.7676, 2.43, 0.261, 272, 249, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2318, d5osfA_, 0.7675, 2.41, 0.296, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2319, d5os3A_, 0.7675, 2.41, 0.296, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2320, d5orwA_, 0.7675, 2.41, 0.296, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2321, d5orpA_, 0.7675, 2.41, 0.296, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2322, d5cxhA1, 0.7675, 2.52, 0.202, 273, 253, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT ORALLY BIOAVAILABLE THIAZOLE INHIBITOR
2323, d4riwD_, 0.7675, 2.55, 0.206, 297, 252, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
2324, d4k1bA_, 0.7675, 2.42, 0.261, 273, 249, STRUCTURE OF PIM-1 KINASE BOUND TO N-(5-(2-FLUOROPHENYL)-1H-PYRROLO[2 3-B]PYRIDIN-3-YL)-5-((((3R4R)-3-FLUOROPIPERIDIN-4-YL)METHYL)AMINO) PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2325, d4hgsA1, 0.7675, 2.71, 0.187, 301, 257, CRYSTAL STRUCTURE OF CK1GS WITH COMPOUND 13
2326, d1yxuA_, 0.7675, 2.37, 0.257, 273, 249, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2327, d1ywvA_, 0.7675, 2.40, 0.265, 274, 249, CRYSTAL STRUCTURES OF PROTO-ONCOGENE KINASE PIM1: A TARGET OF ABERRANT SOMATIC HYPERMUTATIONS IN DIFFUSE LARGE CELL LYMPHOMA
2328, d5orvA_, 0.7674, 2.41, 0.296, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2329, d5op5A_, 0.7674, 2.31, 0.267, 259, 247, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
2330, d5kgeA_, 0.7674, 2.42, 0.261, 273, 249, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 5-(34-DICHLOROPHENYL)- 1~{H}-PYRAZOL-3-AMINE
2331, d3vbxA_, 0.7674, 2.30, 0.258, 268, 248, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2332, d3nsvB_, 0.7674, 2.44, 0.232, 264, 250,  
2333, d3nsvA_, 0.7674, 2.47, 0.224, 264, 250,  
2334, d3bhhC1, 0.7674, 2.60, 0.292, 284, 253, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2335, d2brgA_, 0.7674, 2.30, 0.271, 257, 247, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2336, d5texA_, 0.7673, 2.53, 0.260, 274, 250, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2337, d5os5A_, 0.7673, 2.41, 0.296, 267, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2338, d5l8kA_, 0.7673, 2.60, 0.298, 266, 252, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 2)
2339, d4xliA_, 0.7673, 2.31, 0.223, 264, 247, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
2340, d4xh6A_, 0.7673, 2.28, 0.258, 273, 248, CRYSTAL STRUCTURE OF PROTO-ONCOGENE KINASE PIM1 BOUND TO HISPIDULIN
2341, d4uxlA_, 0.7673, 2.30, 0.230, 288, 248, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH PF-06463922
2342, d4jiaA_, 0.7673, 2.82, 0.244, 298, 254, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 9
2343, d3ri1A_, 0.7673, 2.73, 0.228, 285, 254, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
2344, d2psqA_, 0.7673, 2.78, 0.231, 287, 255, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
2345, d1tkiB_, 0.7673, 2.96, 0.217, 321, 258, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
2346, d5os0A_, 0.7672, 2.41, 0.296, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2347, d4wnpA_, 0.7672, 2.55, 0.296, 273, 250, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2348, d4gfgA1, 0.7672, 2.52, 0.202, 273, 253, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R9021
2349, d4ft0A_, 0.7672, 2.42, 0.274, 266, 248, CRYSTAL STRUCTURE OF THE CHK1
2350, d4fsyA_, 0.7672, 2.54, 0.273, 267, 249, CRYSTAL STRUCTURE OF THE CHK1
2351, d4as0A_, 0.7672, 2.29, 0.262, 273, 248, CYCLOMETALATED PHTHALIMIDES AS PROTEIN KINASE INHIBITORS
2352, d3vbvA_, 0.7672, 2.31, 0.258, 268, 248, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2353, d2x8eA_, 0.7672, 2.44, 0.265, 259, 249, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
2354, d2wmvA_, 0.7672, 2.28, 0.272, 251, 246, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2355, d1tkiA_, 0.7672, 2.96, 0.217, 321, 258, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
2356, d5os1A_, 0.7671, 2.41, 0.296, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2357, d5orxA_, 0.7671, 2.41, 0.296, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2358, d5ornA_, 0.7671, 2.42, 0.296, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2359, d5kgiA_, 0.7671, 2.28, 0.258, 273, 248, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR 2-[34-BIS(CHLORANYL) PHENOXY]ETHANAMINE
2360, d4k18A_, 0.7671, 2.48, 0.264, 277, 250, STRUCTURE OF PIM-1 KINASE BOUND TO 5-(4-CYANOBENZYL)-N-(4- FLUOROPHENYL)-7-HYDROXYPYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2361, d4g16A1, 0.7671, 2.72, 0.195, 301, 257, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-{[3-(TRIFLUOROMETHYL)PYRIDIN2- YL]OXY}PHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE
2362, d3q4zA1, 0.7671, 2.31, 0.274, 281, 248, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
2363, d2xynB_, 0.7671, 2.44, 0.232, 264, 250, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
2364, d1yxvA_, 0.7671, 2.42, 0.257, 274, 249, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH 34-DIHYDROXY-1- METHYLQUINOLIN-2(1H)-ONE
2365, d3sxsA1, 0.7670, 2.31, 0.210, 261, 248, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEXED WITH PP2
2366, d3r01A_, 0.7670, 2.30, 0.258, 274, 248, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2367, d2py3B_, 0.7670, 2.66, 0.229, 284, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2368, d5walA1, 0.7669, 2.52, 0.215, 285, 251, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
2369, d5oroA_, 0.7669, 2.42, 0.296, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2370, d4hokO_, 0.7669, 2.86, 0.183, 290, 257, CRYSTAL STRUCTURE OF APO CK1E
2371, d4hokI_, 0.7669, 2.92, 0.182, 291, 258, CRYSTAL STRUCTURE OF APO CK1E
2372, d4fttA_, 0.7669, 2.44, 0.274, 266, 248, CRYSTAL STRUCTURE OF THE CHK1
2373, d5mjbA_, 0.7668, 2.43, 0.219, 276, 251, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
2374, d5kgkA_, 0.7668, 2.41, 0.261, 273, 249, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 3-(4-METHOXYPHENYL)-1~{H}- PYRAZOL-5-AMINE
2375, d3uysC_, 0.7668, 2.76, 0.179, 286, 257, CRYSTAL STRUCTURE OF APO HUMAN CK1D
2376, d3nrmA_, 0.7668, 2.49, 0.291, 263, 251, IMIDAZO[12-A]PYRAZINE-BASED AURORA KINASE INHIBITORS
2377, d3jpvA_, 0.7668, 2.29, 0.258, 273, 248, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A PYRROLO[23- A]CARBAZOLE LIGAND
2378, d2bikB_, 0.7668, 2.34, 0.266, 272, 248, HUMAN PIM1 PHOSPHORYLATED ON SER261
2379, d5j9yA_, 0.7667, 2.57, 0.206, 300, 252, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1B
2380, d4jx3A_, 0.7667, 2.50, 0.260, 274, 250, CRYSTAL STRUCTURE OF PIM1 KINASE
2381, d4bbeD_, 0.7667, 2.60, 0.242, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2382, d3we8A_, 0.7667, 2.44, 0.261, 273, 249, PIM-1 KINASE IN COMPLEX WITH RUTHENIUM-BASED INHIBITOR
2383, d1yxxA_, 0.7667, 2.42, 0.257, 274, 249, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH (3E)-3-[(4- HYDROXYPHENYL)IMINO]-1H-INDOL-2(3H)-ONE
2384, d5orsA_, 0.7666, 2.42, 0.296, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2385, d4ty1A_, 0.7666, 2.41, 0.257, 273, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AMINOOXADIAZOLE-INDOLE INHIBITOR.
2386, d4rixD_, 0.7666, 2.58, 0.210, 297, 252, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
2387, d4jx7A_, 0.7666, 2.51, 0.256, 274, 250, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR 2-[(TRANS- 4-AMINOCYCLOHEXYL)AMINO]-4-{[3-(TRIFLUOROMETHYL) PHENYL]AMINO}PYRIDO[43-D]PYRIMIDIN-5(6H)-ONE
2388, d3jyaA_, 0.7666, 2.31, 0.258, 274, 248, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2389, d2o3pA_, 0.7666, 2.45, 0.261, 274, 249, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETIN
2390, d2izsA_, 0.7666, 2.72, 0.187, 298, 257, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
2391, d5l3aA_, 0.7665, 2.61, 0.250, 290, 252, FRAGMENT-BASED DISCOVERY OF 6-ARYLINDAZOLE JAK INHIBITORS
2392, d4gmyA_, 0.7665, 2.71, 0.249, 298, 253, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH 26-DICHLORO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
2393, d4ftcA_, 0.7665, 2.44, 0.274, 266, 248, CRYSTAL STRUCTURE OF THE CHK1
2394, d4bn1A_, 0.7665, 2.45, 0.293, 261, 249, CRYSTAL STRUCTURE OF V174M MUTANT OF AURORA-A KINASE
2395, d2chlA_, 0.7665, 2.72, 0.187, 298, 257, STRUCTURE OF CASEIN KINASE 1 GAMMA 3
2396, d1oecA_, 0.7665, 2.70, 0.238, 280, 252, FGFR2 KINASE DOMAIN
2397, d5opuA_, 0.7664, 2.38, 0.270, 261, 248, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
2398, d5kcxA_, 0.7664, 2.41, 0.257, 272, 249, PIM-1 KINASE IN COMPLEX WITH A SELECTIVE N-SUBSTITUTED 7-AZAINDOLE INHIBITOR
2399, d3vbwA_, 0.7664, 2.34, 0.262, 264, 248, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2400, d3r04A_, 0.7664, 2.30, 0.258, 271, 248, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2401, d3jxwA_, 0.7664, 2.43, 0.257, 274, 249, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2402, d2o65A_, 0.7664, 2.53, 0.264, 274, 250, CRYSTAL STRUCTURE OF PIM1 WITH PENTAHYDROXYFLAVONE
2403, d2o63A_, 0.7664, 2.53, 0.260, 274, 250, CRYSTAL STRUCTURE OF PIM1 WITH MYRICETIN
2404, d1gjoA_, 0.7664, 2.72, 0.238, 280, 252, THE FGFR2 TYROSINE KINASE DOMAIN
2405, d2izrA_, 0.7663, 2.75, 0.191, 298, 257, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
2406, d5wevA_, 0.7662, 2.64, 0.254, 293, 252, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
2407, d5turA_, 0.7662, 2.43, 0.257, 270, 249, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2408, d4rpvA_, 0.7662, 2.39, 0.261, 273, 249, CO-CRYSTAL STRUCTURE OF PIM1 WITH COMPOUND 3
2409, d4kbkB_, 0.7662, 2.86, 0.183, 289, 257, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
2410, d4bbeB_, 0.7662, 2.62, 0.250, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2411, d6brcB_, 0.7661, 2.21, 0.293, 260, 246, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
2412, d5v82A_, 0.7661, 2.39, 0.257, 273, 249, PIM1 KINASE IN COMPLEX WITH CPD17 (1-(6-(44-DIFLUOROPIPERIDIN-3-YL) PYRIDIN-2-YL)-6-(6-METHYLPYRAZIN-2-YL)-1H-PYRAZOLO[43-C]PYRIDINE)
2413, d5ortA_, 0.7661, 2.42, 0.296, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2414, d4k0yA_, 0.7661, 2.39, 0.257, 274, 249, STRUCTURE OF PIM-1 KINASE BOUND TO N-(4-FLUOROPHENYL)-7-HYDROXY-5- (PIPERIDIN-4-YL)PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2415, d4bbeC_, 0.7661, 2.62, 0.250, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2416, d3kf4B_, 0.7661, 2.50, 0.229, 270, 249, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
2417, d3kckA_, 0.7661, 2.56, 0.254, 285, 252, A NOVEL CHEMOTYPE OF KINASE INHIBITORS
2418, d5dhjA_, 0.7660, 2.42, 0.257, 273, 249, PIM1 IN COMPLEX WITH CPD4 (3-METHYL-5-(PYRIDIN-3-YL)-1H-PYRAZOLO[34- C]PYRIDINE)
2419, d4medA_, 0.7660, 2.37, 0.266, 272, 248, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE DERIVATIVES
2420, d3vc4A_, 0.7660, 2.31, 0.258, 274, 248, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2421, d3r00A_, 0.7660, 2.31, 0.258, 274, 248, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2422, d4zogA_, 0.7659, 2.62, 0.215, 269, 251, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
2423, d4k33A_, 0.7659, 2.73, 0.236, 293, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 3 (FGFR3) KINASE DOMAIN HARBORING THE K650E MUTATION A GAIN-OF-FUNCTION MUTATION RESPONSIBLE FOR THANATOPHORIC DYSPLASIA TYPE II AND SPERMATOCYTIC SEMINOMA
2424, d4gihA1, 0.7659, 2.65, 0.218, 287, 252, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}BENZAMIDE
2425, d3jy0A_, 0.7659, 2.32, 0.258, 275, 248, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2426, d1ir3A_, 0.7659, 2.81, 0.192, 300, 255, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH PEPTIDE SUBSTRATE AND ATP ANALOG
2427, d5toeA_, 0.7658, 2.47, 0.261, 272, 249, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2428, d4zs0A_, 0.7658, 2.23, 0.301, 257, 246, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO SB-6-OH
2429, d4j95C_, 0.7658, 2.59, 0.231, 281, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
2430, d4hglA1, 0.7658, 2.73, 0.187, 301, 257, CRYSTAL STRUCTURE OF CK1G3 WITH COMPOUND 1
2431, d4aluA_, 0.7658, 2.32, 0.258, 274, 248, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2432, d1ol7A_, 0.7658, 2.39, 0.297, 261, 249, STRUCTURE OF HUMAN AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288
2433, d5os4A_, 0.7657, 2.44, 0.296, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2434, d4a7cA_, 0.7657, 2.34, 0.262, 273, 248, CRYSTAL STRUCTURE OF PIM1 KINASE WITH ETP46546
2435, d3qc4A_, 0.7657, 2.57, 0.271, 276, 251, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
2436, d1gagA_, 0.7657, 2.82, 0.192, 300, 255, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
2437, d5kggA_, 0.7656, 2.32, 0.258, 273, 248, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-(5-CHLORANYL-1~{H}-INDOL- 3-YL)ETHANAMINE
2438, d4g17A1, 0.7656, 2.75, 0.206, 301, 257, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-TERT-BUTYLPHENYL)AMINO]-1H- BENZIMIDAZOLE-6-CARBONITRILE
2439, d4alvA_, 0.7656, 2.32, 0.258, 274, 248, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2440, d3sxrA1, 0.7656, 2.41, 0.209, 257, 249, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
2441, d3bwfA_, 0.7656, 2.45, 0.261, 273, 249, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AN OSMIUM COMPOUND
2442, d4wnpD_, 0.7655, 2.62, 0.296, 272, 250, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2443, d4mtaA_, 0.7655, 2.32, 0.258, 273, 248, CRYSTAL STRUCTURE OF PIM-1 KINASE DOMAIN IN COMPLEX WITH 2-METHYL-5- PHENYLFURAN-3-CARBOXYLIC ACID
2444, d4li5A1, 0.7655, 2.64, 0.206, 303, 252, EGFR-K IN COMPLEX WITH N-[3-[[5-CHLORO-4-(1H-INDOL-3-YL)PYRIMIDIN-2- YL]AMINO]-4-METHOXY-PHENYL] PROP-2-ENAMIDE
2445, d4l45A_, 0.7655, 2.39, 0.304, 317, 247, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389E
2446, d4kbcA_, 0.7655, 2.93, 0.194, 288, 258, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
2447, d2yakA_, 0.7655, 2.50, 0.271, 277, 251, STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OSV)
2448, d2j0lA_, 0.7655, 2.49, 0.247, 274, 251, CRYSTAL STRUCTURE OF A THE ACTIVE CONFORMATION OF THE KINASE DOMAIN OF FOCAL ADHESION KINASE WITH A PHOSPHORYLATED ACTIVATION LOOP.
2449, d2bziB_, 0.7655, 2.40, 0.262, 272, 248, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU2
2450, d5os6A_, 0.7654, 2.44, 0.296, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2451, d5ipjA_, 0.7654, 2.43, 0.257, 273, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A QUINAZOLINONE-PYRROLOPYRROLONE INHIBITOR.
2452, d5d7aB_, 0.7654, 2.39, 0.248, 286, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2453, d4tw9A_, 0.7654, 2.85, 0.182, 290, 258, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
2454, d4bbeA_, 0.7654, 2.79, 0.251, 288, 255, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2455, d2jiuA_, 0.7654, 2.66, 0.193, 303, 254, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
2456, d4gj2A1, 0.7653, 2.66, 0.218, 287, 252, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
2457, d4dtkA_, 0.7653, 2.32, 0.258, 273, 248, NOVEL AND SELECTIVE PAN-PIM KINASE INHIBITOR
2458, d4cegA_, 0.7653, 2.46, 0.296, 264, 250, CRYSTAL STRUCTURE OF AURORA A 122-403 C290A C393A BOUND TO ADP
2459, d1xqzA_, 0.7653, 2.53, 0.264, 277, 250, CRYSTAL STRUCTURE OF HPIM-1 KINASE AT 2.1 A RESOLUTION
2460, d6b16B_, 0.7652, 2.45, 0.294, 281, 248, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
2461, d4gj3A1, 0.7652, 2.67, 0.214, 287, 252, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
2462, d4bbfB_, 0.7652, 2.77, 0.251, 288, 255, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2463, d2c47B_, 0.7652, 2.75, 0.203, 289, 256, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
2464, d1zwsB_, 0.7652, 2.51, 0.255, 278, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2465, d5vc5A_, 0.7651, 2.40, 0.231, 261, 247, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PD- 166285
2466, d4rc3A_, 0.7651, 2.42, 0.266, 271, 248, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2467, d4n6yA_, 0.7651, 2.27, 0.263, 273, 247, PIM1 COMPLEXED WITH A PHENYLCARBOXAMIDE
2468, d4lm5A_, 0.7651, 2.28, 0.259, 264, 247, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH 2-{4-[(3-AMINOPROPYL) AMINO]QUINAZOLIN-2-YL}PHENOL (RESULTING FROM DISPLACEMENT OF SKF86002)
2469, d4hokU_, 0.7651, 2.92, 0.186, 289, 258, CRYSTAL STRUCTURE OF APO CK1E
2470, d4giiA1, 0.7651, 2.67, 0.218, 287, 252, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
2471, d4ftrA_, 0.7651, 2.42, 0.275, 258, 247, CRYSTAL STRUCTURE OF THE CHK1
2472, d3r02A_, 0.7651, 2.33, 0.258, 271, 248, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2473, d5hg5A_, 0.7650, 3.03, 0.203, 302, 256, EGFR (L858R T790M V948R) IN COMPLEX WITH N-{3-[(2-{[4-(4- METHYLPIPERAZIN-1-YL)PHENYL]AMINO}-7H-PYRROLO[23-D]PYRIMIDIN-4-YL) OXY]PHENYL}PROP-2-ENAMIDE
2474, d4bbfC_, 0.7650, 2.80, 0.247, 288, 255, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2475, d3c4eD_, 0.7650, 2.32, 0.258, 273, 248, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2476, d2pwlA_, 0.7650, 2.78, 0.232, 284, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
2477, d5te0A_, 0.7649, 2.37, 0.254, 316, 248, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH BIBF 1120
2478, d4i41A_, 0.7649, 2.42, 0.266, 272, 248, CRYSTAL STRUCTURE OF HUMAN SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE
2479, d4ftmA_, 0.7649, 2.42, 0.275, 263, 247, CRYSTAL STRUCTURE OF THE CHK1
2480, d1jktA_, 0.7649, 2.56, 0.266, 276, 252, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2481, d5ugxA_, 0.7648, 2.80, 0.224, 297, 254, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
2482, d5l8lA_, 0.7648, 2.46, 0.300, 263, 250, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 1)
2483, d3vjoA_, 0.7648, 2.55, 0.208, 298, 250, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH AMPPNP.
2484, d3lvpC_, 0.7648, 2.68, 0.209, 293, 254, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
2485, d3a99A_, 0.7648, 2.45, 0.257, 273, 249, STRUCTURE OF PIM-1 KINASE CRYSTALLIZED IN THE PRESENCE OF P27KIP1 CARBOXY-TERMINAL PEPTIDE
2486, d2x7fA_, 0.7648, 2.16, 0.257, 276, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2487, d1wvxA_, 0.7648, 2.45, 0.268, 275, 250, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2488, d5hg8A_, 0.7647, 3.03, 0.199, 300, 256, EGFR (L858R T790M V948R) IN COMPLEX WITH N-[3-({2-[(1-METHYL-1H- PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- 2-ENAMIDE
2489, d5diaA_, 0.7647, 2.34, 0.258, 273, 248, PIM1 IN COMPLEX WITH CPD36 ((1S3S)-N1-(6-(5-(PYRIDIN-3-YL)-1H- PYRAZOLO[34-C]PYRIDIN-3-YL)PYRIDIN-2-YL)CYCLOHEXANE-13-DIAMINE)
2490, d2zm3A2, 0.7647, 2.71, 0.216, 299, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2491, d4w9wA_, 0.7646, 2.31, 0.263, 306, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH SMALL MOLECULE AZD-7762
2492, d3tkhA_, 0.7646, 2.53, 0.274, 269, 248, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S01
2493, d2xeyA_, 0.7646, 2.31, 0.272, 252, 246, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2494, d2pzpA_, 0.7646, 2.91, 0.227, 280, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
2495, d2pwlB_, 0.7646, 2.69, 0.229, 286, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
2496, d4rc4A_, 0.7645, 2.41, 0.262, 272, 248, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2497, d4kbkC_, 0.7645, 2.93, 0.190, 280, 258, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
2498, d4hokA_, 0.7645, 2.96, 0.182, 290, 258, CRYSTAL STRUCTURE OF APO CK1E
2499, d3cr0A_, 0.7645, 2.29, 0.229, 257, 245, WEE1 KINASE COMPLEX WITH INHIBITOR PD259_809
2500, d2zm3D2, 0.7645, 2.65, 0.209, 292, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2501, d2pz5A_, 0.7645, 2.91, 0.227, 280, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2502, d2ivtA1, 0.7645, 2.76, 0.237, 283, 253, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
2503, d2c47A_, 0.7645, 2.71, 0.200, 288, 255, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
2504, d5mjbB_, 0.7644, 2.62, 0.221, 278, 253, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
2505, d4ckiA1, 0.7644, 2.76, 0.237, 288, 253, CRYSTAL STRUCTURE OF ONCOGENIC RET TYROSINE KINASE M918T BOUND TO ADENOSINE
2506, d5x18A_, 0.7643, 2.84, 0.206, 294, 257, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
2507, d5iisA_, 0.7643, 2.43, 0.262, 273, 248, DESIGN SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIP OF POTENT PAN- PIM KINASE INHIBITORS DERIVED FROM THE PYRIDYL-AMIDE SCAFFOLD
2508, d5gtzA_, 0.7643, 2.91, 0.208, 317, 255, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH JTS-1-39
2509, d5eolA_, 0.7643, 2.45, 0.257, 273, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A MACROCYCLIC QUINOXALINE-PYRROLODIHYDROPIPERIDINONE INHIBITOR
2510, d4yznA_, 0.7643, 2.60, 0.238, 269, 248, HUMANIZED ROCO4 BOUND TO COMPOUND 19
2511, d4txcA_, 0.7643, 2.53, 0.271, 276, 251, CRYSTAL STRUCTURE OF DAPK1 KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
2512, d2xiyA_, 0.7643, 2.42, 0.262, 273, 248, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-2 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2513, d2qohA2, 0.7643, 2.46, 0.229, 270, 249, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
2514, d3dcvA_, 0.7642, 2.39, 0.262, 273, 248, CRYSTAL STRUCTURE OF HUMAN PIM1 KINASE COMPLEXED WITH 4-(4- HYDROXY-3-METHYL-PHENYL)-6-PHENYLPYRIMIDIN-2(1H)-ONE
2515, d2q0bA_, 0.7642, 2.82, 0.232, 280, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2516, d2pz5B_, 0.7642, 2.65, 0.230, 280, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2517, d2py3A_, 0.7642, 3.05, 0.222, 282, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2518, d2ckeC_, 0.7642, 2.81, 0.240, 300, 254, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2519, d1yxuD_, 0.7642, 2.33, 0.258, 273, 248, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2520, d6bqlA1, 0.7641, 2.63, 0.276, 276, 250, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH TAE-226
2521, d4rc2A_, 0.7641, 2.29, 0.263, 272, 247, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2522, d4gvjA1, 0.7641, 2.71, 0.222, 288, 252, TYK2 (JH1) IN COMPLEX WITH ADENOSINE DI-PHOSPHATE
2523, d4btjB_, 0.7641, 2.81, 0.182, 293, 258, TTBK1 IN COMPLEX WITH ATP
2524, d3f9nA_, 0.7641, 2.39, 0.271, 253, 247, CRYSTAL STRUCTURE OF CHK1 KINASE IN COMPLEX WITH INHIBITOR 38
2525, d3bhyA1, 0.7641, 2.33, 0.260, 267, 246, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH A BETA-CARBOLINE LIGAND
2526, d2xj0A_, 0.7641, 2.48, 0.257, 274, 249, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-4 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2527, d2g2hA_, 0.7641, 2.60, 0.219, 272, 251, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2528, d1pkgA_, 0.7641, 2.68, 0.222, 290, 252, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
2529, d4rblA_, 0.7640, 2.43, 0.266, 271, 248, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2530, d4ftkA_, 0.7640, 2.43, 0.275, 263, 247, CRYSTAL STRUCTURE OF THE CHK1
2531, d3f2aA_, 0.7640, 2.43, 0.261, 276, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 IN COMPLEX WITH DAPPA
2532, d2x2kA1, 0.7640, 2.78, 0.237, 284, 253, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
2533, d1oplB2, 0.7640, 2.52, 0.212, 267, 250, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
2534, d5dwrA_, 0.7639, 2.42, 0.262, 273, 248, IDENTIFICATION OF N-(4-((1R3S5S)-3-AMINO-5-METHYLCYCLOHEXYL)PYRIDIN- 3-YL)-6-(26-DIFLUOROPHENYL)-5-FLUOROPICOLINAMIDE (PIM447) A POTENT AND SELECTIVE PROVIRAL INSERTION SITE OF MOLONEY MURINE LEUKEMIA (PIM) 12 AND 3 KINASE INHIBITOR IN CLINICAL TRIALS FOR HEMATOLOGICAL MALIGNANCIES
2535, d4fsuA_, 0.7639, 2.51, 0.274, 260, 248, CRYSTAL STRUCTURE OF THE CHK1
2536, d3nz0A1, 0.7639, 2.61, 0.223, 283, 251, NON-PHOSPHORYLATED TYK2 KINASE WITH CMP6
2537, d2x2mA1, 0.7639, 2.67, 0.239, 281, 251, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
2538, d2q0bB_, 0.7639, 2.71, 0.225, 282, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2539, d2pzpB_, 0.7639, 2.66, 0.230, 282, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
2540, d5oq6A_, 0.7638, 2.33, 0.268, 257, 246, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
2541, d4ckjA1, 0.7638, 2.78, 0.237, 287, 253, CRYSTAL STRUCTURE OF RET TYROSINE KINASE DOMAIN BOUND TO ADENOSINE
2542, d3uytA_, 0.7638, 2.69, 0.189, 287, 254, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2543, d3bgpA_, 0.7638, 2.30, 0.263, 272, 247, HUMAN PIM-1 COMPLEXED WITH A BENZOISOXAZOLE INHIBITOR VX1
2544, d5c26A1, 0.7637, 2.55, 0.194, 271, 252, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 1
2545, d3vbqA_, 0.7637, 2.36, 0.258, 271, 248, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2546, d3ug2A_, 0.7637, 2.64, 0.195, 299, 251, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH GEFITINIB
2547, d3t9iA_, 0.7637, 2.50, 0.257, 273, 249, PIM1 COMPLEXED WITH A NOVEL 36-DISUBSTITUTED INDOLE AT 2.6 ANG RESOLUTION
2548, d3kf4A_, 0.7637, 2.57, 0.221, 281, 249, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
2549, d2x0gA_, 0.7637, 2.81, 0.255, 318, 255, X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX
2550, d1zwsG_, 0.7637, 2.52, 0.255, 278, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2551, d5x17A_, 0.7636, 2.85, 0.191, 290, 257, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
2552, d5op4A_, 0.7636, 2.32, 0.268, 259, 246, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDINE LRRK2 INHIBITOR
2553, d4zy6B_, 0.7636, 2.79, 0.303, 280, 251, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
2554, d4n70A_, 0.7636, 2.41, 0.262, 274, 248, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
2555, d4ftlA_, 0.7636, 2.56, 0.274, 263, 248, CRYSTAL STRUCTURE OF THE CHK1
2556, d2yabB_, 0.7636, 2.77, 0.268, 299, 254, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
2557, d2xizA_, 0.7636, 2.30, 0.263, 273, 247, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-3 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2558, d2psqB_, 0.7636, 2.84, 0.231, 286, 255, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
2559, d4l42A_, 0.7635, 2.50, 0.297, 299, 249, CRYSTAL STRUCTURES OF HUMAN P70S6K1-PIF
2560, d3uytC_, 0.7635, 2.87, 0.186, 286, 258, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2561, d3uytB_, 0.7635, 2.83, 0.188, 286, 255, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2562, d2dq7X_, 0.7635, 2.37, 0.231, 262, 247, CRYSTAL STRUCTURE OF FYN KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
2563, d1mq4A_, 0.7635, 2.45, 0.293, 261, 249, CRYSTAL STRUCTURE OF AURORA-A PROTEIN KINASE
2564, d2x2lA1, 0.7634, 2.80, 0.237, 282, 253, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
2565, d1zwsF_, 0.7634, 2.61, 0.250, 278, 252, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2566, d1wvwA_, 0.7634, 2.45, 0.272, 275, 250, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2567, d5dlsA_, 0.7633, 2.45, 0.271, 257, 247, IDENTIFICATION OF NOVEL IN VIVO ACTIVE CHK1 INHIBITORS UTILIZING STRUCTURE GUIDED DRUG DESIGN
2568, d5cwzB_, 0.7633, 2.42, 0.248, 284, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
2569, d3sxrB1, 0.7633, 2.39, 0.206, 255, 248, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
2570, d2x2mB1, 0.7633, 2.62, 0.240, 274, 250, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
2571, d1zwsD_, 0.7633, 2.52, 0.255, 278, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2572, d4trlA_, 0.7632, 2.38, 0.206, 268, 248, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
2573, d4tn6B_, 0.7632, 2.84, 0.183, 285, 257, CK1D IN COMPLEX WITH INHIBITOR
2574, d4tl0A_, 0.7632, 2.79, 0.256, 300, 254, CRYSTAL STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 WITH A CRUCIAL PHOSPHOMIMICKING MUTATION
2575, d4iaaA_, 0.7632, 2.40, 0.266, 272, 248, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE
2576, d4dhfA_, 0.7632, 2.42, 0.298, 258, 248, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
2577, d5fqdF_, 0.7631, 2.90, 0.198, 294, 258, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
2578, d5es1A_, 0.7631, 1.99, 0.333, 304, 240, CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
2579, d4ytfA_, 0.7631, 2.62, 0.250, 283, 252, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
2580, d4f1oA1, 0.7631, 2.56, 0.229, 274, 249, CRYSTAL STRUCTURE OF THE L1180T MUTANT ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO APPCP
2581, d4bznA_, 0.7631, 2.31, 0.263, 272, 247, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO(12-A) PYRAZINONE INHIBITOR
2582, d3lm5A1, 0.7631, 2.35, 0.247, 267, 247, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B) IN COMPLEX WITH QUERCETIN
2583, d3clyA_, 0.7631, 2.80, 0.232, 289, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAINS TRAPPED IN TRANS-PHOSPHORYLATION REACTION
2584, d1yrpB_, 0.7631, 2.47, 0.256, 275, 250, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
2585, d1yrpA_, 0.7631, 2.47, 0.256, 275, 250, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
2586, d5oprA_, 0.7630, 2.34, 0.268, 258, 246, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIDINE LRRK2 INHIBITOR
2587, d4j99A_, 0.7630, 2.67, 0.231, 280, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
2588, d3iokA_, 0.7630, 2.62, 0.250, 285, 252, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
2589, d2qg5A1, 0.7630, 2.60, 0.258, 268, 252, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
2590, d6bleA1, 0.7629, 2.37, 0.286, 263, 248, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CP673451
2591, d5ax9A_, 0.7629, 2.33, 0.250, 282, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2592, d5amnA1, 0.7629, 2.78, 0.237, 282, 253, THE DISCOVERY OF 2-SUBSTITUTED PHENOL QUINAZOLINES AS POTENT AND SELECTIVE RET KINASE INHIBITORS
2593, d4ythA_, 0.7629, 2.60, 0.254, 287, 252, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
2594, d4twcA_, 0.7629, 2.86, 0.190, 293, 258, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
2595, d4jrvA_, 0.7629, 2.47, 0.209, 300, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4C
2596, d4fsmA_, 0.7629, 2.44, 0.275, 265, 247, CRYSTAL STRUCTURE OF THE CHK1
2597, d2of4A_, 0.7629, 2.60, 0.220, 271, 250, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 1 BOUND TO LCK
2598, d2objA_, 0.7629, 2.32, 0.263, 272, 247, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH INHIBITOR
2599, d5uhnA_, 0.7628, 2.89, 0.224, 282, 254, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
2600, d4xhkB_, 0.7628, 2.31, 0.263, 269, 247, PIM1 KINASE IN COMPLEX WITH COMPOUND 1S
2601, d4u42A_, 0.7628, 2.41, 0.253, 282, 249, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
2602, d4dhfB_, 0.7628, 2.42, 0.294, 258, 248, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
2603, d4btjA_, 0.7628, 2.80, 0.191, 292, 257, TTBK1 IN COMPLEX WITH ATP
2604, d3bgzA_, 0.7628, 2.32, 0.263, 267, 247, HUMAN PIM-1 KINASE IN COMPLEX WITH DIPHENYL INDOLE INHIBITOR VX3
2605, d2z60A1, 0.7628, 2.67, 0.227, 280, 251, CRYSTAL STRUCTURE OF THE T315I MUTANT OF ABL KINASE BOUND WITH PPY-A
2606, d2ckeB_, 0.7628, 2.84, 0.240, 300, 254, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2607, d3bgqA_, 0.7627, 2.46, 0.262, 272, 248, HUMAN PIM-1 KINASE IN COMPLEX WITH AN TRIAZOLO PYRIDAZINE INHIBITOR VX2
2608, d3bceC_, 0.7627, 2.62, 0.215, 286, 251, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
2609, d2ckeD_, 0.7627, 2.81, 0.240, 300, 254, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2610, d1y57A3, 0.7627, 2.47, 0.233, 285, 249, STRUCTURE OF UNPHOSPHORYLATED C-SRC IN COMPLEX WITH AN INHIBITOR
2611, d1oplA3, 0.7627, 2.72, 0.215, 291, 251, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
2612, d5vuaB_, 0.7626, 2.32, 0.259, 270, 247, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
2613, d4btmB_, 0.7626, 2.82, 0.182, 293, 258, TTBK1 IN COMPLEX WITH INHIBITOR
2614, d3u9nA_, 0.7626, 2.43, 0.275, 257, 247, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
2615, d2yabA_, 0.7626, 2.73, 0.261, 299, 253, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
2616, d1yxtA_, 0.7626, 2.52, 0.257, 274, 249, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMPPNP
2617, d1yhsA_, 0.7626, 2.27, 0.264, 267, 246, CRYSTAL STRUCTURE OF PIM-1 BOUND TO STAUROSPORINE
2618, d5orlA_, 0.7625, 2.48, 0.300, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2619, d5op2A_, 0.7625, 2.45, 0.268, 263, 250, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2620, d4lmuA_, 0.7625, 2.34, 0.267, 265, 247, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH THE INHIBITOR QUERCETIN (RESULTING FROM DISPLACEMENT OF SKF86002)
2621, d2pzrA_, 0.7625, 2.66, 0.230, 280, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2622, d1zwsC_, 0.7625, 2.55, 0.255, 278, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2623, d1opkA3, 0.7625, 2.72, 0.215, 291, 251, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
2624, d5objA_, 0.7624, 2.45, 0.306, 260, 248, AURORA A KINASE IN COMPLEX WITH 2-(3-FLUOROPHENYL)QUINOLINE-4- CARBOXYLIC ACID AND ATP
2625, d5imeA1, 0.7624, 2.13, 0.291, 279, 244, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
2626, d4gfmA_, 0.7624, 2.63, 0.250, 289, 252, JAK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
2627, d3uysD_, 0.7624, 2.70, 0.185, 284, 254, CRYSTAL STRUCTURE OF APO HUMAN CK1D
2628, d2w4kA_, 0.7624, 2.84, 0.256, 301, 254, X-RAY STRUCTURE OF A DAP-KINASE 2-302
2629, d5vc4A_, 0.7623, 2.41, 0.224, 261, 246, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB-ISOMER
2630, d5uglA_, 0.7623, 2.84, 0.228, 285, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
2631, d5ar2B_, 0.7623, 2.91, 0.214, 285, 257, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
2632, d4hokK_, 0.7623, 2.92, 0.187, 290, 257, CRYSTAL STRUCTURE OF APO CK1E
2633, d4hnfA_, 0.7623, 2.84, 0.184, 289, 255, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
2634, d4bzoA_, 0.7623, 2.45, 0.262, 272, 248, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO- PYRAZINONE INHIBITOR
2635, d4alwA_, 0.7623, 2.54, 0.257, 273, 249, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2636, d1yi4A_, 0.7623, 2.28, 0.268, 267, 246, STRUCTURE OF PIM-1 BOUND TO ADENOSINE
2637, d5j95A_, 0.7622, 2.47, 0.256, 284, 250, MAP4K4 IN COMPLEX WITH INHIBITOR
2638, d4nfnA_, 0.7622, 2.86, 0.190, 293, 258, HUMAN TAU TUBULIN KINASE 1 (TTBK1) COMPLEXED WITH 3-({5-[(4-AMINO-4- METHYLPIPERIDIN-1-YL)METHYL]PYRROLO[21-F][124]TRIAZIN-4-YL}AMINO)- 5-BROMOPHENOL
2639, d4n6zA_, 0.7622, 2.47, 0.262, 272, 248, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
2640, d4hokG_, 0.7622, 2.98, 0.182, 290, 258, CRYSTAL STRUCTURE OF APO CK1E
2641, d4hokE_, 0.7622, 2.98, 0.182, 291, 258, CRYSTAL STRUCTURE OF APO CK1E
2642, d4f1mA1, 0.7622, 2.58, 0.229, 274, 249, CRYSTAL STRUCTURE OF THE G1179S ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM.
2643, d4btmA_, 0.7622, 2.79, 0.195, 292, 257, TTBK1 IN COMPLEX WITH INHIBITOR
2644, d2z2wA_, 0.7622, 2.34, 0.224, 260, 245, HUMAND WEE1 KINASE COMPLEXED WITH INHIBITOR PF0335770
2645, d1zwsH_, 0.7622, 2.55, 0.255, 278, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2646, d4py1A_, 0.7621, 2.72, 0.226, 289, 252, CRYSTAL STRUCTURE OF TYK2 IN COMPLEX WITH COMPOUND 15 6-((25- DIMETHOXYPHENYL)THIO)-3-(1-METHYL-1H-PYRAZOL-4-YL)-[124]TRIAZOLO[4 3-B]PYRIDAZINE
2647, d2pvyC_, 0.7621, 2.65, 0.232, 285, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
2648, d2of2A_, 0.7621, 2.61, 0.220, 271, 250, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 8 BOUND TO LCK
2649, d2ckeA_, 0.7621, 2.82, 0.240, 301, 254, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2650, d5x18B_, 0.7620, 2.87, 0.195, 294, 257, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
2651, d4uv0A_, 0.7620, 2.71, 0.257, 300, 253, STRUCTURE OF A SEMISYNTHETIC PHOSPHORYLATED DAPK
2652, d4l44A_, 0.7620, 2.51, 0.305, 321, 249, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM II)
2653, d4jboA_, 0.7620, 2.61, 0.295, 266, 251, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
2654, d4j95A_, 0.7620, 2.68, 0.231, 279, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
2655, d4f0fA1, 0.7620, 2.54, 0.225, 274, 249, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM
2656, d4d0xA_, 0.7620, 2.81, 0.244, 291, 254, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
2657, d3ri1B_, 0.7620, 2.77, 0.224, 283, 254, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
2658, d2yaaB_, 0.7620, 2.74, 0.261, 299, 253, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
2659, d4wnoA_, 0.7619, 2.64, 0.296, 272, 250, STRUCTURE OF ULK1 BOUND TO AN INHIBITOR
2660, d4d0wA_, 0.7619, 2.63, 0.250, 289, 252, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
2661, d2zm3C2, 0.7619, 2.76, 0.212, 295, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2662, d2xj1A_, 0.7619, 2.45, 0.262, 273, 248, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INIBITOR
2663, d4z16B_, 0.7618, 2.53, 0.253, 276, 249, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
2664, d3lm0A1, 0.7618, 2.43, 0.242, 271, 248, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B)
2665, d3kmmA_, 0.7618, 2.49, 0.221, 270, 249, STRUCTURE OF HUMAN LCK KINASE WITH A SMALL MOLECULE INHIBITOR
2666, d3bymA_, 0.7618, 2.62, 0.220, 271, 250, X-RAY CO-CRYSTAL STRUCTURE AMINOBENZIMIDAZOLE TRIAZINE 1 BOUND TO LCK
2667, d2vz6A1, 0.7618, 2.90, 0.300, 285, 253, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
2668, d5opsA_, 0.7617, 2.31, 0.269, 258, 245, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
2669, d4hzrA_, 0.7617, 2.24, 0.257, 261, 245, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
2670, d2xj2A_, 0.7617, 2.33, 0.263, 273, 247, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2671, d5u94A_, 0.7616, 2.25, 0.269, 263, 245, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PASTA KINASE PKNB IN COMPLEX WITH THE POTENTIAL THERAPUTIC KINASE INHIBITOR GSK690693.
2672, d5ih5A_, 0.7616, 2.90, 0.182, 286, 258, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A
2673, d4hokS_, 0.7616, 2.98, 0.194, 286, 258, CRYSTAL STRUCTURE OF APO CK1E
2674, d3ug1A_, 0.7616, 2.39, 0.202, 296, 247, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN THE APO FORM
2675, d6bqpA1, 0.7615, 2.38, 0.290, 262, 248, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CRENOLANIB
2676, d5o12A_, 0.7615, 2.31, 0.268, 264, 246, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
2677, d5e8uA1, 0.7615, 2.69, 0.210, 303, 252, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F)
2678, d4wsqA_, 0.7615, 2.34, 0.251, 317, 247, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2679, d4fswA_, 0.7615, 2.55, 0.275, 265, 247, CRYSTAL STRUCTURE OF THE CHK1
2680, d2qohB2, 0.7615, 2.69, 0.223, 280, 251, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
2681, d2a2aD_, 0.7615, 2.82, 0.240, 303, 254, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2682, d5ih6A_, 0.7614, 2.94, 0.186, 286, 258, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A DERIVATIVE
2683, d5fqdC_, 0.7614, 2.92, 0.198, 294, 258, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
2684, d4ytcA_, 0.7614, 2.64, 0.250, 284, 252, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
2685, d1u54B_, 0.7614, 2.25, 0.261, 261, 245, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
2686, d5e8wA1, 0.7613, 2.78, 0.206, 302, 252, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE
2687, d4x2kA1, 0.7613, 2.71, 0.211, 302, 251, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2688, d4x2jA1, 0.7613, 2.71, 0.211, 302, 251, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2689, d2ivuA1, 0.7613, 2.76, 0.238, 283, 252, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR ZD6474
2690, d5o13A_, 0.7611, 2.30, 0.264, 270, 246, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
2691, d3ppzA_, 0.7611, 2.18, 0.255, 264, 243, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2692, d3e63A_, 0.7611, 2.73, 0.245, 290, 253, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
2693, d2bujB1, 0.7611, 2.65, 0.243, 277, 251, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
2694, d2a2aC_, 0.7611, 2.84, 0.240, 303, 254, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2695, d1yi3A_, 0.7611, 2.28, 0.264, 267, 246, CRYSTAL STRUCTURE OF PIM-1 BOUND TO LY294002
2696, d5kziA_, 0.7610, 2.38, 0.258, 273, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN IMIDAZOPYRIDAZINE INHIBITOR.
2697, d5aepA_, 0.7610, 2.64, 0.250, 287, 252, NOVEL PYRROLE CARBOXAMIDE INHIBITORS OF JAK2 AS POTENTIAL TREATMENT OF MYELOPROLIFERATIVE DISORDERS
2698, d4x2nA1, 0.7610, 2.71, 0.207, 302, 251, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2699, d4nt4A1, 0.7610, 2.85, 0.198, 299, 258, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF GILGAMESH ISOFORM I FROM DROSOPHILA MELANOGASTER
2700, d3dqwB_, 0.7610, 2.57, 0.240, 278, 250, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
2701, d3bi6A_, 0.7610, 2.35, 0.224, 258, 245, WEE1 KINASE COMPLEX WITH INHIBITOR PD352396
2702, d2csnA_, 0.7610, 2.87, 0.179, 293, 257, BINARY COMPLEX OF CASEIN KINASE-1 WITH CKI7
2703, d1zwsA_, 0.7610, 2.57, 0.251, 278, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2704, d5oq7B_, 0.7609, 2.42, 0.274, 256, 248, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2705, d3byoA_, 0.7609, 2.62, 0.220, 270, 250, X-RAY CO-CRYSTAL STRUCTURE OF 2-AMINO-6-PHENYLPYRIMIDO[5  4 :56]PYRIMIDO[12-A]BENZIMIDAZOL-5(6H)-ONE 25 BOUND TO LCK
2706, d2c47C_, 0.7609, 2.65, 0.202, 282, 253, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
2707, d5vc6A_, 0.7608, 2.41, 0.224, 259, 245, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
2708, d5mjaB_, 0.7608, 2.52, 0.219, 274, 251, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
2709, d5dosA_, 0.7608, 2.46, 0.308, 259, 247, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
2710, d5c27A1, 0.7608, 2.60, 0.194, 271, 252, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 2
2711, d4zimB1, 0.7608, 2.76, 0.249, 292, 253, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
2712, d4j99D_, 0.7608, 2.61, 0.233, 281, 249, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
2713, d3kulA_, 0.7608, 2.50, 0.201, 267, 249, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
2714, d3dqwA_, 0.7608, 2.57, 0.240, 278, 250, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
2715, d4x2gA1, 0.7607, 2.71, 0.211, 302, 251, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2716, d4ftaA_, 0.7607, 2.55, 0.275, 264, 247, CRYSTAL STRUCTURE OF THE CHK1
2717, d3eyhA_, 0.7607, 2.62, 0.240, 285, 250, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
2718, d3cqeA_, 0.7607, 2.29, 0.230, 258, 244, WEE1 KINASE COMPLEX WITH INHIBITOR PD074291
2719, d2yaaA_, 0.7607, 2.75, 0.261, 300, 253, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
2720, d1ckiA_, 0.7607, 2.85, 0.195, 292, 257, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
2721, d4e4mD_, 0.7606, 2.71, 0.254, 296, 252, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2722, d4bbfD_, 0.7606, 2.70, 0.246, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2723, d2pzrB_, 0.7606, 2.74, 0.225, 282, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2724, d1u4dB_, 0.7606, 2.14, 0.259, 262, 243, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
2725, d5v5yA_, 0.7605, 2.37, 0.238, 259, 244, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH MK1775
2726, d5nk5A_, 0.7605, 2.59, 0.202, 287, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1M
2727, d4x2fA1, 0.7605, 2.71, 0.211, 302, 251, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2728, d4hokC_, 0.7605, 3.00, 0.182, 289, 258, CRYSTAL STRUCTURE OF APO CK1E
2729, d4e4mB_, 0.7605, 2.71, 0.250, 296, 252, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2730, d3jvsA_, 0.7605, 2.38, 0.273, 256, 245, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
2731, d3e62A_, 0.7605, 2.74, 0.245, 291, 253, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
2732, d2hziA_, 0.7605, 2.72, 0.215, 268, 251, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
2733, d3uixA_, 0.7604, 2.30, 0.260, 266, 246, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2734, d2x4fB_, 0.7604, 2.74, 0.257, 288, 253, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
2735, d2x4fA_, 0.7604, 2.72, 0.253, 289, 253, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
2736, d5e90A1, 0.7603, 2.69, 0.212, 300, 250, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249F S280T Y282FS287NA350CL352F) IN COMPLEX WITH 3-AMINO-6- [4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2- CARBOXAMIDE
2737, d5ci7A_, 0.7603, 2.64, 0.297, 276, 249, STRUCTURE OF ULK1 BOUND TO A SELECTIVE INHIBITOR
2738, d4x0mA1, 0.7603, 2.72, 0.211, 302, 251, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2739, d4hokM_, 0.7603, 2.94, 0.183, 291, 257, CRYSTAL STRUCTURE OF APO CK1E
2740, d2xixA_, 0.7603, 2.43, 0.267, 272, 247, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-1 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2741, d2brhA_, 0.7603, 2.38, 0.276, 257, 246, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2742, d5lmaA_, 0.7602, 2.51, 0.188, 267, 250, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
2743, d2qg5D1, 0.7602, 2.50, 0.264, 267, 250, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
2744, d2ivvA1, 0.7602, 2.66, 0.240, 277, 250, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR PP1
2745, d5nkeA_, 0.7601, 2.68, 0.202, 292, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3A
2746, d4e4mA_, 0.7601, 2.83, 0.245, 296, 253, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2747, d3jy9A_, 0.7601, 2.60, 0.259, 282, 251, JANUS KINASE 2 INHIBITORS
2748, d3e64A_, 0.7601, 2.74, 0.245, 291, 253, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
2749, d2ofuA_, 0.7601, 2.64, 0.220, 272, 250, X-RAY CRYSTAL STRUCTURE OF 2-AMINOPYRIMIDINE CARBAMATE 43 BOUND TO LCK
2750, d2a2aA_, 0.7601, 2.85, 0.240, 304, 254, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2751, d5dt4A_, 0.7600, 2.45, 0.308, 259, 247, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
2752, d4hokQ_, 0.7600, 2.99, 0.178, 290, 258, CRYSTAL STRUCTURE OF APO CK1E
2753, d4bbfA_, 0.7600, 2.71, 0.246, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2754, d3r7oA1, 0.7600, 2.83, 0.209, 295, 253, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG
2755, d2fo0A3, 0.7600, 2.69, 0.215, 291, 251, ORGANIZATION OF THE SH3-SH2 UNIT IN ACTIVE AND INACTIVE FORMS OF THE C-ABL TYROSINE KINASE
2756, d1ckjA_, 0.7600, 2.84, 0.191, 296, 257, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
2757, d5vubB_, 0.7599, 2.43, 0.259, 269, 247, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
2758, d5deyB_, 0.7599, 2.62, 0.297, 281, 249, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
2759, d4ytiA_, 0.7599, 2.61, 0.255, 284, 251, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
2760, d4wnpC_, 0.7599, 2.63, 0.301, 271, 249, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2761, d4gh2A_, 0.7599, 2.35, 0.278, 266, 245, CRYSTAL STRUCTURE OF THE CHK1
2762, d3op5A_, 0.7599, 2.90, 0.143, 320, 259, HUMAN VACCINIA-RELATED KINASE 1
2763, d5nkhA_, 0.7598, 2.59, 0.202, 295, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3E
2764, d4xg6A1, 0.7598, 2.49, 0.204, 270, 250, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2765, d4e4mE_, 0.7598, 2.84, 0.245, 296, 253, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2766, d5e8yA_, 0.7597, 2.69, 0.232, 298, 250, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH STAUROSPORINE
2767, d5v24B_, 0.7596, 2.50, 0.278, 263, 245, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
2768, d5uoxA_, 0.7596, 2.49, 0.278, 263, 245, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2769, d4ftjA_, 0.7596, 2.46, 0.276, 266, 246, CRYSTAL STRUCTURE OF THE CHK1
2770, d4e20A_, 0.7596, 2.66, 0.220, 282, 250, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
2771, d2b4sB_, 0.7596, 3.00, 0.196, 294, 255, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
2772, d1zwsE_, 0.7596, 2.65, 0.242, 278, 252, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2773, d1qpdA_, 0.7596, 2.57, 0.221, 270, 249, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
2774, d5usyB_, 0.7595, 2.55, 0.253, 287, 249, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
2775, d5lwmA_, 0.7595, 2.70, 0.245, 290, 253, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 4 (FM381)
2776, d4fsqA_, 0.7595, 2.46, 0.276, 263, 246, CRYSTAL STRUCTURE OF THE CHK1
2777, d3pp0B_, 0.7595, 2.79, 0.192, 296, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
2778, d3pa4A_, 0.7595, 2.56, 0.274, 257, 248, X-RAY CRYSTAL STRUCTURE OF COMPOUND 2A BOUND TO HUMAN CHK1 KINASE DOMAIN
2779, d1qpcA_, 0.7595, 2.54, 0.221, 270, 249, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
2780, d5i3oB_, 0.7594, 2.44, 0.258, 302, 248, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2781, d4xg3B_, 0.7594, 2.41, 0.198, 267, 248, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2782, d4twpA_, 0.7594, 2.44, 0.231, 266, 247, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
2783, d3ac5A_, 0.7594, 2.66, 0.220, 270, 250, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2784, d1qpjA_, 0.7594, 2.56, 0.221, 265, 249, CRYSTAL STRUCTURE OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH STAUROSPORINE.
2785, d5e8zA1, 0.7593, 2.71, 0.212, 300, 250, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3- AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3- YL]PYRAZINE-2-CARBOXAMIDE
2786, d3q6wA1, 0.7593, 2.81, 0.213, 293, 253, STRUCTURE OF DUALLY-PHOSPHORYLATED MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG WITH SPECIFICITY FOR THE ACTIVATED RECEPTOR
2787, d3pa3A_, 0.7593, 2.56, 0.274, 259, 248, X-RAY CRYSTAL STRUCTURE OF COMPOUND 70 BOUND TO HUMAN CHK1 KINASE DOMAIN
2788, d2zm1A_, 0.7593, 2.66, 0.220, 270, 250, CRYSTAL STRUCTURE OF IMIDAZO PYRAZIN 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2789, d2dylA_, 0.7593, 2.28, 0.229, 272, 245, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 7 ACTIVATED MUTANT (S287D T291D)
2790, d2bvaA_, 0.7593, 2.29, 0.260, 272, 246, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
2791, d5w4wD_, 0.7592, 2.84, 0.181, 287, 254, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2792, d5o11A_, 0.7592, 2.31, 0.264, 268, 246, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
2793, d5lwnA_, 0.7592, 2.70, 0.245, 290, 253, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 5 (FM409)
2794, d5cy3A1, 0.7592, 2.56, 0.203, 274, 251, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT AND ORALLY BIOAVAILABLE BENZISOTHIAZOLE INHIBITOR
2795, d3lckA_, 0.7592, 2.55, 0.221, 270, 249, THE KINASE DOMAIN OF HUMAN LYMPHOCYTE KINASE (LCK) ACTIVATED FORM (AUTO-PHOSPHORYLATED ON TYR394)
2796, d2wotA_, 0.7592, 2.73, 0.212, 303, 250, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
2797, d2wotA1, 0.7592, 2.73, 0.212, 301, 250, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
2798, d6bu6A_, 0.7591, 2.94, 0.142, 322, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
2799, d5ih4A_, 0.7591, 2.96, 0.190, 286, 258, HUMAN CASEIN KINASE 1 ISOFORM DELTA APO (KINASE DOMAIN)
2800, d5cf5B1, 0.7591, 2.77, 0.245, 292, 253, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2801, d4iwdA1, 0.7591, 2.86, 0.213, 295, 254, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-8033 ANALOG
2802, d3op5B_, 0.7591, 2.93, 0.138, 319, 260, HUMAN VACCINIA-RELATED KINASE 1
2803, d3ac2A_, 0.7591, 2.66, 0.220, 270, 250, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2804, d3ac1A_, 0.7591, 2.55, 0.221, 270, 249, CRYSTAL STRUCTURE OF PYRAZIN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2805, d1csnA_, 0.7591, 2.91, 0.179, 293, 257, BINARY COMPLEX OF CASEIN KINASE-1 WITH MGATP
2806, d4xeyB2, 0.7590, 2.71, 0.200, 264, 250, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
2807, d2dwbA_, 0.7590, 2.34, 0.305, 259, 246, AURORA-A KINASE COMPLEXED WITH AMPPNP
2808, d1x8bA_, 0.7590, 2.26, 0.230, 259, 243, STRUCTURE OF HUMAN WEE1A KINASE: KINASE DOMAIN COMPLEXED WITH INHIBITOR PD0407824
2809, d5vucB_, 0.7589, 2.46, 0.259, 269, 247, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
2810, d5oq8A_, 0.7589, 2.50, 0.265, 261, 249, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2811, d4l43A_, 0.7589, 2.46, 0.304, 316, 247, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM I)
2812, d4enyA_, 0.7589, 2.32, 0.260, 261, 246, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH (2E5Z)-2-(2- CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-METHOXYBENZYLIDENE)THIAZOLIDIN-4- ONE
2813, d3io7A_, 0.7589, 2.62, 0.259, 282, 251, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
2814, d2xf0A_, 0.7589, 2.31, 0.270, 251, 244, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2815, d2x6dA_, 0.7589, 2.17, 0.295, 255, 244, AURORA-A BOUND TO AN INHIBITOR
2816, d2a27D_, 0.7589, 2.87, 0.240, 304, 254, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2817, d5tozA_, 0.7588, 2.57, 0.248, 278, 250, JAK3 WITH COVALENT INHIBITOR PF-06651600
2818, d5cwzA_, 0.7588, 2.54, 0.247, 284, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
2819, d5cf4B_, 0.7588, 2.79, 0.249, 291, 253, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2820, d4enxA_, 0.7588, 2.32, 0.260, 266, 246, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH INHIBITOR (2E5Z)-2- (2-CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-NITROBENZYLIDENE)THIAZOLIDIN-4- ONE
2821, d3lvpB_, 0.7588, 2.85, 0.212, 295, 255, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
2822, d2xzsA_, 0.7588, 2.87, 0.252, 301, 254, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
2823, d2clqA_, 0.7588, 2.46, 0.273, 263, 245, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2824, d5opbA_, 0.7587, 2.51, 0.268, 262, 250, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH INDAZOLE LRRK2 INHIBITOR
2825, d3f5pD1, 0.7587, 2.76, 0.208, 296, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2826, d3f5pA1, 0.7587, 2.76, 0.208, 298, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2827, d3ad6A_, 0.7587, 2.66, 0.220, 272, 250, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2828, d3ac3A_, 0.7587, 2.55, 0.221, 270, 249, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2829, d4tn6A_, 0.7586, 3.05, 0.186, 292, 258, CK1D IN COMPLEX WITH INHIBITOR
2830, d3f5pC1, 0.7586, 2.76, 0.208, 300, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2831, d3acjA_, 0.7586, 2.55, 0.221, 270, 249, CRYSTAL STRUCTURE OF IMIDAZO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2832, d2ya9A_, 0.7586, 2.88, 0.248, 299, 254, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
2833, d2b4sD_, 0.7586, 3.01, 0.196, 294, 255, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
2834, d2auhA1, 0.7586, 2.93, 0.196, 294, 255, CRYSTAL STRUCTURE OF THE GRB14 BPS REGION IN COMPLEX WITH THE INSULIN RECEPTOR TYROSINE KINASE
2835, d2a2aB_, 0.7586, 2.89, 0.240, 303, 254, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2836, d4rx7A1, 0.7585, 2.52, 0.204, 270, 250, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR
2837, d3lxlA_, 0.7585, 2.61, 0.248, 281, 250, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
2838, d3f5pH1, 0.7585, 2.76, 0.208, 298, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2839, d2zm4A_, 0.7585, 2.66, 0.220, 270, 250, CRYSTAL STRUCTURE OF IMIDAZO QUINOXALINE 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK ACTIVATED FORM (AUTO- PHOSPHORYLATED ON TYR394)
2840, d4rioA_, 0.7584, 2.61, 0.247, 285, 251, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE CARBOXAMIDE INHIBITOR
2841, d3f5pT1, 0.7584, 2.73, 0.209, 294, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2842, d2zybA_, 0.7584, 2.56, 0.221, 270, 249, CRYSTAL STRUCTURE OF PHENYLIMIDAZO PYRAZIN 2 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2843, d2xezA_, 0.7584, 2.33, 0.270, 249, 244, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2844, d2pvyB_, 0.7584, 2.65, 0.233, 286, 249, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
2845, d5usyA_, 0.7583, 2.61, 0.253, 287, 249, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
2846, d5os2A_, 0.7583, 2.40, 0.300, 261, 247, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2847, d5i3rB_, 0.7583, 2.45, 0.258, 302, 248, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2848, d4xg7A1, 0.7583, 2.60, 0.203, 265, 251, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2849, d4hzrB_, 0.7583, 2.30, 0.261, 258, 245, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
2850, d3ma3A_, 0.7583, 2.30, 0.265, 266, 245, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A NAPHTHO-DIFURAN LIGAND
2851, d2w1iA_, 0.7583, 2.70, 0.247, 284, 251, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2852, d4rixB_, 0.7582, 2.58, 0.217, 293, 249, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
2853, d3naxA_, 0.7582, 2.63, 0.255, 278, 251, PDK1 IN COMPLEX WITH INHIBITOR MP7
2854, d3ac4A_, 0.7582, 2.56, 0.221, 270, 249, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2855, d2ydkA_, 0.7582, 2.62, 0.264, 263, 250, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
2856, d2w1iB_, 0.7582, 2.62, 0.252, 284, 250, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2857, d1xbcA1, 0.7582, 2.38, 0.206, 267, 247, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH STAUROSPORIN
2858, d1qpeA_, 0.7582, 2.55, 0.221, 270, 249, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
2859, d4kb8D_, 0.7581, 2.83, 0.190, 278, 253, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
2860, d3ad4A_, 0.7581, 2.56, 0.221, 270, 249, CRYSTAL STRUCTURE OF METHOXY BENZOFURAN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2861, d3ackA_, 0.7581, 2.56, 0.221, 270, 249, CRYSTAL STRUCTURE OF PYRROLO PYRAZINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2862, d2wmrA_, 0.7581, 2.33, 0.270, 254, 244, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2863, d3f5pB1, 0.7580, 2.77, 0.208, 297, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2864, d3ad5A_, 0.7580, 2.57, 0.221, 270, 249, CRYSTAL STRUCTURE OF TRIAZOLONE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2865, d2y0aA_, 0.7580, 2.77, 0.257, 300, 253, STRUCTURE OF DAPK1 CONSTRUCT RESIDUES 1-304
2866, d2hziB_, 0.7580, 2.52, 0.219, 264, 247, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
2867, d5ukfA_, 0.7579, 2.95, 0.142, 322, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
2868, d5tt7A1, 0.7579, 2.43, 0.206, 270, 248, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
2869, d5gmpA_, 0.7579, 2.77, 0.204, 305, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH XTF-262
2870, d4riwB_, 0.7579, 2.51, 0.206, 293, 248, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
2871, d3f5pG1, 0.7579, 2.77, 0.208, 298, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2872, d2a27H_, 0.7579, 2.89, 0.240, 304, 254, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2873, d2a27F_, 0.7579, 2.89, 0.240, 303, 254, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2874, d3krrA1, 0.7578, 2.79, 0.245, 290, 253, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT QUINOXALINE ATP SITE INHIBITOR
2875, d5drdA_, 0.7577, 2.49, 0.296, 259, 247, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
2876, d4wkqA1, 0.7577, 2.46, 0.206, 294, 247, 1.85 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN WITH GEFITINIB
2877, d3umwA_, 0.7577, 2.36, 0.268, 264, 246, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDAZOL-3-YL)METHYLENE]-6-METHOXY-7-(PIPERAZIN-1-YLMETHYL)BENZOFURAN- 3(2H)-ONE
2878, d1u54A_, 0.7577, 2.30, 0.257, 262, 245, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
2879, d5ghvA_, 0.7576, 2.27, 0.200, 265, 245, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2880, d4xg5A_, 0.7576, 2.27, 0.200, 265, 245,  
2881, d3ac8A_, 0.7576, 2.58, 0.221, 270, 249, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2882, d2wmxA_, 0.7576, 2.26, 0.272, 248, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2883, d6bruA_, 0.7575, 2.96, 0.138, 322, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
2884, d5ghvB_, 0.7575, 2.28, 0.200, 265, 245, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2885, d5d9lA_, 0.7575, 2.41, 0.296, 299, 247, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BIS-PHENOL PYRAZOLE
2886, d4xg5B_, 0.7575, 2.28, 0.200, 265, 245,  
2887, d4wnmA1, 0.7575, 2.47, 0.205, 269, 249, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT TRIAZOLOPYRIDINE INHIBITOR
2888, d4kbaD_, 0.7575, 2.84, 0.194, 274, 253, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
2889, d2hk5A2, 0.7575, 2.52, 0.242, 268, 248, HCK KINASE IN COMPLEX WITH LCK TARGETTED INHIBITOR PG-1009247
2890, d5eakA_, 0.7574, 2.44, 0.322, 305, 242, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
2891, d5di1A_, 0.7574, 2.56, 0.256, 285, 250, MAP4K4 IN COMPLEX WITH AN INHIBITOR
2892, d3q32A_, 0.7574, 2.72, 0.250, 291, 252, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
2893, d3dqwC_, 0.7574, 2.60, 0.237, 275, 249, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
2894, d2a27C_, 0.7574, 2.90, 0.240, 303, 254, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2895, d4kbaC_, 0.7573, 2.85, 0.181, 277, 254, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
2896, d2ya9B_, 0.7573, 2.89, 0.248, 299, 254, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
2897, d2ituA_, 0.7573, 2.88, 0.198, 304, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AFN941
2898, d5ax9B_, 0.7572, 2.21, 0.250, 274, 244, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2899, d2ym5A_, 0.7572, 2.28, 0.267, 248, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2900, d5dt0A_, 0.7571, 2.50, 0.304, 259, 247, AURORA A KINASE IN COMPLEX WITH JNJ-7706621 IN SPACE GROUP P6122
2901, d3pjcA_, 0.7571, 2.59, 0.252, 286, 250, CRYSTAL STRUCTURE OF JAK3 COMPLEXED WITH A POTENT ATP SITE INHIBITOR SHOWING HIGH SELECTIVITY WITHIN THE JANUS KINASE FAMILY
2902, d3bceA_, 0.7571, 2.59, 0.217, 285, 249, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
2903, d2a27E_, 0.7571, 2.90, 0.240, 303, 254, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2904, d5usqA_, 0.7570, 2.64, 0.213, 299, 249, ALK-5 KINASE INHIBITOR COMPLEX
2905, d5hznG_, 0.7570, 2.85, 0.206, 296, 252, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2906, d5hznC_, 0.7570, 2.85, 0.206, 296, 252, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2907, d4yjoA_, 0.7570, 2.44, 0.190, 267, 248, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222
2908, d4hvgA_, 0.7570, 2.60, 0.248, 281, 250, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-2-HYDROXY-12-DIMETHYL-PROPYL)- AMIDE
2909, d5e8sA1, 0.7569, 2.64, 0.213, 299, 249, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)
2910, d4w9xA_, 0.7569, 2.38, 0.264, 300, 246, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH BARICITINIB
2911, d4lg4F_, 0.7569, 2.18, 0.276, 276, 243, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2912, d4ftnA_, 0.7569, 2.47, 0.278, 253, 245, CRYSTAL STRUCTURE OF THE CHK1
2913, d2a27B_, 0.7569, 2.85, 0.252, 303, 254, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2914, d5tq3B_, 0.7568, 2.76, 0.250, 285, 252, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
2915, d4kb8C_, 0.7568, 2.88, 0.185, 277, 254, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
2916, d3f5pF1, 0.7568, 2.79, 0.208, 298, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2917, d3dqwD_, 0.7568, 2.59, 0.237, 276, 249, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
2918, d2a27A_, 0.7568, 2.95, 0.251, 304, 255, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2919, d4kbkD_, 0.7567, 2.85, 0.190, 281, 253, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
2920, d3uysA_, 0.7567, 2.85, 0.182, 281, 253, CRYSTAL STRUCTURE OF APO HUMAN CK1D
2921, d4riyB_, 0.7566, 2.55, 0.206, 293, 248, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
2922, d3lxnA_, 0.7566, 2.71, 0.220, 287, 250, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
2923, d2a27G_, 0.7566, 2.85, 0.252, 303, 254, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2924, d5ar5A_, 0.7565, 2.77, 0.221, 284, 253, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
2925, d3lxpA_, 0.7565, 2.62, 0.222, 285, 248, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
2926, d3f5pE1, 0.7565, 2.79, 0.208, 298, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2927, d5hznE_, 0.7563, 2.97, 0.206, 296, 253, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2928, d5hznA_, 0.7563, 2.99, 0.202, 296, 253, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2929, d4yc8A_, 0.7563, 2.71, 0.213, 259, 249, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
2930, d4fl1A_, 0.7563, 2.48, 0.206, 268, 248, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
2931, d3zewA_, 0.7563, 2.35, 0.216, 269, 245, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
2932, d1u46B_, 0.7563, 2.15, 0.264, 257, 242, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
2933, d4mneB_, 0.7562, 2.59, 0.196, 270, 250, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
2934, d5cxzA1, 0.7560, 2.40, 0.206, 267, 247, SYK CATALYTIC DOMAIN COMPLEXED WITH NAPHTHYRIDINE INHIBITOR
2935, d4xg3A_, 0.7560, 2.44, 0.206, 262, 248, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2936, d3q32B1, 0.7560, 2.84, 0.245, 293, 253, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
2937, d4r5sA_, 0.7559, 2.72, 0.203, 299, 251, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH FIIN-3
2938, d4jikA_, 0.7559, 2.38, 0.270, 256, 244, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22A (R)-2-(4-CHLOROPHENYL)-8- (PIPERIDIN-3-YLAMINO)IMIDAZO[12-C]PYRIMIDINE-5-CARBOXAMIDE BOUND TO HUMAN CHK1 KINASE DOMAIN
2939, d1rw8A_, 0.7559, 2.93, 0.219, 301, 251, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH ATP SITE INHIBITOR
2940, d4fstA_, 0.7558, 2.43, 0.275, 253, 244, CRYSTAL STRUCTURE OF THE CHK1
2941, d3sv0A_, 0.7558, 3.00, 0.178, 294, 258, CRYSTAL STRUCTURE OF CASEIN KINASE-1 LIKE PROTEIN IN PLANT
2942, d5hznH_, 0.7557, 2.85, 0.206, 303, 252, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2943, d5hznD_, 0.7557, 2.85, 0.206, 304, 252, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2944, d5cf6A_, 0.7557, 2.69, 0.255, 285, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2945, d4rssA_, 0.7557, 2.60, 0.196, 269, 250, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE SYK WITH AN INHIBITOR
2946, d4kbaB_, 0.7557, 2.81, 0.187, 285, 252, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
2947, d3bceB_, 0.7557, 2.51, 0.211, 286, 247, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
2948, d5x17B_, 0.7556, 2.96, 0.191, 289, 257, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
2949, d5uorB_, 0.7556, 2.52, 0.279, 262, 244, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2950, d5cf5A1, 0.7556, 2.72, 0.255, 286, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2951, d5hznF_, 0.7555, 2.87, 0.206, 296, 252, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2952, d5hznB_, 0.7555, 2.87, 0.206, 296, 252, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2953, d4f1tA1, 0.7555, 2.58, 0.227, 267, 247, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO THE ROCK INHIBITOR H1152
2954, d4aqcB_, 0.7555, 2.83, 0.249, 295, 253, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
2955, d3f5pI1, 0.7555, 2.76, 0.209, 293, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2956, d3dk3B_, 0.7555, 2.74, 0.217, 269, 249, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
2957, d2itnA_, 0.7555, 2.75, 0.200, 304, 250, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AMP-PNP
2958, d5dpvA_, 0.7554, 2.35, 0.302, 257, 245, AURORA A KINASE IN COMPLEX WITH AA35 AND JNJ-7706621 IN SPACE GROUP P6122
2959, d2ym6A_, 0.7554, 2.32, 0.272, 253, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2960, d2wouA_, 0.7554, 2.61, 0.218, 299, 248, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
2961, d2wouA1, 0.7554, 2.61, 0.218, 297, 248, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
2962, d4e6qA_, 0.7553, 2.82, 0.253, 296, 253, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
2963, d4dflA1, 0.7553, 2.41, 0.206, 262, 247, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A SULFONAMIDOPYRAZINE PIPERIDINE INHIBITOR
2964, d3kxzA_, 0.7553, 2.63, 0.221, 263, 249, THE COMPLEX CRYSTAL STRUCTURE OF LCK WITH A PROBE MOLECULE W259
2965, d3f5pM1, 0.7553, 2.79, 0.208, 294, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2966, d2ittA_, 0.7553, 2.74, 0.200, 302, 250, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AEE788
2967, d2io6A_, 0.7553, 2.32, 0.227, 252, 242, WEE1 KINASE COMPLEXED WITH INHIBITOR PD330961
2968, d1bi8C_, 0.7553, 2.37, 0.483, 264, 242, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX
2969, d1bi8A_, 0.7553, 2.37, 0.483, 264, 242, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX
2970, d4wsqB_, 0.7552, 2.42, 0.251, 310, 247, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2971, d2wmtA_, 0.7552, 2.32, 0.267, 248, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2972, d5fedA_, 0.7551, 2.46, 0.203, 288, 246, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
2973, d5e91A_, 0.7551, 2.75, 0.233, 297, 249, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4- (MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE
2974, d4kb8B_, 0.7551, 2.83, 0.187, 285, 252, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
2975, d2vz6B1, 0.7551, 2.97, 0.287, 288, 254, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
2976, d1py5A_, 0.7551, 2.95, 0.215, 301, 251, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH INHIBITOR
2977, d5ng2B_, 0.7550, 2.67, 0.220, 278, 250, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
2978, d3fqhA_, 0.7550, 2.47, 0.206, 262, 248, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
2979, d3f5pS1, 0.7550, 2.77, 0.209, 294, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2980, d5mqvC_, 0.7549, 2.92, 0.191, 288, 256, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
2981, d4pv0A1, 0.7549, 2.46, 0.206, 266, 248, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH AN IMIDAZOPYRAZINE INHIBITOR
2982, d3dk7B_, 0.7549, 2.71, 0.225, 268, 249, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
2983, d5friA1, 0.7548, 2.67, 0.213, 299, 249, ALK5 IN COMPLEX WITHA AN N-(4-ANILINO-2-PYRIDYL)ACETAMIDE INHIBITOR.
2984, d5e8tA1, 0.7548, 2.77, 0.212, 300, 250, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)
2985, d4d1sA_, 0.7548, 2.56, 0.259, 280, 247, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
2986, d3zbfA_, 0.7547, 2.32, 0.234, 281, 244, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH CRIZOTINIB
2987, d2in6A_, 0.7547, 2.33, 0.227, 256, 242, WEE1 KINASE COMPLEX WITH INHIBITOR PD311839
2988, d1yvjA_, 0.7547, 2.73, 0.246, 288, 252, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN IN COMPLEX WITH A STAUROSPORINE ANALOGUE
2989, d1iasB_, 0.7547, 2.78, 0.208, 324, 250, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
2990, d2bdwA_, 0.7546, 2.82, 0.297, 309, 256, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
2991, d2j5fA_, 0.7545, 2.89, 0.206, 308, 253, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 34-JAB
2992, d5tr6A1, 0.7544, 2.43, 0.206, 268, 247, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
2993, d4dfnA1, 0.7544, 2.49, 0.206, 268, 248, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH AN ADAMANTYLPYRAZINE INHIBITOR
2994, d4rx9A1, 0.7543, 2.45, 0.202, 264, 247, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT PYRIMIDINE INHIBITOR
2995, d4lg4B_, 0.7543, 2.55, 0.272, 284, 246, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2996, d4ivaA_, 0.7543, 2.84, 0.241, 290, 253, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-[(8AS)- 2-[(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(8AH)- YL]CYCLOHEXANECARBONITRILE
2997, d2ym3A_, 0.7543, 2.29, 0.269, 247, 242, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2998, d1k2pA_, 0.7543, 2.49, 0.186, 258, 247, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
2999, d6btwA_, 0.7542, 2.97, 0.151, 317, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
3000, d4p2wB_, 0.7542, 2.23, 0.210, 253, 243,  
3001, d2itvA_, 0.7542, 2.76, 0.200, 303, 250, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AMP-PNP
3002, d5oq7A_, 0.7540, 2.49, 0.274, 259, 248, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3003, d5ikwA_, 0.7540, 2.47, 0.263, 297, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3004, d5ar2A_, 0.7540, 2.58, 0.225, 277, 249, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
3005, d4aqcA_, 0.7540, 2.84, 0.249, 289, 253, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
3006, d3bizA_, 0.7540, 2.34, 0.223, 250, 242, WEE1 KINASE COMPLEX WITH INHIBITOR PD331618
3007, d2xzsB_, 0.7540, 2.81, 0.254, 293, 252, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
3008, d5dr9A_, 0.7539, 2.43, 0.306, 257, 245, AURORA A KINASE IN COMPLEX WITH AA29 AND JNJ-7706621 IN SPACE GROUP P6122
3009, d2wmwA_, 0.7539, 2.27, 0.273, 247, 242, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3010, d5j79A_, 0.7538, 2.69, 0.224, 283, 250, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
3011, d3zhpD_, 0.7538, 2.63, 0.259, 264, 251, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
3012, d3nyxA1, 0.7538, 2.62, 0.204, 285, 250, NON-PHOSPHORYLATED TYK2 JH1 DOMAIN WITH QUINOLINE-THIADIAZOLE- THIOPHENE INHIBITOR
3013, d5uvfB_, 0.7537, 2.95, 0.155, 316, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
3014, d4xg4A_, 0.7537, 2.30, 0.201, 264, 244, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3015, d6babC_, 0.7536, 2.67, 0.297, 284, 249, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
3016, d5uvfA_, 0.7536, 2.99, 0.147, 317, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
3017, d5dewB_, 0.7536, 2.72, 0.293, 281, 249, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
3018, d5ukfC_, 0.7535, 3.00, 0.154, 317, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
3019, d5ttvA_, 0.7535, 2.64, 0.249, 280, 249, JAK3 WITH COVALENT INHIBITOR 6
3020, d5eakB_, 0.7535, 2.22, 0.326, 300, 239, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
3021, d5cf6B1, 0.7535, 2.77, 0.247, 288, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3022, d4jjrB_, 0.7535, 3.03, 0.171, 283, 258, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
3023, d4f09A_, 0.7535, 2.85, 0.249, 288, 253, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
3024, d2fumA_, 0.7535, 2.32, 0.261, 263, 245, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3025, d1xbaA1, 0.7535, 2.44, 0.206, 265, 247, CRYSTAL STRUCTURE OF APO SYK TYROSINE KINASE DOMAIN
3026, d4lqmA_, 0.7534, 2.80, 0.199, 305, 251, EGFR L858R IN COMPLEX WITH PD168393
3027, d4lg4E_, 0.7534, 2.50, 0.286, 275, 248, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3028, d3vf8A_, 0.7534, 2.46, 0.206, 265, 247, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH PYRAZOLYLBENZIMIDAZOLE INHIBITOR 416
3029, d3f5pK1, 0.7534, 2.75, 0.209, 292, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3030, d5ttuA_, 0.7533, 2.51, 0.251, 271, 247, JAK3 WITH COVALENT INHIBITOR 7
3031, d5tq5A_, 0.7533, 2.77, 0.254, 291, 252, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3032, d5tiuA1, 0.7533, 2.40, 0.199, 262, 246, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH INHIBITOR
3033, d4kbkA_, 0.7532, 2.85, 0.187, 283, 252, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
3034, d3zepC_, 0.7532, 2.68, 0.254, 276, 248, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3035, d2j4zB_, 0.7532, 2.32, 0.309, 269, 243, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
3036, d5tq8A_, 0.7531, 2.78, 0.254, 291, 252, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3037, d4zp5A_, 0.7531, 2.63, 0.256, 284, 250, MAP4K4 IN COMPLEX WITH INHIBITOR
3038, d4u40A_, 0.7531, 2.86, 0.252, 295, 254, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
3039, d3lxkA_, 0.7531, 2.68, 0.248, 279, 250, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3040, d1ckiB_, 0.7531, 2.97, 0.183, 286, 257, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
3041, d4mneC_, 0.7530, 2.51, 0.202, 260, 247, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3042, d2wzjA_, 0.7530, 2.46, 0.317, 310, 243, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3043, d1ckjB_, 0.7530, 2.96, 0.183, 293, 257, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
3044, d4ixpA_, 0.7529, 2.98, 0.316, 334, 253, CRYSTAL STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK)
3045, d4e6qB_, 0.7529, 2.85, 0.257, 296, 253, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
3046, d3vf9A_, 0.7529, 2.41, 0.199, 265, 246, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 027
3047, d3eygA_, 0.7529, 2.58, 0.243, 280, 247, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3048, d5mjaA_, 0.7528, 2.42, 0.224, 271, 246, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
3049, d3f5pL1, 0.7528, 2.76, 0.209, 292, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3050, d6bp0A_, 0.7527, 2.99, 0.147, 317, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3051, d5dr6A_, 0.7527, 2.46, 0.306, 257, 245, AURORA A KINASE IN COMPLEX WITH AA30 AND JNJ-7706621 IN SPACE GROUP P6122
3052, d4xg2A1, 0.7527, 2.31, 0.201, 258, 244, CRYSTAL STRUCTURE OF LIGAND-FREE SYK
3053, d3uysB_, 0.7527, 2.80, 0.179, 279, 251, CRYSTAL STRUCTURE OF APO HUMAN CK1D
3054, d2jitA_, 0.7527, 2.69, 0.187, 299, 251, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
3055, d5k00A_, 0.7526, 2.15, 0.329, 311, 240, MELK IN COMPLEX WITH NVS-MELK5
3056, d5i9vA_, 0.7526, 2.25, 0.210, 279, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH AGS
3057, d4zimA_, 0.7526, 2.76, 0.251, 285, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
3058, d4mneG_, 0.7526, 2.46, 0.199, 259, 246, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3059, d4f08B_, 0.7526, 2.84, 0.249, 288, 253, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
3060, d3zepA_, 0.7526, 2.62, 0.255, 274, 247, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3061, d3wf7A_, 0.7526, 2.80, 0.300, 288, 250, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PURINE DERIVATIVE 1-(9H-PURIN-6-YL)-N-[3-(TRIFLUOROMETHYL)PHENYL]PIPERIDINE- 4-CARBOXAMIDE
3062, d4yjqA_, 0.7525, 2.69, 0.188, 264, 250, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000224
3063, d4rx8A1, 0.7525, 2.47, 0.202, 266, 247, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR2
3064, d3srvB_, 0.7525, 2.42, 0.199, 263, 246, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
3065, d3f5pR1, 0.7525, 2.80, 0.209, 293, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3066, d2ym7A_, 0.7525, 2.39, 0.276, 248, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3067, d5e92A_, 0.7524, 2.85, 0.236, 298, 250, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH AMPPNP
3068, d1p4fA_, 0.7524, 2.42, 0.265, 269, 245, DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT
3069, d1o6yA_, 0.7524, 2.23, 0.269, 260, 242, CATALYTIC DOMAIN OF PKNB KINASE FROM MYCOBACTERIUM TUBERCULOSIS
3070, d4yjvA_, 0.7523, 2.69, 0.188, 263, 250, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000250
3071, d4g5pA_, 0.7523, 2.73, 0.198, 299, 252, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
3072, d3qc4B1, 0.7523, 2.39, 0.287, 268, 244, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
3073, d5lmbB_, 0.7522, 2.43, 0.191, 261, 246, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
3074, d4f08A_, 0.7522, 2.86, 0.253, 288, 253, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
3075, d2ityA1, 0.7522, 2.62, 0.210, 299, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH IRESSA
3076, d1iasD_, 0.7522, 2.93, 0.206, 330, 252, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3077, d5imeB_, 0.7521, 2.42, 0.296, 280, 243, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
3078, d4yjrA_, 0.7521, 2.71, 0.188, 263, 250, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000225
3079, d3umxA_, 0.7521, 2.35, 0.270, 261, 244, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDOL-3-YL)METHYLENE]-7-(AZEPAN-1-YLMETHYL)-6-HYDROXYBENZOFURAN- 3(2H)-ONE
3080, d2fumB_, 0.7521, 2.32, 0.270, 262, 244, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3081, d5ng0A_, 0.7519, 2.61, 0.222, 274, 248, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
3082, d4xg9B_, 0.7519, 2.42, 0.207, 265, 246, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3083, d4hvdA_, 0.7519, 2.59, 0.250, 276, 248, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-122-TRIMETHYL-PROPYL)-AMIDE
3084, d2w1gA1, 0.7519, 2.26, 0.306, 254, 242, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3085, d2itzA_, 0.7519, 2.89, 0.203, 302, 251, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH IRESSA
3086, d5vdkA_, 0.7518, 2.53, 0.250, 260, 244, CRYSTAL STRUCTURE OF HUMAN WEE2 KINASE DOMAIN IN COMPLEX WITH MK1775
3087, d5tq3A_, 0.7518, 2.75, 0.252, 282, 250, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3088, d5feeA_, 0.7518, 2.44, 0.204, 287, 245, EGFR KINASE DOMAIN T790M MUTANT IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
3089, d4bicA_, 0.7518, 2.45, 0.281, 260, 242, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3090, d3tjcB_, 0.7518, 2.79, 0.251, 287, 251, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
3091, d2np8A_, 0.7518, 2.41, 0.302, 256, 245, STRUCTURAL BASIS FOR THE INHIBITION OF AURORA A KINASE BY A NOVEL CLASS OF HIGH AFFINITY DISUBSTITUTED PYRIMIDINE INHIBITORS
3092, d5lmbA_, 0.7517, 2.48, 0.206, 264, 247, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
3093, d5i9uA_, 0.7517, 2.37, 0.209, 281, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
3094, d4qt1A_, 0.7517, 2.58, 0.250, 277, 248, JAK3 KINASE DOMAIN IN COMPLEX WITH 1-[(3S)-1-ISOBUTYLSULFONYL-3- PIPERIDYL]-3-(5H-PYRROLO[23-B]PYRAZIN-2-YL)UREA
3095, d4g5jA_, 0.7517, 2.50, 0.204, 307, 245, CRYSTAL STRUCTURE OF EGFR KINASE IN COMPLEX WITH BIBW2992
3096, d3zepD_, 0.7517, 2.58, 0.256, 272, 246, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3097, d3tzmA_, 0.7517, 2.67, 0.215, 295, 247, TGF-BETA RECEPTOR TYPE 1 IN COMPLEX WITH SB431542
3098, d2x8iA_, 0.7517, 2.54, 0.267, 261, 247, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
3099, d1vjyA_, 0.7517, 2.84, 0.216, 299, 250, CRYSTAL STRUCTURE OF A NAPHTHYRIDINE INHIBITOR OF HUMAN TGF- BETA TYPE I RECEPTOR
3100, d5mqvF_, 0.7516, 2.99, 0.195, 286, 256, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3101, d4hvhA_, 0.7516, 2.59, 0.250, 278, 248, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-2-HYDROXY-12-DIMETHYL-PROPYL
3102, d4ftqA_, 0.7516, 2.44, 0.276, 254, 243, CRYSTAL STRUCTURE OF THE CHK1
3103, d3dk6A_, 0.7516, 2.76, 0.218, 262, 248, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3104, d2ym8A_, 0.7516, 2.27, 0.270, 246, 241, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3105, d4yjtA_, 0.7515, 2.63, 0.189, 268, 249, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000233
3106, d4bicB_, 0.7515, 2.38, 0.282, 259, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3107, d3pa5A_, 0.7515, 2.50, 0.275, 255, 244, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
3108, d4i6qA_, 0.7513, 2.60, 0.250, 277, 248, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-PHENOXY-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-1-CYCLOPROPYL-ETHYL)-AMIDE
3109, d3ot8A_, 0.7513, 2.45, 0.276, 251, 243, X-RAY CRYSTAL STRUCTURE OF COMPOUND 17R BOUND TO HUMAN CHK1 KINASE DOMAIN
3110, d3f5pJ1, 0.7513, 2.78, 0.209, 292, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3111, d2zvaA1, 0.7513, 2.73, 0.230, 260, 248, LYN TYROSINE KINASE DOMAIN-DASATINIB COMPLEX
3112, d3zosA_, 0.7512, 2.92, 0.211, 301, 251, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
3113, d2wzjF_, 0.7512, 2.50, 0.317, 310, 243, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3114, d6bu6C_, 0.7511, 2.94, 0.156, 315, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3115, d4at3A1, 0.7511, 2.77, 0.228, 286, 250, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH CPD5N
3116, d3lctA_, 0.7511, 3.04, 0.181, 308, 254, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3117, d3dk6B_, 0.7511, 2.69, 0.220, 259, 246, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3118, d2ydjA_, 0.7511, 2.32, 0.273, 252, 242, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
3119, d2clqB_, 0.7511, 2.36, 0.282, 259, 241, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
3120, d3lvpA_, 0.7510, 2.76, 0.215, 289, 251, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
3121, d2qnjA1, 0.7510, 2.46, 0.324, 317, 244, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
3122, d2cmwA_, 0.7510, 2.83, 0.198, 294, 253, STRUCTURE OF HUMAN CASEIN KINASE 1 GAMMA-1 IN COMPLEX WITH 2-(2-HYDROXYETHYLAMINO)-6-(3-CHLOROANILINO)-9- ISOPROPYLPURINE (CASP TARGET)
3123, d6bruC_, 0.7509, 2.94, 0.152, 315, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3124, d5v19B_, 0.7509, 2.43, 0.277, 260, 242, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3125, d4e26A_, 0.7508, 2.47, 0.203, 270, 246, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
3126, d2wzjC_, 0.7508, 2.53, 0.313, 310, 243, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3127, d5i3oA_, 0.7507, 2.55, 0.258, 302, 248, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3128, d5cf8B1, 0.7507, 2.77, 0.252, 287, 250, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3129, d5cf4A_, 0.7507, 2.75, 0.252, 283, 250, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3130, d4z16A_, 0.7507, 2.45, 0.254, 271, 244, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3131, d4ji9B_, 0.7507, 2.84, 0.251, 288, 251, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
3132, d3dk7A_, 0.7507, 2.80, 0.217, 265, 249, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3133, d3dk3A_, 0.7506, 2.57, 0.227, 266, 247, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3134, d4ji9A_, 0.7504, 2.75, 0.252, 284, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
3135, d5t68B_, 0.7503, 2.35, 0.201, 264, 244, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
3136, d5ng2A_, 0.7503, 2.59, 0.215, 274, 247, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
3137, d4z16C_, 0.7503, 2.47, 0.254, 271, 244, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3138, d4rvtA_, 0.7503, 2.52, 0.259, 281, 247, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
3139, d3srvA_, 0.7503, 2.54, 0.206, 262, 247, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
3140, d3kcfB_, 0.7503, 2.86, 0.208, 324, 250, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3141, d6bp0C_, 0.7502, 2.95, 0.152, 315, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3142, d4o0tB_, 0.7502, 2.63, 0.296, 280, 247, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3143, d3l9pA_, 0.7502, 2.95, 0.178, 303, 253, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3144, d5t68A1, 0.7501, 2.37, 0.201, 264, 244, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
3145, d4bc6A_, 0.7501, 2.80, 0.309, 285, 246, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO NOVEL BOSUTINIB ISOFORM 1 PREVIOUSLY THOUGHT TO BE BOSUTINIB
3146, d2j4zA_, 0.7501, 2.38, 0.309, 263, 243, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
3147, d6btwC_, 0.7500, 2.95, 0.156, 315, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
3148, d4useA_, 0.7500, 2.75, 0.309, 286, 246, HUMAN STK10 (LOK) WITH SB-633825
3149, d4u43A_, 0.7500, 2.66, 0.251, 287, 251, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
3150, d2wmuA_, 0.7500, 2.31, 0.270, 246, 241, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3151, d1mruA_, 0.7500, 2.45, 0.266, 269, 244, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
3152, d5vt1A1, 0.7499, 2.71, 0.281, 264, 249, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO A BENZAMIDE INHIBITOR
3153, d1iasE_, 0.7499, 2.86, 0.212, 330, 250, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3154, d5fm3A_, 0.7498, 2.90, 0.233, 276, 249, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
3155, d4o0rB_, 0.7498, 2.66, 0.310, 282, 245, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3156, d3lcsA_, 0.7498, 3.08, 0.181, 304, 254, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3157, d1iasC_, 0.7498, 2.85, 0.212, 330, 250, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3158, d6bu6D_, 0.7497, 3.07, 0.154, 318, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3159, d4z16D_, 0.7497, 2.49, 0.258, 271, 244, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3160, d3zhpC1, 0.7497, 2.72, 0.271, 267, 251, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
3161, d3kcfC_, 0.7497, 2.95, 0.207, 330, 251, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3162, d2b7aA_, 0.7497, 2.78, 0.252, 284, 250, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
3163, d5up3A_, 0.7496, 2.37, 0.283, 258, 240, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3164, d5e8vA_, 0.7496, 2.74, 0.238, 296, 248, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A)
3165, d5ar5B_, 0.7496, 2.56, 0.227, 279, 247, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
3166, d5kbqB_, 0.7495, 2.65, 0.293, 273, 246, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
3167, d1jktB_, 0.7495, 2.79, 0.266, 276, 252, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
3168, d6eimA_, 0.7494, 2.63, 0.310, 286, 245, HUMAN STK10 BOUND TO GW683134A
3169, d5cf8A1, 0.7494, 2.72, 0.253, 284, 249, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3170, d1u46A_, 0.7494, 2.32, 0.256, 255, 242, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
3171, d4puzA_, 0.7493, 2.57, 0.191, 263, 246, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
3172, d2zv2A_, 0.7493, 2.26, 0.292, 256, 243, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2 BETA CAMKK2 KINASE DOMAIN IN COMPLEX WITH STO-609
3173, d5vd2A_, 0.7492, 2.55, 0.233, 258, 245, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PF- 03814735
3174, d4p7eB_, 0.7492, 2.83, 0.255, 285, 251, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
3175, d4jbqA_, 0.7492, 2.29, 0.302, 257, 242, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3176, d4byiA_, 0.7492, 2.28, 0.302, 254, 242, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
3177, d4bibB_, 0.7492, 2.38, 0.279, 258, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3178, d5vc3A_, 0.7490, 2.60, 0.224, 260, 246, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
3179, d5ttsA_, 0.7490, 2.53, 0.252, 274, 246, JAK3 WITH COVALENT INHIBITOR 4
3180, d4kbcB_, 0.7490, 2.85, 0.194, 277, 252, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
3181, d5i3rA_, 0.7489, 2.58, 0.258, 302, 248, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3182, d3fqsA1, 0.7489, 2.38, 0.201, 264, 244, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R406
3183, d3fe3B_, 0.7489, 2.43, 0.321, 317, 243, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
3184, d2b7aB_, 0.7489, 2.83, 0.251, 287, 251, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
3185, d1b6cF_, 0.7489, 2.99, 0.215, 326, 251, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
3186, d4yjpA_, 0.7488, 2.50, 0.191, 263, 246, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000223
3187, d2wzjB_, 0.7488, 2.58, 0.313, 310, 243, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3188, d1iasA_, 0.7488, 3.07, 0.209, 330, 253, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3189, d4mkcA_, 0.7487, 2.94, 0.183, 303, 252, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE COMPLEXED WITH LDK378
3190, d3d15A_, 0.7487, 2.41, 0.291, 256, 244, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-(3-CHLORO-PHENYL)-3-{5-[2-(THIENO[32- D]PYRIMIDIN-4-YLAMINO)- ETHYL]-THIAZOL-2-YL}-UREA [SNS-314]
3191, d2qnjB1, 0.7487, 2.44, 0.321, 321, 243, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
3192, d1wvyA_, 0.7487, 2.77, 0.259, 273, 251, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
3193, d3kcfE_, 0.7486, 2.76, 0.213, 330, 249, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3194, d1yi6B_, 0.7486, 2.68, 0.242, 274, 248, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
3195, d3hmiA_, 0.7485, 2.77, 0.212, 268, 250, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
3196, d6bp0B_, 0.7484, 3.02, 0.152, 304, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3197, d4fynA1, 0.7484, 2.38, 0.201, 263, 244, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 3-(8-{4- [ETHYL-(2-HYDROXY-ETHYL)-AMINO]-PHENYLAMINO}-IMIDAZO[12-A]PYRAZIN-5- YL)-PHENOL
3198, d4bidB_, 0.7484, 2.37, 0.279, 258, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3199, d4p90A_, 0.7483, 2.19, 0.271, 272, 240, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
3200, d4wrgA1, 0.7482, 2.41, 0.210, 287, 243, 1.9 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN
3201, d4p2wA_, 0.7482, 2.23, 0.212, 250, 241,  
3202, d4o0wA_, 0.7482, 2.39, 0.305, 259, 243, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3203, d4jjrA_, 0.7482, 2.72, 0.196, 284, 250, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
3204, d2r0iA_, 0.7482, 2.11, 0.325, 300, 237, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
3205, d1b6cD_, 0.7481, 3.03, 0.215, 326, 251, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
3206, d3kcfA_, 0.7480, 2.91, 0.208, 328, 250, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3207, d4hgeA_, 0.7479, 2.79, 0.252, 284, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
3208, d4aotA1, 0.7479, 2.39, 0.333, 276, 243, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
3209, d3zfxD_, 0.7479, 2.44, 0.225, 265, 244, CRYSTAL STRUCTURE OF EPHB1
3210, d2r0iB_, 0.7479, 2.13, 0.325, 300, 237, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
3211, d1u4dA_, 0.7479, 2.34, 0.256, 258, 242, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
3212, d3zfxA_, 0.7478, 2.53, 0.224, 267, 245, CRYSTAL STRUCTURE OF EPHB1
3213, d3dj7A_, 0.7478, 2.47, 0.286, 257, 245, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 130.
3214, d1mruB_, 0.7477, 2.39, 0.267, 271, 243, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
3215, d5am7A_, 0.7476, 2.78, 0.229, 294, 249, FGFR1 MUTANT WITH AN INHIBITOR
3216, d4yjuA_, 0.7476, 2.65, 0.190, 262, 248, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249
3217, d4j8mA_, 0.7476, 2.25, 0.310, 265, 239, AURORA A IN COMPLEX WITH CD532
3218, d4e1zA_, 0.7476, 2.82, 0.220, 288, 250, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
3219, d5ugxB_, 0.7475, 2.68, 0.232, 282, 246, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
3220, d4p7eA_, 0.7475, 2.81, 0.252, 281, 250, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
3221, d3zosB1, 0.7475, 2.95, 0.211, 301, 251, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
3222, d3r21A_, 0.7475, 2.32, 0.302, 254, 242, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
3223, d1mqbB_, 0.7475, 2.36, 0.206, 265, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
3224, d5mqvA_, 0.7474, 2.94, 0.193, 286, 254, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3225, d4ftoA_, 0.7474, 2.52, 0.276, 252, 243, CRYSTAL STRUCTURE OF THE CHK1
3226, d3d14A1, 0.7474, 2.48, 0.286, 257, 245, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-{5-[2-(THIENO[32-D]PYRIMIDIN-4-YLAMINO)- ETHYL]- THIAZOL-2-YL}-3-(3-TRIFLUOROMETHYL-PHENYL)-UREA
3227, p5oatF_, 0.7473, 2.95, 0.231, 359, 251, PINK1 STRUCTURE
3228, d4hviA_, 0.7473, 2.57, 0.252, 274, 246, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-1-METHYL-2-OXO-2-PIPERIDIN-1-YL- ETHYL)-AMIDE
3229, d3lpbA_, 0.7473, 2.74, 0.253, 278, 249, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
3230, d3fupA_, 0.7473, 2.81, 0.252, 284, 250, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3231, d5mqvB_, 0.7472, 3.05, 0.187, 287, 256, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3232, d3rvgA_, 0.7472, 2.66, 0.255, 285, 247, CRYSTALS STRUCTURE OF JAK2 WITH A 1-AMINO-5H-PYRIDO[43-B]INDOL-4- CARBOXAMIDE INHIBITOR
3233, d2w1fA1, 0.7472, 2.28, 0.307, 253, 241, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3234, d4i0sA1, 0.7471, 2.36, 0.202, 263, 243, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(6- CHLORO-1-METHYL-1H-INDAZOL-3-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID ISOPROPYLAMIDE
3235, d3fqeA1, 0.7471, 2.46, 0.200, 265, 245, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH YM193306
3236, d3kcfD_, 0.7470, 3.01, 0.206, 330, 252, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3237, d3d2iA_, 0.7470, 2.43, 0.291, 255, 244, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH 1-{5-[2-(1-METHYL-1H- PYRAZOLO[43-D]PYRIMIDIN-7-YLAMINO)-ETHYL]-THIAZOL-2-YL}-3- (3-TRIFLUOROMETHYL-PHENYL)-UREA
3238, d1xbbA1, 0.7469, 2.42, 0.201, 266, 244, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH GLEEVEC
3239, d4asxA1, 0.7468, 2.70, 0.228, 295, 246, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
3240, d3uytD_, 0.7468, 2.74, 0.189, 268, 249, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
3241, d2xngA_, 0.7468, 2.31, 0.307, 253, 241, STRUCTURE OF AURORA-A BOUND TO A SELECTIVE IMIDAZOPYRAZINE INHIBITOR
3242, d2qocA_, 0.7468, 2.43, 0.204, 283, 245, HUMAN EPHA3 KINASE DOMAIN PHOSPHORYLATED AMP-PNP BOUND STRUCTURE
3243, d5ew8A_, 0.7467, 2.78, 0.229, 291, 249, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
3244, d4px6A1, 0.7467, 2.42, 0.201, 261, 244, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT PYRIDOPYRIMIDINONE INHIBITOR
3245, d2hz0A_, 0.7467, 2.84, 0.201, 265, 249, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
3246, d5mqvD_, 0.7466, 3.04, 0.192, 287, 255, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3247, d4mneF_, 0.7466, 2.37, 0.198, 258, 243, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3248, d4c62A_, 0.7466, 2.64, 0.264, 273, 246, INHIBITORS OF JAK2 KINASE DOMAIN
3249, d4bieB_, 0.7466, 2.36, 0.285, 257, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3250, d3tjcA_, 0.7466, 2.90, 0.247, 284, 251, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
3251, d3r22A_, 0.7466, 2.44, 0.292, 255, 243, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
3252, d3fupB_, 0.7466, 2.86, 0.251, 287, 251, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3253, d5nkfA_, 0.7465, 2.79, 0.215, 291, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3B
3254, d5ajqB_, 0.7465, 2.34, 0.322, 267, 242, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
3255, d4u5jB_, 0.7465, 2.44, 0.244, 267, 242, C-SRC IN COMPLEX WITH RUXOLITINIB
3256, d4hgeB_, 0.7465, 2.90, 0.251, 288, 251, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
3257, d3zepB_, 0.7465, 2.64, 0.257, 268, 245, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3258, d3c4fA_, 0.7465, 2.78, 0.229, 290, 249, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
3259, d3zmmA_, 0.7463, 2.65, 0.264, 273, 246, INHIBITORS OF JAK2 KINASE DOMAIN
3260, d3uzpB_, 0.7463, 2.85, 0.183, 284, 252, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
3261, d3js2A_, 0.7463, 2.78, 0.225, 295, 249, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
3262, d2wzjE_, 0.7463, 2.55, 0.317, 310, 243, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3263, d3eknA_, 0.7462, 2.96, 0.194, 297, 252, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
3264, d3ckwA_, 0.7462, 2.18, 0.279, 255, 240, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24)
3265, d5am6A1, 0.7461, 2.77, 0.233, 294, 249, NATIVE FGFR1 WITH AN INHIBITOR
3266, d3fqhB_, 0.7461, 2.47, 0.193, 258, 244, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
3267, d5ih8A_, 0.7460, 2.23, 0.332, 306, 238, MELK IN COMPLEX WITH NVS-MELK1
3268, d5ia2A_, 0.7460, 2.59, 0.212, 287, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 66
3269, d4xg8A_, 0.7460, 2.47, 0.208, 258, 245, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3270, d6bu6B_, 0.7459, 3.04, 0.140, 307, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3271, d5j79B_, 0.7459, 2.68, 0.219, 277, 247, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
3272, d4puzB_, 0.7459, 2.49, 0.200, 265, 245, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
3273, d4asxB1, 0.7459, 2.83, 0.222, 296, 248, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
3274, d3wf5A_, 0.7459, 2.37, 0.307, 277, 241, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-BENZIMIDAZOL-2-YL)PIPERIDIN-1- YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
3275, d3tjdB_, 0.7459, 2.82, 0.252, 287, 250, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
3276, d1fgiA_, 0.7459, 2.78, 0.225, 283, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
3277, d6eimB_, 0.7458, 2.77, 0.312, 295, 247, HUMAN STK10 BOUND TO GW683134A
3278, d5nkgA_, 0.7458, 2.76, 0.211, 292, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3D
3279, d5khwA_, 0.7458, 2.56, 0.245, 276, 245, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
3280, d5ek7B_, 0.7458, 2.52, 0.208, 286, 245, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
3281, d1fgkA_, 0.7458, 2.77, 0.225, 278, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
3282, d5obrA_, 0.7457, 2.42, 0.306, 255, 242, AURORA A KINASE IN COMPLEX WITH 2-(3-CHLORO-5-FLUOROPHENYL)QUINOLINE- 4-CARBOXYLIC ACID AND JNJ-7706621
3283, d5nk3A_, 0.7457, 2.70, 0.198, 281, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1L
3284, d4wa9B1, 0.7457, 2.49, 0.225, 263, 244, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
3285, d3f69B_, 0.7457, 2.70, 0.233, 282, 249, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
3286, d1agwA_, 0.7457, 2.78, 0.225, 278, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
3287, d4qqjA_, 0.7456, 2.84, 0.241, 282, 249, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN HARBORING THE V550L GATE-KEEPER MUTATION
3288, d4f63A_, 0.7456, 2.79, 0.225, 278, 249, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
3289, d4z55A_, 0.7455, 3.00, 0.187, 294, 251, ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE DERIVATIVE OF LDK378
3290, d4f64A_, 0.7455, 2.79, 0.225, 278, 249, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
3291, d3rhxA_, 0.7455, 2.78, 0.225, 289, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
3292, d3c4fB_, 0.7455, 2.80, 0.229, 290, 249, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
3293, d5ih9A_, 0.7454, 2.16, 0.329, 308, 237, MELK IN COMPLEX WITH NVS-MELK8A
3294, d5aafA_, 0.7454, 2.36, 0.298, 254, 242, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14A)
3295, d4bieA_, 0.7454, 2.42, 0.280, 257, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3296, d5ei6A1, 0.7453, 2.22, 0.310, 261, 239, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3297, d4v0gA_, 0.7453, 2.58, 0.266, 267, 244, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
3298, d4fyoA1, 0.7453, 2.40, 0.202, 263, 243, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH N-{(S)-1- [7-(34-DIMETHOXY-PHENYLAMINO)-THIAZOLO[54-D]PYRIMIDIN-5-YL]- PYRROLIDIN-3-YL}-TEREPHTHALAMIC ACID
3299, d3tt0A_, 0.7453, 2.99, 0.223, 305, 251, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
3300, d5owrA_, 0.7451, 2.76, 0.311, 282, 244, HUMAN STK10 BOUND TO DASATINIB
3301, d5oneA_, 0.7451, 2.38, 0.312, 257, 240, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH FMF-03-145-1 (COMPOUND 2)
3302, d4qrcA_, 0.7451, 2.81, 0.242, 297, 248, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 4 IN COMPLEX WITH PONATINIB
3303, d2c6eA_, 0.7451, 2.24, 0.312, 251, 240, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
3304, d3zfxH_, 0.7450, 2.43, 0.222, 266, 243, CRYSTAL STRUCTURE OF EPHB1
3305, d3wf6A_, 0.7450, 2.40, 0.307, 277, 241, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-INDOL-3-YL)-36- DIHYDROPYRIDIN-1(2H)-YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
3306, d2w1eA1, 0.7450, 2.26, 0.308, 252, 240, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3307, d5mqvE_, 0.7449, 3.06, 0.192, 287, 255, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3308, d4zsaA_, 0.7449, 2.82, 0.225, 289, 249, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
3309, d4xcuA1, 0.7449, 2.67, 0.248, 287, 246, CRYSTAL STRUCTURE OF FGFR4 WITH AN IRREVERSIBLE INHIBITOR
3310, d5nk6A_, 0.7447, 2.68, 0.212, 284, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2D
3311, d5ehlA1, 0.7447, 2.41, 0.303, 254, 241, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3312, d4i0rA1, 0.7447, 2.45, 0.201, 260, 244, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(345- TRIMETHOXY-PHENYL)-5H-PYRROLO[23-B]PYRAZINE-7-CARBOXYLIC ACID ISOPROPYLAMIDE
3313, d4fz6A1, 0.7447, 2.44, 0.201, 262, 244, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH [6-((S)-2- METHYL-PYRROLIDIN-1-YL)-PYRIDIN-2-YL]-(6-PHENYL-IMIDAZO[12- B]PYRIDAZIN-8-YL)-AMINE
3314, d4apcB1, 0.7447, 2.88, 0.274, 291, 252, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
3315, d5a46B_, 0.7446, 3.06, 0.218, 297, 252, FGFR1 IN COMPLEX WITH DOVITINIB
3316, d4b9dB1, 0.7446, 2.90, 0.274, 291, 252, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
3317, d3socB1, 0.7446, 2.74, 0.228, 294, 246, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
3318, d1k2pB_, 0.7446, 2.60, 0.190, 258, 247, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
3319, d5f1zA1, 0.7445, 2.40, 0.223, 280, 242, STRUCTURE OF TYK2 WITH INHIBITOR 16: 3-AZANYL-5-[(2~{S})-3- METHYLBUTAN-2-YL]-7-[1-METHYL-5-(2-OXIDANYLPROPAN-2-YL)PYRAZOL-3-YL]- 1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
3320, d4e6dA_, 0.7445, 2.79, 0.257, 286, 249, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
3321, d3cekA1, 0.7444, 2.44, 0.299, 252, 241, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK)
3322, d2fgiA_, 0.7444, 2.75, 0.222, 274, 248, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
3323, d1zmwA_, 0.7444, 2.40, 0.315, 302, 238, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
3324, d6bruD_, 0.7442, 3.11, 0.147, 311, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3325, d5vndB_, 0.7442, 3.05, 0.222, 295, 252, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
3326, d5nkbA_, 0.7442, 2.78, 0.207, 285, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4A
3327, d3js2B_, 0.7442, 2.81, 0.225, 291, 249, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
3328, d2eb3A_, 0.7442, 2.73, 0.203, 294, 246, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (L858R) IN COMPLEX WITH AMPPNP
3329, d5ftoA1, 0.7441, 2.94, 0.180, 297, 250, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH ENTRECTINIB
3330, d4uwcA_, 0.7441, 2.83, 0.225, 300, 249, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
3331, d3tjdA_, 0.7441, 2.86, 0.252, 284, 250, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
3332, d3k5uA_, 0.7441, 2.38, 0.298, 260, 242, IDENTIFICATION SAR STUDIES AND X-RAY COCRYSTAL ANALYSIS OF A NOVEL FURANO-PYRIMIDINE AURORA KINASE A INHIBITOR
3333, d2wzjD_, 0.7441, 2.51, 0.314, 313, 242, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3334, d1b6cB_, 0.7441, 2.99, 0.216, 326, 250, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
3335, d5ar4B_, 0.7440, 2.72, 0.218, 279, 248, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
3336, d4usfB1, 0.7440, 2.75, 0.281, 283, 249, HUMAN SLK WITH SB-440719
3337, d4zjiB_, 0.7439, 2.53, 0.306, 276, 245, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
3338, d4yjsA_, 0.7439, 2.54, 0.200, 257, 245, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000226
3339, d4uwyA_, 0.7439, 2.86, 0.233, 296, 249, FGFR1 APO STRUCTURE
3340, d4rwkA1, 0.7439, 3.04, 0.231, 307, 251, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
3341, d4gk4A_, 0.7439, 2.39, 0.206, 275, 243, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 90
3342, d4bhnB_, 0.7439, 2.42, 0.285, 257, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3343, d2hz4B1, 0.7439, 2.57, 0.230, 248, 244, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
3344, d5nk9A_, 0.7438, 2.78, 0.207, 285, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2E
3345, d5nk1A_, 0.7438, 2.78, 0.211, 284, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1K
3346, d5aagA_, 0.7438, 2.38, 0.302, 253, 242, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14B)
3347, d2wtvB_, 0.7438, 2.37, 0.311, 261, 241, AURORA-A INHIBITOR STRUCTURE
3348, d5w86C_, 0.7437, 2.49, 0.260, 273, 242, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
3349, d4c61A_, 0.7437, 2.64, 0.269, 272, 245, INHIBITORS OF JAK2 KINASE DOMAIN
3350, d3eqhA_, 0.7437, 3.07, 0.268, 314, 254, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH U0126 ADP AND MG2P
3351, d2xa4A_, 0.7437, 2.67, 0.272, 276, 246, INHIBITORS OF JAK2 KINASE DOMAIN
3352, d5ew8B_, 0.7436, 2.96, 0.224, 290, 250, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
3353, d4uwbA_, 0.7436, 2.79, 0.226, 299, 248, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
3354, d2wtvC_, 0.7436, 2.38, 0.311, 261, 241, AURORA-A INHIBITOR STRUCTURE
3355, d5n84A1, 0.7435, 2.47, 0.303, 253, 241, TTK KINASE DOMAIN IN COMPLEX WITH MPS-BAY2B
3356, d5i9yA_, 0.7435, 2.65, 0.212, 287, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DASATINIB
3357, d4f4pA1, 0.7435, 2.45, 0.209, 260, 244, SYK IN COMPLEX WITH LIGAND LASW836
3358, d2ydjB_, 0.7435, 2.38, 0.274, 251, 241, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
3359, d5nk2A_, 0.7434, 2.58, 0.213, 290, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2B
3360, d5cwzC_, 0.7434, 2.30, 0.257, 271, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
3361, d5ajqA_, 0.7434, 2.80, 0.323, 280, 248, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
3362, d4hgtA_, 0.7434, 2.92, 0.187, 283, 252, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
3363, d3q4tB1, 0.7434, 2.75, 0.228, 293, 246, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
3364, d5ek7A_, 0.7433, 2.54, 0.208, 286, 245, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
3365, d1fvrB_, 0.7433, 2.58, 0.216, 300, 245, TIE2 KINASE DOMAIN
3366, d5wfjA_, 0.7432, 2.56, 0.253, 265, 245, THE JAK3 KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR
3367, d5i9xA_, 0.7432, 2.78, 0.215, 284, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH BOSUTINIB (SKI-606)
3368, d5c8mA_, 0.7432, 2.82, 0.195, 302, 246, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 17
3369, d4tt7A_, 0.7432, 3.13, 0.179, 291, 251, CRYSTAL STRUCTURE OF HUMAN ALK WITH A COVALENT MODIFICATION
3370, d4uwcB_, 0.7431, 2.81, 0.237, 301, 249, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
3371, d4u5jA_, 0.7431, 2.45, 0.248, 267, 242, C-SRC IN COMPLEX WITH RUXOLITINIB
3372, d4rwiA_, 0.7431, 2.95, 0.232, 305, 250, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
3373, d5ei2A_, 0.7430, 2.21, 0.315, 256, 238, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3374, d4gk3A_, 0.7430, 2.36, 0.207, 275, 242, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 87
3375, d5nk7A_, 0.7429, 2.80, 0.211, 284, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2A
3376, d5n87A1, 0.7429, 2.38, 0.300, 252, 240, TTK KINASE DOMAIN IN COMPLEX WITH NTRC 0066-0
3377, d3pp0A_, 0.7429, 2.81, 0.192, 286, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
3378, d5i9zA_, 0.7428, 2.62, 0.209, 273, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DANUSERTIB (PHA739358)
3379, d4j95D_, 0.7428, 2.48, 0.240, 271, 242, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
3380, d3ky2A1, 0.7428, 2.94, 0.232, 305, 250, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
3381, d3h10A_, 0.7428, 2.60, 0.317, 268, 243, AURORA A INHIBITOR COMPLEX
3382, d3fdnA_, 0.7428, 2.47, 0.300, 261, 243, STRUCTURE-BASED DRUG DESIGN OF NOVEL AURORA KINASE A INHIBITORS: STRUCTURE BASIS FOR POTENCY AND SPECIFICITY
3383, d1fvrA_, 0.7428, 2.42, 0.218, 299, 243, TIE2 KINASE DOMAIN
3384, d4fz7A1, 0.7427, 2.42, 0.202, 261, 243, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 6-((1R2S)- 2-AMINO-CYCLOHEXYLAMINO)-4-(6-ETHYL-PYRIDIN-2-YLAMINO)-PYRIDAZINE-3- CARBOXYLIC ACID AMIDE
3385, d2vwyA_, 0.7427, 2.76, 0.214, 274, 248, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3386, d2ivsB1, 0.7427, 2.69, 0.246, 272, 244, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
3387, d1ol6A_, 0.7427, 2.10, 0.295, 245, 237, STRUCTURE OF UNPHOSPHORYLATED D274N MUTANT OF AURORA-A
3388, d4rwjA1, 0.7426, 2.98, 0.224, 306, 250, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
3389, d5iuiA_, 0.7425, 3.07, 0.183, 303, 252, CRYSTAL STRUCTURE OF ANAPLASTIC LYPHOMA KINASE (ALK) IN COMPLEX WITH 4
3390, d4zjiA_, 0.7425, 2.75, 0.306, 278, 248, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
3391, d3fe3A_, 0.7425, 2.60, 0.324, 317, 244, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
3392, d2vx1A_, 0.7424, 2.76, 0.214, 274, 248, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3393, d5vo6A_, 0.7423, 2.63, 0.248, 271, 246, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR
3394, d5tq4A_, 0.7423, 2.90, 0.254, 290, 252, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3395, d5capA_, 0.7423, 2.86, 0.202, 303, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 30
3396, d4zegA_, 0.7423, 2.47, 0.296, 260, 240, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
3397, d4e26B_, 0.7423, 2.52, 0.202, 264, 243, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
3398, d3dqxB_, 0.7423, 2.56, 0.251, 268, 243, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
3399, d3dqxA_, 0.7423, 2.53, 0.247, 267, 243, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
3400, d1yi6A_, 0.7423, 2.77, 0.234, 274, 248, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
3401, d5nttA1, 0.7422, 2.49, 0.303, 268, 241, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604Y MUTANT IN COMPLEX WITH NMS-P715
3402, d5aadA_, 0.7422, 2.38, 0.290, 252, 241, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (7A)
3403, d4zauA_, 0.7422, 2.40, 0.207, 283, 241, AZD9291 COMPLEX WITH WILD TYPE EGFR
3404, d4fobA_, 0.7422, 2.91, 0.181, 295, 249, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 1
3405, d2vwzA_, 0.7422, 2.76, 0.214, 274, 248, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3406, d2jiuB_, 0.7422, 3.32, 0.165, 309, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
3407, d1zmwB_, 0.7422, 2.44, 0.315, 302, 238, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
3408, d5nkcA_, 0.7421, 2.55, 0.214, 286, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2H
3409, d5caqA_, 0.7421, 2.75, 0.196, 301, 245, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 33
3410, d4v0gB_, 0.7421, 2.58, 0.263, 272, 243, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
3411, d2xruA_, 0.7421, 2.41, 0.303, 253, 241, AURORA-A T288E COMPLEXED WITH PHA-828300
3412, d2vwxA_, 0.7421, 2.76, 0.214, 274, 248, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3413, d4equB_, 0.7420, 2.39, 0.315, 282, 238, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
3414, d4cd0A_, 0.7420, 2.78, 0.182, 295, 247, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPANE-12-DIOL
3415, d3eqfA_, 0.7420, 2.94, 0.259, 314, 251, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH K252A AND MG2P
3416, d3socA1, 0.7419, 2.92, 0.226, 296, 248, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
3417, d2qo9A_, 0.7419, 2.41, 0.206, 277, 243, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION PHOSPHORYLATED AMP-PNP BOUND
3418, d1bi7A_, 0.7419, 2.63, 0.467, 269, 242, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURE OF THE CDK6-P16INK4A TUMOR SUPPRESSOR COMPLEX
3419, d5oy6D_, 0.7418, 2.90, 0.234, 292, 248, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
3420, d5canA_, 0.7418, 2.75, 0.200, 301, 245, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 27
3421, d4i0tA1, 0.7418, 2.44, 0.202, 262, 243, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(5678- TETRAHYDRO-IMIDAZO[15-A]PYRIDIN-1-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID TERT-BUTYLAMIDE
3422, d4hvsA1, 0.7418, 2.59, 0.225, 323, 244, CRYSTAL STRUCTURE OF KIT KINASE DOMAIN WITH A SMALL MOLECULE INHIBITOR PLX647
3423, d2vx0A_, 0.7418, 2.81, 0.214, 273, 248, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3424, d2jitB_, 0.7418, 3.30, 0.185, 312, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
3425, d6bp0D_, 0.7417, 3.17, 0.154, 311, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3426, d5nk4A_, 0.7417, 2.77, 0.212, 290, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2C
3427, d3e8nA1, 0.7417, 3.15, 0.263, 290, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) COMPLEXED WITH A POTENT INHIBITOR RDEA119 AND MGATP
3428, d1zmvB_, 0.7417, 2.10, 0.315, 296, 235, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
3429, d1lufA_, 0.7417, 2.45, 0.228, 275, 241, CRYSTAL STRUCTURE OF THE MUSK TYROSINE KINASE: INSIGHTS INTO RECEPTOR AUTOREGULATION
3430, d6bruB_, 0.7416, 2.96, 0.150, 301, 253, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3431, d4qqtA_, 0.7416, 2.77, 0.240, 283, 246, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 TYROSINE KINASE DOMAIN
3432, d4c8bB_, 0.7416, 2.78, 0.219, 281, 247, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
3433, d3m11A_, 0.7416, 2.38, 0.303, 256, 241, CRYSTAL STRUCTURE OF AURORA A KINASE COMPLEXED WITH INHIBITOR
3434, d4uwbB_, 0.7415, 3.01, 0.220, 299, 250, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
3435, d4u0iA_, 0.7415, 2.55, 0.221, 297, 244, CRYSTAL STRUCTURE OF KIT IN COMPLEX WITH PONATINIB
3436, d4lmnA1, 0.7415, 3.20, 0.260, 291, 254, CRYSTAL STRUCTURE OF MEK1 KINASE BOUND TO GDC0973
3437, d3lpbB1, 0.7415, 2.81, 0.251, 283, 247, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
3438, d5vndA_, 0.7414, 3.04, 0.219, 302, 251, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
3439, d5j7bA_, 0.7414, 2.72, 0.219, 277, 247, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
3440, d3hmpA_, 0.7414, 2.35, 0.310, 258, 239, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH A QUINAZOLIN LIGAND COMPOUND 4
3441, d2zv8A1, 0.7414, 2.60, 0.226, 256, 243, LYN TYROSINE KINASE DOMAIN-AMP-PNP COMPLEX
3442, d1zmuB_, 0.7414, 2.13, 0.319, 296, 235, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
3443, d5ihaA_, 0.7413, 2.19, 0.335, 303, 236, MELK IN COMPLEX WITH NVS-MELK8F
3444, d4b9dA1, 0.7413, 2.96, 0.254, 286, 252, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
3445, d3zfxE_, 0.7413, 2.44, 0.227, 262, 242, CRYSTAL STRUCTURE OF EPHB1
3446, d3kfaB1, 0.7413, 2.74, 0.238, 283, 244, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3447, d3kfaA1, 0.7413, 2.74, 0.238, 283, 244, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3448, d5hcyA_, 0.7412, 2.80, 0.195, 302, 246, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-CARBOXAMIDE AZAINDOLE COMPOUND 13
3449, d2zmcA_, 0.7412, 2.36, 0.308, 260, 240, CRYSTAL STRUCTURE OF HUMAN MITOTIC CHECKPOINT KINASE MPS1 CATALYTIC DOMAIN APO FORM
3450, d5ehyA1, 0.7411, 2.46, 0.304, 251, 240, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3451, d4prjA_, 0.7411, 2.38, 0.299, 251, 241, AURORA A KINASE DOMAIN WITH COMPOUND 2 (N-[1-(3-CYANOBENZYL)-1H- PYRAZOL-4-YL]-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)
3452, d4e6dB_, 0.7411, 2.81, 0.257, 286, 249, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
3453, d2j7tA_, 0.7411, 2.74, 0.318, 285, 242, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO SU11274
3454, d5w86B_, 0.7410, 2.48, 0.261, 267, 241, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
3455, d5uvfC_, 0.7410, 3.00, 0.150, 301, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
3456, d5j7bB_, 0.7410, 2.81, 0.218, 281, 248, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
3457, d5em7A_, 0.7410, 2.83, 0.200, 300, 245, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 13: 4-[(2- METHOXYPHENYL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
3458, d4bi0A1, 0.7410, 2.39, 0.305, 251, 239, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3459, d3q4tA1, 0.7410, 2.94, 0.226, 294, 248, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
3460, d3hmmA_, 0.7410, 2.73, 0.212, 293, 245, STRUCTURE OF ALK5 + GW855857
3461, d3gfwA1, 0.7410, 2.26, 0.303, 249, 238, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYROLO-PYRIDIN LIGAND
3462, d3emgA_, 0.7410, 2.34, 0.195, 255, 241, DISCOVERY AND SAR OF NOVEL 4-THIAZOLYL-2- PHENYLAMINOPYRIMIDINES AS POTENT INHIBITORS OF SPLEEN TYROSINE KINASE (SYK)
3463, d5am7B_, 0.7409, 2.81, 0.227, 287, 247, FGFR1 MUTANT WITH AN INHIBITOR
3464, d4zloB_, 0.7408, 2.15, 0.291, 263, 237, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
3465, d2ym4A_, 0.7408, 2.42, 0.276, 251, 239, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3466, d5grnA_, 0.7407, 2.84, 0.211, 285, 247, CRYSTAL STRUCTURE OF PDGFRA IN COMPLEX WITH WQ-C-159
3467, d4c4jA1, 0.7407, 2.59, 0.299, 258, 241, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3468, d2zmdA_, 0.7407, 2.51, 0.307, 259, 241, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN T686A MUTANT IN COMPLEX WITH SP600125 INHIBITOR
3469, d1b6cH_, 0.7407, 3.04, 0.216, 326, 250, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
3470, d4bhzA1, 0.7406, 2.39, 0.305, 248, 239, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3471, d4arkA1, 0.7406, 3.18, 0.264, 290, 254, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH  A SMALL MOLECULE INHIBITOR AND ADP
3472, d4usdB_, 0.7405, 2.54, 0.327, 267, 245, HUMAN STK10 (LOK) WITH SB-633825
3473, d3lvpD_, 0.7405, 2.54, 0.218, 282, 243, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
3474, d5nkdA_, 0.7404, 2.59, 0.214, 287, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2I
3475, d4qpsC_, 0.7404, 2.67, 0.256, 276, 246, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
3476, d4hgtB_, 0.7404, 2.79, 0.180, 280, 250, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
3477, d4c02A_, 0.7404, 2.84, 0.231, 313, 247, CRYSTAL STRUCTURE OF HUMAN ACVR1 (ALK2) IN COMPLEX WITH FKBP12.6 AND DORSOMORPHIN
3478, d3ik3A1, 0.7404, 2.75, 0.234, 279, 244, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
3479, d3hmoA_, 0.7404, 2.51, 0.300, 257, 240, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH THE INHIBITOR STAUROSPORINE
3480, d5c8nA_, 0.7403, 2.71, 0.201, 300, 244, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 23
3481, d3oy3A1, 0.7403, 2.75, 0.238, 283, 244, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
3482, d2wtvD_, 0.7403, 2.43, 0.311, 262, 241, AURORA-A INHIBITOR STRUCTURE
3483, d5n9sA1, 0.7402, 2.42, 0.301, 256, 239, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1161909
3484, d5casA_, 0.7402, 2.73, 0.197, 299, 244, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41A
3485, d4h58B_, 0.7402, 2.39, 0.204, 262, 240, BRAF IN COMPLEX WITH COMPOUND 3
3486, d3q4zB_, 0.7402, 2.71, 0.287, 279, 244, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
3487, d3ppkB_, 0.7402, 2.41, 0.203, 264, 241, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
3488, d3hmnA_, 0.7402, 2.49, 0.300, 255, 240, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH ATP
3489, d3h10B_, 0.7402, 2.64, 0.317, 267, 243, AURORA A INHIBITOR COMPLEX
3490, d3f6xD_, 0.7401, 2.39, 0.250, 267, 240, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3491, d2hakF_, 0.7401, 2.67, 0.325, 318, 243, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
3492, d1zmuA_, 0.7401, 2.29, 0.305, 293, 236, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
3493, d5w86D_, 0.7400, 2.48, 0.261, 272, 241, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
3494, d5khxA_, 0.7400, 2.78, 0.246, 276, 248, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH PF-4950736
3495, d5e1eA_, 0.7400, 2.73, 0.244, 279, 246, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
3496, d4cljA_, 0.7400, 2.89, 0.177, 295, 248, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
3497, d3zfxI_, 0.7400, 2.41, 0.228, 263, 241, CRYSTAL STRUCTURE OF EPHB1
3498, d2wtvA_, 0.7400, 2.44, 0.311, 262, 241, AURORA-A INHIBITOR STRUCTURE
3499, d2w1dA1, 0.7400, 2.31, 0.310, 251, 239, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3500, d5xdlA_, 0.7399, 2.66, 0.198, 292, 243, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH CO-1686
3501, d4d55A_, 0.7399, 2.45, 0.257, 260, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3502, d4c4fA1, 0.7399, 2.31, 0.303, 250, 238, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3503, d4bhnA_, 0.7399, 2.45, 0.290, 256, 238, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3504, d3oy3B1, 0.7399, 2.75, 0.238, 283, 244, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
3505, d5khwB_, 0.7398, 2.65, 0.245, 276, 245, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
3506, d5hx8A_, 0.7398, 2.81, 0.242, 291, 248, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
3507, d4cnhB_, 0.7398, 2.82, 0.194, 293, 247, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
3508, d4c8bA_, 0.7398, 2.66, 0.220, 279, 245, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
3509, d4c3rA_, 0.7398, 2.39, 0.295, 252, 241, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP
3510, d3vw6A_, 0.7398, 2.34, 0.283, 255, 237, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
3511, d3dv3A_, 0.7398, 3.06, 0.262, 288, 252, MEK1 WITH PF-04622664 BOUND
3512, d4c4iA1, 0.7396, 2.43, 0.301, 250, 239, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3513, d1zmvA_, 0.7396, 2.14, 0.302, 293, 235, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
3514, d4qpsA_, 0.7395, 2.34, 0.264, 270, 239, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
3515, d4kb8A_, 0.7395, 2.76, 0.199, 265, 246, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
3516, d4bi1A1, 0.7395, 2.36, 0.307, 249, 238, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3517, d3wyxA_, 0.7395, 2.41, 0.314, 258, 239, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 6- ((3-(CYANOMETHOXY)-4-(1-METHYL-1H-PYRAZOL-4-YL)PHENYL)AMINO)-2- (CYCLOHEXYLAMINO)NICOTINONITRILE
3518, d1t46A_, 0.7395, 2.58, 0.221, 297, 244, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE
3519, d5ia3A_, 0.7394, 2.56, 0.207, 275, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH PD173955
3520, d5ap0A1, 0.7394, 2.31, 0.303, 250, 238, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3521, d4yhtB_, 0.7394, 2.44, 0.203, 258, 241, BRAF COMPLEXED WITH AN INHIBITOR
3522, d5uhnB_, 0.7393, 2.69, 0.230, 269, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
3523, d5ehoA1, 0.7393, 2.24, 0.312, 255, 237, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3524, d4usdA_, 0.7393, 2.50, 0.324, 268, 244, HUMAN STK10 (LOK) WITH SB-633825
3525, d4g2fA_, 0.7393, 2.37, 0.207, 275, 241, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 7
3526, d3zlsA_, 0.7393, 3.06, 0.269, 315, 253, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 6
3527, d3ik3B1, 0.7393, 2.77, 0.234, 285, 244, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
3528, d4xg9A_, 0.7392, 2.39, 0.195, 259, 241, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3529, d4u7zA1, 0.7392, 3.17, 0.268, 290, 254, MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK1) BOUND TO G805
3530, d4k77A_, 0.7392, 2.82, 0.242, 282, 248, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
3531, d4fodA_, 0.7392, 2.90, 0.185, 308, 248, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 36
3532, d3q4uB1, 0.7392, 2.94, 0.230, 298, 248, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3533, d3dbqA_, 0.7392, 2.47, 0.304, 259, 240, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN
3534, d5ar7B_, 0.7391, 2.74, 0.223, 278, 247, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
3535, d5ap6A1, 0.7391, 2.26, 0.311, 259, 238, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3536, d4apcA1, 0.7391, 2.99, 0.254, 289, 252, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
3537, d4aotB1, 0.7391, 2.70, 0.331, 277, 245, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
3538, d3mygA_, 0.7391, 2.38, 0.304, 252, 240, AURORA A KINASE COMPLEXED WITH SCH 1473759
3539, d3g6hA_, 0.7391, 2.40, 0.250, 266, 240, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
3540, d5w5oM_, 0.7390, 2.73, 0.220, 276, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3541, d4zjjA_, 0.7390, 2.69, 0.305, 280, 246, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
3542, d4bi2A1, 0.7390, 2.35, 0.307, 250, 238, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3543, d5ia0B_, 0.7389, 2.44, 0.207, 266, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
3544, d5f20A_, 0.7389, 2.38, 0.225, 274, 240, STRUCTURE OF TYK2 WITH INHIBITOR 4: 3-AZANYL-5-(2-METHYLPHENYL)-7-(1- METHYLPYRAZOL-3-YL)-1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
3545, d5aaeA_, 0.7389, 2.38, 0.308, 252, 240, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14D)
3546, d4o6lA_, 0.7389, 2.39, 0.311, 257, 238, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
3547, d3g0fB_, 0.7389, 2.64, 0.230, 293, 244, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
3548, d3f6xB_, 0.7389, 2.35, 0.251, 267, 239, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3549, d3eqdA_, 0.7389, 3.14, 0.269, 315, 253, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ATP-GS AND MG2P
3550, d3d4qA_, 0.7389, 2.47, 0.203, 264, 241, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
3551, d5hicA_, 0.7388, 2.80, 0.196, 302, 245, EGFR KINASE DOMAIN MUTANT TMLR WITH A IMIDAZOPYRIDINYL- AMINOPYRIMIDINE INHIBITOR
3552, d4rj4A_, 0.7388, 2.74, 0.197, 299, 244, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 6
3553, d4dfyE_, 0.7388, 2.62, 0.266, 312, 248, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
3554, d4cvaA1, 0.7388, 2.31, 0.298, 250, 238, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
3555, d4aszA1, 0.7388, 3.08, 0.227, 286, 251, CRYSTAL STRUCTURE OF APO TRKB KINASE DOMAIN
3556, d3eqgA_, 0.7388, 3.12, 0.268, 314, 254, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH PD ADP AND MG2P
3557, d3eqcA_, 0.7388, 3.08, 0.269, 312, 253, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH COMPOUND 1 ATP-GS AND MG2P
3558, d2i1mA_, 0.7388, 2.92, 0.211, 311, 247, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
3559, d1t45A_, 0.7388, 2.73, 0.224, 331, 245, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C- KIT TYROSINE KINASE
3560, d6btwB_, 0.7387, 3.03, 0.154, 301, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
3561, d5v19A_, 0.7387, 2.17, 0.289, 250, 235, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3562, d5c8kA_, 0.7387, 2.75, 0.197, 300, 244, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 1
3563, d4u43B_, 0.7387, 3.14, 0.239, 302, 255, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
3564, d4rwlA_, 0.7387, 2.82, 0.227, 282, 247, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
3565, d3lw0A_, 0.7387, 2.74, 0.209, 292, 244, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3566, d5tq6A_, 0.7386, 2.89, 0.250, 274, 248, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3567, d5ihcA_, 0.7386, 2.31, 0.329, 305, 237, MELK IN COMPLEX WITH NVS-MELK12B
3568, d4b8lA_, 0.7386, 2.35, 0.311, 249, 238, AURORA B KINASE P353G MUTANT
3569, d3wj6A_, 0.7386, 2.85, 0.231, 282, 247,  
3570, d2qluA1, 0.7386, 2.89, 0.224, 295, 246, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE II KINASE DOMAIN FROM HUMAN
3571, d5b7vA_, 0.7385, 2.85, 0.231, 282, 247, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
3572, d3zz2A_, 0.7385, 2.66, 0.320, 281, 241,  
3573, d3lw0D_, 0.7385, 2.74, 0.209, 292, 244, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3574, d3lw0C_, 0.7385, 2.74, 0.209, 292, 244, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3575, p2y4iC_, 0.7385, 3.30, 0.263, 313, 255, KSR2-MEK1 HETERODIMER
3576, d4u41A_, 0.7383, 2.68, 0.257, 275, 245, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
3577, d3zlxA_, 0.7383, 3.05, 0.266, 312, 252, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 18
3578, d3pp1A1, 0.7383, 3.20, 0.263, 290, 255, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGATP
3579, d2wmsA_, 0.7383, 2.35, 0.277, 243, 238, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3580, d5uglB_, 0.7382, 2.69, 0.235, 271, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
3581, d4mxxA_, 0.7382, 2.35, 0.243, 266, 239, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3582, d4c4eA1, 0.7382, 2.43, 0.303, 253, 238, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3583, d3wyyA_, 0.7382, 2.44, 0.314, 258, 239, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH (E)- 3-(4-((6-(((3S5S7S)-ADAMANTAN-1-YL)AMINO)-4-AMINO-5-CYANOPYRIDIN-2- YL)AMINO)-2-(CYANOMETHOXY)PHENYL)-N-(2-METHOXYETHYL)ACRYLAMIDE
3584, d3mblA_, 0.7382, 3.17, 0.260, 290, 254, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGADP
3585, d3lw0B_, 0.7382, 2.74, 0.209, 292, 244, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3586, d3eqiA_, 0.7382, 3.04, 0.270, 315, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ADP AND MG2P
3587, d3d94A_, 0.7382, 2.74, 0.205, 288, 244, CRYSTAL STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE IN COMPLEX WITH PQIP
3588, d5n7vA1, 0.7381, 2.43, 0.310, 257, 239, TTK KINASE DOMAIN IN COMPLEX WITH MPI-0479605
3589, d5hcxA_, 0.7381, 2.75, 0.201, 298, 244, EGFR KINASE DOMAIN MUTANT TMLR WITH AZABENZIMIDAZOLE COMPOUND 7
3590, d5a46A_, 0.7381, 2.85, 0.227, 289, 247, FGFR1 IN COMPLEX WITH DOVITINIB
3591, d4ymjA1, 0.7381, 2.61, 0.231, 267, 242, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
3592, d4o0uA_, 0.7381, 2.62, 0.307, 259, 244, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3593, d3h9fA1, 0.7381, 2.50, 0.308, 256, 240, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYRIMIDO-DIAZEPIN LIGAND
3594, d3d4qB_, 0.7381, 2.48, 0.203, 264, 241, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
3595, d5njzA_, 0.7380, 2.51, 0.212, 273, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1G
3596, d4ztsA_, 0.7380, 2.23, 0.303, 249, 238, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1142
3597, d2zv9A1, 0.7380, 2.56, 0.227, 255, 242, LYN TYROSINE KINASE DOMAIN-PP2 COMPLEX
3598, d2wtkF1, 0.7380, 2.28, 0.280, 250, 236, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
3599, d5wo4A_, 0.7379, 2.85, 0.242, 292, 248, JAK1 COMPLEXED WITH COMPOUND 28
3600, d5w86A_, 0.7379, 2.54, 0.261, 269, 241, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
3601, d4oa2A_, 0.7379, 2.84, 0.220, 280, 246,  
3602, d4at4A1, 0.7378, 3.07, 0.227, 289, 251, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH EX429
3603, d5w5oE_, 0.7377, 2.70, 0.220, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3604, d5calA_, 0.7377, 2.76, 0.197, 300, 244, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 24
3605, d4xg8C_, 0.7377, 2.35, 0.196, 254, 240, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3606, d3aoxA_, 0.7377, 2.86, 0.182, 298, 247, X-RAY CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CH5424802
3607, d2bdfB_, 0.7377, 2.58, 0.252, 265, 242, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
3608, d3zlwA_, 0.7376, 3.06, 0.266, 312, 252, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 3
3609, d5m57A1, 0.7375, 2.12, 0.286, 253, 234, NEK2 BOUND TO ARYLAMINOPURINE 6
3610, d4fk6B_, 0.7375, 2.91, 0.248, 284, 250, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
3611, d3txoA_, 0.7375, 2.67, 0.269, 317, 242, PKC ETA KINASE IN COMPLEX WITH A NAPHTHYRIDINE
3612, d3ohtA_, 0.7375, 3.17, 0.319, 331, 254, CRYSTAL STRUCTURE OF SALMO SALAR P38ALPHA
3613, d2z7rA_, 0.7375, 2.20, 0.314, 265, 236, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO STAUROSPORINE
3614, d1muoA_, 0.7375, 2.36, 0.311, 251, 238, CRYSTAL STRUCTURE OF AURORA-2 AN ONCOGENIC SERINE- THREONINE KINASE
3615, d5e1eB_, 0.7374, 2.80, 0.243, 280, 247, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
3616, d4jbpA_, 0.7374, 2.50, 0.299, 255, 241, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3617, d4fk6A_, 0.7374, 2.92, 0.248, 285, 250, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
3618, d4e4nB_, 0.7374, 2.81, 0.243, 280, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
3619, d3zzeA_, 0.7374, 2.93, 0.215, 286, 246, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH N - ((3Z)-4-CHLORO-7-METHYL-2-OXO-12-DIHYDRO-3H-INDOL-3- YLIDENE)-2-(4-HYDROXYPHENYL)PROPANOHYDRAZIDE
3620, d3vvhA1, 0.7374, 3.04, 0.263, 286, 251, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
3621, d3prfA_, 0.7374, 2.37, 0.197, 262, 239, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
3622, d3g0fA_, 0.7374, 2.66, 0.230, 291, 244, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
3623, d4rj8A_, 0.7373, 2.73, 0.198, 298, 243, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 8
3624, d4obqA_, 0.7373, 2.46, 0.261, 275, 241, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
3625, d4i5cA_, 0.7373, 2.81, 0.243, 279, 247, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3626, d3ohtB_, 0.7373, 3.16, 0.319, 331, 254, CRYSTAL STRUCTURE OF SALMO SALAR P38ALPHA
3627, d2p55A2, 0.7373, 3.09, 0.266, 288, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
3628, d5lpzA_, 0.7372, 2.80, 0.220, 283, 245, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1196) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
3629, d5j7hA_, 0.7372, 2.66, 0.197, 291, 244, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) BOUND BY BRIGATINIB
3630, d4v05B_, 0.7372, 2.78, 0.220, 286, 246, FGFR1 IN COMPLEX WITH AZD4547.
3631, d4focA_, 0.7372, 2.87, 0.182, 296, 247, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 2
3632, d4at5A1, 0.7371, 2.93, 0.228, 291, 250, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH GW2580
3633, d3zlyA_, 0.7371, 2.98, 0.259, 310, 251, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 8
3634, d2zv7A1, 0.7371, 2.70, 0.230, 256, 244, LYN TYROSINE KINASE DOMAIN APO FORM
3635, d5m51A1, 0.7370, 2.12, 0.282, 253, 234, NEK2 BOUND TO ARYLAMINOPURINE COMPOUND 8
3636, d5hhwA_, 0.7370, 2.78, 0.191, 306, 246, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH CIS-(R)-7-(3-(AZETIDIN-1-YLMETHYL)CYCLOBUTYL)-5-(3-((TETRAHYDRO-2H- PYRAN-2-YL)METHOXY)PHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE.
3637, d2w5bA1, 0.7370, 2.62, 0.278, 263, 241, HUMAN NEK2 KINASE ATPGAMMAS-BOUND
3638, d4zjjB_, 0.7369, 2.65, 0.311, 277, 244, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
3639, d1k9aE3, 0.7369, 2.48, 0.229, 268, 240, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3640, d5em6A_, 0.7368, 2.76, 0.197, 301, 244, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 19: 4-[(2- AZANYLPYRIMIDIN-4-YL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]- 2-OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
3641, d5bx0A_, 0.7368, 3.14, 0.273, 315, 253, AN AUTOMATED MICROSCALE THERMOPHORESIS SCREENING APPROACH FOR FRAGMENT-BASED LEAD DISCOVERY
3642, d5aaaA_, 0.7368, 2.90, 0.182, 294, 247, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3643, d4p2kA_, 0.7368, 2.46, 0.202, 259, 242, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
3644, d4k77B_, 0.7368, 2.81, 0.243, 280, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
3645, d3op5D_, 0.7368, 3.15, 0.144, 302, 257, HUMAN VACCINIA-RELATED KINASE 1
3646, d5ia4A_, 0.7367, 2.64, 0.205, 269, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH FORETINIB (XL880)
3647, d5bvkA_, 0.7367, 3.02, 0.221, 278, 249, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3648, d4ivdB_, 0.7367, 2.81, 0.243, 280, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
3649, d5w5oO_, 0.7366, 2.77, 0.220, 276, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3650, d5uorA_, 0.7366, 2.19, 0.286, 249, 234, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3651, d5cauA_, 0.7366, 2.75, 0.198, 297, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41B
3652, d4uynA_, 0.7366, 2.09, 0.306, 249, 235, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
3653, d4o6lB_, 0.7366, 2.48, 0.303, 256, 238, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
3654, d4mxzB_, 0.7366, 2.41, 0.255, 264, 239, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3655, d4mxyB_, 0.7366, 2.41, 0.255, 264, 239, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3656, d4ccuA_, 0.7366, 2.92, 0.202, 292, 247, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPAN-2-OL
3657, d5vamA_, 0.7365, 2.64, 0.197, 269, 244, BRAF IN COMPLEX WITH RAF709
3658, d5a4cB1, 0.7365, 3.00, 0.218, 284, 248, FGFR1 LIGAND COMPLEX
3659, d4mxoA_, 0.7365, 2.38, 0.247, 266, 239, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
3660, d4h58A_, 0.7365, 2.39, 0.204, 263, 240, BRAF IN COMPLEX WITH COMPOUND 3
3661, d4e5wB_, 0.7365, 2.74, 0.244, 278, 246, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
3662, d4cmuA_, 0.7365, 3.00, 0.185, 294, 248, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (10R)-7-AMINO-12-FLUORO-1310 16-TETRAMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(43- H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
3663, d4cmoA_, 0.7365, 2.81, 0.183, 295, 246, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 2-((1R)-1-((3-AMINO-6-(2- METHOXYPYRIDIN- -YL)PYRAZIN-2-YL)OXY)ETHYL)-4-FLUORO-N-METHYLBENZAMIDE
3664, d3uojB_, 0.7365, 2.41, 0.314, 263, 239, AURORA A IN COMPLEX WITH RPM1715
3665, d3uojA_, 0.7365, 2.41, 0.314, 263, 239, AURORA A IN COMPLEX WITH RPM1715
3666, d3fzrA_, 0.7365, 2.49, 0.202, 261, 242, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-431396
3667, d3et7A_, 0.7365, 2.49, 0.198, 261, 242, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-2318841
3668, d5mrbA1, 0.7364, 2.51, 0.314, 259, 239, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH CPD-5
3669, d5hx8B_, 0.7364, 2.82, 0.243, 279, 247, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
3670, d5bvoA_, 0.7364, 3.05, 0.215, 276, 251, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3671, d3vquA_, 0.7364, 2.62, 0.312, 258, 240, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4- [(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2- YL)AMINO]BENZAMIDE
3672, d3unzB_, 0.7364, 2.47, 0.310, 263, 239, AURORA A IN COMPLEX WITH RPM1679
3673, d3unzA_, 0.7364, 2.47, 0.310, 263, 239, AURORA A IN COMPLEX WITH RPM1679
3674, d3lauA1, 0.7364, 2.15, 0.311, 250, 235, CRYSTAL STRUCTURE OF AURORA2 KINASE IN COMPLEX WITH A GSK3BETA INHIBITOR
3675, d5ap3A1, 0.7363, 2.32, 0.304, 250, 237, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3676, d4fnwA_, 0.7363, 2.87, 0.190, 304, 247, CRYSTAL STRUCTURE OF THE APO F1174L ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3677, d3eqbA1, 0.7363, 3.08, 0.270, 288, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
3678, d2bdjA_, 0.7363, 2.52, 0.250, 254, 240, SRC KINASE IN COMPLEX WITH INHIBITOR AP23464
3679, d6eixA_, 0.7362, 3.20, 0.231, 312, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE Q207E MUTANT OF ACVR1 (ALK2) IN COMPLEX WITH A 2-AMINOPYRIDINE INHIBITOR K02288
3680, d5w5oA_, 0.7362, 2.74, 0.220, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3681, d4cv9A1, 0.7362, 2.48, 0.301, 250, 239, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
3682, d3uo6B_, 0.7362, 2.43, 0.314, 264, 239, AURORA A IN COMPLEX WITH YL5-083
3683, d3uo6A_, 0.7362, 2.43, 0.314, 264, 239, AURORA A IN COMPLEX WITH YL5-083
3684, d3etaB_, 0.7362, 2.86, 0.199, 292, 246, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
3685, d4f0iB_, 0.7361, 2.68, 0.214, 294, 243, CRYSTAL STRUCTURE OF APO TRKA
3686, d4v05A_, 0.7360, 2.81, 0.224, 287, 246, FGFR1 IN COMPLEX WITH AZD4547.
3687, d4u81A1, 0.7360, 3.15, 0.269, 288, 253, MEK1 KINASE BOUND TO SMALL MOLECULE INHIBITOR G659
3688, d4rj6A_, 0.7360, 2.84, 0.197, 297, 244, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 4
3689, d4bf2B_, 0.7360, 2.28, 0.289, 252, 235, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3690, d5edpA_, 0.7359, 2.73, 0.197, 295, 244, EGFR KINASE (T790M/L858R) APO
3691, d2helA_, 0.7359, 2.31, 0.192, 256, 239, CRYSTAL STRUCTURE OF A MUTANT EPHA4 KINASE DOMAIN (Y742A)
3692, d4ivcB_, 0.7358, 2.82, 0.243, 280, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
3693, d4c4gA1, 0.7358, 2.24, 0.305, 247, 236, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3694, d3h0zA_, 0.7358, 2.36, 0.307, 248, 238, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3695, d1s9jA1, 0.7358, 3.11, 0.265, 288, 253, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
3696, d5w5oJ_, 0.7357, 2.75, 0.220, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3697, d5tq6B_, 0.7357, 2.89, 0.259, 271, 247, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3698, d5ljjA1, 0.7357, 2.38, 0.308, 260, 237, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH REVERSINE
3699, d5edqA_, 0.7357, 2.80, 0.200, 298, 245, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 15: ~{N}-(7- CHLORANYL-1~{H}-INDAZOL-3-YL)-77-DIMETHYL-2-(1~{H}-PYRAZOL-4-YL)- 5~{H}-FURO[34-D]PYRIMIDIN-4-AMINE
3700, d4rj7A_, 0.7357, 2.78, 0.198, 295, 243, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 1
3701, d4nkaB_, 0.7357, 2.92, 0.207, 287, 246, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
3702, d4cliA_, 0.7357, 2.92, 0.186, 294, 247, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-21016-TRIMETHYL-15 -OXO-10151617-TETRAHYDRO-2H-84-(METHENO)PYRAZOLO(43-H) (2511)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
3703, d4anqA_, 0.7357, 2.91, 0.190, 293, 247, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3704, d2wmqA_, 0.7357, 2.27, 0.275, 246, 236, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3705, d2fb8A_, 0.7357, 2.47, 0.203, 259, 241, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
3706, d5aabA_, 0.7356, 2.82, 0.187, 293, 246, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3707, d5aa9A_, 0.7356, 2.82, 0.187, 295, 246, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
3708, d4oboA_, 0.7356, 2.71, 0.257, 275, 245, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
3709, d4ctbA_, 0.7356, 3.02, 0.194, 292, 248, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (5R)-8-AMINO-3-FLUORO-519-DIMETHYL-20-OXO-5181920- TETRAHYDRO-711-(AZENO)PYRIDO(2 1 :23)IMIDAZO(45-H)(2511) BENZOXADIAZACYCLOTETRADECINE-14-CARBONITRILE
3710, d3g0eA1, 0.7356, 2.83, 0.229, 330, 245, KIT KINASE DOMAIN IN COMPLEX WITH SUNITINIB
3711, d2wgjA_, 0.7356, 2.95, 0.220, 289, 246, X-RAY STRUCTURE OF PF-02341066 BOUND TO THE KINASE DOMAIN OF C-MET
3712, d5ia5A_, 0.7355, 2.65, 0.201, 273, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH GOLVATINIB (E7050)
3713, d5bvwA_, 0.7355, 2.96, 0.222, 274, 248, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3714, d5ap7A1, 0.7355, 2.38, 0.312, 253, 237, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3715, d4kbaA_, 0.7355, 2.69, 0.193, 263, 244, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
3716, d4ap7A_, 0.7355, 2.91, 0.220, 289, 245, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( (6-(4- FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN-3-YL)METHYL) PHENOL
3717, d3v04A1, 0.7355, 3.15, 0.265, 288, 253, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
3718, d3uqgA_, 0.7355, 2.30, 0.253, 263, 237, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
3719, d3ppkA_, 0.7355, 2.40, 0.205, 262, 239, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
3720, d5t0pB_, 0.7354, 2.34, 0.245, 263, 237, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
3721, d5hczA_, 0.7354, 2.78, 0.197, 300, 244, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-AZETIDINYL AZAINDAZOLE COMPOUND 21
3722, d5ap5A1, 0.7354, 2.29, 0.304, 248, 237, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3723, d4cv8A1, 0.7354, 2.57, 0.300, 252, 240, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
3724, d3vw6B_, 0.7354, 2.34, 0.292, 253, 236, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
3725, d3mdyA_, 0.7354, 2.92, 0.230, 320, 248, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
3726, d3cohB_, 0.7354, 2.41, 0.303, 247, 238, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
3727, d2oiqB_, 0.7354, 2.48, 0.250, 265, 240, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
3728, d4oa6A_, 0.7353, 2.81, 0.220, 279, 245,  
3729, d4ckrA1, 0.7353, 3.14, 0.207, 294, 251, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH DDR1-IN-1
3730, d4bkiA1, 0.7353, 3.14, 0.207, 294, 251,  
3731, d4anlA_, 0.7353, 3.01, 0.185, 292, 248, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE
3732, d3gxlA_, 0.7353, 2.48, 0.208, 285, 240, ALK-5 KINASE COMPLEX WITH GW857175
3733, d3beaA_, 0.7353, 2.67, 0.209, 310, 244, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH A PYRIMIDINOPYRIDONE INHIBITOR
3734, d2xvdA_, 0.7353, 2.56, 0.222, 270, 243, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3735, d2qobA_, 0.7353, 2.54, 0.198, 279, 243, HUMAN EPHA3 KINASE DOMAIN BASE STRUCTURE
3736, d2j51A_, 0.7353, 2.50, 0.275, 288, 240, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 5- AMINO-3-((4-(AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-124-TRIAZOLE-1-CARBOTHIOAMIDE
3737, d1p4oA_, 0.7353, 2.96, 0.206, 308, 247, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
3738, d5w5oK_, 0.7352, 2.75, 0.220, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3739, d5tq7A_, 0.7352, 2.87, 0.251, 275, 247, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3740, d4zjiD_, 0.7352, 2.99, 0.294, 280, 248, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
3741, d5oxgD_, 0.7351, 3.06, 0.229, 293, 249, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3742, d5ap1A1, 0.7351, 2.41, 0.314, 264, 239, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3743, d5aa8A_, 0.7351, 2.93, 0.190, 292, 247, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12- FLUORO-21016-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H- 84-(METHENO)PYRAZOLO(43-H)(2511) BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
3744, d5a9uA_, 0.7351, 2.93, 0.182, 292, 247, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
3745, d4uzhA1, 0.7351, 2.23, 0.315, 250, 235, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
3746, d3zm4A_, 0.7351, 2.93, 0.257, 309, 249, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 1
3747, d3v01A1, 0.7351, 3.11, 0.270, 288, 252, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
3748, d3mdyC_, 0.7351, 2.98, 0.221, 320, 249, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
3749, d2wkmA_, 0.7351, 2.99, 0.219, 286, 247, X-RAY STRUCTURE OF PHA-00665752 BOUND TO THE KINASE DOMAIN OF C-MET
3750, d1s9iB_, 0.7351, 3.09, 0.275, 291, 251, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
3751, d5wr7A_, 0.7350, 2.78, 0.225, 301, 244, CRYSTAL STRUCTURE OF TRK-A COMPLEXED WITH A SELECTIVE INHIBITOR CH7057288
3752, d5w5oD_, 0.7350, 2.75, 0.220, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3753, d4hniA_, 0.7350, 2.94, 0.192, 284, 250, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
3754, d2uv2A1, 0.7350, 2.51, 0.275, 286, 240, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 4-(4-( 5-CYCLOPROPYL-1H-PYRAZOL-3-YLAMINO)-QUINAZOLIN-2-YLAMINO)- PHENYL)-ACETONITRILE
3755, d4ansA_, 0.7349, 2.83, 0.191, 293, 246, STRUCTURE OF L1196MG1269A DOUBLE MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3756, d3uohB_, 0.7349, 2.46, 0.314, 264, 239, AURORA A IN COMPLEX WITH RPM1722
3757, d3q4uD_, 0.7349, 3.05, 0.229, 299, 249, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3758, d3cohA_, 0.7349, 2.42, 0.303, 247, 238, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
3759, d3b2wA_, 0.7349, 2.76, 0.230, 261, 244, CRYSTAL STRUCTURE OF PYRIMIDINE AMIDE 11 BOUND TO LCK
3760, d2xa4B_, 0.7349, 2.60, 0.269, 275, 242, INHIBITORS OF JAK2 KINASE DOMAIN
3761, d2x9fA_, 0.7349, 2.52, 0.219, 265, 242, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3762, d5nkaA_, 0.7348, 2.28, 0.206, 271, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2G
3763, d5n93A1, 0.7348, 2.41, 0.290, 256, 238, TTK KINASE DOMAIN IN COMPLEX WITH TC-MPS1-12
3764, d5kz0A_, 0.7348, 2.88, 0.187, 293, 246, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-[(1R)- 1-{[2-AMINO-5-(13-DIMETHYL-1H-PYRAZOL-4-YL)PYRIDIN-3-YL]OXY}ETHYL]- 4-FLUORO-NN-DIMETHYLBENZAMIDE
3765, d4ymjB1, 0.7348, 2.60, 0.232, 272, 241, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
3766, d4ivbB_, 0.7348, 2.84, 0.243, 280, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
3767, d4e5wA1, 0.7348, 2.84, 0.243, 291, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
3768, d3wj6B_, 0.7348, 2.79, 0.224, 277, 245,  
3769, d3uohA_, 0.7348, 2.46, 0.314, 264, 239, AURORA A IN COMPLEX WITH RPM1722
3770, d3krjA_, 0.7348, 2.70, 0.206, 304, 243, CFMS TYROSINE KINASE IN COMPLEX WITH 4-CYANO-1H-IMIDAZOLE-2-CARBOXYLIC ACID (2-CYCLOHEX-1-ENYL-4-PIPERIDIN-4-YL-PHENYL)-AMIDE
3771, d2hiwA1, 0.7348, 2.66, 0.219, 270, 242, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
3772, d5w5oI_, 0.7347, 2.67, 0.221, 275, 244, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3773, d5w5oH_, 0.7347, 2.66, 0.221, 275, 244, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3774, d5na0A1, 0.7347, 2.41, 0.298, 250, 238, TTK KINASE DOMAIN IN COMPLEX WITH A PEG-LINKED PYRIMIDO-INDOLIZINE
3775, d4rwlB_, 0.7347, 2.99, 0.215, 285, 247, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
3776, d4c62B_, 0.7347, 2.56, 0.266, 271, 241, INHIBITORS OF JAK2 KINASE DOMAIN
3777, d3d7uC1, 0.7347, 2.43, 0.234, 255, 239, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
3778, d3d7uA1, 0.7347, 2.43, 0.234, 255, 239, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
3779, d1k9aA3, 0.7347, 2.43, 0.230, 267, 239, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3780, d5oxgC1, 0.7346, 3.07, 0.229, 299, 249, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3781, d5aacA_, 0.7346, 2.94, 0.182, 292, 247, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3782, d4twoA_, 0.7346, 2.43, 0.207, 278, 241, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 164
3783, d4bggB_, 0.7346, 3.01, 0.230, 293, 248, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3784, d3w1fA_, 0.7346, 2.59, 0.304, 259, 240, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 5-(5- ETHOXY-6-(1-METHYL-1H-PYRAZOL-4-YL)-1H-INDAZOL-3-YL)-2- METHYLBENZENESULFONAMIDE
3785, d2fb8B_, 0.7346, 2.34, 0.205, 259, 239, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
3786, d1p4oB_, 0.7346, 2.97, 0.206, 314, 247, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
3787, d5w5oG_, 0.7345, 2.77, 0.220, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3788, d5caoA_, 0.7345, 2.79, 0.198, 300, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 29
3789, d4ztrA_, 0.7345, 2.29, 0.298, 249, 238, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1141
3790, d4yhtA_, 0.7345, 2.37, 0.205, 256, 239, BRAF COMPLEXED WITH AN INHIBITOR
3791, d4mxoB_, 0.7345, 2.37, 0.248, 264, 238, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
3792, d4ehzA_, 0.7345, 2.88, 0.246, 290, 248, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3793, d4e4nA1, 0.7345, 2.81, 0.244, 290, 246, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
3794, d3my0L1, 0.7345, 2.97, 0.224, 295, 246, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3795, d3en4B_, 0.7345, 2.46, 0.251, 266, 239, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
3796, d3cjgA_, 0.7345, 2.59, 0.215, 280, 242, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
3797, d2w5aA1, 0.7345, 2.66, 0.271, 259, 240, HUMAN NEK2 KINASE ADP-BOUND
3798, d2c6dA_, 0.7345, 2.42, 0.314, 254, 239, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH ADPNP
3799, d5wo4B_, 0.7344, 2.85, 0.243, 280, 247, JAK1 COMPLEXED WITH COMPOUND 28
3800, d5bvnA_, 0.7344, 3.08, 0.219, 278, 251, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3801, d5ap2A1, 0.7344, 2.23, 0.314, 253, 236, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3802, d4bggA_, 0.7344, 3.01, 0.230, 296, 248, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3803, d3zclA_, 0.7344, 2.93, 0.220, 289, 245, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-3-(1-(1H-PYRROLO(23-B)PYRIDIN-3-YL)ETHYL)-N-ISOPROPYL-( 124)TRIAZOLO(43-B)PYRIDAZIN-6-AMINE
3804, d2etmB_, 0.7344, 2.58, 0.253, 263, 241, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
3805, d4tygA1, 0.7343, 2.81, 0.244, 290, 246, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
3806, d4js8A_, 0.7343, 2.31, 0.308, 259, 237, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401348
3807, d3my0B_, 0.7343, 2.93, 0.224, 295, 246, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3808, d6btwD_, 0.7342, 3.14, 0.156, 307, 256, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
3809, d5xy1A1, 0.7342, 2.48, 0.234, 252, 239, CRYSTAL STRUCTURE OF LYN KINASE DOMAIN IN COMPLEX WITH N-(1H-INDAZOL- 6-YL)-8-(PIPERIDIN-4-YLOXY)-6-PROPYLQUINAZOLIN-2-AMINE
3810, d5lpvA_, 0.7342, 2.84, 0.220, 282, 246, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH AMPPNP AND MN FROM ARABIDOPSIS THALIANA
3811, d4p5qA_, 0.7342, 2.39, 0.208, 275, 240, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
3812, d4k6zA_, 0.7342, 2.80, 0.244, 279, 246, THE JAK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 37
3813, d3q4uC_, 0.7342, 3.04, 0.229, 296, 249, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3814, d3prfB_, 0.7342, 2.41, 0.197, 262, 239, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
3815, d1iepA1, 0.7342, 2.58, 0.232, 270, 241, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
3816, d5nadA1, 0.7341, 2.36, 0.304, 253, 237, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1217389
3817, d4bf2A_, 0.7341, 2.36, 0.285, 253, 235, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3818, d3uokB_, 0.7341, 2.38, 0.311, 265, 238, AURORA A IN COMPLEX WITH YL5-81-1
3819, d3uokA_, 0.7341, 2.38, 0.311, 265, 238, AURORA A IN COMPLEX WITH YL5-81-1
3820, d2qokA_, 0.7341, 2.44, 0.212, 281, 241, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:S768A TRIPLE MUTANT
3821, d2hakD_, 0.7341, 2.38, 0.331, 309, 239, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
3822, d4c61B_, 0.7340, 2.58, 0.270, 274, 241, INHIBITORS OF JAK2 KINASE DOMAIN
3823, d3ggfA_, 0.7340, 2.94, 0.268, 275, 250, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
3824, d1pkgB_, 0.7340, 2.80, 0.230, 277, 243, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
3825, d5ftqA1, 0.7339, 2.90, 0.191, 292, 246, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH CMPD 17
3826, d1iepB1, 0.7339, 2.59, 0.224, 270, 241, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
3827, d5xp7A_, 0.7338, 2.37, 0.252, 265, 238, C-SRC IN COMPLEX WITH ATP-CHCL
3828, d5l8jA_, 0.7338, 2.56, 0.283, 253, 240, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 S93R
3829, d5kmnA1, 0.7338, 2.67, 0.215, 290, 242, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
3830, d5b7vB_, 0.7338, 2.70, 0.225, 277, 244, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
3831, d5uoxB_, 0.7337, 2.36, 0.285, 252, 235, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3832, d5lpwA_, 0.7337, 2.80, 0.230, 280, 244, CRYSTAL STRUCTURE OF THE APO-BRI1 KINASE DOMAIN (865-1160)
3833, d4zk5B_, 0.7337, 3.18, 0.243, 294, 255, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
3834, d4oa9A_, 0.7337, 2.90, 0.220, 280, 246,  
3835, d4ivcA1, 0.7337, 2.82, 0.244, 290, 246, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
3836, d4ag8A_, 0.7337, 2.82, 0.216, 296, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H- INDAZOL-6- YLSULFANYL)-BENZAMIDE)
3837, d3zbxA_, 0.7337, 2.94, 0.220, 282, 245, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR 6- ((6-(4-FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN- 3-YL)METHYL)QUINOLINE.
3838, d3vvhC1, 0.7337, 3.28, 0.255, 282, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
3839, d3op5C_, 0.7337, 3.18, 0.148, 308, 257, HUMAN VACCINIA-RELATED KINASE 1
3840, d3a62A_, 0.7337, 2.24, 0.322, 263, 236, CRYSTAL STRUCTURE OF PHOSPHORYLATED P70S6K1
3841, d2yhvA_, 0.7337, 2.96, 0.186, 291, 247, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE
3842, d5oxgB_, 0.7336, 3.03, 0.230, 296, 248, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3843, d4mnfA_, 0.7336, 2.40, 0.206, 257, 238, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
3844, d4ei4B_, 0.7336, 2.86, 0.243, 280, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
3845, d3zmmB_, 0.7336, 2.60, 0.266, 274, 241, INHIBITORS OF JAK2 KINASE DOMAIN
3846, d3my0N1, 0.7336, 2.93, 0.228, 299, 246, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3847, d2ja0A_, 0.7336, 2.47, 0.276, 285, 239,  
3848, d1fpuA1, 0.7336, 2.72, 0.222, 271, 243, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
3849, d4nk9B_, 0.7335, 3.12, 0.206, 282, 247, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
3850, d4c4hA1, 0.7335, 2.19, 0.306, 245, 235, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3851, d4aoiA_, 0.7335, 2.94, 0.220, 289, 245, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( 3-((1H- PYRROLO(23-B)PYRIDIN-3-YL)METHYL)-(124)TRIAZOLO( 43-B)(124) TRIAZIN-6-YL)BENZONITRILE
3852, d3h3cA_, 0.7335, 2.35, 0.205, 263, 239, CRYSTAL STRUCTURE OF PYK2 IN COMPLEX WITH SULFOXIMINE- SUBSTITUTED TRIFLUOROMETHYLPYRIMIDINE ANALOG
3853, d2jflA_, 0.7335, 2.46, 0.276, 286, 239, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE ( DIPHOSPHORYLATED FORM) BOUND TO 5- AMINO-3-((4-( AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-12 4-TRIAZOLE-1-CARBOTHIOAMIDE
3854, d2j50B_, 0.7335, 2.52, 0.301, 249, 239, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
3855, d2j50A_, 0.7335, 2.52, 0.301, 249, 239, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
3856, d2etmA_, 0.7335, 2.78, 0.254, 262, 244, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
3857, d1jqhA_, 0.7335, 3.03, 0.195, 291, 251, IGF-1 RECEPTOR KINASE DOMAIN
3858, d5w5oL_, 0.7334, 2.78, 0.220, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3859, d4ibmA_, 0.7334, 2.92, 0.190, 301, 247, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
3860, d2jfmA_, 0.7334, 2.45, 0.276, 287, 239, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (UNLIGANDED FORM)
3861, d4zjiC_, 0.7333, 2.98, 0.300, 281, 247, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
3862, d4mxzA_, 0.7333, 2.44, 0.251, 266, 239, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3863, d4mxyA_, 0.7333, 2.44, 0.251, 266, 239, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3864, d4dfyA_, 0.7333, 2.61, 0.268, 310, 246, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
3865, d3my0M1, 0.7333, 3.19, 0.220, 297, 250, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3866, d2xneA_, 0.7333, 2.20, 0.297, 246, 236, STRUCTURE OF AURORA-A BOUND TO AN IMIDAZOPYRAZINE INHIBITOR
3867, p5x02A_, 0.7332, 2.62, 0.214, 305, 243, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR FF- 10101
3868, d5w5oP_, 0.7332, 2.77, 0.220, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3869, d4r7hA_, 0.7332, 2.75, 0.213, 308, 244, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX3397
3870, d4k8aB_, 0.7332, 2.48, 0.254, 258, 240, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
3871, d4agcA_, 0.7332, 2.86, 0.212, 304, 245, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-( 3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)- BENZAMIDE)
3872, d2yfxA_, 0.7332, 2.97, 0.182, 292, 247, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3873, d5w5oC_, 0.7331, 2.79, 0.220, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3874, d1m7nB_, 0.7331, 2.88, 0.207, 299, 246, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
3875, d5w5oF_, 0.7330, 2.78, 0.220, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3876, d5kmlA1, 0.7330, 2.66, 0.215, 290, 242, TRKA JM-KINASE WITH 1-(5-METHYL-3-PHENYL-12-OXAZOL-4-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
3877, d5hezB_, 0.7330, 2.96, 0.260, 289, 246, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
3878, d5ar4A_, 0.7330, 2.71, 0.217, 274, 244, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
3879, d4aojA_, 0.7330, 2.30, 0.210, 260, 238, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
3880, d3zxzA_, 0.7330, 2.95, 0.220, 289, 245, X-RAY STRUCTURE OF PF-04217903 BOUND TO THE KINASE DOMAIN OF C-MET
3881, d5l4qB_, 0.7329, 2.29, 0.257, 287, 237, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
3882, d5ap4A1, 0.7329, 2.39, 0.312, 253, 237, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3883, d4u80A_, 0.7329, 3.15, 0.262, 286, 252, MEK 1 KINASE BOUND TO G799
3884, d4ivbA1, 0.7329, 2.83, 0.244, 290, 246, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
3885, d3wzeA_, 0.7329, 2.68, 0.218, 298, 243, KDR IN COMPLEX WITH LIGAND SORAFENIB
3886, d3h10D_, 0.7329, 2.39, 0.315, 255, 238, AURORA A INHIBITOR COMPLEX
3887, d1fpuB1, 0.7329, 2.62, 0.224, 266, 241, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
3888, d4oacA_, 0.7328, 2.90, 0.220, 280, 246,  
3889, d1jqhC_, 0.7328, 3.03, 0.195, 291, 251, IGF-1 RECEPTOR KINASE DOMAIN
3890, d4o2pB_, 0.7327, 2.45, 0.255, 265, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
3891, d2hyyA_, 0.7327, 2.57, 0.233, 263, 240, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
3892, d3gqlA_, 0.7326, 2.95, 0.215, 287, 246, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
3893, d5oy6B_, 0.7325, 2.97, 0.235, 292, 247, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
3894, d5iuhA_, 0.7325, 2.67, 0.198, 285, 242, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5D
3895, d4i5cB1, 0.7325, 2.84, 0.244, 290, 246, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3896, d4aojC_, 0.7325, 2.29, 0.218, 261, 238, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
3897, d3vo3A_, 0.7325, 2.87, 0.212, 303, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH IMIDAZO[1 2-B]PYRIDAZINE DERIVATIVE
3898, d3vntA_, 0.7325, 2.77, 0.213, 301, 244, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
3899, d2hiwB1, 0.7325, 2.60, 0.228, 270, 241, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
3900, d5nk0A_, 0.7324, 2.38, 0.210, 273, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1J
3901, d4asdA_, 0.7324, 2.77, 0.213, 305, 244, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SORAFENIB (BAY 43-9006)
3902, d3l8vA_, 0.7324, 2.89, 0.216, 293, 245, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A BIARYLAMINE BASED INHIBITOR
3903, d3fzpA_, 0.7324, 2.31, 0.202, 259, 238, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH ATPGS
3904, d1opjB1, 0.7324, 2.83, 0.235, 284, 243, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
3905, d1m7nA_, 0.7324, 2.95, 0.215, 299, 246, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
3906, d5w5oB_, 0.7323, 2.79, 0.220, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3907, d5ar7A_, 0.7323, 2.90, 0.227, 278, 247, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
3908, d4equA_, 0.7323, 2.30, 0.316, 274, 234, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
3909, d4ctcA_, 0.7323, 2.82, 0.192, 288, 245, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 7-AMINO-3-CYCLOPROPYL-12-FLUORO- 11016-TRIMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(4 3-H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
3910, d5j9zA_, 0.7322, 2.63, 0.216, 291, 241, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1A
3911, d4r7iA_, 0.7322, 2.73, 0.214, 290, 243, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR GLEEVEC
3912, d4fnxA_, 0.7322, 2.96, 0.186, 292, 247, CRYSTAL STRUCTURE OF THE APO R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3913, d4ccbA_, 0.7322, 2.85, 0.189, 287, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 3-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(5-METHYL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE
3914, d4bkjB1, 0.7322, 3.16, 0.207, 296, 251, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
3915, d4bggD_, 0.7322, 2.98, 0.232, 286, 246, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3916, d3v5qB1, 0.7322, 2.56, 0.226, 262, 239, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
3917, d3uolB_, 0.7322, 2.50, 0.314, 263, 239, AURORA A IN COMPLEX WITH SO2-162
3918, d3uolA_, 0.7322, 2.50, 0.314, 263, 239, AURORA A IN COMPLEX WITH SO2-162
3919, d3u6jA1, 0.7322, 2.79, 0.216, 305, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
3920, d4hw7A_, 0.7321, 2.74, 0.210, 289, 243, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX647-OME
3921, d2j0mB_, 0.7321, 2.29, 0.253, 257, 237, CRYSTAL STRUCTURE A TWO-CHAIN COMPLEX BETWEEN THE FERM AND KINASE DOMAINS OF FOCAL ADHESION KINASE.
3922, d2hakE_, 0.7321, 2.43, 0.329, 318, 240, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
3923, d4rwiB_, 0.7320, 2.80, 0.225, 280, 244, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
3924, d4gu9B_, 0.7320, 2.56, 0.253, 255, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
3925, d3my0A1, 0.7320, 3.17, 0.221, 295, 249, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3926, d4nkaA_, 0.7319, 2.72, 0.214, 279, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
3927, d4cmtA_, 0.7319, 2.85, 0.184, 284, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(3-(METHYLSULFONYL)PHENYL)PYRIDIN-2-AMINE
3928, p3eocA2, 0.7319, 0.59, 1.000, 216, 216, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
3929, d5edrA_, 0.7318, 2.79, 0.198, 299, 243, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 27: ~{N}-(1~{H}- INDAZOL-3-YL)-77-DIMETHYL-2-(2-METHYLPYRAZOL-3-YL)-5~{H}-FURO[34- D]PYRIMIDIN-4-AMINE
3930, d5am6B_, 0.7318, 2.55, 0.228, 280, 241, NATIVE FGFR1 WITH AN INHIBITOR
3931, d4uxqA_, 0.7318, 2.96, 0.227, 286, 247, FGFR4 IN COMPLEX WITH PONATINIB
3932, d3oomA_, 0.7318, 3.13, 0.229, 297, 249, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00507
3933, p3ej1A2, 0.7318, 0.60, 1.000, 216, 216, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
3934, d5oxgA_, 0.7317, 3.07, 0.230, 293, 248, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3935, d4gu6A_, 0.7317, 2.96, 0.252, 271, 246, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
3936, d3vvhB1, 0.7317, 3.29, 0.251, 289, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
3937, d2yjsA_, 0.7317, 2.86, 0.188, 286, 245, STRUCTURE OF C1156Y MUTANT ANAPLASTIC LYMPHOMA KINASE
3938, d2hznA2, 0.7317, 2.65, 0.233, 268, 240, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AFG210
3939, d3ii5A_, 0.7316, 2.78, 0.198, 262, 242, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
3940, d3og7B_, 0.7315, 2.44, 0.214, 254, 238, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
3941, d3k5vA1, 0.7315, 2.74, 0.228, 281, 241, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
3942, d4kabB_, 0.7313, 2.57, 0.253, 258, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
3943, d5a4cA_, 0.7312, 2.79, 0.221, 294, 244, FGFR1 LIGAND COMPLEX
3944, d4nk9A_, 0.7312, 2.76, 0.214, 281, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
3945, d4ivdA1, 0.7312, 2.81, 0.245, 289, 245, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
3946, d4cnhA_, 0.7312, 2.78, 0.193, 285, 243, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
3947, d3etaA_, 0.7312, 2.93, 0.199, 293, 246, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
3948, d2xp2A_, 0.7312, 2.86, 0.193, 285, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB (PF-02341066)
3949, d5fdxA_, 0.7311, 3.06, 0.220, 280, 250, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
3950, d4zsaB_, 0.7311, 2.68, 0.222, 282, 243, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
3951, d4y95A1, 0.7311, 2.85, 0.173, 265, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
3952, d4nksB_, 0.7311, 2.92, 0.225, 271, 244, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
3953, d3f69A_, 0.7311, 2.49, 0.245, 270, 241, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
3954, d3b8rA1, 0.7311, 2.50, 0.221, 282, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
3955, d3an0A_, 0.7311, 3.47, 0.226, 291, 257,  
3956, d4gt5A_, 0.7310, 2.85, 0.221, 290, 244, CRYSTAL STRUCTURE OF THE INACTIVE TRKA KINASE DOMAIN
3957, d4bb4A_, 0.7310, 2.47, 0.212, 265, 240, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3958, d3h0yA_, 0.7310, 2.42, 0.294, 250, 238, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3959, d3d7tB_, 0.7310, 2.45, 0.234, 265, 239, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
3960, d2x9eA_, 0.7310, 2.40, 0.308, 253, 237, HUMAN MPS1 IN COMPLEX WITH NMS-P715
3961, d2bdfA_, 0.7310, 2.57, 0.250, 261, 240, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
3962, d4nksA_, 0.7309, 2.74, 0.222, 265, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
3963, d4ehzB_, 0.7309, 2.88, 0.243, 280, 247, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3964, d4bidA_, 0.7309, 2.49, 0.280, 254, 236, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3965, d3zc5A_, 0.7309, 2.88, 0.221, 289, 244, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-6-(1-(6-(1-METHYL-1H-PYRAZOL-4-YL)-(124)TRIAZOLO(43- B)PYRIDAZIN-3-YL)ETHYL)QUINOLINE.
3966, d3w10A_, 0.7309, 2.72, 0.285, 263, 242, AURORA KINASE A COMPLEXED TO PYRAZOLE AMINOQUINOLINE I
3967, d2ogvA_, 0.7309, 2.90, 0.204, 317, 245, CRYSTAL STRUCTURE OF THE AUTOINHIBITED HUMAN C-FMS KINASE DOMAIN
3968, d2c6eB_, 0.7309, 2.35, 0.305, 246, 236, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
3969, d1f3mC_, 0.7309, 2.85, 0.312, 287, 247, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
3970, d5iugA_, 0.7308, 2.80, 0.198, 285, 243, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5A
3971, d4y95C1, 0.7308, 2.85, 0.181, 265, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
3972, d4u44B_, 0.7308, 3.21, 0.243, 296, 255, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
3973, d3gxjA_, 0.7308, 2.78, 0.206, 288, 243,  
3974, d3gqlB_, 0.7308, 2.70, 0.218, 276, 243, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
3975, d2jkmA_, 0.7308, 2.60, 0.258, 260, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
3976, d1jqhB_, 0.7308, 3.03, 0.196, 287, 250, IGF-1 RECEPTOR KINASE DOMAIN
3977, d4y95B1, 0.7307, 2.85, 0.181, 265, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
3978, d4usfA1, 0.7307, 2.81, 0.285, 275, 246, HUMAN SLK WITH SB-440719
3979, d4b0gA_, 0.7307, 2.12, 0.309, 247, 233, COMPLEX OF AURORA-A BOUND TO AN IMIDAZOPYRIDINE-BASED INHIBITOR
3980, d4agdA_, 0.7307, 2.89, 0.212, 303, 245, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SUNITINIB (SU11248) (N-2- DIETHYLAMINOETHYL)-5-((Z)-(5-FLUORO-2-OXO-1H-INDOL-3- YLIDENE)METHYL)-24-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE)
3981, d3vn9A_, 0.7307, 3.48, 0.226, 291, 257, RIFINED CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED MAP2K6 IN A PUTATIVE AUTO-INHIBITION STATE
3982, d2i0vA_, 0.7307, 2.78, 0.214, 303, 243, C-FMS TYROSINE KINASE IN COMPLEX WITH A QUINOLONE INHIBITOR
3983, d2gsfA_, 0.7307, 2.44, 0.208, 281, 240, THE HUMAN EPHA3 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
3984, d5v24A_, 0.7306, 2.36, 0.291, 249, 234, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3985, d5dg5A_, 0.7306, 2.72, 0.215, 297, 242, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
3986, d4zloA_, 0.7306, 2.91, 0.307, 277, 244, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
3987, d4uwyB_, 0.7306, 2.62, 0.231, 273, 242, FGFR1 APO STRUCTURE
3988, d1k9aB3, 0.7306, 2.48, 0.230, 267, 239, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3989, d5hezD_, 0.7304, 2.99, 0.264, 289, 246, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
3990, d5dg5B_, 0.7304, 2.63, 0.216, 297, 241, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
3991, d4bkjA1, 0.7304, 3.13, 0.208, 294, 250, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
3992, d4bibA_, 0.7304, 2.50, 0.284, 254, 236, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3993, d2yjrA_, 0.7304, 2.48, 0.197, 278, 238, STRUCTURE OF F1174L MUTANT ANAPLASTIC LYMPHOMA KINASE
3994, d5kmjA_, 0.7303, 2.72, 0.216, 300, 241, TRKA JM-KINASE WITH {N}-(2-PYRIDYLMETHYL)-2-[2-(2-THIENYL)INDOL-1- YL]ACETAMIDE
3995, d4v04B_, 0.7303, 2.97, 0.204, 287, 245, FGFR1 IN COMPLEX WITH PONATINIB.
3996, d4jt3A_, 0.7303, 2.64, 0.301, 254, 239, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 400740
3997, d4f64B_, 0.7303, 2.82, 0.226, 272, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
3998, d3el8A_, 0.7303, 2.39, 0.249, 263, 237, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
3999, d6b4wA_, 0.7302, 2.40, 0.304, 259, 237, TTK IN COMPLEX WITH INHIBITOR
4000, d4mnfB_, 0.7302, 2.45, 0.210, 257, 238, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
4001, d5lpyA_, 0.7301, 2.87, 0.221, 282, 244, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ATP FROM ARABIDOPSIS THALIANA
4002, d3my0U1, 0.7301, 3.14, 0.222, 284, 248, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4003, d4aseA_, 0.7300, 2.81, 0.213, 305, 244, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH TIVOZANIB (AV-951)
4004, d2ijmB_, 0.7300, 2.44, 0.255, 261, 239, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
4005, d1fgiB_, 0.7300, 2.91, 0.225, 272, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
4006, d5k9iB_, 0.7299, 2.40, 0.245, 262, 237, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
4007, d5i9wA_, 0.7299, 2.37, 0.207, 267, 237, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ANP
4008, d4v04A_, 0.7299, 2.98, 0.204, 290, 245, FGFR1 IN COMPLEX WITH PONATINIB.
4009, d4mcvB_, 0.7299, 2.46, 0.261, 265, 238, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
4010, d4fnyA_, 0.7299, 2.58, 0.184, 273, 239, CRYSTAL STRUCTURE OF THE R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
4011, d3wzkA_, 0.7299, 2.46, 0.311, 258, 238, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH N- CYCLOPROPYL-4-(8-((THIOPHEN-2-YLMETHYL)AMINO)IMIDAZO[12-A]PYRAZIN-3- YL)BENZAMIDE
4012, d3rhxB_, 0.7299, 2.91, 0.225, 275, 244, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
4013, d3o23A_, 0.7299, 2.85, 0.197, 293, 244, HUMAN UNPHOSPHORYLATED IGF1-R KINASE DOMAIN IN COMPLEX WITH AN HYDANTOIN INHIBITOR
4014, d2xb7A_, 0.7299, 2.65, 0.199, 286, 241, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH NVP- TAE684
4015, d1agwB_, 0.7299, 2.92, 0.225, 272, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
4016, d5t0pA_, 0.7298, 2.44, 0.249, 264, 237, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
4017, d4rj5A_, 0.7298, 2.74, 0.195, 296, 241, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 5
4018, d3zfxF_, 0.7298, 2.29, 0.225, 254, 236, CRYSTAL STRUCTURE OF EPHB1
4019, d3zfxB_, 0.7298, 2.29, 0.225, 254, 236, CRYSTAL STRUCTURE OF EPHB1
4020, d5vamB_, 0.7297, 2.61, 0.196, 260, 240, BRAF IN COMPLEX WITH RAF709
4021, d5j95B_, 0.7297, 3.26, 0.247, 300, 255, MAP4K4 IN COMPLEX WITH INHIBITOR
4022, d5e1sA_, 0.7297, 2.57, 0.187, 284, 240, THE CRYSTAL STRUCTURE OF INSR TYROSINE KINASE IN COMPLEX WITH THE INHIBITOR BI 885578
4023, d4e4lD_, 0.7297, 2.93, 0.247, 281, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
4024, d3wzdA_, 0.7297, 2.62, 0.216, 278, 241, KDR IN COMPLEX WITH LIGAND LENVATINIB
4025, d4oabA_, 0.7296, 2.89, 0.220, 279, 245,  
4026, d4f63B_, 0.7296, 2.82, 0.230, 271, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
4027, d4dceA_, 0.7296, 2.76, 0.177, 288, 243, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
4028, d4mwiA_, 0.7295, 2.54, 0.200, 266, 240, CRYSTAL STRUCTURE OF THE HUMAN MLKL PSEUDOKINASE DOMAIN
4029, d5l4qA_, 0.7294, 2.35, 0.257, 293, 237, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
4030, d5ia1A_, 0.7294, 2.44, 0.210, 261, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH MLN8054
4031, d1f3mD_, 0.7294, 2.80, 0.297, 285, 246, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
4032, d5xp7B_, 0.7293, 2.59, 0.247, 267, 239, C-SRC IN COMPLEX WITH ATP-CHCL
4033, d5di1B_, 0.7293, 3.25, 0.247, 300, 255, MAP4K4 IN COMPLEX WITH AN INHIBITOR
4034, d1opjA1, 0.7293, 2.84, 0.223, 282, 242, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
4035, d1fgkB_, 0.7293, 2.94, 0.225, 272, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
4036, d5htiA_, 0.7292, 2.93, 0.209, 290, 244, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH LXM108
4037, d4fnzA_, 0.7292, 2.70, 0.174, 287, 242, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PIPERIDINE-CARBOXAMIDE INHIBITOR 2
4038, d1k9aD3, 0.7292, 2.54, 0.225, 268, 240, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4039, d4rfyA_, 0.7291, 2.84, 0.174, 263, 242, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(MORPHOLINE-4- CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-34- DIHYDROISOQUINOLIN-1-ONE
4040, d4fg7A_, 0.7290, 2.13, 0.289, 250, 232, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-293 IN COMPLEX WITH ATP
4041, d3my0C1, 0.7290, 3.16, 0.222, 298, 248, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4042, d2fumD_, 0.7290, 2.38, 0.256, 258, 238, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
4043, d2fgiB_, 0.7290, 2.93, 0.225, 272, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
4044, d5lpbA_, 0.7289, 2.87, 0.221, 280, 244, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
4045, d5ia0C_, 0.7289, 2.39, 0.211, 269, 237, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
4046, d4y95D_, 0.7289, 2.90, 0.189, 265, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
4047, d4rwkB_, 0.7289, 2.80, 0.222, 282, 243, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
4048, d4c7tA_, 0.7289, 2.78, 0.256, 259, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
4049, d2w96B_, 0.7289, 3.00, 0.482, 267, 245, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4050, d2qonA_, 0.7289, 2.47, 0.208, 281, 240, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742A TRIPLE MUTANT
4051, d5oy6C_, 0.7288, 3.04, 0.235, 291, 247, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4052, d4ztqA_, 0.7288, 2.28, 0.301, 247, 236, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK932
4053, d4dceB_, 0.7288, 2.67, 0.187, 284, 241, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
4054, d4pmmA1, 0.7287, 2.52, 0.218, 281, 239, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N-(3-CYCLOPROPYL- 1-PHENYL-1H-PYRAZOL-5-YL)-2-{4-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1- YL)PHENYL]-1H-123-TRIAZOL-1-YL}ACETAMIDE
4055, d4p90B_, 0.7287, 2.47, 0.315, 262, 235, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
4056, d3mtfB_, 0.7287, 3.17, 0.229, 298, 249, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
4057, d5nk8A_, 0.7286, 2.39, 0.207, 266, 237, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2F
4058, d5kmiA_, 0.7286, 2.67, 0.217, 300, 240, TRKA JM-KINASE WITH 1-(9{H}-FLUOREN-9-YL)-3-(2-METHYL-4-PHENYL- PYRIMIDIN-5-YL)UREA
4059, d4zp5B_, 0.7286, 3.26, 0.247, 300, 255, MAP4K4 IN COMPLEX WITH INHIBITOR
4060, d5w5oN_, 0.7285, 2.72, 0.223, 272, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4061, d5oy6A_, 0.7285, 3.03, 0.235, 291, 247, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4062, d4ehzD_, 0.7285, 2.92, 0.243, 280, 247, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4063, d3my0D1, 0.7285, 2.92, 0.230, 297, 244, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4064, d3db8A_, 0.7285, 2.13, 0.262, 261, 233, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 041
4065, d1mqbA_, 0.7285, 2.42, 0.205, 263, 239, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
4066, d5nkiA_, 0.7283, 2.47, 0.207, 268, 237, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4B
4067, d4v01A_, 0.7283, 2.75, 0.215, 273, 242, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
4068, d4bggC_, 0.7283, 3.04, 0.236, 279, 246, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
4069, d3v5qA1, 0.7283, 2.58, 0.223, 260, 238, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
4070, d5xgnB_, 0.7282, 3.34, 0.156, 308, 257, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
4071, d5kmoA1, 0.7282, 2.56, 0.218, 290, 239, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(2- PYRIDYL)UREA
4072, d5ia0A_, 0.7282, 2.35, 0.203, 263, 237, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
4073, d3q4uA_, 0.7282, 3.17, 0.229, 298, 249, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
4074, d3my0E1, 0.7282, 3.10, 0.219, 293, 247, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4075, d3gvuA1, 0.7282, 2.64, 0.230, 261, 239, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH GLEEVEC
4076, d3dbdA_, 0.7282, 2.13, 0.262, 261, 233, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 094
4077, d5p9fA_, 0.7281, 2.97, 0.180, 266, 244, BTK IN COMPLEX WITH GDC-0834
4078, d5hzeA_, 0.7281, 3.13, 0.260, 305, 250, MEK1 ADOPTS DFG-OUT CONFORMATION WHEN BOUND TO AN ANALOG OF E6201.
4079, d5em5A_, 0.7281, 2.85, 0.198, 298, 242, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 2: 4-[2-(4- CHLOROPHENYL)ETHYLAMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
4080, d4d4sB_, 0.7281, 2.64, 0.258, 260, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4081, d3my0G1, 0.7281, 3.11, 0.219, 293, 247, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4082, d3ewhA1, 0.7281, 2.98, 0.220, 295, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDYL-PYRIMIDINE BENZIMIDAZOLE INHIBITOR
4083, d3wzjA_, 0.7280, 2.59, 0.290, 257, 238, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(6- (CYCLOHEXYLAMINO)-8-(((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)AMINO) IMIDAZO[12-B]PYRIDAZIN-3-YL)-N-CYCLOPROPYLBENZAMIDE
4084, d3tudA1, 0.7280, 2.49, 0.192, 255, 239, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH N-(4-METHYL-3-(8-METHYL-7- OXO-2-(PHENYLAMINO)-78-DIHYDROPYRIDO[23-D]PYRIMIDIN-6-YL)PHENYL)-3- (TRIFLUOROMETHYL)BENZAMIDE
4085, d3my0R1, 0.7280, 3.11, 0.219, 293, 247, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4086, d1i44A_, 0.7280, 2.69, 0.202, 282, 242, CRYSTALLOGRAPHIC STUDIES OF AN ACTIVATION LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
4087, d3geqB1, 0.7279, 2.47, 0.249, 270, 237, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
4088, d5tq7B_, 0.7278, 2.82, 0.254, 269, 244, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4089, d4v01B_, 0.7278, 2.71, 0.212, 275, 241, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
4090, d4mcvA_, 0.7278, 2.62, 0.258, 267, 240, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
4091, p3ej1C2, 0.7278, 0.63, 1.000, 215, 215, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
4092, d3cthA_, 0.7277, 2.92, 0.212, 295, 245, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
4093, d5u9dA_, 0.7276, 2.86, 0.181, 271, 243, DISCOVERY OF A POTENT BTK INHIBITOR WITH A NOVEL BINDING MODE USING PARALLEL SELECTIONS WITH A DNA-ENCODED CHEMICAL LIBRARY
4094, d5l6oA_, 0.7276, 2.55, 0.204, 267, 240, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 3)
4095, d4rvtB_, 0.7276, 3.28, 0.231, 297, 255, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
4096, d4rfzA_, 0.7276, 2.85, 0.174, 263, 242, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-8-FLUORO-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5- (MORPHOLINE-4-CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3- PYRIDYL]PHENYL]ISOQUINOLIN-1-ONE
4097, d3mtfA_, 0.7276, 2.98, 0.220, 296, 245, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
4098, d5uvfD_, 0.7275, 3.24, 0.148, 296, 256, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4099, d4otqA_, 0.7275, 2.88, 0.182, 263, 242, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 1-[5-[3-(7-TERT- BUTYL-4-OXO-QUINAZOLIN-3-YL)-2-METHYL-PHENYL]-1-METHYL-2-OXO-3- PYRIDYL]-3-METHYL-UREA
4100, d4mxcA_, 0.7275, 2.71, 0.211, 290, 242, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4101, d3nw6A_, 0.7275, 2.90, 0.199, 301, 246, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11A)
4102, d2w5hA1, 0.7275, 2.52, 0.283, 257, 237, HUMAN NEK2 KINASE APO
4103, d2reiA1, 0.7275, 2.37, 0.211, 274, 237, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7)
4104, d2g15A_, 0.7275, 3.20, 0.222, 301, 248, STRUCTURAL CHARACTERIZATION OF AUTOINHIBITED C-MET KINASE
4105, d3qriA1, 0.7274, 2.75, 0.233, 270, 240, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
4106, d3dajA_, 0.7274, 2.16, 0.296, 245, 233, CRYSTAL STRUCTURE OF AURORA A COMPLEXED WITH AN INHIBITOR DISCOVERED THROUGH SITE-DIRECTED DYNAMIC TETHERING
4107, d2i0yA_, 0.7274, 2.58, 0.212, 289, 240, CFMS TYROSINE KINASE (FGF KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
4108, d5jfsA_, 0.7273, 2.58, 0.210, 277, 238, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-00593174
4109, d5fdpA_, 0.7273, 3.18, 0.223, 285, 251, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2099 INHIBITOR AT 2.25 ANGSTROMS RESOLUTION.
4110, d4rg0A_, 0.7273, 2.84, 0.174, 263, 242, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[8-FLUORO-2- [2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(4-METHYLPIPERAZIN-1-YL)-2- PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-1-OXO-34-DIHYDROISOQUINOLIN- 6-YL]-2-METHYL-PROPANENITRILE
4111, d4otrA_, 0.7273, 2.86, 0.174, 263, 242, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-CYCLOPROPYL-2- [3-[5-[[5-(4-ETHYLPIPERAZIN-1-YL)-2-PYRIDYL]AMINO]-1-METHYL-6-OXO-3- PYRIDYL]-2-(HYDROXYMETHYL)PHENYL]-8-FLUORO-ISOQUINOLIN-1-ONE
4112, d4hniB_, 0.7273, 2.96, 0.194, 284, 248, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
4113, d3ggfB_, 0.7273, 2.88, 0.261, 270, 249, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
4114, d3g6gA_, 0.7273, 2.39, 0.237, 264, 236, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
4115, d2ijmA_, 0.7273, 2.53, 0.255, 260, 239, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
4116, d1uwhA_, 0.7273, 2.59, 0.201, 264, 239, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
4117, d1irkA_, 0.7273, 2.92, 0.193, 303, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN RECEPTOR
4118, d5xgmA_, 0.7272, 2.68, 0.204, 288, 240, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH GO6976
4119, d4u40B_, 0.7272, 3.23, 0.239, 299, 255, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
4120, d4obqB_, 0.7272, 3.21, 0.244, 293, 254, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
4121, d3my0S1, 0.7272, 3.12, 0.223, 293, 247, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4122, d3my0H1, 0.7272, 3.13, 0.223, 293, 247, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4123, d1s9iA_, 0.7272, 3.28, 0.273, 303, 253, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
4124, d5jfvA_, 0.7271, 2.57, 0.214, 277, 238, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05206283
4125, d3tl8D_, 0.7271, 3.34, 0.203, 306, 251, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
4126, d3oriB_, 0.7271, 2.65, 0.245, 267, 241, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4127, d4e4lE_, 0.7270, 2.90, 0.244, 280, 246, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
4128, d2qu5A_, 0.7270, 2.80, 0.226, 292, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
4129, d4f65B_, 0.7269, 2.86, 0.214, 279, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
4130, d2nryB_, 0.7269, 3.10, 0.266, 286, 248, CRYSTAL STRUCTURE OF IRAK-4
4131, d4yneA1, 0.7268, 2.49, 0.224, 276, 237, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
4132, d3zfxG_, 0.7268, 2.29, 0.226, 253, 235, CRYSTAL STRUCTURE OF EPHB1
4133, d3oriA_, 0.7268, 2.75, 0.244, 267, 242, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4134, d5p9kA_, 0.7267, 3.00, 0.176, 271, 244, CRYSTAL STRUCTURE OF BTK WITH CNX 774
4135, d5kmkA1, 0.7267, 2.69, 0.217, 302, 240, TRKA JM-KINASE WITH 2-FLUORO-{N}-[2-(4-FLUOROPHENYL)-6-METHYL-3- PYRIDYL]-4-(TRIFLUOROMETHYL)BENZAMIDE
4136, d3ky2B_, 0.7267, 2.94, 0.239, 280, 243, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
4137, d2e2bA1, 0.7267, 2.78, 0.221, 266, 240, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
4138, d5kmmA1, 0.7266, 2.69, 0.217, 300, 240, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(1- NAPHTHYL)UREA
4139, d5hezA_, 0.7266, 2.97, 0.265, 287, 245, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
4140, d4u45B_, 0.7266, 3.32, 0.243, 295, 255, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
4141, d4tyjA1, 0.7266, 2.66, 0.234, 275, 239, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
4142, d4gk2A_, 0.7266, 2.38, 0.207, 265, 237, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 66
4143, d4d58B_, 0.7266, 2.67, 0.258, 261, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4144, d1uwhB_, 0.7266, 2.70, 0.200, 264, 240, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
4145, d5p9gA_, 0.7265, 2.93, 0.189, 265, 243, STRUCTURE OF BTK WITH RN486
4146, d4ot5A_, 0.7265, 2.87, 0.174, 263, 242, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4-TERT-BUTYL-N- (3-{8-[4-(4-METHYL-PIPERAZINE-1-CARBONYL)-PHENYLAMINO]-IMIDAZO[12- A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
4147, d3my0P_, 0.7265, 2.92, 0.222, 290, 243, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4148, d3my0F1, 0.7265, 3.16, 0.219, 293, 247, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4149, d5hezC_, 0.7264, 3.05, 0.264, 289, 246, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
4150, d3ikaB_, 0.7264, 3.38, 0.156, 310, 257, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
4151, d5p9iA_, 0.7263, 2.92, 0.177, 271, 243, BTK1 SOAKED WITH IBRUTINIB-REV
4152, d4brxA_, 0.7263, 2.78, 0.244, 259, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
4153, d3my0Q1, 0.7263, 3.16, 0.219, 293, 247, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4154, d3f6xC_, 0.7263, 2.44, 0.250, 265, 236, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4155, d2rl5A1, 0.7263, 2.80, 0.215, 290, 242, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A 23-DIHYDRO-14-BENZOXAZINE INHIBITOR
4156, d5p9jA_, 0.7262, 2.87, 0.174, 263, 242, BTK1 COCRYSTALLIZED WITH IBRUTINIB
4157, d4ypsA1, 0.7262, 2.60, 0.214, 275, 238, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
4158, d4g5pB_, 0.7262, 3.23, 0.173, 303, 254, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
4159, d3my0O1, 0.7262, 2.90, 0.235, 296, 243, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4160, d2xbaA_, 0.7262, 2.85, 0.185, 283, 243, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PHA-E429
4161, d4pdoA_, 0.7260, 2.31, 0.208, 261, 236, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
4162, d3d2kA_, 0.7260, 2.38, 0.298, 245, 235, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH [7-(2-{2-[3-(3-CHLORO- PHENYL)-UREIDO]-THIAZOL-5-YL}-ETHYLAMINO)-PYRAZOLO[43- D]PYRIMIDIN-1-YL]-ACETIC ACID
4163, d5jfxA_, 0.7259, 2.47, 0.207, 277, 237, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-06273340
4164, d4pdoB_, 0.7259, 2.33, 0.199, 261, 236, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
4165, d3g5dB_, 0.7259, 2.32, 0.252, 257, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
4166, p5w5qB_, 0.7258, 3.27, 0.227, 297, 255, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
4167, d4rwjB_, 0.7258, 2.73, 0.224, 282, 241, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
4168, d4pmsA1, 0.7258, 2.49, 0.218, 279, 238, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 4-NAPHTHALEN-1-YL- 1-[(5-PHENYL-124-OXADIAZOL-3-YL)METHYL]-1H-PYRROLO[32-C]PYRIDINE- 2-CARBOXYLIC ACID
4169, d5fdxB_, 0.7257, 3.09, 0.219, 274, 247, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
4170, d4dymA_, 0.7257, 3.14, 0.231, 293, 247, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00135
4171, d4aw5A_, 0.7257, 2.38, 0.215, 261, 237, COMPLEX OF THE EPHB4 KINASE DOMAIN WITH AN OXINDOLE INHIBITOR
4172, d2oibB_, 0.7257, 2.91, 0.255, 278, 243, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4173, d4aojB_, 0.7256, 2.37, 0.216, 258, 236, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
4174, d3dtwA1, 0.7256, 2.49, 0.210, 281, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
4175, d2jkqA_, 0.7256, 2.59, 0.259, 258, 239, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4176, d4f0iA_, 0.7255, 2.77, 0.217, 284, 240, CRYSTAL STRUCTURE OF APO TRKA
4177, d4d5hB_, 0.7255, 2.69, 0.258, 260, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4178, d4d4yB_, 0.7255, 2.69, 0.258, 260, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4179, d3f6xA_, 0.7255, 2.36, 0.251, 264, 235, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4180, d2jkkA_, 0.7255, 2.67, 0.258, 258, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4181, d4ehzC_, 0.7254, 2.93, 0.244, 278, 246, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4182, d3vapA_, 0.7254, 2.57, 0.311, 249, 238, SYNTHESIS AND SAR STUDIES OF IMIDAZO-[12-A]-PYRAZINE AURORA KINASE INHIBITORS WITH IMPROVED OFF TARGET KINASE SELECTIVITY
4183, d2z7sA_, 0.7254, 1.99, 0.322, 256, 230, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO PURVALNOL A
4184, d4k8aA_, 0.7253, 2.46, 0.253, 251, 237, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
4185, d3slsA1, 0.7253, 3.15, 0.259, 289, 251, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
4186, d3my0I1, 0.7253, 3.11, 0.220, 292, 246, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4187, d2oiqA_, 0.7253, 2.49, 0.245, 265, 237, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
4188, d4pmpA1, 0.7252, 2.56, 0.218, 276, 238, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 1-CYCLOPROPYL-1- [3-(13-THIAZOL-2-YL)BENZYL]-3-[4-(TRIFLUOROMETHOXY)PHENYL]UREA
4189, d3uc3A_, 0.7252, 2.47, 0.287, 272, 237, THE CRYSTAL STRUCTURE OF SNF1-RELATED KINASE 2.3
4190, d3ms9B1, 0.7252, 2.60, 0.231, 267, 238, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
4191, d5jfwA_, 0.7251, 2.59, 0.214, 277, 238, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05247452
4192, d5ur1A_, 0.7250, 2.79, 0.224, 278, 241, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
4193, d4ot6A_, 0.7250, 2.87, 0.174, 265, 242, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4- METHANESULFONYL-N-(3-{8-[4-(MORPHOLINE-4-CARBONYL)-PHENYLAMINO]- IMIDAZO[12-A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
4194, d3svvA_, 0.7250, 2.44, 0.242, 261, 236, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
4195, d3h9rA_, 0.7250, 2.72, 0.237, 312, 240, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TYPE I ACTIVIN RECEPTOR (ACVR1) IN COMPLEX WITH FKBP12 AND DORSOMORPHIN
4196, p3eocC2, 0.7250, 0.60, 1.000, 214, 214, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
4197, d2iwiB_, 0.7250, 1.97, 0.265, 249, 230, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4198, d1y8gA_, 0.7250, 2.52, 0.318, 292, 233, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: INACTIVE DOUBLE MUTANT WITH SELENOMETHIONINE
4199, d5ar8B_, 0.7249, 2.96, 0.220, 274, 245, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
4200, d5vgoA1, 0.7248, 2.86, 0.174, 264, 242, BRUTON S TYROSINE KINASE (BTK) WITH COMPOUND G-744
4201, d4z3vA_, 0.7248, 2.86, 0.174, 271, 242, FRAGMENT-BASED DISCOVERY OF A SMALL MOLECULE REVERSIBLE INHIBITOR OF BRUTON S TYROSINE KINASE
4202, d5ew9A_, 0.7247, 2.97, 0.279, 257, 244, CRYSTAL STRUCTURE OF AURORA A KINASE DOMAIN BOUND TO MK-5108
4203, d4ei4A1, 0.7247, 2.87, 0.246, 288, 244, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
4204, d5kupA1, 0.7246, 2.86, 0.174, 264, 242, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 9
4205, d5ew3A_, 0.7246, 2.48, 0.223, 274, 238, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
4206, d3my0V1, 0.7246, 2.80, 0.232, 281, 241, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4207, d3cs9A_, 0.7246, 2.67, 0.231, 264, 238, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4208, d5eobA_, 0.7245, 3.19, 0.223, 288, 247, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4209, d3u6iA_, 0.7243, 2.81, 0.194, 281, 242, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 58A
4210, d3rhkA_, 0.7243, 3.01, 0.200, 298, 245, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
4211, d3qquA_, 0.7243, 2.94, 0.209, 285, 244, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4212, d3pxkB_, 0.7243, 2.51, 0.261, 258, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
4213, d3mj2A_, 0.7243, 2.91, 0.215, 259, 242, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR BMS-509744
4214, d4d4vB_, 0.7242, 2.46, 0.257, 255, 237, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4215, d5ew3B_, 0.7241, 2.49, 0.218, 266, 238, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
4216, d4wunB_, 0.7241, 2.65, 0.225, 268, 240, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
4217, d3genA_, 0.7241, 2.90, 0.182, 264, 242, THE 1.6 A CRYSTAL STRUCTURE OF HUMAN BRUTON S TYROSINE KINASE BOUND TO A PYRROLOPYRIMIDINE-CONTAINING COMPOUND
4218, d3my0T1, 0.7240, 3.10, 0.220, 291, 245, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4219, d3l8pA_, 0.7240, 2.38, 0.237, 292, 236, CRYSTAL STRUCTURE OF CYTOPLASMIC KINASE DOMAIN OF TIE2 COMPLEXED WITH INHIBITOR CEP11207
4220, d3geqA1, 0.7240, 2.49, 0.250, 269, 236, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
4221, d5hu9A1, 0.7239, 2.97, 0.215, 262, 242, CRYSTAL STRUCTURE OF ABL1 IN COMPLEX WITH CHMFL-074
4222, d4gu6B_, 0.7239, 2.67, 0.250, 258, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
4223, d4rx5A1, 0.7238, 2.86, 0.174, 264, 242, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 23
4224, d4f65A_, 0.7238, 2.87, 0.220, 279, 241, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
4225, d2xkdA1, 0.7238, 2.17, 0.277, 243, 231, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 12
4226, d2w9fB_, 0.7238, 2.96, 0.477, 261, 243, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4227, d3ormA_, 0.7237, 2.74, 0.241, 266, 241, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN D76A MUTANT
4228, d3h0zC_, 0.7237, 2.30, 0.303, 246, 234, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4229, d2wd1A_, 0.7237, 3.02, 0.221, 289, 244, HUMAN C-MET KINASE IN COMPLEX WITH AZAINDOLE INHIBITOR
4230, d2p2hA1, 0.7237, 2.96, 0.217, 289, 244, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDINYL-TRIAZINE INHIBITOR
4231, d1y8gB_, 0.7237, 2.50, 0.328, 292, 232, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: INACTIVE DOUBLE MUTANT WITH SELENOMETHIONINE
4232, d5p9hA_, 0.7236, 2.84, 0.187, 264, 241, BTK1 COCRYSTALLIZED WITH RN983
4233, d4oboB_, 0.7236, 3.36, 0.231, 297, 255, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
4234, d4mneD_, 0.7236, 3.41, 0.260, 285, 254, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4235, d3uqfA_, 0.7236, 2.34, 0.248, 260, 234, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
4236, d2iwiA_, 0.7236, 2.05, 0.265, 244, 230, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4237, d1uwjB_, 0.7236, 2.71, 0.204, 263, 240, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
4238, d5l6pA_, 0.7235, 2.80, 0.202, 274, 242, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 6)
4239, d4ztmA_, 0.7235, 3.06, 0.257, 287, 245, IRAK4-INHIBITOR CO-STRUCTURE
4240, d4wunA_, 0.7235, 2.83, 0.220, 282, 241, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
4241, d4u3yB_, 0.7235, 3.37, 0.242, 300, 256, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
4242, d3k5vB1, 0.7235, 2.77, 0.230, 279, 239, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
4243, d3b8qA1, 0.7235, 2.53, 0.210, 285, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4244, d1vzoA_, 0.7235, 2.79, 0.261, 319, 241, THE STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF MSK1 REVEALS A NOVEL AUTOINHIBITORY CONFORMATION FOR A DUAL KINASE PROTEIN
4245, d1k9aF3, 0.7235, 2.52, 0.219, 264, 237, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4246, d4yo6C_, 0.7234, 3.20, 0.256, 286, 246, IRAK4-INHIBITOR CO-STRUCTURE
4247, d3g6gB_, 0.7234, 2.41, 0.234, 263, 235, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
4248, d2xkfA1, 0.7234, 2.36, 0.279, 242, 233, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 2
4249, d5ko1A_, 0.7233, 2.52, 0.206, 265, 238, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 4.
4250, d3w16A_, 0.7233, 2.45, 0.300, 249, 237, STRUCTURE OF AURORA KINASE A COMPLEXED TO PYRAZOLE-AMINOQUINOLINE INHIBITOR III
4251, d2qoqA_, 0.7233, 2.46, 0.202, 284, 238, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BASE AMP-PNP BOUND STRUCTURE
4252, d4r1vA_, 0.7232, 3.08, 0.224, 289, 245, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITORS
4253, d4o2pA_, 0.7232, 2.51, 0.229, 265, 236, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
4254, d4m67A_, 0.7232, 2.48, 0.211, 264, 237, CRYSTAL STRUCTURE OF THE HUMAN MLKL KINASE-LIKE DOMAIN
4255, d5j87A_, 0.7231, 2.99, 0.189, 263, 243, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
4256, d4h1jA_, 0.7231, 2.74, 0.193, 263, 244, CRYSTAL STRUCTURE OF PYK2 WITH THE PYRAZOLE 13A
4257, d3be2A1, 0.7231, 2.60, 0.218, 285, 239, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZAMIDE INHIBITOR
4258, d5uq0A_, 0.7230, 2.69, 0.226, 266, 239, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
4259, d5fboA_, 0.7230, 2.63, 0.189, 255, 238, BTK-INHIBITOR CO-STRUCTURE
4260, d5fbnC_, 0.7230, 2.91, 0.174, 256, 241, BTK KINASE DOMAIN WITH INHIBITOR 1
4261, d3pixA_, 0.7230, 2.79, 0.195, 268, 241, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-ISOPROPYL-7- (4-METHYL-PIPERAZIN-1-YL)-4-(5-METHYL-2H-PYRAZOL-3-YLAMINO)-2H- PHTHALAZIN-1-ONE
4262, d3ocsA1, 0.7230, 2.88, 0.174, 262, 242, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI1746
4263, d3ma6B_, 0.7230, 3.01, 0.296, 266, 243, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
4264, d3cpbA1, 0.7230, 2.49, 0.207, 278, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
4265, d2hakC_, 0.7230, 2.65, 0.329, 310, 240, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4266, d5m53A1, 0.7229, 2.21, 0.286, 248, 231, NEK2 BOUND TO ARYLAMINOPURINE INHIBITOR 11
4267, d5kbrA_, 0.7229, 2.16, 0.307, 259, 231, PAK1 IN COMPLEX WITH 7-AZAINDOLE INHIBITOR
4268, d4d5kB_, 0.7229, 2.49, 0.257, 256, 237, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4269, d3cc6A_, 0.7229, 2.87, 0.200, 269, 245, CRYSTAL STRUCTURE OF KINASE DOMAIN OF PROTEIN TYROSINE KINASE 2 BETA (PTK2B)
4270, d5dbxA_, 0.7228, 3.28, 0.258, 284, 244, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
4271, d3f3tB_, 0.7228, 2.39, 0.256, 259, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
4272, d4obpB_, 0.7227, 3.20, 0.242, 290, 252, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
4273, d4mneH_, 0.7227, 3.44, 0.256, 275, 254, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4274, d3b8qB_, 0.7227, 2.55, 0.214, 271, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4275, d2a19B1, 0.7227, 2.64, 0.252, 261, 238, PKR KINASE DOMAIN- EIF2ALPHA- AMP-PNP COMPLEX.
4276, d3u6hA_, 0.7226, 2.80, 0.207, 280, 241, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 26
4277, d3rhkB_, 0.7226, 3.01, 0.208, 299, 245, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
4278, d3p9jA_, 0.7226, 2.47, 0.300, 249, 237, AURORA A KINASE DOMAIN WITH PHTHALAZINONE PYRAZOLE INHIBITOR
4279, d3is5F1, 0.7226, 3.07, 0.290, 259, 245, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4280, d2nruA_, 0.7225, 3.37, 0.255, 293, 251, CRYSTAL STRUCTURE OF IRAK-4
4281, d5t1tC_, 0.7224, 3.08, 0.256, 286, 246, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4282, d4gg5A_, 0.7224, 2.65, 0.206, 274, 238, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4283, d3ugcA_, 0.7224, 2.80, 0.268, 274, 239, STRUCTURAL BASIS OF JAK2 INHIBITION BY THE TYPE II INHIBTOR NVP-BBT594
4284, d3tt0B_, 0.7224, 2.57, 0.231, 272, 238, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
4285, d3bz3A_, 0.7224, 2.75, 0.249, 259, 241, CRYSTAL STRUCTURE ANALYSIS OF FOCAL ADHESION KINASE WITH A METHANESULFONAMIDE DIAMINOPYRIMIDINE INHIBITOR
4286, d1uwjA_, 0.7224, 2.91, 0.203, 264, 241, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
4287, d1p14A_, 0.7224, 2.64, 0.201, 287, 239, CRYSTAL STRUCTURE OF A CATALYTIC-LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
4288, d5kbrB_, 0.7223, 2.50, 0.295, 260, 234, PAK1 IN COMPLEX WITH 7-AZAINDOLE INHIBITOR
4289, d3slsB1, 0.7223, 3.33, 0.257, 291, 253, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
4290, d3o50B_, 0.7223, 2.46, 0.305, 249, 236, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
4291, d3gqlC_, 0.7223, 2.78, 0.219, 275, 242, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
4292, d2x7fE_, 0.7223, 2.09, 0.265, 251, 230, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
4293, d5tehA_, 0.7222, 2.30, 0.232, 261, 233, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
4294, d5bpyA1, 0.7222, 2.95, 0.181, 262, 243, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
4295, d3o50A_, 0.7222, 2.38, 0.303, 246, 234, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
4296, d3nw5A_, 0.7222, 3.13, 0.198, 302, 247, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11B)
4297, d3d5vA_, 0.7222, 2.21, 0.259, 260, 232, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
4298, d4u41B_, 0.7221, 3.37, 0.231, 297, 255, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
4299, d4otfA1, 0.7221, 2.89, 0.174, 261, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH GDC0834
4300, d4kioC1, 0.7221, 2.51, 0.220, 249, 236, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4301, d4gfoA1, 0.7221, 2.48, 0.229, 270, 236, TYK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
4302, d3nw7A_, 0.7220, 2.96, 0.200, 297, 245, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (34)
4303, d4kaoB_, 0.7219, 2.47, 0.253, 254, 237, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
4304, d3oxzA1, 0.7219, 2.65, 0.233, 267, 236, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN BOUND WITH A DFG-OUT INHIBITOR AP24534
4305, d4yhfA_, 0.7218, 2.90, 0.174, 268, 242, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
4306, d4useB_, 0.7218, 2.68, 0.314, 278, 236, HUMAN STK10 (LOK) WITH SB-633825
4307, d3b8rB_, 0.7218, 2.45, 0.220, 267, 236, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4308, d3krlA_, 0.7217, 2.54, 0.211, 281, 237, CFMS TYROSINE KINASE IN COMPLEX WITH 5-CYANO-FURAN-2-CARBOXYLIC ACID [4-(4-METHYL-PIPERAZIN-1-YL)-2-PIPERIDIN-1-YL-PHENYL]-AMIDE
4309, d2oibD_, 0.7217, 3.17, 0.248, 288, 246, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4310, d4mxxB_, 0.7216, 2.39, 0.231, 260, 234, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4311, d4gg7A_, 0.7216, 2.89, 0.207, 278, 242, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4312, d4d4vA_, 0.7216, 2.53, 0.252, 256, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4313, d5up3B_, 0.7215, 2.07, 0.298, 243, 228, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4314, d4e4lB_, 0.7215, 2.94, 0.245, 279, 245, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
4315, d3qrkA1, 0.7215, 2.68, 0.239, 268, 238, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DP- 987
4316, d3ii5B_, 0.7215, 2.58, 0.203, 257, 237, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
4317, d3ekkA_, 0.7215, 2.70, 0.200, 285, 240, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
4318, d3dzqA_, 0.7215, 2.57, 0.189, 268, 238, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH INHIBITOR AWL-II- 38.3
4319, d2fumC_, 0.7215, 2.42, 0.250, 254, 236, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
4320, d1k9aC3, 0.7215, 2.57, 0.223, 266, 238, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4321, d4x7qB_, 0.7214, 1.99, 0.265, 243, 230, PIM2 KINASE IN COMPLEX WITH COMPOUND 1S
4322, d3cp9A1, 0.7214, 2.55, 0.227, 281, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4323, d2wqbA_, 0.7214, 2.67, 0.221, 289, 240, STRUCTURE OF THE TIE2 KINASE DOMAIN IN COMPLEX WITH A THIAZOLOPYRIMIDINE INHIBITOR
4324, d2nruB_, 0.7214, 3.29, 0.256, 294, 250, CRYSTAL STRUCTURE OF IRAK-4
4325, d3t9tA_, 0.7213, 2.88, 0.198, 263, 242, CRYSTAL STRUCTURE OF BTK MUTANT (F435TK596R) COMPLEXED WITH IMIDAZO[15-A]QUINOXALINE
4326, d3oroA_, 0.7213, 2.87, 0.244, 272, 242, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 4)
4327, d5t1sC_, 0.7212, 3.14, 0.266, 284, 244, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4328, d5j87B_, 0.7212, 2.94, 0.174, 274, 242, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
4329, d5d12A_, 0.7212, 2.35, 0.253, 260, 233, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
4330, d4zlzA_, 0.7212, 3.00, 0.177, 270, 243, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH A SUBSTITUTED CINNOLINE
4331, d3fmeA1, 0.7212, 2.80, 0.244, 267, 238, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (MEK6) ACTIVATED MUTANT (S207D T211D)
4332, d3zfxC_, 0.7211, 2.28, 0.227, 248, 233, CRYSTAL STRUCTURE OF EPHB1
4333, d3c4dB1, 0.7211, 2.40, 0.200, 256, 235,  
4334, d5ng3A_, 0.7210, 3.25, 0.221, 283, 249, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
4335, d4zlyA_, 0.7210, 2.97, 0.177, 270, 243, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE BOUND TO A CINNOLINE FRAGMENT
4336, d4yhfB_, 0.7210, 2.86, 0.166, 269, 241, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
4337, d3i81A_, 0.7210, 3.04, 0.200, 296, 245, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH BMS-754807 [1-(4-((5-CYCLOPROPYL- 1H-PYRAZOL-3-YL)AMINO)PYRROLO[21-F][124]TRIAZIN-2-YL)-N- (6-FLUORO-3-PYRIDINYL)-2-METHYL-L-PROLINAMIDE]
4338, d2jkoA_, 0.7210, 2.50, 0.248, 256, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4339, d5j87C_, 0.7209, 2.95, 0.186, 261, 242, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
4340, d3my0W1, 0.7209, 3.03, 0.226, 280, 243, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4341, d2xyuA_, 0.7209, 2.53, 0.190, 260, 237, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH VUF 12058
4342, d4dbnA_, 0.7208, 2.51, 0.203, 257, 236, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
4343, d3q6uA1, 0.7208, 2.73, 0.208, 281, 240, STRUCTURE OF THE APO MET RECEPTOR KINASE IN THE DUALLY-PHOSPHORYLATED ACTIVATED STATE
4344, d3daeB_, 0.7208, 2.40, 0.294, 246, 235, CRYSTAL STRUCTURE OF PHOSPHORYLATED SNF1 KINASE DOMAIN
4345, d4xs2A_, 0.7207, 3.03, 0.254, 283, 244, IRAK4-INHIBITOR CO-STRUCTURE
4346, d3tl8G_, 0.7207, 3.47, 0.203, 301, 251, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
4347, d3g5dA_, 0.7207, 2.29, 0.254, 256, 232, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
4348, d2x81A_, 0.7207, 2.31, 0.299, 242, 234, STRUCTURE OF AURORA A IN COMPLEX WITH MLN8054
4349, d4mneE_, 0.7206, 3.50, 0.259, 286, 255, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4350, d4kabA_, 0.7206, 2.49, 0.250, 255, 236, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
4351, d3uqgB_, 0.7206, 2.38, 0.258, 257, 233, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
4352, d3bqrA1, 0.7206, 2.87, 0.249, 273, 241, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH AN IMIDAZO-PYRIDAZINE LIGAND
4353, d4tyeA_, 0.7205, 2.92, 0.217, 292, 244, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
4354, d4mneA_, 0.7204, 3.48, 0.260, 286, 254, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4355, d3tz8B_, 0.7204, 2.51, 0.247, 263, 235, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
4356, d4ztnA_, 0.7203, 3.15, 0.253, 286, 245, IRAK4-INHIBITOR CO-STRUCTURE
4357, d4gu9A_, 0.7203, 2.50, 0.250, 252, 236, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
4358, d5j87D_, 0.7202, 2.88, 0.174, 263, 241, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
4359, d4y73C_, 0.7202, 3.19, 0.259, 290, 247, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4360, d3qgwA_, 0.7202, 2.49, 0.213, 244, 235, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
4361, d3p86A_, 0.7202, 2.50, 0.230, 250, 235, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
4362, d3mssA1, 0.7202, 2.52, 0.230, 260, 235, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4363, d4e4lA_, 0.7201, 2.92, 0.246, 277, 244, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
4364, d3w2sA_, 0.7201, 3.25, 0.193, 307, 249, EGFR KINASE DOMAIN WITH COMPOUND4
4365, d3pxkA_, 0.7201, 2.50, 0.253, 256, 237, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
4366, d5ct7A_, 0.7200, 2.64, 0.203, 257, 237, BRAF IN COMPLEX WITH RAF265
4367, d4ztnC_, 0.7200, 3.01, 0.262, 284, 244, IRAK4-INHIBITOR CO-STRUCTURE
4368, d4u3zA_, 0.7200, 3.56, 0.216, 282, 255, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
4369, d4d4sA_, 0.7200, 2.57, 0.249, 255, 237, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4370, d4c3pA_, 0.7200, 2.54, 0.289, 264, 235, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO TPX2 AND AMPPCP
4371, d3zewB_, 0.7200, 2.34, 0.215, 252, 233, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
4372, d3qlgA_, 0.7200, 2.35, 0.240, 259, 233, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
4373, d2qu6B_, 0.7200, 2.51, 0.211, 260, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
4374, d5fbnD_, 0.7199, 2.80, 0.167, 255, 239, BTK KINASE DOMAIN WITH INHIBITOR 1
4375, d4u3zB_, 0.7199, 3.25, 0.237, 294, 253, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
4376, d4nwmB_, 0.7199, 2.98, 0.186, 261, 242, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
4377, d3tubA_, 0.7199, 2.61, 0.193, 253, 238, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-3-((1R2S)-2- PHENYLCYCLOPROPYL)UREA
4378, d2nruC_, 0.7199, 3.32, 0.256, 293, 250, CRYSTAL STRUCTURE OF IRAK-4
4379, d5eydA_, 0.7198, 3.24, 0.229, 289, 245, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH AMG 337
4380, d3f3uA_, 0.7198, 2.42, 0.244, 261, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
4381, d2y6oA_, 0.7198, 2.44, 0.191, 263, 236, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH DASATINIB.
4382, d2oh4A1, 0.7198, 2.73, 0.217, 296, 240, CRYSTAL STRUCTURE OF VEGFR2 WITH A BENZIMIDAZOLE-UREA INHIBITOR
4383, d2cl1A_, 0.7198, 2.56, 0.285, 250, 235,  
4384, d3cjfA_, 0.7197, 2.76, 0.217, 276, 240, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
4385, d1rjbA_, 0.7197, 2.60, 0.219, 298, 237, CRYSTAL STRUCTURE OF FLT3
4386, d5p9mA_, 0.7196, 2.98, 0.178, 271, 241, BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059
4387, d4kspA_, 0.7196, 2.55, 0.199, 257, 236, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
4388, d5lohA_, 0.7195, 2.62, 0.314, 248, 236, KINASE DOMAIN OF HUMAN GREATWALL
4389, d4fc0A_, 0.7195, 2.44, 0.200, 254, 235, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
4390, d4d2rA_, 0.7195, 2.97, 0.200, 300, 245, HUMAN IGF IN COMPLEX WITH A DYRK1B INHIBITOR
4391, d3c1xA_, 0.7195, 2.69, 0.206, 290, 238, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOTRIAZINE BASED INHIBITOR
4392, d2oj9A_, 0.7195, 3.10, 0.198, 295, 247, STRUCTURE OF IGF-1R KINASE DOMAIN COMPLEXED WITH A BENZIMIDAZOLE INHIBITOR
4393, d2nruD_, 0.7195, 3.41, 0.251, 293, 251, CRYSTAL STRUCTURE OF IRAK-4
4394, d3daeA_, 0.7194, 2.41, 0.294, 248, 235, CRYSTAL STRUCTURE OF PHOSPHORYLATED SNF1 KINASE DOMAIN
4395, d3ce3A_, 0.7194, 3.13, 0.211, 293, 246, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOPYRIDINEPYRIDONE BASED INHIBITOR
4396, d5swhA_, 0.7193, 2.36, 0.233, 258, 232, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
4397, p3c4wB3, 0.7193, 2.34, 0.246, 287, 232, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.7A
4398, d2e2bB1, 0.7193, 2.54, 0.230, 258, 235, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
4399, d5p9lA_, 0.7192, 2.81, 0.180, 252, 239, BTK1 IN COMPLEX WITH CC 292
4400, d5fd2A_, 0.7192, 2.90, 0.202, 264, 242, B-RAF WILD-TYPE KINASE DOMAIN IN COMPLEX WITH A PURINYLPYRIDINYLAMINO- BASED INHIBITOR
4401, d4k9yA_, 0.7192, 3.13, 0.231, 271, 247, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-[4-(6-AMINO- PURIN-9-YL)-PHENYL]-3-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-UREA
4402, d3mssC1, 0.7192, 2.59, 0.229, 260, 236, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4403, d3ms9A1, 0.7192, 2.54, 0.230, 261, 235, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
4404, d4ztlD_, 0.7191, 3.06, 0.260, 285, 246, IRAK4-INHIBITOR CO-STRUCTURE
4405, d3qgyA1, 0.7191, 2.36, 0.215, 244, 233, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
4406, d5t1sA_, 0.7190, 3.11, 0.264, 280, 246, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4407, d5kx8C_, 0.7190, 3.19, 0.259, 287, 247, IRAK4-INHIBITOR CO-STRUCTURE
4408, d5jkgA_, 0.7189, 2.52, 0.229, 266, 236, THE CRYSTAL STRUCTURE OF FGFR4 KINASE DOMAIN IN COMPLEX WITH LY2874455
4409, d4yp8C_, 0.7189, 3.21, 0.255, 287, 247, IRAK4-INHIBITOR CO-STRUCTURE
4410, d4hcuA_, 0.7189, 3.04, 0.217, 263, 244, CRYSTAL STRUCTURE OF ITK IN COMPLEXT WITH COMPOUND 40
4411, d3dtwB_, 0.7189, 2.62, 0.215, 269, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
4412, d2henB1, 0.7189, 2.46, 0.195, 258, 236, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4413, d3is5A1, 0.7188, 2.84, 0.300, 254, 240, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4414, d3f3vA_, 0.7188, 2.46, 0.244, 261, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4415, d4yo6A_, 0.7187, 3.10, 0.257, 286, 245, IRAK4-INHIBITOR CO-STRUCTURE
4416, d4nwmA_, 0.7187, 3.00, 0.186, 261, 242, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
4417, d3mpmA_, 0.7187, 2.68, 0.210, 257, 238, LCK COMPLEXED WITH A PYRAZOLOPYRIMIDINE
4418, d3f3wA_, 0.7187, 2.45, 0.244, 261, 234, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4419, d3f3vB_, 0.7187, 2.45, 0.244, 262, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4420, d3c4cB1, 0.7187, 2.42, 0.200, 256, 235, B-RAF KINASE IN COMPLEX WITH PLX4720
4421, d4afeA1, 0.7186, 2.21, 0.273, 245, 231, NEK2 BOUND TO HYBRID COMPOUND 21
4422, d3oriD_, 0.7186, 2.81, 0.245, 267, 241, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4423, d4u42B_, 0.7185, 2.53, 0.253, 265, 237, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
4424, d1jpaA_, 0.7185, 2.40, 0.196, 273, 235, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
4425, d5fxsA1, 0.7184, 3.02, 0.199, 307, 246, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
4426, d4xyfA_, 0.7184, 3.23, 0.225, 290, 244, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (S)-5-(8-FLUORO-3-(1-(3-(2- METHOXYETHOXY)QUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43-A]PYRIDIN-6- YL)-3-METHYLISOXAZOLE
4427, d2henD1, 0.7184, 2.47, 0.195, 258, 236, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4428, d4hcvA_, 0.7183, 3.08, 0.217, 263, 244, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 53
4429, d4d2sA_, 0.7183, 2.33, 0.310, 249, 232, HUMAN TTK IN COMPLEX WITH A DYRK1B INHIBITOR
4430, d4twnA1, 0.7182, 2.68, 0.204, 275, 240, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH BIRB796
4431, d4eevA_, 0.7182, 2.53, 0.215, 283, 237, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH LY2801653
4432, d3qlgB_, 0.7182, 2.33, 0.250, 260, 232, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
4433, d3fztA_, 0.7182, 2.66, 0.195, 259, 241, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-4618433
4434, d3f3tA_, 0.7182, 2.46, 0.244, 261, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
4435, d2oicD_, 0.7182, 2.96, 0.253, 284, 241, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
4436, d4hctA_, 0.7181, 2.99, 0.218, 265, 243, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 52
4437, d3cpcA1, 0.7181, 2.56, 0.215, 277, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4438, d5lohB_, 0.7180, 2.53, 0.316, 250, 234, KINASE DOMAIN OF HUMAN GREATWALL
4439, d5csxA_, 0.7180, 2.83, 0.207, 261, 241, CRYSTAL STRUCTURE OF B-RAF IN COMPLEX WITH BI 882370
4440, d4dggA_, 0.7180, 2.40, 0.236, 261, 233, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
4441, d3qquB_, 0.7180, 2.96, 0.210, 288, 243, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4442, d3of0A_, 0.7180, 2.39, 0.236, 260, 233, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
4443, d3g6hB_, 0.7180, 2.48, 0.252, 259, 234, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
4444, d3f3wB_, 0.7180, 2.45, 0.244, 260, 234, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4445, d2z7qA_, 0.7180, 2.05, 0.328, 255, 229, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK-1 BOUND TO AMP-PCP
4446, d4xi2A2, 0.7179, 3.13, 0.180, 274, 244, CRYSTAL STRUCTURE OF AN AUTO-INHIBITED FORM OF BRUTON S TRYROSINE KINASE
4447, d4ibmB_, 0.7179, 2.86, 0.202, 294, 242, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
4448, d4d5hA_, 0.7179, 2.61, 0.253, 255, 237, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4449, d3oezA_, 0.7179, 2.47, 0.239, 261, 234, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
4450, d2xnpA1, 0.7179, 2.31, 0.272, 245, 232, STRUCTURE OF NEK2 BOUND TO CCT244858
4451, p4cfxA2, 0.7178, 0.91, 0.972, 215, 214, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
4452, d3idpA_, 0.7178, 2.82, 0.201, 255, 239, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
4453, d3efkA_, 0.7178, 2.78, 0.212, 276, 240, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
4454, p4cfxC2, 0.7177, 0.92, 0.972, 215, 214, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
4455, d3oriC_, 0.7177, 2.85, 0.248, 267, 242, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4456, d3byuA_, 0.7177, 2.55, 0.226, 256, 235, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE REVERSE AMIDE 23
4457, d2qo7A_, 0.7177, 2.46, 0.203, 278, 236, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED AMP-PNP BOUND
4458, d5ur1B_, 0.7176, 2.62, 0.227, 265, 238, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
4459, d5eycA_, 0.7176, 3.25, 0.225, 288, 244, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH NAPHTHYRIDINONE INHIBITOR 5
4460, d3tz8A_, 0.7176, 2.47, 0.244, 261, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
4461, d3mssB1, 0.7176, 2.57, 0.230, 260, 235, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4462, d3cp9B_, 0.7176, 2.56, 0.220, 269, 236, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4463, d3a4pA_, 0.7176, 3.13, 0.230, 285, 243, HUMAN C-MET KINASE DOMAIN COMPLEXED WITH 6-BENZYLOXYQUINOLINE INHIBITOR
4464, d2qo2A_, 0.7176, 2.45, 0.203, 282, 236, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED APO STRUCTURE
4465, d4p5zA_, 0.7175, 2.42, 0.196, 267, 235, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
4466, d4d4yA_, 0.7175, 2.61, 0.249, 255, 237, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4467, d4c3fA_, 0.7175, 2.69, 0.210, 257, 238, STRUCTURE OF LCK IN COMPLEX WITH A COMPOUND DISCOVERED BY VIRTUAL FRAGMENT LINKING
4468, d3mssD1, 0.7175, 2.57, 0.230, 260, 235, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4469, d2p2iA2, 0.7175, 2.57, 0.232, 283, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
4470, d1snuA_, 0.7175, 2.40, 0.219, 245, 233, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4471, d1sm2A_, 0.7175, 2.41, 0.219, 245, 233, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4472, d5t3qA1, 0.7174, 2.83, 0.192, 277, 240, CRYSTAL STRUCTURE OF THE C-MET KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
4473, d4d5kA_, 0.7174, 2.61, 0.249, 255, 237, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4474, d3v5lC1, 0.7174, 2.45, 0.222, 242, 234, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4475, d3tz9A_, 0.7174, 2.47, 0.252, 261, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
4476, d3pj2A_, 0.7174, 2.43, 0.189, 248, 233, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[4-(2- DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-6-(4-FLUORO-PHENOXY)-8-METHYL-8H- PYRIDO[23-D]PYRIMIDIN-7-ONE
4477, d3fzoA_, 0.7174, 2.91, 0.209, 262, 244, CRYSTAL STRUCTURE OF PYK2-APO PROLINE-RICH TYROSINE KINASE
4478, d2y6mA_, 0.7174, 2.53, 0.191, 262, 236, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN
4479, d4l7sA1, 0.7172, 2.58, 0.221, 248, 235, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
4480, d4c3pD_, 0.7172, 2.67, 0.288, 260, 236, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO TPX2 AND AMPPCP
4481, d3w2rA_, 0.7172, 2.83, 0.194, 297, 242, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 4
4482, d4zjjD_, 0.7171, 2.97, 0.300, 274, 243, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4483, d4i4eA_, 0.7171, 2.46, 0.242, 254, 236, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH HINGE BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
4484, d2xk4A1, 0.7171, 2.33, 0.276, 244, 232, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 17
4485, d2xnnA1, 0.7170, 2.16, 0.278, 243, 230, STRUCTURE OF NEK2 BOUND TO CCT242430
4486, d5y8uA_, 0.7169, 2.46, 0.238, 267, 235, CRYSTAL STRUCTURE OF THE C276S MUTANT OF MAP2K7
4487, d3is5B1, 0.7169, 2.90, 0.296, 255, 240, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4488, d5b2kA_, 0.7168, 2.40, 0.238, 264, 235, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
4489, d3dkoA1, 0.7168, 2.48, 0.208, 272, 236, COMPLEX BETWEEN THE KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7) AND INHIBITOR ALW-II-49-7
4490, d2xnmA1, 0.7168, 2.37, 0.289, 250, 232, STRUCTURE OF NEK2 BOUND TO CCT
4491, d4p4cA_, 0.7167, 2.42, 0.200, 266, 235, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
4492, d3qgyB1, 0.7167, 2.36, 0.215, 244, 233, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
4493, d5c9cA_, 0.7166, 2.72, 0.208, 254, 236, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
4494, d4l7sB1, 0.7166, 2.48, 0.218, 248, 234, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
4495, d2yn8B_, 0.7166, 2.38, 0.218, 260, 234, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4496, d4qq5A1, 0.7165, 2.81, 0.212, 272, 241, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
4497, d3tucA_, 0.7165, 2.72, 0.185, 257, 238, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-BENZYL-N-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
4498, d3hyhA_, 0.7165, 2.47, 0.309, 238, 233, CRYSTAL STRUCTURE OF THE PROTEIN KINASE DOMAIN OF YEAST AMP-ACTIVATED PROTEIN KINASE SNF1
4499, d2wqnA_, 0.7165, 2.57, 0.319, 259, 238, STRUCTURE OF ADP-BOUND HUMAN NEK7
4500, d3vw8A_, 0.7164, 2.97, 0.221, 303, 240, CRYSTAL STRUCTURE OF HUMAN C-MET KINASE DOMAIN WITH ITS INHIBITOR
4501, d4ztnD_, 0.7163, 3.19, 0.259, 285, 247, IRAK4-INHIBITOR CO-STRUCTURE
4502, d4d58A_, 0.7163, 2.58, 0.250, 255, 236, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4503, d4qqcA1, 0.7162, 2.72, 0.222, 271, 239, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
4504, p4e3cF1, 0.7162, 3.51, 0.260, 290, 254, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4505, d4mf1B1, 0.7161, 2.48, 0.218, 244, 234, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
4506, d3tl8H_, 0.7161, 3.32, 0.206, 303, 248, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
4507, d3famB_, 0.7161, 2.48, 0.309, 239, 233,  
4508, d2eueB_, 0.7161, 2.48, 0.309, 239, 233,  
4509, d3f66A_, 0.7160, 3.26, 0.220, 288, 245, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
4510, d5kx8A_, 0.7159, 3.13, 0.254, 285, 244, IRAK4-INHIBITOR CO-STRUCTURE
4511, d5h3qA_, 0.7158, 2.75, 0.214, 302, 238, CRYSTAL STRUCTURE OF TRKA KINASE WITH LIGAND
4512, d3qlfB_, 0.7158, 2.36, 0.237, 258, 232, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
4513, d3octA_, 0.7158, 2.38, 0.193, 244, 233, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE MUTANT V555R IN COMPLEX WITH DASATINIB
4514, d1snxA_, 0.7158, 2.46, 0.215, 245, 233, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4515, d5uq0B_, 0.7157, 2.62, 0.229, 256, 236, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
4516, d5ng3D_, 0.7157, 3.14, 0.224, 278, 246, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
4517, d4xmoA_, 0.7157, 3.22, 0.226, 289, 243, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (R)-5-(8-FLUORO-3-(1- FLUORO-1-(3-METHOXYQUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43- A]PYRIDIN-6-YL)-3-METHYLISOXAZOLE
4518, d4pqnA_, 0.7157, 2.41, 0.220, 240, 232, ITK KINASE DOMAIN WITH COMPOUND GNE-9822
4519, d3cpbB_, 0.7156, 2.55, 0.217, 263, 235, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
4520, d3q96A_, 0.7155, 2.58, 0.204, 253, 235, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
4521, d3eflB_, 0.7155, 2.55, 0.208, 263, 236, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
4522, d4f0gA1, 0.7154, 2.62, 0.234, 260, 235, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM
4523, d3tl8A_, 0.7154, 3.40, 0.201, 300, 249, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
4524, d3en4A_, 0.7154, 2.34, 0.242, 257, 231, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
4525, d3el8B_, 0.7154, 2.32, 0.260, 259, 231, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
4526, d3cs9B_, 0.7154, 2.45, 0.233, 247, 232, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4527, d3wzuA_, 0.7153, 2.55, 0.241, 270, 237, THE STRUCTURE OF MAP2K7 IN COMPLEX WITH 5Z-7-OXOZEAENOL
4528, d3q96B_, 0.7153, 2.63, 0.203, 262, 236, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
4529, d3dpkA_, 0.7153, 2.62, 0.217, 279, 235, CFMS TYROSINE KINASE IN COMPLEX WITH A PYRIDOPYRIMIDINONE INHIBITOR
4530, d1r0pA_, 0.7153, 3.12, 0.227, 301, 242, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH THE MICROBIAL ALKALOID K-252A
4531, d4ztmC_, 0.7152, 3.05, 0.266, 282, 241, IRAK4-INHIBITOR CO-STRUCTURE
4532, d4othA_, 0.7152, 2.23, 0.286, 305, 231, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH RO-31-8220
4533, d4deiA_, 0.7152, 3.14, 0.227, 287, 242, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 24
4534, d4dbnB_, 0.7152, 2.62, 0.199, 263, 236, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
4535, d4kspB_, 0.7151, 2.64, 0.199, 256, 236, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
4536, p4e3cC1, 0.7151, 3.45, 0.265, 290, 253, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4537, d3zfyA_, 0.7151, 2.81, 0.201, 260, 239, CRYSTAL STRUCTURE OF EPHB3
4538, d3eflA1, 0.7151, 2.53, 0.225, 279, 236, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
4539, d5kx7B_, 0.7150, 3.22, 0.263, 286, 247, IRAK4-INHIBITOR CO-STRUCTURE
4540, d4byjA_, 0.7150, 2.44, 0.295, 246, 234, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
4541, d3cpcB_, 0.7150, 2.52, 0.217, 262, 235, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4542, d2henA1, 0.7150, 2.51, 0.195, 258, 236, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4543, d3oezB_, 0.7149, 2.43, 0.240, 261, 233, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
4544, d3cs9D_, 0.7149, 2.73, 0.232, 263, 237, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4545, d5i8aA1, 0.7148, 2.40, 0.224, 265, 232, TRKA WITH (6~{R})-3-METHYLSULFANYL-6-PHENYL-1-(1~{H}-PYRAZOL-3-YL)-6 7-DIHYDRO-5~{H}-THIENO[34-C]PYRIDIN-4-ONE
4546, d4a4xA1, 0.7148, 2.28, 0.273, 245, 231, NEK2-EDE BOUND TO CCT248662
4547, d1snxB_, 0.7148, 2.44, 0.219, 245, 233, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4548, d4pp9B1, 0.7147, 2.46, 0.219, 246, 233, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
4549, d4m0zA_, 0.7147, 3.13, 0.213, 264, 244, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 5 {4- (CARBAMOYLAMINO)-1-(7-METHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE}
4550, d2qodA_, 0.7147, 2.45, 0.200, 274, 235, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y602F MUTANT
4551, d2qoiA_, 0.7146, 2.46, 0.200, 274, 235, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F DOUBLE MUTANT
4552, d5uitB_, 0.7145, 3.08, 0.259, 283, 243, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 14
4553, d5jrsA1, 0.7145, 2.83, 0.181, 257, 238, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
4554, d4fc0B_, 0.7145, 2.62, 0.199, 263, 236, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
4555, d5swhB_, 0.7144, 2.45, 0.237, 261, 232, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
4556, d3idpB_, 0.7144, 2.78, 0.206, 256, 238, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
4557, d3f66B_, 0.7144, 2.86, 0.227, 269, 238, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
4558, d3dkfA1, 0.7144, 3.08, 0.232, 293, 241, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
4559, d2xk3A1, 0.7144, 2.22, 0.266, 239, 229, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 35
4560, d2henC1, 0.7144, 2.52, 0.195, 258, 236, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4561, d5uiqC_, 0.7143, 2.99, 0.264, 280, 242, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4562, d5k75D_, 0.7143, 3.09, 0.266, 280, 244, IRAK4 IN COMPLEX WITH COMPOUND 1
4563, d5dbxB_, 0.7143, 3.07, 0.268, 282, 239, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
4564, d3piyA_, 0.7143, 2.55, 0.197, 262, 233, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH R406
4565, d4m13A_, 0.7142, 3.14, 0.213, 264, 244, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 8 [4- (CARBAMOYLAMINO)-1-(7-PROPOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
4566, d4m12A_, 0.7141, 3.15, 0.213, 264, 244, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 7 [4- (CARBAMOYLAMINO)-1-(7-ETHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
4567, d2qooA_, 0.7141, 2.46, 0.200, 273, 235, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742F TRIPLE MUTANT
4568, d2qofA_, 0.7141, 2.46, 0.200, 280, 235, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F MUTANT
4569, d4i4fA_, 0.7140, 2.69, 0.245, 255, 237, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH AN ALLOSTERIC BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
4570, d3qriB_, 0.7140, 2.73, 0.230, 262, 235, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
4571, d1yomA_, 0.7140, 2.41, 0.234, 260, 231, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
4572, d5k75C_, 0.7139, 3.13, 0.258, 282, 244, IRAK4 IN COMPLEX WITH COMPOUND 1
4573, d3qquD_, 0.7139, 3.04, 0.208, 292, 245, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4574, d3d7tA_, 0.7139, 2.44, 0.228, 249, 232, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4575, p5uq1A2, 0.7138, 0.94, 0.977, 214, 213, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
4576, d5k76B_, 0.7138, 3.07, 0.263, 281, 243, IRAK4 IN COMPLEX WITH COMPOUND 28
4577, d3ctjA_, 0.7138, 2.77, 0.206, 289, 238, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
4578, d2nryC_, 0.7138, 2.96, 0.254, 280, 240, CRYSTAL STRUCTURE OF IRAK-4
4579, p5lqeC2, 0.7136, 0.84, 0.967, 213, 212, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
4580, d5imxA_, 0.7136, 2.59, 0.196, 266, 235, ANAPLASTIC LYMPHOMA KINASE (ALK) CATALYTIC DOMAIN COMPLEXED WITH NOVEL INHIBITOR 3-SULFONYLPYRAZOL-4-AMINO PYRIMIDINE
4581, d4m14A_, 0.7136, 3.15, 0.213, 263, 244, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE]
4582, d2exeA_, 0.7136, 2.40, 0.289, 262, 228, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED CLK3
4583, d4ztlC_, 0.7135, 3.04, 0.269, 282, 242, IRAK4-INHIBITOR CO-STRUCTURE
4584, d4uy9A_, 0.7135, 3.07, 0.276, 313, 243, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
4585, d4ebwA_, 0.7135, 2.86, 0.248, 259, 238, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
4586, d2vwvA_, 0.7135, 2.38, 0.215, 255, 233, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4587, d5sysB_, 0.7134, 2.42, 0.237, 258, 232, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
4588, d4ybjA_, 0.7134, 2.45, 0.241, 255, 232, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
4589, d5w85B_, 0.7133, 3.00, 0.266, 279, 241, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)
4590, d5fxqA1, 0.7133, 3.04, 0.205, 301, 244, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
4591, d3tz9B_, 0.7133, 2.40, 0.233, 259, 232, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
4592, d4ztmD_, 0.7132, 3.08, 0.259, 282, 243, IRAK4-INHIBITOR CO-STRUCTURE
4593, d4m15A_, 0.7132, 3.14, 0.213, 263, 244, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE] AND ADP
4594, d4lg4D_, 0.7132, 2.08, 0.278, 250, 227, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4595, d4h58C_, 0.7131, 3.03, 0.195, 272, 241, BRAF IN COMPLEX WITH COMPOUND 3
4596, d3qquC_, 0.7131, 3.14, 0.207, 293, 246, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4597, d5t1tA_, 0.7129, 3.13, 0.258, 283, 244, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4598, d4m0yA_, 0.7129, 3.09, 0.218, 263, 243, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 1 [4- (CARBAMOYLAMINO)-1-(NAPHTHALEN-1-YL)-1H-PYRAZOLE-3-CARBOXAMIDE]
4599, d1vr2A_, 0.7129, 2.76, 0.210, 275, 238, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN
4600, d4eqmB_, 0.7128, 2.82, 0.245, 269, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4601, d5w84A_, 0.7127, 3.02, 0.256, 279, 242, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 4)
4602, d4dehA_, 0.7127, 3.24, 0.223, 286, 242, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 3
4603, d5t1tD_, 0.7126, 3.15, 0.261, 283, 245, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4604, d5ng3B_, 0.7126, 3.08, 0.221, 275, 244, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
4605, d5c9cB_, 0.7126, 2.68, 0.204, 251, 235, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
4606, d4degA_, 0.7126, 3.31, 0.230, 286, 243, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDAZINE INHIBITOR 2
4607, d4rmzA_, 0.7125, 3.29, 0.263, 284, 247, CRYSTAL STRUCTURE OF IRAK-4
4608, d3f3uB_, 0.7125, 2.44, 0.246, 259, 232, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
4609, d2xk8A1, 0.7125, 2.12, 0.273, 238, 227, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 15
4610, d2javA1, 0.7125, 2.37, 0.294, 245, 231, HUMAN KINASE WITH PYRROLE-INDOLINONE LIGAND
4611, d1mp8A_, 0.7125, 2.48, 0.238, 252, 235, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE (FAK)
4612, d5itaB_, 0.7124, 2.72, 0.207, 252, 237, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
4613, d4rmzB_, 0.7124, 3.20, 0.261, 282, 245, CRYSTAL STRUCTURE OF IRAK-4
4614, d3c4cA1, 0.7124, 2.83, 0.202, 257, 238, B-RAF KINASE IN COMPLEX WITH PLX4720
4615, d4ztlA_, 0.7123, 3.03, 0.257, 280, 241, IRAK4-INHIBITOR CO-STRUCTURE
4616, d4ebvA1, 0.7123, 2.77, 0.249, 261, 237, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
4617, d3bysA_, 0.7123, 2.54, 0.223, 255, 233, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE AMIDE 10B
4618, d5j5sA_, 0.7122, 2.45, 0.237, 258, 232, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
4619, d4uy9B_, 0.7122, 3.10, 0.276, 315, 243, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
4620, d3dkgA_, 0.7122, 3.08, 0.220, 281, 241, STRUCTURE OF MUTANT(Y1248L) MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
4621, d2wqmA_, 0.7122, 2.66, 0.290, 258, 238, STRUCTURE OF APO HUMAN NEK7
4622, d4eqmA_, 0.7121, 2.83, 0.245, 269, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4623, d3c4dA1, 0.7121, 2.77, 0.207, 257, 237,  
4624, d2hyyC1, 0.7121, 2.62, 0.226, 249, 234, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4625, d2hyyB1, 0.7121, 2.61, 0.226, 252, 234, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4626, d5kx8D_, 0.7120, 3.09, 0.255, 283, 243, IRAK4-INHIBITOR CO-STRUCTURE
4627, d5tehB_, 0.7119, 2.52, 0.239, 262, 234, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
4628, d2yn8A_, 0.7119, 2.47, 0.219, 253, 233, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4629, d5mo4A3, 0.7118, 2.61, 0.219, 271, 233, ABL1 KINASE (T334I_D382N) IN COMPLEX WITH ASCIMINIB AND NILOTINIB
4630, d4zjjC_, 0.7118, 3.15, 0.298, 276, 242, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4631, d4y73A_, 0.7118, 3.30, 0.259, 289, 247, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4632, d4pp9A1, 0.7118, 2.45, 0.220, 245, 232, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
4633, d4eqmD_, 0.7118, 2.81, 0.258, 268, 240, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4634, d4yp8A_, 0.7117, 3.22, 0.260, 284, 246, IRAK4-INHIBITOR CO-STRUCTURE
4635, d4yo6D_, 0.7117, 3.24, 0.253, 285, 245, IRAK4-INHIBITOR CO-STRUCTURE
4636, d4eqmC_, 0.7117, 2.83, 0.245, 269, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4637, d3lq8A_, 0.7117, 2.68, 0.209, 278, 235, STRUCTURE OF THE KINASE DOMAIN OF C-MET BOUND TO XL880 (GSK1363089)
4638, d5k75B_, 0.7116, 2.96, 0.259, 274, 239, IRAK4 IN COMPLEX WITH COMPOUND 1
4639, d5fxrA1, 0.7116, 3.06, 0.209, 299, 244, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
4640, d4r6vA1, 0.7116, 2.90, 0.216, 271, 241, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-3 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
4641, d4eqmF_, 0.7116, 2.82, 0.258, 268, 240, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4642, d5t18A1, 0.7115, 2.86, 0.173, 259, 237, CRYSTAL STRUCTURE OF BRUTON AGAMMABULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-986142 AKA (2S)-6-FLUORO-5-[3-(8-FLUORO-1-METHYL-24-DIOXO- 1234-TETRAHYDROQUINAZOLIN-3-YL)-2-METHYLPHENYL]-2-(2- HYDROXYPROPAN-2-YL)-2349-TETRAHYDRO-1H-CARBAZOLE-8-CARBOXAMIDE
4643, d4rfmA1, 0.7115, 2.76, 0.224, 248, 237, ITK KINASE DOMAIN IN COMPLEX WITH COMPOUND 1 N-{1-[(11-DIOXO-1-THIAN- 2-YL)(PHENYL)METHYL]-1H- PYRAZOL-4-YL}-55-DIFLUORO-5A-METHYL-1H4H 4AH5H5AH6H-CYCLOPROPA[F]INDAZOLE-3-CARBOXAMIDE
4644, d2xm9A_, 0.7115, 3.02, 0.286, 287, 234, STRUCTURE OF A SMALL MOLECULE INHIBITOR WITH THE KINASE DOMAIN OF CHK2
4645, d5j5sB_, 0.7114, 2.45, 0.241, 258, 232, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
4646, d5eymB_, 0.7114, 2.93, 0.261, 292, 241, MEK1 IN COMPLEX WITH BI 847325
4647, d5cenA_, 0.7114, 2.77, 0.267, 281, 236, CRYSTAL STRUCTURE OF DLK (KINASE DOMAIN)
4648, d3h0zB_, 0.7113, 2.46, 0.302, 240, 232, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4649, d2r4bA_, 0.7113, 2.99, 0.198, 292, 242, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
4650, d4xs2D_, 0.7112, 3.11, 0.252, 277, 242, IRAK4-INHIBITOR CO-STRUCTURE
4651, d4h1mA_, 0.7112, 2.69, 0.213, 256, 239, CRYSTAL STRUCTURE OF PYK2 WITH THE INDOLE 10C
4652, d3dy7A_, 0.7112, 3.16, 0.270, 260, 244, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
4653, d3dxnA_, 0.7112, 3.43, 0.298, 258, 245, CRYSTAL STRUCTURE OF THE CALCIUM-DEPENDENT KINASE FROM TOXOPLASMA GONDII 541.M00134 KINASE DOMAIN.
4654, d2qu6A1, 0.7112, 2.60, 0.221, 276, 235, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
4655, d5ct7B_, 0.7111, 2.48, 0.197, 254, 233, BRAF IN COMPLEX WITH RAF265
4656, d1yomB_, 0.7111, 2.47, 0.233, 261, 232, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
4657, d1yolB_, 0.7111, 2.37, 0.230, 253, 230, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
4658, d5eymA_, 0.7110, 2.94, 0.257, 292, 241, MEK1 IN COMPLEX WITH BI 847325
4659, d4eqmE_, 0.7110, 2.87, 0.253, 268, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4660, d1jpaB_, 0.7110, 2.37, 0.190, 269, 232, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
4661, d2og8B2, 0.7109, 2.59, 0.236, 247, 233, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
4662, d4q9sA_, 0.7108, 2.56, 0.243, 252, 235, CRYSTAL STRUCTURE OF HUMAN FOCAL ADHESION KINASE (FAK) BOUND TO COMPOUND1 (35-DIHYDRO[124]TRIAZINO[34-C][14]BENZOXAZIN-2(1H)- ONE)
4663, d2pl0A_, 0.7108, 2.93, 0.230, 268, 239, LCK BOUND TO IMATINIB
4664, d3efwB_, 0.7107, 2.27, 0.306, 242, 229, STRUCTURE OF AURORAA WITH PYRIDYL-PYRIMIDINE UREA INHIBITOR
4665, d3efjA_, 0.7106, 2.91, 0.212, 276, 240, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
4666, d3is5C1, 0.7105, 2.94, 0.301, 254, 239, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4667, d5w85A_, 0.7104, 3.01, 0.261, 278, 241, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)
4668, d5t1sD_, 0.7103, 3.10, 0.259, 281, 243, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4669, d4bdiA1, 0.7103, 2.96, 0.288, 289, 233, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4670, d2vwwA_, 0.7103, 2.37, 0.216, 253, 232, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4671, d2r4bB_, 0.7102, 2.95, 0.199, 291, 241, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
4672, d2oibC_, 0.7102, 3.00, 0.257, 278, 241, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4673, d5valA_, 0.7100, 2.67, 0.200, 254, 235, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
4674, d5to8A_, 0.7100, 2.38, 0.203, 250, 232, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
4675, d2nryD_, 0.7099, 3.19, 0.262, 282, 244, CRYSTAL STRUCTURE OF IRAK-4
4676, d5k7gC_, 0.7098, 3.21, 0.266, 283, 244, IRAK4 IN COMPLEX WITH AZ3862
4677, d2rfnB_, 0.7098, 2.89, 0.209, 269, 239, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
4678, d2oibA_, 0.7098, 3.08, 0.263, 280, 243, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4679, d6b8uA_, 0.7097, 2.82, 0.203, 253, 237, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
4680, d5sysA_, 0.7097, 2.51, 0.237, 258, 232, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
4681, d2xnoA1, 0.7097, 2.16, 0.268, 243, 228, STRUCTURE OF NEK2 BOUND TO CCT243779
4682, d5hlwA_, 0.7096, 3.22, 0.220, 284, 241, CRYSTAL STRUCTURE OF C-MET MUTANT Y1230H IN COMPLEX WITH COMPOUND 14
4683, d4otiA_, 0.7096, 2.23, 0.288, 303, 229, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH TOFACITINIB
4684, d5ng3C_, 0.7094, 3.15, 0.222, 272, 243, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
4685, p5lqeA2, 0.7094, 0.85, 0.972, 212, 211, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
4686, d4d4rB_, 0.7094, 3.13, 0.236, 270, 246, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4687, d2rfnA_, 0.7094, 2.89, 0.209, 268, 239, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
4688, d3u51A_, 0.7093, 2.58, 0.236, 256, 233, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
4689, p5yj9D_, 0.7092, 3.14, 0.256, 333, 242, CRYSTAL STRUCTURE OF TRIBOLIUM CASTANEUM PINK1 KINASE DOMAIN IN COMPLEX WITH AMP-PNP 
4690, d5flfE_, 0.7092, 2.76, 0.229, 258, 236, DISEASE LINKED MUTATION IN FGFR
4691, d4knbA_, 0.7092, 2.99, 0.226, 273, 239, C-MET IN COMPLEX WITH OSI LIGAND
4692, d3p08A_, 0.7092, 2.91, 0.197, 252, 238, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
4693, d2xkeA1, 0.7092, 1.92, 0.281, 235, 224, STRUCTURE OF NEK2 BOUND TO AMINIPYRAZINE COMPOUND 5
4694, d3zutA_, 0.7091, 2.77, 0.259, 281, 239, THE STRUCTURE OF OST1 (D160A) KINASE
4695, d2xk6A1, 0.7091, 2.19, 0.273, 235, 227, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 36
4696, d3vs1A3, 0.7089, 2.87, 0.249, 268, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
4697, d3pizA_, 0.7089, 2.39, 0.196, 245, 230, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH (5-AMINO-1-O- TOLYL-1H-PYRAZOL-4-YL)-[3-(1-METHANESULFONYL-PIPERIDIN-4-YL)-PHENYL]- METHANONE
4698, d2rioA_, 0.7089, 2.40, 0.309, 396, 230, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4699, d4agwB_, 0.7088, 2.45, 0.234, 257, 231, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
4700, d3efkB_, 0.7088, 2.75, 0.212, 272, 236, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
4701, d3efjB_, 0.7088, 2.90, 0.205, 275, 239, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
4702, d4cqeB_, 0.7087, 2.60, 0.205, 248, 234, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
4703, d3w18B_, 0.7087, 2.11, 0.310, 236, 226, STRUCTURE OF AURORA KINASE A COMPLEXED TO BENZOIMIDAZOLE-INDAZOLE INHIBITOR XIII
4704, d3vs7A3, 0.7087, 2.81, 0.250, 267, 236, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
4705, d2p2iB_, 0.7087, 2.49, 0.197, 263, 233, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
4706, d5a6nA1, 0.7086, 2.79, 0.241, 270, 237, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH COMPOUND 2
4707, d2hakA_, 0.7085, 2.83, 0.329, 309, 240, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4708, d5valB_, 0.7084, 2.55, 0.202, 254, 233, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
4709, d4pmtA1, 0.7084, 2.56, 0.210, 269, 233, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N~4~-(4-MORPHOLIN- 4-YLPHENYL)-N~6~-(PYRIDIN-3-YLMETHYL)PYRIDO[32-D]PYRIMIDINE-46- DIAMINE
4710, d3svvB_, 0.7084, 2.51, 0.250, 257, 232, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
4711, d3f82A_, 0.7084, 2.74, 0.218, 278, 234, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH N- (4-(2-AMINO-3-CHLOROPYRIDIN-4-YLOXY)-3-FLUOROPHENYL)-4- ETHOXY-1-(4-FLUOROPHENYL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
4712, p3hdmA_, 0.7083, 3.09, 0.269, 285, 242, CRYSTAL STRUCTURE OF SERUM AND GLUCOCORTICOID-REGULATED KINASE 1 IN COMPLEX WITH COMPOUND 1
4713, d2vwuA_, 0.7083, 2.40, 0.216, 253, 232, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4714, d1snuB_, 0.7083, 2.57, 0.220, 241, 232, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4715, d4a9tA1, 0.7082, 2.96, 0.288, 288, 233, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4716, d3vs3B3, 0.7082, 2.95, 0.234, 271, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
4717, d3zuuA_, 0.7081, 2.78, 0.264, 281, 239, THE STRUCTURE OF OST1 (D160A S175D) KINASE IN COMPLEX WITH GOLD
4718, d3v8tB1, 0.7081, 2.46, 0.216, 242, 231, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
4719, d2wtiA_, 0.7081, 2.98, 0.279, 286, 233, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4720, d5uitA_, 0.7080, 3.15, 0.260, 284, 242, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 14
4721, d5hx6A_, 0.7080, 3.29, 0.219, 259, 242, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
4722, d3plsA_, 0.7080, 3.28, 0.215, 298, 247, RON IN COMPLEX WITH LIGAND AMP-PNP
4723, d2bmcD_, 0.7079, 2.86, 0.295, 256, 234, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4724, d5k72A_, 0.7077, 2.96, 0.259, 277, 239, IRAK4 IN COMPLEX WITH COMPOUND 21
4725, d5d11B_, 0.7077, 2.30, 0.259, 255, 228, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
4726, d2og8A_, 0.7077, 2.65, 0.227, 246, 233, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
4727, d5u6bA_, 0.7076, 2.95, 0.212, 270, 241, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
4728, d5k9iA_, 0.7076, 2.57, 0.240, 258, 233, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
4729, d5k7gD_, 0.7076, 3.22, 0.262, 283, 244, IRAK4 IN COMPLEX WITH AZ3862
4730, d2qolA_, 0.7076, 2.56, 0.192, 271, 234, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596:Y602:S768G TRIPLE MUTANT
4731, d5t1sB_, 0.7074, 3.01, 0.255, 282, 239, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4732, d3vrzB3, 0.7074, 2.84, 0.232, 269, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
4733, d1sm2B_, 0.7074, 2.60, 0.220, 241, 232, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4734, d5o21B_, 0.7073, 3.38, 0.232, 273, 246, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
4735, d3v5lD1, 0.7073, 2.66, 0.223, 244, 233, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4736, d5hnvA1, 0.7072, 2.67, 0.197, 278, 234, CRYSTAL STRUCTURE OF PPKA
4737, d3u51B_, 0.7072, 2.57, 0.237, 255, 232, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
4738, d4mf1A1, 0.7070, 2.49, 0.216, 241, 231, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
4739, d4agwA_, 0.7070, 2.48, 0.234, 258, 231, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
4740, d2bmcE_, 0.7070, 2.89, 0.295, 256, 234, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4741, d4ztnB_, 0.7069, 3.05, 0.255, 282, 239, IRAK4-INHIBITOR CO-STRUCTURE
4742, d3efwA_, 0.7069, 2.25, 0.303, 240, 228, STRUCTURE OF AURORAA WITH PYRIDYL-PYRIMIDINE UREA INHIBITOR
4743, d5d11A_, 0.7068, 2.32, 0.246, 254, 228, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
4744, d2oidB_, 0.7068, 2.93, 0.253, 272, 237, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
4745, d3miyB1, 0.7067, 2.29, 0.219, 238, 228, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
4746, d2bmcF_, 0.7067, 2.72, 0.297, 257, 232, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4747, d3fzsA_, 0.7066, 2.66, 0.207, 254, 237, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH BIRB796
4748, d2bmcC_, 0.7066, 2.76, 0.296, 257, 233, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4749, d1xkkA_, 0.7066, 3.34, 0.187, 289, 246, EGFR KINASE DOMAIN COMPLEXED WITH A QUINAZOLINE INHIBITOR- GW572016
4750, d5knjB_, 0.7065, 2.42, 0.198, 259, 232, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 1.
4751, d2xk7A1, 0.7065, 2.26, 0.282, 238, 227, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 23
4752, d2hyyD1, 0.7065, 2.67, 0.227, 251, 233, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4753, d2c0tB3, 0.7065, 2.83, 0.233, 268, 236, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
4754, d3vs1B3, 0.7064, 2.91, 0.257, 268, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
4755, d3pozA_, 0.7064, 3.21, 0.192, 293, 245, EGFR KINASE DOMAIN COMPLEXED WITH TAK-285
4756, d2wtdA_, 0.7064, 2.93, 0.280, 285, 232, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4757, d2bmcB_, 0.7064, 2.84, 0.291, 258, 234, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4758, d4x7hA_, 0.7063, 2.95, 0.271, 256, 236, CO-CRYSTAL STRUCTURE OF PERK BOUND TO N-{5-[(67-DIMETHOXYQUINOLIN-4- YL)OXY]PYRIDIN-2-YL}-1-METHYL-3-OXO-2-PHENYL-5-(PYRIDIN-4-YL)-23- DIHYDRO-1H-PYRAZOLE-4-CARBOXAMIDE INHIBITOR
4759, d4a9rA_, 0.7063, 3.05, 0.283, 285, 233, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4760, d3zxtA_, 0.7063, 2.39, 0.268, 249, 228, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN IN COMPLEX WITH AMPPCP-MG
4761, d3en5B_, 0.7063, 2.57, 0.245, 261, 233, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP494 A MULTITARGETED KINASE INHIBITOR
4762, d2xkcA1, 0.7063, 2.03, 0.272, 236, 224, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 14
4763, d2wtcA_, 0.7063, 2.93, 0.280, 284, 232, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4764, d2rioB_, 0.7063, 2.39, 0.314, 395, 229, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4765, d2c0tA3, 0.7063, 2.81, 0.233, 268, 236, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
4766, d4xs2C_, 0.7062, 3.09, 0.270, 281, 241, IRAK4-INHIBITOR CO-STRUCTURE
4767, d3vs2A3, 0.7062, 2.83, 0.233, 268, 236, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
4768, d3vs0B3, 0.7062, 2.82, 0.233, 268, 236, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
4769, d2cn5A1, 0.7062, 2.97, 0.284, 281, 232, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH ADP
4770, d3v5lB1, 0.7060, 2.49, 0.225, 239, 231, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4771, d2bmcA_, 0.7060, 2.74, 0.292, 256, 233, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4772, d5k76A_, 0.7059, 2.97, 0.274, 270, 237, IRAK4 IN COMPLEX WITH COMPOUND 28
4773, d5a6oA_, 0.7059, 2.74, 0.243, 265, 235, CRYSTAL STRUCTURE OF THE APO FORM OF THE UNPHOSPHORYLATED HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3)
4774, d3qgwB_, 0.7059, 2.42, 0.213, 240, 230, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
4775, d2c0iA3, 0.7059, 2.81, 0.233, 268, 236, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
4776, d5o21A_, 0.7058, 3.33, 0.229, 272, 245, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
4777, d3qtiA_, 0.7058, 3.25, 0.233, 292, 240, C-MET KINASE IN COMPLEX WITH NVP-BVU972
4778, d1yolA_, 0.7058, 2.48, 0.230, 256, 230, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
4779, d4d4rA_, 0.7057, 2.73, 0.237, 251, 236, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4780, d4a9uA1, 0.7057, 2.99, 0.279, 286, 233, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4781, d3vs7B3, 0.7057, 2.78, 0.247, 266, 235, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
4782, d4y73D_, 0.7055, 3.37, 0.260, 288, 246, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4783, d3vrzA3, 0.7054, 2.91, 0.245, 268, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
4784, d4gt4B_, 0.7053, 2.89, 0.205, 273, 239, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
4785, d3hyhB_, 0.7053, 2.44, 0.306, 233, 229, CRYSTAL STRUCTURE OF THE PROTEIN KINASE DOMAIN OF YEAST AMP-ACTIVATED PROTEIN KINASE SNF1
4786, d3famA_, 0.7053, 2.47, 0.306, 235, 229,  
4787, d2eueA_, 0.7053, 2.47, 0.306, 235, 229,  
4788, d4x7jA_, 0.7052, 2.95, 0.264, 257, 235, CO-CRYSTAL STRUCTURE OF PERK WITH 2-AMINO-N-[4-METHOXY-3- (TRIFLUOROMETHYL)PHENYL]-4-METHYL-3-[2-(METHYLAMINO)QUINAZOLIN-6- YL]BENZAMIDE INHIBITOR
4789, d4u3yA_, 0.7051, 4.05, 0.199, 295, 256, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
4790, d3zfyB_, 0.7051, 2.78, 0.204, 255, 235, CRYSTAL STRUCTURE OF EPHB3
4791, d2hw7A1, 0.7050, 2.51, 0.248, 269, 226, CRYSTAL STRUCTURE OF MNK2-D228G IN COMPLEX WITH STAUROSPORINE
4792, d5u6bC_, 0.7049, 2.98, 0.212, 270, 241, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
4793, d3vs3A3, 0.7049, 2.87, 0.232, 269, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
4794, d3dj6A_, 0.7049, 2.67, 0.288, 252, 233, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 823.
4795, d2qi8A_, 0.7049, 2.34, 0.259, 255, 228, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
4796, d5itaA_, 0.7048, 2.53, 0.216, 250, 232, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
4797, d4kioA1, 0.7048, 2.38, 0.223, 238, 229, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4798, d4cqeA_, 0.7048, 2.80, 0.209, 250, 235, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
4799, d2wqeA_, 0.7048, 2.51, 0.304, 241, 230, STRUCTURE OF S155R AURORA-A SOMATIC MUTANT
4800, d3vs4A3, 0.7047, 2.95, 0.235, 270, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
4801, d3vs2B3, 0.7047, 2.82, 0.229, 268, 236, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
4802, d3w18A_, 0.7046, 2.16, 0.298, 234, 225, STRUCTURE OF AURORA KINASE A COMPLEXED TO BENZOIMIDAZOLE-INDAZOLE INHIBITOR XIII
4803, d5h0gA3, 0.7045, 3.02, 0.230, 281, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-N4-DIMETHYLPENTANAMIDE
4804, d4af3A_, 0.7045, 2.97, 0.282, 253, 234, HUMAN AURORA B KINASE IN COMPLEX WITH INCENP AND VX-680
4805, d2c0oB3, 0.7044, 2.82, 0.233, 268, 236, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
4806, d4yp8D_, 0.7043, 3.45, 0.263, 285, 247, IRAK4-INHIBITOR CO-STRUCTURE
4807, d2xbjA_, 0.7043, 2.92, 0.286, 286, 231, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4808, d2c0oA3, 0.7043, 2.83, 0.233, 268, 236, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
4809, d3vs0A3, 0.7042, 2.93, 0.249, 268, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
4810, d3v5lA1, 0.7042, 2.45, 0.222, 238, 230, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4811, d3c7qA_, 0.7042, 2.80, 0.203, 286, 236, STRUCTURE OF VEGFR2 KINASE DOMAIN IN COMPLEX WITH BIBF1120
4812, d2wqoA1, 0.7042, 2.02, 0.274, 234, 223, STRUCTURE OF NEK2 BOUND TO THE AMINOPYRIDINE CCT241950
4813, d2c0iB3, 0.7042, 2.92, 0.249, 268, 237, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
4814, d3v8wA1, 0.7041, 2.55, 0.208, 241, 231, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
4815, d5uiuA_, 0.7040, 3.39, 0.260, 286, 246, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 30
4816, d4y73B_, 0.7040, 3.38, 0.257, 289, 245, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4817, d4x7lA_, 0.7040, 2.91, 0.268, 260, 235, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-4-METHYL-3-[2- (METHYLAMINO)-13-BENZOTHIAZOL-6-YL]BENZOYL}-1-METHYL-25-DIPHENYL-1 2-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
4818, d1ywnA_, 0.7040, 2.59, 0.210, 279, 233, VEGFR2 IN COMPLEX WITH A NOVEL 4-AMINO-FURO[23-D]PYRIMIDINE
4819, d5a6nB1, 0.7039, 2.91, 0.253, 265, 237, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH COMPOUND 2
4820, d4x7kA_, 0.7039, 2.90, 0.268, 260, 235, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-3-[5-FLUORO-2- (METHYLAMINO)QUINAZOLIN-6-YL]-4-METHYLBENZOYL}-1-METHYL-25-DIPHENYL- 12-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
4821, d2yzaA_, 0.7039, 2.75, 0.277, 258, 235, CRYSTAL STRUCTURE OF KINASE DOMAIN OF HUMAN 5 -AMP-ACTIVATED PROTEIN KINASE ALPHA-2 SUBUNIT MUTANT (T172D)
4822, d5uiuB_, 0.7038, 3.39, 0.260, 287, 246, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 30
4823, d2wtjA1, 0.7038, 2.94, 0.284, 286, 232, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4824, p4d28C_, 0.7037, 3.13, 0.314, 279, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
4825, d3p08B_, 0.7036, 2.90, 0.199, 258, 236, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
4826, d3dj5A_, 0.7036, 2.58, 0.289, 252, 232, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 290.
4827, d5h0eA3, 0.7035, 3.03, 0.230, 281, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANAMIDE
4828, d5jsmB1, 0.7034, 3.03, 0.213, 259, 239, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4829, d5jrqA1, 0.7034, 2.97, 0.213, 257, 239, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
4830, d5hieB_, 0.7034, 2.83, 0.196, 259, 235, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4831, d4kioD1, 0.7034, 2.40, 0.223, 240, 229, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4832, d4kaoA_, 0.7034, 2.79, 0.236, 252, 237, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
4833, d4ybjB_, 0.7033, 2.40, 0.246, 253, 228, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
4834, d4x7nA_, 0.7032, 2.92, 0.268, 259, 235, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-[2-AMINO-4-METHYL-3-(2- METHYLQUINOLIN-6-YL)BENZOYL]-1-METHYL-25-DIPHENYL-12-DIHYDRO-3H- PYRAZOL-3-ONE INHIBITOR
4835, d2rgpA_, 0.7032, 3.12, 0.186, 284, 242, STRUCTURE OF EGFR IN COMPLEX WITH HYDRAZONE A POTENT DUAL INHIBITOR
4836, d5tx5A_, 0.7031, 3.31, 0.220, 259, 241, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
4837, d5d7vB1, 0.7031, 3.12, 0.230, 262, 243, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
4838, d3vs6A3, 0.7031, 2.88, 0.232, 269, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
4839, d5h2uB1, 0.7030, 3.10, 0.231, 261, 242, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
4840, d5h09A3, 0.7029, 3.04, 0.230, 281, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-ETHYL2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOATE
4841, d4zseA_, 0.7029, 3.24, 0.184, 297, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
4842, d4kioB1, 0.7029, 2.35, 0.224, 237, 228, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4843, d3vryA3, 0.7029, 2.91, 0.232, 269, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
4844, d3w33A_, 0.7028, 3.16, 0.198, 297, 243, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 19B
4845, d3v8wB1, 0.7028, 2.49, 0.222, 240, 230, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
4846, d5h0bA3, 0.7027, 3.04, 0.230, 281, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOIC ACID
4847, d5bpyB1, 0.7027, 2.83, 0.184, 246, 234, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
4848, d4itjB_, 0.7027, 3.30, 0.211, 276, 242, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
4849, d4fg8B_, 0.7027, 2.82, 0.282, 268, 234, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
4850, d4bdfA1, 0.7027, 2.99, 0.290, 284, 231, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4851, d3u4wA_, 0.7027, 3.27, 0.259, 275, 243, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC4B
4852, d5we8A_, 0.7026, 3.16, 0.255, 270, 239, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH N-{(3R)-1-[(4-CHLOROPHENYL) METHYL]PYRROLIDIN-3-YL}-2-(3-METHOXYPHENYL)-N-METHYLQUINOLINE-4- CARBOXAMIDE (COMPOUND 8)
4853, d5k75A_, 0.7026, 2.84, 0.248, 271, 234, IRAK4 IN COMPLEX WITH COMPOUND 1
4854, d5cswA_, 0.7026, 2.71, 0.206, 254, 233, B-RAF IN COMPLEX WITH DABRAFENIB
4855, d5a6oB1, 0.7026, 2.89, 0.250, 264, 236, CRYSTAL STRUCTURE OF THE APO FORM OF THE UNPHOSPHORYLATED HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3)
4856, d4zseB_, 0.7026, 3.23, 0.189, 313, 244, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
4857, d2a1aB1, 0.7026, 2.73, 0.250, 266, 236, PKR KINASE DOMAIN-EIF2ALPHA COMPLEX
4858, d3pj1A_, 0.7025, 2.24, 0.199, 241, 226, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 3-(26-DICHLORO- PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-1-METHYL-34- DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
4859, d1gzoA_, 0.7025, 2.62, 0.295, 271, 234, STRUCTURE OF PROTEIN KINASE B UNPHOSPHORYLATED
4860, d5tobA_, 0.7024, 2.32, 0.206, 245, 228, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
4861, d5h0hA3, 0.7024, 3.05, 0.226, 281, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-NN4-TRIMETHYLPENTANAMIDE
4862, d3zfmA_, 0.7024, 2.49, 0.199, 248, 231, CRYSTAL STRUCTURE OF EPHB2
4863, d3w32A_, 0.7024, 3.62, 0.197, 317, 254, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 20A
4864, d4dggB_, 0.7023, 2.59, 0.247, 259, 231, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
4865, d3zuuB_, 0.7023, 2.90, 0.268, 282, 239, THE STRUCTURE OF OST1 (D160A S175D) KINASE IN COMPLEX WITH GOLD
4866, d3vs4B3, 0.7023, 2.90, 0.232, 269, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
4867, d3zutB_, 0.7022, 2.90, 0.268, 282, 239, THE STRUCTURE OF OST1 (D160A) KINASE
4868, d4a9sA_, 0.7021, 2.95, 0.281, 282, 231, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4869, d2rfsA_, 0.7021, 3.00, 0.233, 264, 236, X-RAY STRUCTURE OF SU11274 BOUND TO C-MET
4870, d1r1wA_, 0.7021, 3.02, 0.233, 287, 236, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET
4871, d4zseC_, 0.7020, 3.14, 0.189, 301, 243, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
4872, d4ludB3, 0.7019, 2.74, 0.235, 264, 234, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
4873, d5uisB_, 0.7018, 2.97, 0.266, 274, 237, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 12
4874, d5jsmA1, 0.7018, 3.10, 0.212, 262, 240, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4875, d3ulzA_, 0.7018, 3.23, 0.195, 291, 241, CRYSTAL STRUCTURE OF APO BAK1
4876, d2rfeD_, 0.7018, 3.05, 0.192, 278, 239, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
4877, d5k7gA_, 0.7016, 3.05, 0.259, 277, 239, IRAK4 IN COMPLEX WITH AZ3862
4878, d4ithB_, 0.7016, 3.16, 0.220, 270, 241, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
4879, d3vs6B3, 0.7016, 2.90, 0.232, 269, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
4880, d3pyyA1, 0.7016, 2.74, 0.228, 251, 232, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
4881, d3mn3A_, 0.7016, 2.52, 0.319, 252, 232, AN INHIBITED CONFORMATION FOR THE PROTEIN KINASE DOMAIN OF THE SACCHAROMYCES CEREVISIAE AMPK HOMOLOG SNF1
4882, d2x7fD_, 0.7016, 2.31, 0.252, 236, 226, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
4883, d4yfiB_, 0.7015, 2.48, 0.211, 262, 228, TNNI3K COMPLEXED WITH INHIBITOR 1
4884, d4lggB_, 0.7015, 2.53, 0.245, 245, 229, STRUCTURE OF 3MB-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
4885, d3el7A_, 0.7015, 2.53, 0.249, 254, 229, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 3
4886, d3dkcA1, 0.7015, 3.46, 0.194, 310, 247, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH ATP
4887, d3miyA1, 0.7014, 2.35, 0.220, 237, 227, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
4888, d2j90A1, 0.7014, 2.77, 0.258, 259, 233, CRYSTAL STRUCTURE OF HUMAN ZIP KINASE IN COMPLEX WITH A TETRACYCLIC PYRIDONE INHIBITOR (PYRIDONE 6)
4889, p4d28B_, 0.7012, 3.22, 0.317, 277, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
4890, d3belA_, 0.7012, 3.07, 0.187, 280, 241, X-RAY STRUCTURE OF EGFR IN COMPLEX WITH OXIME INHIBITOR
4891, d5d10A_, 0.7011, 2.33, 0.243, 248, 226, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL236
4892, d5hieA_, 0.7010, 2.71, 0.206, 258, 233, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4893, d4itiB_, 0.7010, 3.29, 0.207, 270, 242, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-3 ANALOG
4894, d3vs5A3, 0.7010, 2.88, 0.233, 268, 236, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
4895, d3v5jA1, 0.7010, 2.47, 0.218, 239, 229, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
4896, d3uimA_, 0.7010, 3.26, 0.198, 291, 242, STRUCTURAL BASIS FOR THE IMPACT OF PHOSPHORYLATION ON PLANT RECEPTOR- LIKE KINASE BAK1 ACTIVATION
4897, d1gznA_, 0.7010, 2.63, 0.291, 271, 234, STRUCTURE OF PKB KINASE DOMAIN
4898, d4bdhA_, 0.7009, 2.98, 0.287, 282, 230, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4899, d3aqvA_, 0.7009, 3.00, 0.268, 267, 239, HUMAN AMP-ACTIVATED PROTEIN KINASE ALPHA 2 SUBUNIT KINASE DOMAIN (T172D) COMPLEXED WITH COMPOUND C
4900, d4hjoA_, 0.7008, 3.33, 0.187, 278, 246, CRYSTAL STRUCTURE OF THE INACTIVE EGFR TYROSINE KINASE DOMAIN WITH ERLOTINIB
4901, d3a60A_, 0.7008, 2.24, 0.305, 263, 226, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED P70S6K1 (FORM I)
4902, d1gzkA_, 0.7008, 2.64, 0.295, 271, 234, MOLECULAR MECHANISM FOR THE REGULATION OF PROTEIN KINASE B/ AKT BY HYDROPHOBIC MOTIF PHOSPHORYLATION
4903, d4gt4A_, 0.7007, 2.93, 0.214, 274, 238, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
4904, d5owqA_, 0.7006, 2.59, 0.329, 255, 228, HUMAN STK10 BOUND TO DOVITINIB
4905, d4bdgA1, 0.7006, 3.02, 0.286, 285, 231, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4906, d2weiA1, 0.7006, 3.41, 0.295, 269, 244, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE IN COMPLEX WITH 3- MB-PP1
4907, d4ynzB1, 0.7005, 3.08, 0.273, 316, 242, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
4908, d4nifD_, 0.7005, 3.05, 0.289, 313, 235, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
4909, d3cs9C_, 0.7005, 2.53, 0.240, 243, 229, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4910, d5owqB_, 0.7004, 2.59, 0.329, 254, 228, HUMAN STK10 BOUND TO DOVITINIB
4911, d5k72C_, 0.7004, 3.12, 0.268, 277, 239, IRAK4 IN COMPLEX WITH COMPOUND 21
4912, d1qcfA3, 0.7003, 3.26, 0.239, 281, 243, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH A SRC FAMILY- SELECTIVE TYROSINE KINASE INHIBITOR
4913, d4bdjA_, 0.7002, 2.95, 0.283, 282, 230, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4914, p4d28A_, 0.7000, 3.18, 0.318, 274, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
4915, d2hckA3, 0.7000, 3.19, 0.246, 271, 240, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
4916, d1ad5A3, 0.7000, 3.19, 0.242, 271, 240, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
4917, d4ztmB_, 0.6999, 3.02, 0.253, 280, 237, IRAK4-INHIBITOR CO-STRUCTURE
4918, d4itjA_, 0.6998, 3.20, 0.222, 261, 239, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
4919, d2oidD_, 0.6998, 3.00, 0.266, 274, 237, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
4920, d5i4nA1, 0.6997, 3.19, 0.205, 273, 244, CRYSTAL STRUCTURE OF THE E596A V617F MUTANT JAK2 PSEUDOKINASE DOMAIN BOUND TO MG-ATP
4921, d5d12B_, 0.6997, 2.42, 0.251, 253, 227, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
4922, d4xs2B_, 0.6997, 3.03, 0.249, 278, 237, IRAK4-INHIBITOR CO-STRUCTURE
4923, d3k54A_, 0.6997, 2.27, 0.195, 243, 226, STRUCTURES OF HUMAN BRUTON S TYROSINE KINASE IN ACTIVE AND INACTIVE CONFORMATIONS SUGGESTS A MECHANISM OF ACTIVATION FOR TEC FAMILY KINASES.
4924, d5h2uD1, 0.6996, 3.14, 0.231, 261, 242, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
4925, d5d7vC1, 0.6996, 3.16, 0.230, 262, 243, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
4926, d5k72D_, 0.6995, 3.09, 0.265, 276, 238, IRAK4 IN COMPLEX WITH COMPOUND 21
4927, d4bdeA1, 0.6995, 2.95, 0.278, 282, 230, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4928, d5d7vD1, 0.6994, 3.17, 0.230, 262, 243, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
4929, d5cswB_, 0.6994, 2.64, 0.216, 252, 231, B-RAF IN COMPLEX WITH DABRAFENIB
4930, d3qrjB1, 0.6994, 2.69, 0.242, 252, 231, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN T315I MUTANT IN COMPLEX WITH DCC-2036
4931, d3pj3A_, 0.6994, 2.32, 0.187, 240, 225, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-METHYL-5-[(E)- (3-PHENYL-ACRYLOYL)AMINO]-N-(2-PHENYL-3H-IMIDAZO[45-B]PYRIDIN-6-YL)- BENZAMIDE
4932, d3kmwA_, 0.6994, 3.14, 0.158, 268, 241, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MGATP)
4933, d2y4pC_, 0.6994, 2.61, 0.278, 264, 230, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN
4934, d4bdcA_, 0.6993, 2.96, 0.283, 283, 230, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4935, d3cd8A_, 0.6993, 3.13, 0.225, 278, 236, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
4936, d3vryB3, 0.6992, 2.95, 0.232, 269, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
4937, d3g51A_, 0.6992, 2.76, 0.316, 280, 234, STRUCTURAL DIVERSITY OF THE ACTIVE CONFORMATION OF THE N- TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2
4938, d2qq7A_, 0.6992, 2.29, 0.267, 251, 225, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN WITH IRREVERSIBLE INHIBITOR
4939, d2h6dA_, 0.6992, 2.71, 0.275, 256, 233, PROTEIN KINASE DOMAIN OF THE HUMAN 5 -AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2 (AMPK ALPHA-2 CHAIN)
4940, d2yitA_, 0.6991, 2.99, 0.281, 286, 231, STRUCTURAL ANALYSIS OF CHECKPOINT KINASE 2 IN COMPLEX WITH PV1162 A NOVEL INHIBITOR
4941, d5uiqB_, 0.6990, 2.98, 0.262, 272, 237, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4942, d5h2uC1, 0.6988, 3.14, 0.231, 261, 242, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
4943, d4u97A_, 0.6988, 2.98, 0.263, 272, 236, CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4944, d3repA_, 0.6988, 3.20, 0.157, 268, 242, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MNATP)
4945, d3qtiB_, 0.6987, 2.99, 0.244, 280, 234, C-MET KINASE IN COMPLEX WITH NVP-BVU972
4946, d3vs5B3, 0.6986, 2.99, 0.249, 268, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
4947, d5hieC_, 0.6985, 2.59, 0.203, 253, 231, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4948, d4m69B_, 0.6985, 3.01, 0.204, 264, 240, CRYSTAL STRUCTURE OF THE MOUSE RIP3-MLKL COMPLEX
4949, d4bdbA1, 0.6985, 2.99, 0.278, 282, 230, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4950, d4bdaA1, 0.6985, 3.00, 0.283, 283, 230, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4951, d1ad5B3, 0.6985, 3.23, 0.246, 271, 240, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
4952, d5t1tB_, 0.6983, 3.10, 0.264, 280, 239, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4953, d5gtyH_, 0.6982, 3.25, 0.194, 300, 242, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
4954, d3uc4A_, 0.6982, 3.05, 0.258, 295, 240, THE CRYSTAL STRUCTURE OF SNF1-RELATED KINASE 2.6
4955, d4ynzA1, 0.6980, 3.00, 0.285, 306, 239, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
4956, d4r1yA_, 0.6980, 2.79, 0.225, 265, 231, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITOR
4957, d2jc6A_, 0.6980, 2.66, 0.287, 278, 230, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4958, d5uiqD_, 0.6979, 2.90, 0.260, 271, 235, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4959, d5jsmC1, 0.6979, 3.02, 0.218, 259, 238, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4960, d3v5jB1, 0.6978, 2.49, 0.219, 239, 228, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
4961, d5jsmD1, 0.6977, 3.09, 0.218, 255, 238, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4962, d2yirA_, 0.6977, 3.12, 0.280, 286, 232, STRUCTURAL ANALYSIS OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV1352
4963, d4yfiD_, 0.6976, 2.51, 0.207, 261, 227, TNNI3K COMPLEXED WITH INHIBITOR 1
4964, d4u9aA_, 0.6976, 2.91, 0.255, 272, 235, SULPHUR ANOMALOUS CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4965, d2qi8B_, 0.6976, 2.39, 0.252, 249, 226, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
4966, d5h2uA1, 0.6975, 3.16, 0.231, 261, 242, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
4967, d4i24B_, 0.6973, 3.47, 0.192, 304, 245, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
4968, d3i5nA_, 0.6973, 3.09, 0.221, 280, 235, CRYSTAL STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR 13
4969, d2gs7A_, 0.6973, 3.39, 0.183, 281, 246, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
4970, p5uq3A2, 0.6972, 1.06, 0.962, 210, 209, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1-P27 TERNARY COMPLEX
4971, d5hx6B_, 0.6972, 3.19, 0.216, 264, 236, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
4972, d2ycrA_, 0.6972, 2.96, 0.287, 282, 230, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV976
4973, d5uiqA_, 0.6971, 2.94, 0.261, 268, 234, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4974, d2vwiD_, 0.6971, 3.36, 0.258, 284, 240, STRUCTURE OF THE OSR1 KINASE A HYPERTENSION DRUG TARGET
4975, d5cnnB_, 0.6970, 3.32, 0.184, 304, 245, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
4976, d3zzwA_, 0.6970, 3.13, 0.204, 269, 240, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF ROR2
4977, d3zxtC_, 0.6970, 2.71, 0.268, 259, 231, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN IN COMPLEX WITH AMPPCP-MG
4978, d3dakB_, 0.6970, 3.19, 0.266, 278, 237, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4979, d1kswA3, 0.6968, 3.34, 0.230, 284, 243, STRUCTURE OF HUMAN C-SRC TYROSINE KINASE (THR338GLY MUTANT) IN COMPLEX WITH N6-BENZYL ADP
4980, d5hesA_, 0.6965, 2.92, 0.255, 287, 235, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
4981, d3orkA1, 0.6965, 2.94, 0.246, 272, 236, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 2)
4982, d2xk9A_, 0.6965, 3.07, 0.286, 284, 231, STRUCTURAL ANALYSIS OF CHECKPOINT KINASE 2 (CHK2) IN COMPLEX WITH INHIBITOR PV1533
4983, d5d7vA1, 0.6964, 3.20, 0.230, 262, 243, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
4984, d3orpA_, 0.6964, 3.03, 0.244, 274, 238, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 5)
4985, d2srcA3, 0.6962, 3.34, 0.226, 284, 243, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC IN COMPLEX WITH AMP-PNP
4986, d5uafA_, 0.6961, 3.08, 0.231, 291, 234, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
4987, d5uadA_, 0.6961, 3.08, 0.231, 291, 234, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
4988, d4knbC_, 0.6961, 3.01, 0.231, 271, 234, C-MET IN COMPLEX WITH OSI LIGAND
4989, d2hckB3, 0.6961, 3.25, 0.246, 271, 240, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
4990, d5b2mA_, 0.6960, 2.32, 0.233, 255, 227, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
4991, d2ycfA_, 0.6960, 3.09, 0.281, 286, 231, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV1531
4992, d2w7xA_, 0.6960, 3.12, 0.286, 285, 231, CELLULAR INHIBITION OF CHECKPOINT KINASE 2 AND POTENTIATION OF CYTOTOXIC DRUGS BY NOVEL CHK2 INHIBITOR PV1019
4993, d2jc6C_, 0.6960, 2.65, 0.293, 277, 229, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4994, d5tx5B_, 0.6959, 3.24, 0.216, 263, 236, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
4995, d5d41B_, 0.6958, 3.25, 0.189, 302, 244, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
4996, d5hieD_, 0.6957, 2.60, 0.187, 253, 230, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4997, d4yfiC_, 0.6957, 2.61, 0.228, 269, 228, TNNI3K COMPLEXED WITH INHIBITOR 1
4998, d5gtyE_, 0.6956, 3.13, 0.183, 297, 240, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
4999, d5gnkA_, 0.6956, 3.10, 0.188, 277, 239, CRYSTAL STRUCTURE OF EGFR 696-988 T790M IN COMPLEX WITH LXX-6-34
5000, d5d9hA_, 0.6956, 3.69, 0.254, 290, 248, CRYSTAL STRUCTURE OF SPAK (STK39) DIMER IN THE BASAL ACTIVITY STATE
